DDI-MedLine.d161.s3.p0	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	false	in the present study , we tested whether the highly specific metabotropic glutamate receptor # antagonist , druga , reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of drugb .
DDI-MedLine.d161.s4.p0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	false	weekly intramuscular druga injections -lcb- ## mg/kg body weight -rcb- , in combination with daily administration of drugb or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups -lcb- drugn / drugn versus drugn / vehicle -rcb- .
DDI-MedLine.d161.s4.p2	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	false	weekly intramuscular druga injections -lcb- ## mg/kg body weight -rcb- , in combination with daily administration of drugn or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups -lcb- drugn / drugb versus drugn / vehicle -rcb- .
DDI-MedLine.d161.s4.p4	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	false	weekly intramuscular drugn injections -lcb- ## mg/kg body weight -rcb- , in combination with daily administration of druga or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups -lcb- drugb / drugn versus drugn / vehicle -rcb- .
DDI-MedLine.d161.s4.p6	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	false	weekly intramuscular drugn injections -lcb- ## mg/kg body weight -rcb- , in combination with daily administration of druga or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups -lcb- drugn / drugn versus drugb / vehicle -rcb- .
DDI-MedLine.d161.s5.p2	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	false	after # weeks of druga treatment , all drugn / vehicle-treated animals displayed parkinsonian symptoms , whereas none of the drugn / drugb - treated monkeys were significantly affected .
DDI-MedLine.d161.s5.p4	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	false	after # weeks of drugn treatment , all druga / vehicle-treated animals displayed parkinsonian symptoms , whereas none of the drugn / drugb - treated monkeys were significantly affected .
DDI-MedLine.d161.s5.p5	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	effect	after # weeks of drugn treatment , all drugn / vehicle-treated animals displayed parkinsonian symptoms , whereas none of the druga / drugb - treated monkeys were significantly affected .
DDI-MedLine.d161.s6.p0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	effect	these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post-mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in druga / drugb - treated animals than in drugn / vehicle-treated monkeys .
DDI-MedLine.d161.s6.p2	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	false	these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post-mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in drugn / druga - treated animals than in drugb / vehicle-treated monkeys .
DDI-MedLine.d161.s7.p0	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	effect	the druga treatment also had a significant effect on the drugb - induced loss of norepinephrine neurons in the locus coeruleus and adjoining a5 and a7 noradrenaline cell groups .
DDI-MedLine.d161.s8.p1	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	false	in druga / vehicle-treated animals , almost 40 % loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/a5/a7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than 15 % of control values in drugn / drugb - treated monkeys .
DDI-MedLine.d161.s8.p2	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	effect	in drugn / vehicle-treated animals , almost 40 % loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/a5/a7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than 15 % of control values in druga / drugb - treated monkeys .
DDI-MedLine.d161.s9.p0	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	_	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	_	effect	our data demonstrate that chronic treatment with the metabotropic glutamate receptor # antagonist , druga , significantly reduces drugb toxicity towards dopaminergic and noradrenergic cell groups in non-human primates .
DDI-MedLine.d185.s0.p0	ketoconazole	drug	_	panobinostat	drug	_	false	effect of druga - mediated cyp3a4 inhibition on clinical pharmacokinetics of drugb -lcb- drugn -rcb- , an orally active drugn .
DDI-MedLine.d185.s0.p1	ketoconazole	drug	_	LBH589	drug	_	false	effect of druga - mediated cyp3a4 inhibition on clinical pharmacokinetics of drugn -lcb- drugb -rcb- , an orally active drugn .
DDI-MedLine.d185.s0.p2	ketoconazole	drug	_	histone deacetylase inhibitor	group	_	false	effect of druga - mediated cyp3a4 inhibition on clinical pharmacokinetics of drugn -lcb- drugn -rcb- , an orally active drugb .
DDI-MedLine.d185.s0.p4	panobinostat	drug	_	histone deacetylase inhibitor	group	_	false	effect of drugn - mediated cyp3a4 inhibition on clinical pharmacokinetics of druga -lcb- drugn -rcb- , an orally active drugb .
DDI-MedLine.d185.s0.p5	LBH589	drug	_	histone deacetylase inhibitor	group	_	false	effect of drugn - mediated cyp3a4 inhibition on clinical pharmacokinetics of drugn -lcb- druga -rcb- , an orally active drugb .
DDI-MedLine.d185.s2.p0	ketoconazole	drug	_	panobinostat	drug	_	false	this study evaluated the effect of a potent cyp3a inhibitor , druga , on the pharmacokinetics and safety of drugb .
DDI-MedLine.d185.s5.p0	panobinostat	drug	_	ketoconazole	drug	_	false	on day 8 , a single druga dose was co-administered with drugb .
DDI-MedLine.d185.s7.p0	ketoconazole	drug	_	panobinostat	drug	_	mechanism	in the presence of druga , there was # - and # - fold increase in c -lcb- max -rcb- and auc of drugb , respectively .
DDI-MedLine.d231.s0.p0	moxifloxacin	drug	_	lomefloxacin	drug	_	false	interaction study of druga and drugb with co-administered drugs .
DDI-MedLine.d231.s1.p0	Moxifloxacin	drug	_	lomefloxacin	drug	_	false	druga and drugb are drugn used in treating urinary and respiratory tract infections .
DDI-MedLine.d231.s1.p1	Moxifloxacin	drug	_	fluoroquinolone antibiotics	group	_	false	druga and drugn are drugb used in treating urinary and respiratory tract infections .
DDI-MedLine.d231.s1.p2	lomefloxacin	drug	_	fluoroquinolone antibiotics	group	_	false	drugn and druga are drugb used in treating urinary and respiratory tract infections .
DDI-MedLine.d231.s3.p0	moxifloxacin	drug	_	fluoroquinolones	group	_	false	being druga and lomefloxacin drugb the interaction study of was carried out with drugn , drugn , drugn and drugn .
DDI-MedLine.d231.s3.p1	moxifloxacin	drug	_	sucralfate	drug	_	false	being druga and lomefloxacin drugn the interaction study of was carried out with drugb , drugn , drugn and drugn .
DDI-MedLine.d231.s3.p2	moxifloxacin	drug	_	gelusil	brand	_	false	being druga and lomefloxacin drugn the interaction study of was carried out with drugn , drugb , drugn and drugn .
DDI-MedLine.d231.s3.p3	moxifloxacin	drug	_	erythromycin	drug	_	false	being druga and lomefloxacin drugn the interaction study of was carried out with drugn , drugn , drugb and drugn .
DDI-MedLine.d231.s3.p4	moxifloxacin	drug	_	multi minerals	group	_	false	being druga and lomefloxacin drugn the interaction study of was carried out with drugn , drugn , drugn and drugb .
DDI-MedLine.d231.s3.p5	fluoroquinolones	group	_	sucralfate	drug	_	false	being drugn and lomefloxacin druga the interaction study of was carried out with drugb , drugn , drugn and drugn .
DDI-MedLine.d231.s3.p6	fluoroquinolones	group	_	gelusil	brand	_	false	being drugn and lomefloxacin druga the interaction study of was carried out with drugn , drugb , drugn and drugn .
DDI-MedLine.d231.s3.p7	fluoroquinolones	group	_	erythromycin	drug	_	false	being drugn and lomefloxacin druga the interaction study of was carried out with drugn , drugn , drugb and drugn .
DDI-MedLine.d231.s3.p8	fluoroquinolones	group	_	multi minerals	group	_	false	being drugn and lomefloxacin druga the interaction study of was carried out with drugn , drugn , drugn and drugb .
DDI-MedLine.d231.s6.p0	moxifloxacin	drug	_	lomefloxacin	drug	_	false	the response of druga and drugb after interaction with co-administered drugs at different conditions and temperature were noted using a shimadzu hplc system with pda detector .
DDI-MedLine.d231.s8.p0	Moxifloxacin	drug	_	Lomefloxacin	drug	_	false	druga and drugb reacts faster with drugn and drugn in acidic media whereas with drugn in basic media and drugn in neutral media .
DDI-MedLine.d231.s8.p1	Moxifloxacin	drug	_	sucralfate	drug	_	mechanism	druga and drugn reacts faster with drugb and drugn in acidic media whereas with drugn in basic media and drugn in neutral media .
DDI-MedLine.d231.s8.p2	Moxifloxacin	drug	_	gelusil	brand	_	mechanism	druga and drugn reacts faster with drugn and drugb in acidic media whereas with drugn in basic media and drugn in neutral media .
DDI-MedLine.d231.s8.p3	Moxifloxacin	drug	_	erythromycin	drug	_	mechanism	druga and drugn reacts faster with drugn and drugn in acidic media whereas with drugb in basic media and drugn in neutral media .
DDI-MedLine.d231.s8.p4	Moxifloxacin	drug	_	multi-minerals	group	_	mechanism	druga and drugn reacts faster with drugn and drugn in acidic media whereas with drugn in basic media and drugb in neutral media .
DDI-MedLine.d231.s8.p5	Lomefloxacin	drug	_	sucralfate	drug	_	mechanism	drugn and druga reacts faster with drugb and drugn in acidic media whereas with drugn in basic media and drugn in neutral media .
DDI-MedLine.d231.s8.p6	Lomefloxacin	drug	_	gelusil	brand	_	mechanism	drugn and druga reacts faster with drugn and drugb in acidic media whereas with drugn in basic media and drugn in neutral media .
DDI-MedLine.d231.s8.p7	Lomefloxacin	drug	_	erythromycin	drug	_	mechanism	drugn and druga reacts faster with drugn and drugn in acidic media whereas with drugb in basic media and drugn in neutral media .
DDI-MedLine.d231.s8.p8	Lomefloxacin	drug	_	multi-minerals	group	_	mechanism	drugn and druga reacts faster with drugn and drugn in acidic media whereas with drugn in basic media and drugb in neutral media .
DDI-MedLine.d231.s8.p9	sucralfate	drug	_	gelusil	brand	_	false	drugn and drugn reacts faster with druga and drugb in acidic media whereas with drugn in basic media and drugn in neutral media .
DDI-MedLine.d231.s8.p10	sucralfate	drug	_	erythromycin	drug	_	false	drugn and drugn reacts faster with druga and drugn in acidic media whereas with drugb in basic media and drugn in neutral media .
DDI-MedLine.d231.s8.p11	sucralfate	drug	_	multi-minerals	group	_	false	drugn and drugn reacts faster with druga and drugn in acidic media whereas with drugn in basic media and drugb in neutral media .
DDI-MedLine.d231.s8.p12	gelusil	brand	_	erythromycin	drug	_	false	drugn and drugn reacts faster with drugn and druga in acidic media whereas with drugb in basic media and drugn in neutral media .
DDI-MedLine.d231.s8.p13	gelusil	brand	_	multi-minerals	group	_	false	drugn and drugn reacts faster with drugn and druga in acidic media whereas with drugn in basic media and drugb in neutral media .
DDI-MedLine.d231.s8.p14	erythromycin	drug	_	multi-minerals	group	_	false	drugn and drugn reacts faster with drugn and drugn in acidic media whereas with druga in basic media and drugb in neutral media .
DDI-MedLine.d216.s0.p0	S-ketamine	drug	_	itraconazole	drug	_	false	exposure to oral druga is unaffected by drugb but greatly increased by drugn .
DDI-MedLine.d216.s0.p1	S-ketamine	drug	_	ticlopidine	drug	_	effect	exposure to oral druga is unaffected by drugn but greatly increased by drugb .
DDI-MedLine.d216.s0.p2	itraconazole	drug	_	ticlopidine	drug	_	false	exposure to oral drugn is unaffected by druga but greatly increased by drugb .
DDI-MedLine.d216.s1.p0	S-ketamine	drug	_	ticlopidine	drug	_	false	this study examined drug-drug interactions of oral druga with the cytochrome cyp2b6 -lcb- cyp -rcb- 2b6 inhibitor drugb and the cytochrome_p450_family_3_subfamily_a inhibitor drugn .
DDI-MedLine.d216.s1.p1	S-ketamine	drug	_	itraconazole	drug	_	false	this study examined drug-drug interactions of oral druga with the cytochrome cyp2b6 -lcb- cyp -rcb- 2b6 inhibitor drugn and the cytochrome_p450_family_3_subfamily_a inhibitor drugb .
DDI-MedLine.d216.s1.p2	ticlopidine	drug	_	itraconazole	drug	_	false	this study examined drug-drug interactions of oral drugn with the cytochrome cyp2b6 -lcb- cyp -rcb- 2b6 inhibitor druga and the cytochrome_p450_family_3_subfamily_a inhibitor drugb .
DDI-MedLine.d216.s2.p0	S-ketamine	drug	_	ticlopidine	drug	_	false	in this randomized , blinded , crossover study , # healthy volunteers ingested # mg/kg druga after pretreatments with oral drugb -lcb- 250 mg twice daily -rcb- , drugn -lcb- 200 mg once daily -rcb- , or placebo in 6-day treatment periods at intervals of # weeks .
DDI-MedLine.d216.s2.p1	S-ketamine	drug	_	itraconazole	drug	_	false	in this randomized , blinded , crossover study , # healthy volunteers ingested # mg/kg druga after pretreatments with oral drugn -lcb- 250 mg twice daily -rcb- , drugb -lcb- 200 mg once daily -rcb- , or placebo in 6-day treatment periods at intervals of # weeks .
DDI-MedLine.d216.s3.p0	Ticlopidine	drug	_	ketamine	drug	_	mechanism	druga treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity -lcb- auc -lcb- 0 - -rcb- -rcb- of oral drugb by # - fold , whereas drugn treatment did not increase the exposure to drugn .
DDI-MedLine.d216.s3.p1	Ticlopidine	drug	_	itraconazole	drug	_	false	druga treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity -lcb- auc -lcb- 0 - -rcb- -rcb- of oral drugn by # - fold , whereas drugb treatment did not increase the exposure to drugn .
DDI-MedLine.d216.s3.p2	Ticlopidine	drug	_	S-ketamine	drug	_	false	druga treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity -lcb- auc -lcb- 0 - -rcb- -rcb- of oral drugn by # - fold , whereas drugn treatment did not increase the exposure to drugb .
DDI-MedLine.d216.s3.p3	ketamine	drug	_	itraconazole	drug	_	false	drugn treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity -lcb- auc -lcb- 0 - -rcb- -rcb- of oral druga by # - fold , whereas drugb treatment did not increase the exposure to drugn .
DDI-MedLine.d216.s3.p5	itraconazole	drug	_	S-ketamine	drug	_	false	drugn treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity -lcb- auc -lcb- 0 - -rcb- -rcb- of oral drugn by # - fold , whereas druga treatment did not increase the exposure to drugb .
DDI-MedLine.d216.s4.p1	norketamine	drug_n	_	ticlopidine	drug	_	false	the ratio of druga auc -lcb- 0 - -rcb- to drugn auc -lcb- 0 - -rcb- was significantly decreased in the drugb -lcb- p < # -rcb- and drugn phases -lcb- p = # -rcb- as compared to placebo .
DDI-MedLine.d216.s4.p2	norketamine	drug_n	_	itraconazole	drug	_	false	the ratio of druga auc -lcb- 0 - -rcb- to drugn auc -lcb- 0 - -rcb- was significantly decreased in the drugn -lcb- p < # -rcb- and drugb phases -lcb- p = # -rcb- as compared to placebo .
DDI-MedLine.d216.s4.p3	ketamine	drug	_	ticlopidine	drug	_	false	the ratio of drugn auc -lcb- 0 - -rcb- to druga auc -lcb- 0 - -rcb- was significantly decreased in the drugb -lcb- p < # -rcb- and drugn phases -lcb- p = # -rcb- as compared to placebo .
DDI-MedLine.d216.s4.p4	ketamine	drug	_	itraconazole	drug	_	false	the ratio of drugn auc -lcb- 0 - -rcb- to druga auc -lcb- 0 - -rcb- was significantly decreased in the drugn -lcb- p < # -rcb- and drugb phases -lcb- p = # -rcb- as compared to placebo .
DDI-MedLine.d216.s4.p5	ticlopidine	drug	_	itraconazole	drug	_	false	the ratio of drugn auc -lcb- 0 - -rcb- to drugn auc -lcb- 0 - -rcb- was significantly decreased in the druga -lcb- p < # -rcb- and drugb phases -lcb- p = # -rcb- as compared to placebo .
DDI-MedLine.d216.s5.p0	ticlopidine	drug	_	itraconazole	drug	_	false	in the druga and drugb phases , the areas under the effect-time curves -lcb- self-reported drowsiness and performance -rcb- were significantly higher than those in the placebo phase -lcb- p < # -rcb- .
DDI-MedLine.d216.s6.p0	S-ketamine	drug	_	ticlopidine	drug	_	advise	the findings suggest that the dosage of druga should be reduced in patients receiving drugb .
DDI-MedLine.d180.s10.p1	DZNep	drug_n	_	ABT-737	drug_n	_	false	we also found that bcl-2 was overexpressed in druga insensitive cells , and cotreatment with drugn and drugb , a bcl2 family inhibitor , synergistically inhibited growth and induced apoptosis of drugn insensitive mm cells .
DDI-MedLine.d180.s10.p3	DZNep	drug_n	_	ABT-737	drug_n	_	effect	we also found that bcl-2 was overexpressed in drugn insensitive cells , and cotreatment with druga and drugb , a bcl2 family inhibitor , synergistically inhibited growth and induced apoptosis of drugn insensitive mm cells .
DDI-MedLine.d180.s10.p5	ABT-737	drug_n	_	DZNep	drug_n	_	false	we also found that bcl-2 was overexpressed in drugn insensitive cells , and cotreatment with drugn and druga , a bcl2 family inhibitor , synergistically inhibited growth and induced apoptosis of drugb insensitive mm cells .
DDI-MedLine.d180.s12.p0	DZNep	drug_n	_	ABT-737	drug_n	_	false	in addition , druga insensitivity might be associated with overexpression of bcl-2 , and the combination of drugb and drugn could synergistically induced apoptosis .
DDI-MedLine.d180.s12.p2	ABT-737	drug_n	_	DZNep	drug_n	_	effect	in addition , drugn insensitivity might be associated with overexpression of bcl-2 , and the combination of druga and drugb could synergistically induced apoptosis .
DDI-MedLine.d208.s0.p0	Implanon	brand	_	antiretroviral	group	_	effect	druga failure in an hiv-positive woman on drugb therapy resulting in two ectopic pregnancies .
DDI-MedLine.d208.s3.p0	antiretroviral	group	_	Implanon	brand	_	effect	we present an interesting case of an hiv-positive woman on druga therapy having tubal pregnancies on two separate occasions with drugb in place .
DDI-MedLine.d218.s0.p0	Antidepressant	group	_	warfarin	drug	_	false	druga - drugb interaction and associated gastrointestinal bleeding risk in a case-control study .
DDI-MedLine.d218.s3.p0	antidepressant	group	_	warfarin	drug	_	false	we sought to evaluate whether initiation of an druga increases the risk of hospitalization for gastrointestinal bleeding in drugb users .
DDI-MedLine.d218.s8.p0	Warfarin	drug	_	citalopram	drug	_	effect	druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugb -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- .
DDI-MedLine.d218.s8.p1	Warfarin	drug	_	fluoxetine	drug	_	effect	druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugb -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- .
DDI-MedLine.d218.s8.p2	Warfarin	drug	_	paroxetine	drug	_	effect	druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugb -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- .
DDI-MedLine.d218.s8.p3	Warfarin	drug	_	amitriptyline	drug	_	effect	druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugn -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- , drugb -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- .
DDI-MedLine.d218.s9.p0	mirtazapine	drug	_	warfarin	drug	_	effect	also druga , which is not believed to interact with drugb , increased the risk of gi bleeding -lcb- or = # -lsb- 95 % ci , ## -rsb- -rcb- .
DDI-MedLine.d218.s10.p0	Warfarin	drug	_	citalopram	drug	_	effect	druga users who initiated drugb , drugn , drugn , drugn , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10.p1	Warfarin	drug	_	fluoxetine	drug	_	effect	druga users who initiated drugn , drugb , drugn , drugn , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10.p2	Warfarin	drug	_	paroxetine	drug	_	effect	druga users who initiated drugn , drugn , drugb , drugn , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10.p3	Warfarin	drug	_	amitriptyline	drug	_	effect	druga users who initiated drugn , drugn , drugn , drugb , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10.p4	Warfarin	drug	_	mirtazapine	drug	_	effect	druga users who initiated drugn , drugn , drugn , drugn , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d189.s7.p0	ABT	drug_n	_	precocene I	drug_n	_	effect	druga decreased the toxicity of drugb , increased exposure to parent compound , and decreased metabolite levels in a dose-dependent manner .
DDI-MedLine.d189.s8.p0	precocene I	drug_n	_	tranylcypromine	drug	_	false	of the isoform-specific cyp inhibitors tested for an effect on the druga metabolite profile , only drugb was noticeably effective , indicating a role of ppig 2a6 , 2c9 , 2cl9 , and 2e1 .
DDI-MedLine.d189.s9.p0	ABT	drug_n	_	diethyldithiocarbamate	drug_n	_	false	with respect to toxicity , the order of cyp inhibitor effectiveness was druga > drugb ~ drugn > drugn .
DDI-MedLine.d189.s9.p1	ABT	drug_n	_	tranylcypromine	drug	_	false	with respect to toxicity , the order of cyp inhibitor effectiveness was druga > drugn ~ drugb > drugn .
DDI-MedLine.d189.s9.p2	ABT	drug_n	_	ketoconazole	drug	_	false	with respect to toxicity , the order of cyp inhibitor effectiveness was druga > drugn ~ drugn > drugb .
DDI-MedLine.d189.s9.p3	diethyldithiocarbamate	drug_n	_	tranylcypromine	drug	_	false	with respect to toxicity , the order of cyp inhibitor effectiveness was drugn > druga ~ drugb > drugn .
DDI-MedLine.d189.s9.p4	diethyldithiocarbamate	drug_n	_	ketoconazole	drug	_	false	with respect to toxicity , the order of cyp inhibitor effectiveness was drugn > druga ~ drugn > drugb .
DDI-MedLine.d189.s9.p5	tranylcypromine	drug	_	ketoconazole	drug	_	false	with respect to toxicity , the order of cyp inhibitor effectiveness was drugn > drugn ~ druga > drugb .
DDI-MedLine.d189.s10.p0	Furafylline	drug_n	_	sulfaphenazole	drug_n	_	false	druga and drugb had no effect , while drugn appeared to augment drugn toxicity .
DDI-MedLine.d189.s10.p1	Furafylline	drug_n	_	quinidine	drug	_	false	druga and drugn had no effect , while drugb appeared to augment drugn toxicity .
DDI-MedLine.d189.s10.p2	Furafylline	drug_n	_	precocene I	drug_n	_	false	druga and drugn had no effect , while drugn appeared to augment drugb toxicity .
DDI-MedLine.d189.s10.p3	sulfaphenazole	drug_n	_	quinidine	drug	_	false	drugn and druga had no effect , while drugb appeared to augment drugn toxicity .
DDI-MedLine.d189.s10.p4	sulfaphenazole	drug_n	_	precocene I	drug_n	_	false	drugn and druga had no effect , while drugn appeared to augment drugb toxicity .
DDI-MedLine.d189.s10.p5	quinidine	drug	_	precocene I	drug_n	_	effect	drugn and drugn had no effect , while druga appeared to augment drugb toxicity .
DDI-MedLine.d190.s2.p0	AAV2	drug_n	_	collagenase	drug_n	_	false	druga containing cdna encoding enhanced green fluorescent protein -lcb- gfp -rcb- , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugb , drugn , drugn , or drugn .
DDI-MedLine.d190.s2.p1	AAV2	drug_n	_	hyaluronan lyase	drug_n	_	false	druga containing cdna encoding enhanced green fluorescent protein -lcb- gfp -rcb- , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugn , drugb , drugn , or drugn .
DDI-MedLine.d190.s2.p2	AAV2	drug_n	_	heparinase III	drug_n	_	false	druga containing cdna encoding enhanced green fluorescent protein -lcb- gfp -rcb- , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugn , drugn , drugb , or drugn .
DDI-MedLine.d190.s2.p3	AAV2	drug_n	_	chondroitin ABC lyase	drug_n	_	false	druga containing cdna encoding enhanced green fluorescent protein -lcb- gfp -rcb- , under the control of a chicken - actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugn , drugn , drugn , or drugb .
DDI-MedLine.d190.s5.p0	heparinase III	drug_n	_	chondroitin ABC lyase	drug_n	_	false	the addition of druga or drugb greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina .
DDI-MedLine.d190.s6.p0	Hyaluronan lyase	drug_n	_	collagenase	drug_n	_	false	druga had a limited effect and drugb was ineffective .
DDI-MedLine.d190.s7.p0	heparinase III	drug_n	_	chondroitin ABC lyase	drug_n	_	false	electroretinograms survived with higher concentrations of druga and drugb than were required for optimal retinal transduction .
DDI-MedLine.d190.s8.p0	AAV2	drug_n	_	heparinase III	drug_n	_	effect	druga - mediated retinal transduction is improved by co-injection of drugb or drugn .
DDI-MedLine.d190.s8.p1	AAV2	drug_n	_	chondroitin ABC lyase	drug_n	_	effect	druga - mediated retinal transduction is improved by co-injection of drugn or drugb .
DDI-MedLine.d190.s8.p2	heparinase III	drug_n	_	chondroitin ABC lyase	drug_n	_	false	drugn - mediated retinal transduction is improved by co-injection of druga or drugb .
DDI-MedLine.d199.s0.p0	ketamine	drug	_	propofol	drug	_	false	prevention of emergence agitation in seven children receiving low-dose druga and drugb total intravenous anesthesia .
DDI-MedLine.d199.s2.p0	ketamine	drug	_	propofol	drug	_	false	we retrospectively reviewed the records of # pediatric oncology patients who received low-dose druga in conjunction with drugb for total intravenous anesthesia -lcb- tiva -rcb- repeatedly for radiation therapy .
DDI-MedLine.d199.s3.p0	propofol	drug	_	ketamine	drug	_	false	ea signs were observed in all # patients in association with druga tiva but did not recur in any of # subsequent anesthetics sessions during which low-dose drugb was added to drugn .
DDI-MedLine.d199.s3.p2	ketamine	drug	_	propofol	drug	_	false	ea signs were observed in all # patients in association with drugn tiva but did not recur in any of # subsequent anesthetics sessions during which low-dose druga was added to drugb .
DDI-MedLine.d199.s4.p0	ketamine	drug	_	propofol	drug	_	effect	based on this experience , we suggest that low-dose druga added to drugb may be associated with prevention of ea in children with a history of ea with drugn tiva .
DDI-MedLine.d199.s4.p1	ketamine	drug	_	propofol	drug	_	false	based on this experience , we suggest that low-dose druga added to drugn may be associated with prevention of ea in children with a history of ea with drugb tiva .
DDI-MedLine.d209.s1.p0	Tamoxifen	drug	_	estrogen antagonist	group	_	false	druga , an drugb , is the standard hormone treatment for breast cancer .
DDI-MedLine.d209.s5.p0	Paroxetine	drug	_	fluoxetine	drug	_	false	druga and drugb reduce the plasma concentration of drugn by about 50 % .
DDI-MedLine.d209.s5.p1	Paroxetine	drug	_	endoxifen	drug_n	_	mechanism	druga and drugn reduce the plasma concentration of drugb by about 50 % .
DDI-MedLine.d209.s5.p2	fluoxetine	drug	_	endoxifen	drug_n	_	mechanism	drugn and druga reduce the plasma concentration of drugb by about 50 % .
DDI-MedLine.d209.s9.p0	tamoxifen	drug	_	SSRI antidepressants	group	_	advise	it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with druga for breast cancer , especially drugb such as drugn and drugn .
DDI-MedLine.d209.s9.p1	tamoxifen	drug	_	paroxetine	drug	_	advise	it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with druga for breast cancer , especially drugn such as drugb and drugn .
DDI-MedLine.d209.s9.p2	tamoxifen	drug	_	fluoxetine	drug	_	advise	it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with druga for breast cancer , especially drugn such as drugn and drugb .
DDI-MedLine.d209.s9.p3	SSRI antidepressants	group	_	paroxetine	drug	_	false	it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with drugn for breast cancer , especially druga such as drugb and drugn .
DDI-MedLine.d209.s9.p4	SSRI antidepressants	group	_	fluoxetine	drug	_	false	it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with drugn for breast cancer , especially druga such as drugn and drugb .
DDI-MedLine.d209.s9.p5	paroxetine	drug	_	fluoxetine	drug	_	false	it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with drugn for breast cancer , especially drugn such as druga and drugb .
DDI-MedLine.d209.s10.p0	antidepressant drug	group	_	antidepressants	group	_	false	depression does not always require druga therapy , and drugb have no proven preventive impact on hot flushes linked to the menopause .
DDI-MedLine.d209.s11.p0	antidepressant	group	_	tamoxifen	drug	_	advise	if in certain cases , an druga is considered necessary , it may be advisable to replace drugb with drugn .
DDI-MedLine.d209.s11.p1	antidepressant	group	_	anastrozole	drug	_	false	if in certain cases , an druga is considered necessary , it may be advisable to replace drugn with drugb .
DDI-MedLine.d209.s11.p2	tamoxifen	drug	_	anastrozole	drug	_	false	if in certain cases , an drugn is considered necessary , it may be advisable to replace druga with drugb .
DDI-MedLine.d184.s0.p0	Amphetamine	drug	_	quinpirole	drug_n	_	false	druga locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with drugb .
DDI-MedLine.d184.s2.p0	quinpirole	drug_n	_	amphetamine	drug	_	false	the objective was to analyze the effects of neonatal druga treatment on effects of drugb in adolescent rats using locomotor sensitization and conditioned place preference procedures .
DDI-MedLine.d184.s5.p0	quinpirole	drug_n	_	amphetamine	drug	_	effect	in female rats , neonatal druga treatment enhanced drugb locomotor sensitization compared with drugn - free controls sensitized to drugn .
DDI-MedLine.d184.s5.p2	quinpirole	drug_n	_	amphetamine	drug	_	false	in female rats , neonatal druga treatment enhanced drugn locomotor sensitization compared with drugn - free controls sensitized to drugb .
DDI-MedLine.d184.s5.p3	amphetamine	drug	_	quinpirole	drug_n	_	false	in female rats , neonatal drugn treatment enhanced druga locomotor sensitization compared with drugb - free controls sensitized to drugn .
DDI-MedLine.d184.s5.p5	quinpirole	drug_n	_	amphetamine	drug	_	false	in female rats , neonatal drugn treatment enhanced drugn locomotor sensitization compared with druga - free controls sensitized to drugb .
DDI-MedLine.d184.s6.p0	amphetamine	drug	_	quinpirole	drug_n	_	false	male rats demonstrated sensitization to druga , although this was muted compared with female rats , and were unaffected by neonatal drugb .
DDI-MedLine.d184.s8.p0	quinpirole	drug_n	_	amphetamine	drug	_	false	rats treated with neonatal druga enhanced time spent in the drugb - paired context compared with drugn - free controls conditioned with drugn , but only female controls conditioned with drugn spent more time in the drug-paired context compared with saline-treated controls .
DDI-MedLine.d184.s8.p2	quinpirole	drug_n	_	amphetamine	drug	_	false	rats treated with neonatal druga enhanced time spent in the drugn - paired context compared with drugn - free controls conditioned with drugb , but only female controls conditioned with drugn spent more time in the drug-paired context compared with saline-treated controls .
DDI-MedLine.d184.s8.p3	quinpirole	drug_n	_	amphetamine	drug	_	false	rats treated with neonatal druga enhanced time spent in the drugn - paired context compared with drugn - free controls conditioned with drugn , but only female controls conditioned with drugb spent more time in the drug-paired context compared with saline-treated controls .
DDI-MedLine.d184.s8.p4	amphetamine	drug	_	quinpirole	drug_n	_	false	rats treated with neonatal drugn enhanced time spent in the druga - paired context compared with drugb - free controls conditioned with drugn , but only female controls conditioned with drugn spent more time in the drug-paired context compared with saline-treated controls .
DDI-MedLine.d184.s8.p7	quinpirole	drug_n	_	amphetamine	drug	_	false	rats treated with neonatal drugn enhanced time spent in the drugn - paired context compared with druga - free controls conditioned with drugb , but only female controls conditioned with drugn spent more time in the drug-paired context compared with saline-treated controls .
DDI-MedLine.d184.s8.p8	quinpirole	drug_n	_	amphetamine	drug	_	false	rats treated with neonatal drugn enhanced time spent in the drugn - paired context compared with druga - free controls conditioned with drugn , but only female controls conditioned with drugb spent more time in the drug-paired context compared with saline-treated controls .
DDI-MedLine.d213.s0.p0	cyclosporine	drug	_	tacrolimus	drug	_	false	in vivo cyp3a activity is significantly lower in druga - treated as compared with drugb - treated renal allograft recipients .
DDI-MedLine.d213.s1.p0	cyclosporine	drug	_	tacrolimus	drug	_	false	in vitro studies have identified druga and drugb as cytochrome_p450_family_3_subfamily_a inhibitors .
DDI-MedLine.d213.s3.p0	midazolam	drug	_	cyclosporine	drug	_	mechanism	systemic and apparent oral druga clearance were 24 % -lcb- 269 # vs , # # ml/min , p = # -rcb- and 31 % -lcb- 479 # vs , # # ml/min , p = # -rcb- , respectively , lower in drugb - treated patients -lcb- n = 20 -rcb- than in matched drugn - treated patients -lcb- n = 20 -rcb- .
DDI-MedLine.d213.s3.p1	midazolam	drug	_	tacrolimus	drug	_	false	systemic and apparent oral druga clearance were 24 % -lcb- 269 # vs , # # ml/min , p = # -rcb- and 31 % -lcb- 479 # vs , # # ml/min , p = # -rcb- , respectively , lower in drugn - treated patients -lcb- n = 20 -rcb- than in matched drugb - treated patients -lcb- n = 20 -rcb- .
DDI-MedLine.d213.s3.p2	cyclosporine	drug	_	tacrolimus	drug	_	false	systemic and apparent oral drugn clearance were 24 % -lcb- 269 # vs , # # ml/min , p = # -rcb- and 31 % -lcb- 479 # vs , # # ml/min , p = # -rcb- , respectively , lower in druga - treated patients -lcb- n = 20 -rcb- than in matched drugb - treated patients -lcb- n = 20 -rcb- .
DDI-MedLine.d213.s4.p0	midazolam	drug	_	tacrolimus	drug	_	false	the latter displayed druga clearances similar to those in two larger cohorts of nonmatched drugb - treated patients -lcb- n = # and n = 80 -rcb- and to those receiving a drugn - free regimen -lcb- n = 6 -rcb- .
DDI-MedLine.d213.s4.p1	midazolam	drug	_	calcineurin inhibitor	group	_	false	the latter displayed druga clearances similar to those in two larger cohorts of nonmatched drugn - treated patients -lcb- n = # and n = 80 -rcb- and to those receiving a drugb - free regimen -lcb- n = 6 -rcb- .
DDI-MedLine.d213.s4.p2	tacrolimus	drug	_	calcineurin inhibitor	group	_	false	the latter displayed drugn clearances similar to those in two larger cohorts of nonmatched druga - treated patients -lcb- n = # and n = 80 -rcb- and to those receiving a drugb - free regimen -lcb- n = 6 -rcb- .
DDI-MedLine.d213.s5.p0	cyclosporine	drug	_	tacrolimus	drug	_	false	this implies that in vivo hepatic and first-pass cyp3a activities are significantly lower in patients receiving druga than in those receiving drugb , indicating that , at the doses generally used in clinical practice , drugn is the stronger of the two with respect to cytochrome_p450_family_3_subfamily_a inhibition .
DDI-MedLine.d213.s5.p2	tacrolimus	drug	_	cyclosporine	drug	_	false	this implies that in vivo hepatic and first-pass cyp3a activities are significantly lower in patients receiving drugn than in those receiving druga , indicating that , at the doses generally used in clinical practice , drugb is the stronger of the two with respect to cytochrome_p450_family_3_subfamily_a inhibition .
DDI-MedLine.d166.s0.p0	cinacalcet	drug	_	darbepoetin	drug	_	false	improved parathyroid hormone control by druga is associated with reduction in drugb requirement in patients with end-stage renal disease .
DDI-MedLine.d166.s2.p0	cinacalcet	drug	_	darbepoetin	drug	_	false	medical treatment with druga is effective in reducing plasma pth -lcb- pth -rcb- levels , but its effect on drugb dosing is unknown .
DDI-MedLine.d166.s6.p0	darbepoetin	drug	_	cinacalcet	drug	_	false	the primary objective of the study was to ascertain the difference in druga responsiveness before and after # months of drugb therapy .
DDI-MedLine.d166.s17.p0	cinacalcet	drug	_	darbepoetin	drug	_	effect	reduction of pth by druga is associated with a decrease in drugb requirement .
DDI-MedLine.d217.s0.p0	celecoxib	drug	_	anti-cancer drugs	group	_	effect	interaction of druga with different drugb is antagonistic in breast but not in other cancer cells .
DDI-MedLine.d217.s2.p0	cyclooxygenase-2 inhibitors	group	_	chemotherapeutic agents	group	_	false	this study investigates the ability of druga to sensitize cells from different origins to several drugb .
DDI-MedLine.d217.s5.p1	celecoxib	drug	_	doxorubicin	drug	_	false	we found antagonism between druga and the four drugs in the breast_cancer cells mcf7 following all incubation schedules and between drugn and drugb in all cell_line except for two combinations in hct116 cells .
DDI-MedLine.d217.s5.p2	celecoxib	drug	_	doxorubicin	drug	_	effect	we found antagonism between drugn and the four drugs in the breast_cancer cells mcf7 following all incubation schedules and between druga and drugb in all cell_line except for two combinations in hct116 cells .
DDI-MedLine.d217.s11.p0	celecoxib	drug	_	doxorubicin	drug	_	false	these results , if confirmed in-vivo , indicate that druga is not a suitable chemosensitizer for breast_cancer or with drugb for other cancers .
DDI-MedLine.d143.s0.p0	clopidogrel	drug	_	proton pump inhibitors	group	_	false	-lsb- interaction between druga and drugb -rsb- .
DDI-MedLine.d143.s1.p0	proton pump inhibitors	group	_	clopidogrel	drug	_	false	the drug interaction between druga and drugb has been the subject of much study in recent years .
DDI-MedLine.d143.s2.p0	proton pump inhibitors	group	_	clopidogrel	drug	_	false	contradictory results regarding the effect of druga on platelet reactivity and on clinical outcome in drugb - treated patients have been reported in literature .
DDI-MedLine.d143.s3.p0	omeprazole	drug	_	clopidogrel	drug	_	mechanism	concomitant use of druga and drugb was found to decrease the exposure -lcb- auc -rcb- to clopidogrel 's active metabolite by 50 % and to sharply increase platelet reactivity , as a result of inhibition by drugn of cyp2c19 , a cytochrome cyp2b6 -lcb- cyp -rcb- enzyme .
DDI-MedLine.d143.s3.p2	clopidogrel	drug	_	omeprazole	drug	_	false	concomitant use of drugn and druga was found to decrease the exposure -lcb- auc -rcb- to clopidogrel 's active metabolite by 50 % and to sharply increase platelet reactivity , as a result of inhibition by drugb of cyp2c19 , a cytochrome cyp2b6 -lcb- cyp -rcb- enzyme .
DDI-MedLine.d143.s4.p0	Pantoprazole	drug	_	clopidogrel	drug	_	mechanism	druga has a much weaker effect on drugb 's pharmacokinetics and on platelet reactivity during concomitant use .
DDI-MedLine.d143.s5.p0	proton pump inhibitors	group	_	clopidogrel	drug	_	false	the influence of the other druga when used simultaneously with drugb has not yet been investigated in adequately randomized studies .
DDI-MedLine.d143.s6.p0	clopidogrel	drug	_	omeprazole	drug	_	advise	regulatory agencies state that the combination of druga and the cyp2c19 inhibitors drugb and drugn should be avoided .
DDI-MedLine.d143.s6.p1	clopidogrel	drug	_	esomeprazole	drug	_	advise	regulatory agencies state that the combination of druga and the cyp2c19 inhibitors drugn and drugb should be avoided .
DDI-MedLine.d143.s7.p0	proton pump inhibitors	group	_	clopidogrel	drug	_	false	to date , there is no conclusive evidence of a clinically-relevant interaction between any of the druga and drugb .
DDI-MedLine.d163.s0.p0	minocycline	drug	_	fosfomycin	drug	_	false	in vitro activity of druga combined with drugb against clinical isolates of drugn - resistant staphylococcus aureus .
DDI-MedLine.d163.s0.p1	minocycline	drug	_	methicillin	drug	_	false	in vitro activity of druga combined with drugn against clinical isolates of drugb - resistant staphylococcus aureus .
DDI-MedLine.d163.s0.p2	fosfomycin	drug	_	methicillin	drug	_	false	in vitro activity of drugn combined with druga against clinical isolates of drugb - resistant staphylococcus aureus .
DDI-MedLine.d163.s1.p0	minocycline	drug	_	fosfomycin	drug	_	false	this study aimed to evaluate the in vitro activity of druga combined with drugb against isolates of drugn - resistant staphylococcus aureus -lcb- mrsa -rcb- .
DDI-MedLine.d163.s1.p1	minocycline	drug	_	methicillin	drug	_	false	this study aimed to evaluate the in vitro activity of druga combined with drugn against isolates of drugb - resistant staphylococcus aureus -lcb- mrsa -rcb- .
DDI-MedLine.d163.s1.p2	fosfomycin	drug	_	methicillin	drug	_	false	this study aimed to evaluate the in vitro activity of drugn combined with druga against isolates of drugb - resistant staphylococcus aureus -lcb- mrsa -rcb- .
DDI-MedLine.d163.s4.p0	minocycline	drug	_	fosfomycin	drug	_	false	the susceptibility results for druga and drugb were interpreted according to the most relevant criteria .
DDI-MedLine.d163.s7.p0	minocycline	drug	_	fosfomycin	drug	_	effect	the combination of druga and drugb can be synergistic against mrsa .
DDI-MedLine.d181.s4.p0	levothyroxine	drug	_	simeticone	drug	_	int	the authors report the case of an infant with confirmed congenital hypothyroidism on druga who experienced a possible drug interaction with drugb .
DDI-MedLine.d181.s6.p0	Infacol	brand	_	levothyroxine	drug	_	false	questioning revealed the child was taking druga drops before feeds while on drugb .
DDI-MedLine.d181.s8.p0	thyroxine	drug	_	simeticone	drug	_	false	drug interaction of druga with drugb has not been reported previously and is not listed in the british national formulary for children .
DDI-MedLine.d169.s0.p0	Calcium	drug	_	nonheme iron	drug	_	false	druga does not inhibit the absorption of # milligrams of drugb or drugn at doses less than # milligrams in nonpregnant women .
DDI-MedLine.d169.s0.p1	Calcium	drug	_	heme iron	drug	_	false	druga does not inhibit the absorption of # milligrams of drugn or drugb at doses less than # milligrams in nonpregnant women .
DDI-MedLine.d169.s1.p0	Calcium	drug	_	nonheme iron	drug	_	mechanism	druga is the only known component in the diet that may affect absorption of both drugb and drugn .
DDI-MedLine.d169.s1.p1	Calcium	drug	_	heme iron	drug	_	mechanism	druga is the only known component in the diet that may affect absorption of both drugn and drugb .
DDI-MedLine.d169.s2.p0	calcium	drug	_	iron	drug	_	mechanism	however , the evidence for a druga effect on drugb absorption mainly comes from studies that did not isolate the effect of drugn from that of other dietary components , because it was detected in single-meal studies .
DDI-MedLine.d169.s2.p2	iron	drug	_	calcium	drug	_	false	however , the evidence for a drugn effect on druga absorption mainly comes from studies that did not isolate the effect of drugb from that of other dietary components , because it was detected in single-meal studies .
DDI-MedLine.d169.s3.p0	calcium	drug	_	nonheme iron	drug	_	false	our objective was to establish potential effects of druga on absorption of drugb and drugn n and the dose response for this effect in the absence of a meal .
DDI-MedLine.d169.s3.p1	calcium	drug	_	heme iron	drug	_	false	our objective was to establish potential effects of druga on absorption of drugn and drugb n and the dose response for this effect in the absence of a meal .
DDI-MedLine.d169.s5.p0	calcium	drug	_	nonheme iron	drug	_	false	we evaluated the effects of druga doses between # and # mg on absorption of # mg drugb -lcb- as drugn -rcb- .
DDI-MedLine.d169.s5.p1	calcium	drug	_	ferrous sulfate	drug	_	false	we evaluated the effects of druga doses between # and # mg on absorption of # mg drugn -lcb- as drugb -rcb- .
DDI-MedLine.d169.s6.p0	calcium	drug	_	heme iron	drug	_	false	we also evaluated the effects of druga doses between # and # mg on absorption of # mg drugb -lsb- as concentrated rbc -lcb- crbc -rcb- -rsb- .
DDI-MedLine.d169.s7.p1	Calcium	drug	_	minerals	group	_	false	druga was administered as drugn in all studies and drugb were ingested on an empty stomach .
DDI-MedLine.d169.s7.p2	calcium chloride	drug	_	minerals	group	_	false	drugn was administered as druga in all studies and drugb were ingested on an empty stomach .
DDI-MedLine.d169.s8.p0	Calcium	drug	_	nonheme iron	drug	_	mechanism	druga doses # mg diminished drugb absorption by an average of # % .
DDI-MedLine.d169.s9.p0	calcium	drug	_	heme iron	drug	_	mechanism	a druga dose of # mg diminished absorption of # mg drugb by # % .
DDI-MedLine.d169.s10.p0	calcium	drug	_	nonheme iron	drug	_	mechanism	in conclusion , we demonstrated an isolated effect of druga -lcb- as chloride -rcb- on absorption of # mg of iron provided as drugb -lcb- as sulfate -rcb- and drugn -lcb- as crbc -rcb- .
DDI-MedLine.d169.s10.p1	calcium	drug	_	heme iron	drug	_	mechanism	in conclusion , we demonstrated an isolated effect of druga -lcb- as chloride -rcb- on absorption of # mg of iron provided as drugn -lcb- as sulfate -rcb- and drugb -lcb- as crbc -rcb- .
DDI-MedLine.d179.s0.p0	sunitinib	drug	_	docetaxel	drug	_	int	synergistic interaction between druga and drugb is sequence dependent in human non-small lung_cancer with egfr tkis-resistant mutation .
DDI-MedLine.d179.s2.p1	sunitinib	drug	_	docetaxel	drug	_	false	this study was aimed to investigate the efficacy of single use of druga and that of concurrent or sequential administration of drugn and drugb in non-small_cell_lung_cancer cell lines that are resistant to egfr tkis .
DDI-MedLine.d179.s2.p2	sunitinib	drug	_	docetaxel	drug	_	false	this study was aimed to investigate the efficacy of single use of drugn and that of concurrent or sequential administration of druga and drugb in non-small_cell_lung_cancer cell lines that are resistant to egfr tkis .
DDI-MedLine.d179.s5.p0	Sunitinib	drug	_	docetaxel	drug	_	false	druga exhibited dose-dependent growth inhibition in non-small_cell_lung_cancer cell lines and arrested cell cycle at g1 phase , whereas drugb arrested at s phase .
DDI-MedLine.d179.s6.p0	sunitinib	drug	_	docetaxel	drug	_	effect	although single or concurrent use of druga and drugb has some anti-proliferative effects , the sequential administrations of both drugs remarkably enhanced anti-tumor activity .
DDI-MedLine.d179.s7.p0	docetaxel	drug	_	sunitinib	drug	_	effect	when cells were exposed to druga followed by drugb , synergism was observed .
DDI-MedLine.d179.s8.p0	docetaxel	drug	_	sunitinib	drug	_	effect	the molecular basis of this synergism is that the signaling pathways that were initially activated by druga exposure were efficiently suppressed by the subsequent exposure to drugb .
DDI-MedLine.d179.s10.p0	Sunitinib	drug	_	docetaxel	drug	_	false	druga as a single agent exhibits anti-proliferative effects in vitro in non-small_cell_lung_cancer cell lines with egfr t790m and k-ras mutations but the sequential administration of drugb followed by drugn is superior to drugn followed by drugn and concurrent administration .
DDI-MedLine.d179.s10.p3	Sunitinib	drug	_	docetaxel	drug	_	false	druga as a single agent exhibits anti-proliferative effects in vitro in non-small_cell_lung_cancer cell lines with egfr t790m and k-ras mutations but the sequential administration of drugn followed by drugn is superior to drugn followed by drugb and concurrent administration .
DDI-MedLine.d179.s10.p4	docetaxel	drug	_	sunitinib	drug	_	effect	drugn as a single agent exhibits anti-proliferative effects in vitro in non-small_cell_lung_cancer cell lines with egfr t790m and k-ras mutations but the sequential administration of druga followed by drugb is superior to drugn followed by drugn and concurrent administration .
DDI-MedLine.d179.s10.p5	docetaxel	drug	_	sunitinib	drug	_	false	drugn as a single agent exhibits anti-proliferative effects in vitro in non-small_cell_lung_cancer cell lines with egfr t790m and k-ras mutations but the sequential administration of druga followed by drugn is superior to drugb followed by drugn and concurrent administration .
DDI-MedLine.d179.s10.p8	sunitinib	drug	_	docetaxel	drug	_	false	drugn as a single agent exhibits anti-proliferative effects in vitro in non-small_cell_lung_cancer cell lines with egfr t790m and k-ras mutations but the sequential administration of drugn followed by druga is superior to drugn followed by drugb and concurrent administration .
DDI-MedLine.d179.s10.p9	sunitinib	drug	_	docetaxel	drug	_	false	drugn as a single agent exhibits anti-proliferative effects in vitro in non-small_cell_lung_cancer cell lines with egfr t790m and k-ras mutations but the sequential administration of drugn followed by drugn is superior to druga followed by drugb and concurrent administration .
DDI-MedLine.d204.s0.p0	piperacillin	drug	_	methylglyoxal	drug_n	_	false	distinct synergistic action of druga and drugb against pseudomonas aeruginosa .
DDI-MedLine.d204.s9.p0	methylglyoxal	drug_n	_	piperacillin	drug	_	effect	distinct and statistically significant synergism was observed between druga and drugb by disc diffusion tests when compared with their individual effects .
DDI-MedLine.d204.s11.p0	methylglyoxal	drug_n	_	carbenicillin	drug	_	effect	synergism was also noted when druga was combined with drugb and drugn .
DDI-MedLine.d204.s11.p1	methylglyoxal	drug_n	_	amikacin	drug	_	effect	synergism was also noted when druga was combined with drugn and drugb .
DDI-MedLine.d204.s11.p2	carbenicillin	drug	_	amikacin	drug	_	false	synergism was also noted when drugn was combined with druga and drugb .
DDI-MedLine.d159.s0.p0	acetyl-l-carnitine	drug	_	alpha lipoic acid	drug_n	_	false	protective effect of druga and drugb against the acute toxicity of diepoxybutane to human lymphocytes .
DDI-MedLine.d159.s6.p0	acetyl-l-carnitine	drug	_	alpha-lipoic acid	drug	_	effect	-lcb- ii -rcb- druga elicits a significant protective effect on deb induced toxicity , which was potentiated by drugb .
DDI-MedLine.d214.s0.p0	hemantane	drug_n	_	doxycycline	drug	_	false	-lsb- influence of druga and drugb on mptp-evoked behavior violations in c57bl/6 mice -rsb- .
DDI-MedLine.d214.s1.p0	anti-parkinsonian drug	group	_	hemantane	drug_n	_	false	the effects of druga drugb -lsb- drugn -rsb- -lcb- 10 mg/kg , p , o.
DDI-MedLine.d214.s1.p1	anti-parkinsonian drug	group	_	(2-adamantyl)hexamethylenimine	drug_n	_	false	the effects of druga drugn -lsb- drugb -rsb- -lcb- 10 mg/kg , p , o.
DDI-MedLine.d214.s1.p2	hemantane	drug_n	_	(2-adamantyl)hexamethylenimine	drug_n	_	false	the effects of drugn druga -lsb- drugb -rsb- -lcb- 10 mg/kg , p , o.
DDI-MedLine.d214.s2.p0	antibiotic drug	group	_	doxycycline	drug	_	false	and/or druga drugb -lcb- 100 mg/kg , p , o , -rcb- , as well as that of neurotoxin drugn -lcb- drugn -rcb- -lcb- 4 x # mg/kg , i , p.
DDI-MedLine.d214.s2.p1	antibiotic drug	group	_	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	drug_n	_	false	and/or druga drugn -lcb- 100 mg/kg , p , o , -rcb- , as well as that of neurotoxin drugb -lcb- drugn -rcb- -lcb- 4 x # mg/kg , i , p.
DDI-MedLine.d214.s2.p2	antibiotic drug	group	_	MPTP	drug_n	_	false	and/or druga drugn -lcb- 100 mg/kg , p , o , -rcb- , as well as that of neurotoxin drugn -lcb- drugb -rcb- -lcb- 4 x # mg/kg , i , p.
DDI-MedLine.d214.s2.p3	doxycycline	drug	_	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	drug_n	_	false	and/or drugn druga -lcb- 100 mg/kg , p , o , -rcb- , as well as that of neurotoxin drugb -lcb- drugn -rcb- -lcb- 4 x # mg/kg , i , p.
DDI-MedLine.d214.s2.p4	doxycycline	drug	_	MPTP	drug_n	_	false	and/or drugn druga -lcb- 100 mg/kg , p , o , -rcb- , as well as that of neurotoxin drugn -lcb- drugb -rcb- -lcb- 4 x # mg/kg , i , p.
DDI-MedLine.d214.s5.p0	hemantane	drug_n	_	doxycycline	drug	_	effect	acute administration of druga or drugb failed to influence locomotion in mice , while their combination normalized motor activity .
DDI-MedLine.d194.s0.p0	dasatinib	drug	_	paclitaxel	drug	_	effect	the role of p27 -lcb- kip1 -rcb- in druga - enhanced drugb cytotoxicity in human ovarian_cancer cells .
DDI-MedLine.d194.s4.p0	dasatinib	drug	_	paclitaxel	drug	_	false	the effect of druga , an inhibitor of src and abl1 kinases , on drugb sensitivity was measured in ovarian_cancer cells and hey xenografts .
DDI-MedLine.d194.s5.p0	dasatinib	drug	_	paclitaxel	drug	_	false	the roles of p27 -lcb- kip1 -rcb- , bcl-2 , and cdk1 in apoptosis induced by druga and drugb were assessed using a terminal deoxynucleotidyl transferase-mediated dutp nick-end labeling -lcb- tunel -rcb- assay , sirna knockdown of gene expression , transfection with bcl-2 and cdk1 expression vectors , and flow cytometry .
DDI-MedLine.d194.s9.p0	dasatinib	drug	_	paclitaxel	drug	_	effect	hey cells treated with druga plus drugb formed fewer colonies than did cells treated with either agent alone .
DDI-MedLine.d194.s10.p0	dasatinib	drug	_	paclitaxel	drug	_	effect	treatment of hey xenograft-bearing mice with druga plus drugb inhibited tumor growth more than treatment with either agent alone -lcb- average tumor volume per mouse , drugn + drugn vs drugn : # vs , # cm3 , difference = # cm3 , 95 % confidence interval -lsb- ci -rsb- = # to # cm3 , p = # -rcb- ;
DDI-MedLine.d194.s10.p2	dasatinib	drug	_	paclitaxel	drug	_	false	treatment of hey xenograft-bearing mice with druga plus drugn inhibited tumor growth more than treatment with either agent alone -lcb- average tumor volume per mouse , drugn + drugb vs drugn : # vs , # cm3 , difference = # cm3 , 95 % confidence interval -lsb- ci -rsb- = # to # cm3 , p = # -rcb- ;
DDI-MedLine.d194.s10.p3	dasatinib	drug	_	paclitaxel	drug	_	false	treatment of hey xenograft-bearing mice with druga plus drugn inhibited tumor growth more than treatment with either agent alone -lcb- average tumor volume per mouse , drugn + drugn vs drugb : # vs , # cm3 , difference = # cm3 , 95 % confidence interval -lsb- ci -rsb- = # to # cm3 , p = # -rcb- ;
DDI-MedLine.d194.s10.p4	paclitaxel	drug	_	dasatinib	drug	_	false	treatment of hey xenograft-bearing mice with drugn plus druga inhibited tumor growth more than treatment with either agent alone -lcb- average tumor volume per mouse , drugb + drugn vs drugn : # vs , # cm3 , difference = # cm3 , 95 % confidence interval -lsb- ci -rsb- = # to # cm3 , p = # -rcb- ;
DDI-MedLine.d194.s10.p7	dasatinib	drug	_	paclitaxel	drug	_	false	treatment of hey xenograft-bearing mice with drugn plus drugn inhibited tumor growth more than treatment with either agent alone -lcb- average tumor volume per mouse , druga + drugb vs drugn : # vs , # cm3 , difference = # cm3 , 95 % confidence interval -lsb- ci -rsb- = # to # cm3 , p = # -rcb- ;
DDI-MedLine.d194.s10.p8	dasatinib	drug	_	paclitaxel	drug	_	false	treatment of hey xenograft-bearing mice with drugn plus drugn inhibited tumor growth more than treatment with either agent alone -lcb- average tumor volume per mouse , druga + drugn vs drugb : # vs , # cm3 , difference = # cm3 , 95 % confidence interval -lsb- ci -rsb- = # to # cm3 , p = # -rcb- ;
DDI-MedLine.d194.s11.p0	dasatinib	drug	_	paclitaxel	drug	_	false	druga + drugb vs.
DDI-MedLine.d194.s15.p0	dasatinib	drug	_	paclitaxel	drug	_	false	the sirna knockdown of p27 -lcb- kip1 -rcb- decreased druga - and drugb - induced apoptosis compared with a negative control sirna -lcb- sub-g1 fraction , control sirna vs , p27 -lcb- kip1 -rcb- sirna : # % vs , # % , difference = # % , 95 % ci = # % to # % , p = # -rcb- .
DDI-MedLine.d194.s16.p0	dasatinib	drug	_	paclitaxel	drug	_	effect	studies with forced expression and sirna knockdown of bcl-2 and cdk1 suggest that druga - mediated induction of p27 -lcb- kip1 -rcb- enhanced drugb - induced apoptosis by negatively regulating bcl2 and cdk1 expression .
DDI-MedLine.d194.s17.p0	dasatinib	drug	_	paclitaxel	drug	_	effect	inhibition of src family and abl kinases with either sirnas or druga enhances drugb sensitivity of ovarian_cancer cells through p27 -lcb- kip1 -rcb- - mediated suppression of bcl-2 and cdk1 expression .
DDI-MedLine.d211.s0.p0	lenalidomide	drug	_	CCI-779	drug	_	false	phase i trial of druga and drugb in patients with relapsed multiple myeloma : evidence for drugn - drugn interaction via p-glycoprotein .
DDI-MedLine.d211.s0.p2	lenalidomide	drug	_	CCI-779	drug	_	false	phase i trial of druga and drugn in patients with relapsed multiple myeloma : evidence for drugn - drugb interaction via p-glycoprotein .
DDI-MedLine.d211.s0.p3	CCI-779	drug	_	lenalidomide	drug	_	false	phase i trial of drugn and druga in patients with relapsed multiple myeloma : evidence for drugb - drugn interaction via p-glycoprotein .
DDI-MedLine.d211.s0.p5	lenalidomide	drug	_	CCI-779	drug	_	false	phase i trial of drugn and drugn in patients with relapsed multiple myeloma : evidence for druga - drugb interaction via p-glycoprotein .
DDI-MedLine.d211.s2.p0	lenalidomide	drug	_	CCI-779	drug	_	effect	the preclinical combination of druga with the mtor_inhibitor drugb has displayed synergy in vitro and represents a novel combination in mm .
DDI-MedLine.d154.s0.p0	avian influenza vaccines	group	_	ginseng stem-and-leaf saponins	drug_n	_	false	enhancement of humoral immune responses to inactivated newcastle disease and druga by oral administration of drugb in chickens .
DDI-MedLine.d154.s2.p1	ginseng stem-and-leaf saponins	drug_n	_	inactivated ND vaccines	drug	_	false	the objective of this study was to evaluate the effect of oral administration of druga -lcb- drugn -rcb- on the humoral immune responses of chickens to drugb and drugn .
DDI-MedLine.d154.s2.p2	ginseng stem-and-leaf saponins	drug_n	_	inactivated AI vaccines	drug	_	false	the objective of this study was to evaluate the effect of oral administration of druga -lcb- drugn -rcb- on the humoral immune responses of chickens to drugn and drugb .
DDI-MedLine.d154.s2.p3	GSLS	drug_n	_	inactivated ND vaccines	drug	_	false	the objective of this study was to evaluate the effect of oral administration of drugn -lcb- druga -rcb- on the humoral immune responses of chickens to drugb and drugn .
DDI-MedLine.d154.s2.p4	GSLS	drug_n	_	inactivated AI vaccines	drug	_	false	the objective of this study was to evaluate the effect of oral administration of drugn -lcb- druga -rcb- on the humoral immune responses of chickens to drugn and drugb .
DDI-MedLine.d154.s3.p0	GSLS	drug_n	_	inactivated ND vaccine	drug	_	false	in experiment 1 , oral administration of druga at a dose of # mg/kg of bw for # d on the immune response in chickens intramuscularly injected with drugb was evaluated .
DDI-MedLine.d154.s5.p0	GSLS	drug_n	_	inactivated AI vaccines	drug	_	effect	in experiment 2 , the same regimen of druga was administered to chickens inoculated with drugb , and an enhanced serum antibody response to ai vaccination was also observed .
DDI-MedLine.d147.s0.p0	dacarbazine	drug	_	imexon	drug_n	_	false	interaction of druga and drugb , in vitro and in vivo , in human a-375 melanoma cells .
DDI-MedLine.d147.s1.p1	dacarbazine	drug	_	imexon	drug	_	false	we evaluated mechanisms of interaction between the alkyating agent druga -lcb- drugn -rcb- and the pro-oxidant , drugb , in the human a-375 melanoma cell line .
DDI-MedLine.d147.s1.p2	DTIC	drug	_	imexon	drug	_	false	we evaluated mechanisms of interaction between the alkyating agent drugn -lcb- druga -rcb- and the pro-oxidant , drugb , in the human a-375 melanoma cell line .
DDI-MedLine.d147.s2.p0	DTIC	drug	_	imexon	drug	_	false	the effect of druga and drugb , alone and in combination , was evaluated for growth inhibition -lcb- mtt -rcb- , radiolabeled drug uptake , cellular thiol content -lcb- hplc -rcb- , and dna strand breaks -lcb- comet assay -rcb- .
DDI-MedLine.d147.s6.p0	imexon	drug	_	DTIC	drug	_	false	there was a > 75 % reduction in cellular glutathione and cysteine with druga but not drugb .
DDI-MedLine.d147.s8.p0	Imexon	drug	_	dacarbazine	drug	_	effect	druga and drugb show additive effects in vitro but not in vivo in human a-375 melanoma cells .
DDI-MedLine.d164.s0.p0	Lapatinib	drug	_	herceptin	brand	_	effect	druga enhances drugb - mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface erbb2 expression .
DDI-MedLine.d164.s1.p0	lapatinib	drug	_	Herceptin	brand	_	effect	although it was previously reported that druga combined with drugb improved the progression-free survival rate compared with drugn alone for patients with drugn - refractory her2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
DDI-MedLine.d164.s1.p2	lapatinib	drug	_	Herceptin	brand	_	false	although it was previously reported that druga combined with drugn improved the progression-free survival rate compared with drugn alone for patients with drugb - refractory her2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
DDI-MedLine.d164.s1.p3	Herceptin	brand	_	lapatinib	drug	_	false	although it was previously reported that drugn combined with druga improved the progression-free survival rate compared with drugb alone for patients with drugn - refractory her2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
DDI-MedLine.d164.s1.p5	lapatinib	drug	_	Herceptin	brand	_	false	although it was previously reported that drugn combined with drugn improved the progression-free survival rate compared with druga alone for patients with drugb - refractory her2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
DDI-MedLine.d164.s2.p0	lapatinib	drug	_	Herceptin	brand	_	false	we evaluated how druga interacts with drugb in her2-positive breast cancer , with a particular focus on drugn - mediated antibody-dependent cellular cytotoxicity -lcb- adcc -rcb- .
DDI-MedLine.d164.s2.p1	lapatinib	drug	_	Herceptin	brand	_	false	we evaluated how druga interacts with drugn in her2-positive breast cancer , with a particular focus on drugb - mediated antibody-dependent cellular cytotoxicity -lcb- adcc -rcb- .
DDI-MedLine.d164.s3.p0	lapatinib	drug	_	Herceptin	brand	_	effect	in an in vitro assay , druga induced erbb2 expression at the cell surface of her2-positive breast cancer cell lines , leading to the enhancement of drugb - mediated adcc .
DDI-MedLine.d164.s4.p0	Herceptin	brand	_	lapatinib	drug	_	effect	furthermore , we present a case report in which a second druga treatment following drugb resulted in the marked shrinkage of multiple metastatic tumors in her2-positive breast cancer .
DDI-MedLine.d164.s5.p0	Lapatinib	drug	_	Herceptin	brand	_	false	druga may have the potential to convert drugb - refractory to drugn - sensitive tumors in her2-positive breast_cancer by up-regulation of the cell surface expression of her2 .
DDI-MedLine.d164.s5.p1	Lapatinib	drug	_	Herceptin	brand	_	false	druga may have the potential to convert drugn - refractory to drugb - sensitive tumors in her2-positive breast_cancer by up-regulation of the cell surface expression of her2 .
DDI-MedLine.d201.s5.p0	CRM197	drug_n	_	anticancer agent	group	_	false	we elucidated the expression of hb-egf in t-all cell lines , and evaluated the effect of druga on these cells alone or in combination with drugb .
DDI-MedLine.d201.s9.p1	CRM197	drug_n	_	doxorubicin	drug	_	false	druga induced apoptosis , and furthermore , the combination of drugn plus drugb enhanced cytotoxicity in a t-all cell line .
DDI-MedLine.d201.s9.p2	CRM197	drug_n	_	doxorubicin	drug	_	effect	drugn induced apoptosis , and furthermore , the combination of druga plus drugb enhanced cytotoxicity in a t-all cell line .
DDI-MedLine.d227.s0.p0	Ephedrine	drug	_	dexmedetomidine	drug	_	effect	druga enhances the antinociceptive effect of drugb in mice .
DDI-MedLine.d227.s2.p0	ephedrine	drug	_	dexmedetomidine	drug	_	false	the purpose of this study was to evaluate whether the psychostimulant drug druga has any effect on drugb - induced antinociception and locomotor inhibitor activity in mice in acute application .
DDI-MedLine.d227.s6.p0	ephedrine	drug	_	dexmedetomidine	drug	_	false	saline + saline , druga -lcb- 10 mg/kg -rcb- + saline , saline + drugb -lcb- 15 g/kg -rcb- and drugn -lcb- 10 mg/kg -rcb- + drugn -lcb- 15 g/kg -rcb- , intraperitoneally , # min before hot plate or holed open field tests .
DDI-MedLine.d227.s6.p2	ephedrine	drug	_	dexmedetomidine	drug	_	false	saline + saline , druga -lcb- 10 mg/kg -rcb- + saline , saline + drugn -lcb- 15 g/kg -rcb- and drugn -lcb- 10 mg/kg -rcb- + drugb -lcb- 15 g/kg -rcb- , intraperitoneally , # min before hot plate or holed open field tests .
DDI-MedLine.d227.s6.p3	dexmedetomidine	drug	_	ephedrine	drug	_	false	saline + saline , drugn -lcb- 10 mg/kg -rcb- + saline , saline + druga -lcb- 15 g/kg -rcb- and drugb -lcb- 10 mg/kg -rcb- + drugn -lcb- 15 g/kg -rcb- , intraperitoneally , # min before hot plate or holed open field tests .
DDI-MedLine.d227.s6.p5	ephedrine	drug	_	dexmedetomidine	drug	_	false	saline + saline , drugn -lcb- 10 mg/kg -rcb- + saline , saline + drugn -lcb- 15 g/kg -rcb- and druga -lcb- 10 mg/kg -rcb- + drugb -lcb- 15 g/kg -rcb- , intraperitoneally , # min before hot plate or holed open field tests .
DDI-MedLine.d227.s7.p0	dexmedetomidine	drug	_	ephedrine	drug	_	effect	in the hot plate test in mice , co-administration of # g/kg druga with # mg/kg drugb intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by drugn .
DDI-MedLine.d227.s7.p2	ephedrine	drug	_	dexmedetomidine	drug	_	false	in the hot plate test in mice , co-administration of # g/kg drugn with # mg/kg druga intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by drugb .
DDI-MedLine.d227.s8.p0	dexmedetomidine	drug	_	ephedrine	drug	_	effect	at the same time , the locomotor inhibitory effect of druga was counteracted by drugb .
DDI-MedLine.d227.s9.p0	dexmedetomidine	drug	_	ephedrine	drug	_	effect	we concluded that the combined administration of druga with drugb may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugn as an drugn in humans .
DDI-MedLine.d227.s9.p2	dexmedetomidine	drug	_	analgesic	group	_	false	we concluded that the combined administration of druga with drugn may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugn as an drugb in humans .
DDI-MedLine.d227.s9.p3	ephedrine	drug	_	dexmedetomidine	drug	_	false	we concluded that the combined administration of drugn with druga may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugb as an drugn in humans .
DDI-MedLine.d227.s9.p4	ephedrine	drug	_	analgesic	group	_	false	we concluded that the combined administration of drugn with druga may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugn as an drugb in humans .
DDI-MedLine.d227.s9.p5	dexmedetomidine	drug	_	analgesic	group	_	false	we concluded that the combined administration of drugn with drugn may have beneficial effects in the treatment of pain without causing sedation , which limits the use of druga as an drugb in humans .
DDI-MedLine.d200.s8.p1	amlodipine	drug	_	antihypertensive drugs	group	_	false	but the use of fixed combination druga / drugn compared with traditional therapy was associated with lower clinical and self measured bp , quicker achievement of target bp -lcb- # + / # and # + / # days , respectively , # -rcb- , lesser number of drugb -lcb- # + / # and # + / # days , respectively -rcb- , lower rate of concealed inefficacy of treatment -lcb- 12 and 31 % , respectively , # -rcb- .
DDI-MedLine.d200.s8.p2	valsartan	drug	_	antihypertensive drugs	group	_	false	but the use of fixed combination drugn / druga compared with traditional therapy was associated with lower clinical and self measured bp , quicker achievement of target bp -lcb- # + / # and # + / # days , respectively , # -rcb- , lesser number of drugb -lcb- # + / # and # + / # days , respectively -rcb- , lower rate of concealed inefficacy of treatment -lcb- 12 and 31 % , respectively , # -rcb- .
DDI-MedLine.d200.s10.p1	amlodipine	drug	_	antihypertensive drugs	group	_	false	we have demonstrated appropriateness of inhospital administration of fixed druga / drugn combination as an approach allowing to achieve target bp in shorter time , with the use of fewer drugb , and diminishing concealed inefficacy of treatment .
DDI-MedLine.d200.s10.p2	valsartan	drug	_	antihypertensive drugs	group	_	false	we have demonstrated appropriateness of inhospital administration of fixed drugn / druga combination as an approach allowing to achieve target bp in shorter time , with the use of fewer drugb , and diminishing concealed inefficacy of treatment .
DDI-MedLine.d193.s0.p1	Ticagrelor	drug	_	clopidogrel	drug	_	false	druga -lcb- drugn -rcb- -- better than drugb -lcb- drugn -rcb-
DDI-MedLine.d193.s0.p2	Ticagrelor	drug	_	Plavix	brand	_	false	druga -lcb- drugn -rcb- -- better than drugn -lcb- drugb -rcb-
DDI-MedLine.d193.s0.p3	Brilinta	brand	_	clopidogrel	drug	_	false	drugn -lcb- druga -rcb- -- better than drugb -lcb- drugn -rcb-
DDI-MedLine.d193.s0.p4	Brilinta	brand	_	Plavix	brand	_	false	drugn -lcb- druga -rcb- -- better than drugn -lcb- drugb -rcb-
DDI-MedLine.d193.s1.p1	ticagrelor	drug	_	antiplatelet drug	group	_	false	the fda has approved druga -lcb- drugn - astrazeneca -rcb- , an oral drugb , for use with low-dose drugn to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome -lcb- acs -rcb- .
DDI-MedLine.d193.s1.p2	ticagrelor	drug	_	aspirin	brand	_	effect	the fda has approved druga -lcb- drugn - astrazeneca -rcb- , an oral drugn , for use with low-dose drugb to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome -lcb- acs -rcb- .
DDI-MedLine.d193.s1.p3	Brilinta	brand	_	antiplatelet drug	group	_	false	the fda has approved drugn -lcb- druga - astrazeneca -rcb- , an oral drugb , for use with low-dose drugn to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome -lcb- acs -rcb- .
DDI-MedLine.d193.s1.p4	Brilinta	brand	_	aspirin	brand	_	effect	the fda has approved drugn -lcb- druga - astrazeneca -rcb- , an oral drugn , for use with low-dose drugb to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome -lcb- acs -rcb- .
DDI-MedLine.d193.s1.p5	antiplatelet drug	group	_	aspirin	brand	_	false	the fda has approved drugn -lcb- drugn - astrazeneca -rcb- , an oral druga , for use with low-dose drugb to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome -lcb- acs -rcb- .
DDI-MedLine.d193.s2.p1	clopidogrel	drug	_	prasugrel	drug	_	false	it will compete with druga -lcb- drugn -rcb- and drugb -lcb- drugn -rcb- for such use .
DDI-MedLine.d193.s2.p2	clopidogrel	drug	_	Effient	brand	_	false	it will compete with druga -lcb- drugn -rcb- and drugn -lcb- drugb -rcb- for such use .
DDI-MedLine.d193.s2.p3	Plavix	brand	_	prasugrel	drug	_	false	it will compete with drugn -lcb- druga -rcb- and drugb -lcb- drugn -rcb- for such use .
DDI-MedLine.d193.s2.p4	Plavix	brand	_	Effient	brand	_	false	it will compete with drugn -lcb- druga -rcb- and drugn -lcb- drugb -rcb- for such use .
DDI-MedLine.d195.s0.p0	piperine	drug_n	_	ibuprofen	drug	_	false	influence of druga on drugb induced antinociception and its pharmacokinetics .
DDI-MedLine.d195.s4.p0	piperine	drug_n	_	ibuprofen	drug	_	effect	in the present study druga -lcb- 10 mg/kg -rcb- significantly increased the dose-dependent antinociceptive activity of drugb evaluated by both drugn writhing and formalin test , when it was administered with drugn .
DDI-MedLine.d195.s4.p1	piperine	drug_n	_	acetic acid	drug	_	false	in the present study druga -lcb- 10 mg/kg -rcb- significantly increased the dose-dependent antinociceptive activity of drugn evaluated by both drugb writhing and formalin test , when it was administered with drugn .
DDI-MedLine.d195.s4.p2	piperine	drug_n	_	ibuprofen	drug	_	false	in the present study druga -lcb- 10 mg/kg -rcb- significantly increased the dose-dependent antinociceptive activity of drugn evaluated by both drugn writhing and formalin test , when it was administered with drugb .
DDI-MedLine.d195.s4.p3	ibuprofen	drug	_	acetic acid	drug	_	false	in the present study drugn -lcb- 10 mg/kg -rcb- significantly increased the dose-dependent antinociceptive activity of druga evaluated by both drugb writhing and formalin test , when it was administered with drugn .
DDI-MedLine.d195.s4.p5	acetic acid	drug	_	ibuprofen	drug	_	false	in the present study drugn -lcb- 10 mg/kg -rcb- significantly increased the dose-dependent antinociceptive activity of drugn evaluated by both druga writhing and formalin test , when it was administered with drugb .
DDI-MedLine.d195.s5.p0	Ibuprofen	drug	_	piperine	drug_n	_	mechanism	druga plasma concentration was also increased when it was administered with drugb .
DDI-MedLine.d195.s6.p0	ibuprofen	drug	_	piperine	drug_n	_	mechanism	the synergistic antinociception activity of druga when administered with drugb can be attributed to increased plasma concentration of drugn .
DDI-MedLine.d195.s6.p2	piperine	drug_n	_	ibuprofen	drug	_	false	the synergistic antinociception activity of drugn when administered with druga can be attributed to increased plasma concentration of drugb .
DDI-MedLine.d195.s7.p0	piperine	drug_n	_	ibuprofen	drug	_	effect	from this study it can be concluded that druga can be used as a bioenhancer along with drugb .
DDI-DrugBank.d610.s0.p0	abacavir	drug	_	lamivudine	drug	_	false	pharmacokinetic properties of druga were not altered by the addition of either drugb or drugn or the combination of drugn and drugn .
DDI-DrugBank.d610.s0.p1	abacavir	drug	_	zidovudine	drug	_	false	pharmacokinetic properties of druga were not altered by the addition of either drugn or drugb or the combination of drugn and drugn .
DDI-DrugBank.d610.s0.p2	abacavir	drug	_	lamivudine	drug	_	false	pharmacokinetic properties of druga were not altered by the addition of either drugn or drugn or the combination of drugb and drugn .
DDI-DrugBank.d610.s0.p3	abacavir	drug	_	zidovudine	drug	_	false	pharmacokinetic properties of druga were not altered by the addition of either drugn or drugn or the combination of drugn and drugb .
DDI-DrugBank.d610.s0.p4	lamivudine	drug	_	zidovudine	drug	_	false	pharmacokinetic properties of drugn were not altered by the addition of either druga or drugb or the combination of drugn and drugn .
DDI-DrugBank.d610.s0.p6	lamivudine	drug	_	zidovudine	drug	_	false	pharmacokinetic properties of drugn were not altered by the addition of either druga or drugn or the combination of drugn and drugb .
DDI-DrugBank.d610.s0.p7	zidovudine	drug	_	lamivudine	drug	_	false	pharmacokinetic properties of drugn were not altered by the addition of either drugn or druga or the combination of drugb and drugn .
DDI-DrugBank.d610.s0.p9	lamivudine	drug	_	zidovudine	drug	_	false	pharmacokinetic properties of drugn were not altered by the addition of either drugn or drugn or the combination of druga and drugb .
DDI-DrugBank.d610.s1.p0	lamivudine	drug	_	zidovudine	drug	_	false	no clinically significant changes to druga or drugb pharmacokinetics were observed following concomitant administration of drugn .
DDI-DrugBank.d610.s1.p1	lamivudine	drug	_	abacavir	drug	_	false	no clinically significant changes to druga or drugn pharmacokinetics were observed following concomitant administration of drugb .
DDI-DrugBank.d610.s1.p2	zidovudine	drug	_	abacavir	drug	_	false	no clinically significant changes to drugn or druga pharmacokinetics were observed following concomitant administration of drugb .
DDI-DrugBank.d610.s2.p0	Abacavir	drug	_	ethanol	drug	_	false	druga has no effect on the pharmacokinetic properties of drugb .
DDI-DrugBank.d610.s3.p0	Ethanol	drug	_	abacavir	drug	_	mechanism	druga decreases the elimination of drugb causing an increase in overall exposure , the addition of drugn has no clinically significant effect on the pharmacokinetic properties of drugn .
DDI-DrugBank.d610.s3.p5	methadone	drug	_	abacavir	drug	_	false	drugn decreases the elimination of drugn causing an increase in overall exposure , the addition of druga has no clinically significant effect on the pharmacokinetic properties of drugb .
DDI-DrugBank.d610.s4.p0	methadone	drug	_	ZIAGEN	brand	_	mechanism	in a study of # hiv-infected patients receiving druga - maintenance therapy -lcb- 40 mg and # mg daily -rcb- with # mg of drugb twice daily -lcb- twice the currently recommended dose -rcb- , oral drugn clearance increased 22 % -lcb- 90 % ci 6 % to 42 % -rcb- .
DDI-DrugBank.d610.s4.p2	ZIAGEN	brand	_	methadone	drug	_	false	in a study of # hiv-infected patients receiving drugn - maintenance therapy -lcb- 40 mg and # mg daily -rcb- with # mg of druga twice daily -lcb- twice the currently recommended dose -rcb- , oral drugb clearance increased 22 % -lcb- 90 % ci 6 % to 42 % -rcb- .
DDI-DrugBank.d572.s0.p1	Cholestyramine	drug	_	ezetimibe	drug	_	false	druga : concomitant drugn administration decreased the mean auc of total drugb approximately 55 % .
DDI-DrugBank.d572.s0.p2	cholestyramine	drug	_	ezetimibe	drug	_	mechanism	drugn : concomitant druga administration decreased the mean auc of total drugb approximately 55 % .
DDI-DrugBank.d572.s1.p0	ezetimibe	drug	_	cholestyramine	drug	_	effect	the incremental ldl-c reduction due to adding druga to drugb may be reduced by this interaction .
DDI-DrugBank.d572.s2.p2	ezetimibe	drug	_	fibrates	group	_	false	drugn : the safety and effectiveness of druga administered with drugb have not been established .
DDI-DrugBank.d572.s5.p0	ZETIA	brand	_	fibrates	group	_	advise	co-administration of druga with drugb is not recommended until use in patients is studied .
DDI-DrugBank.d572.s6.p1	Fenofibrate	drug	_	ezetimibe	drug	_	false	druga : in a pharmacokinetic study , concomitant drugn administration increased total drugb concentrations approximately # - fold .
DDI-DrugBank.d572.s6.p2	fenofibrate	drug	_	ezetimibe	drug	_	mechanism	drugn : in a pharmacokinetic study , concomitant druga administration increased total drugb concentrations approximately # - fold .
DDI-DrugBank.d572.s7.p1	Gemfibrozil	drug	_	ezetimibe	drug	_	false	druga : in a pharmacokinetic study , concomitant drugn administration increased total drugb concentrations approximately # - fold .
DDI-DrugBank.d572.s7.p2	gemfibrozil	drug	_	ezetimibe	drug	_	false	drugn : in a pharmacokinetic study , concomitant druga administration increased total drugb concentrations approximately # - fold .
DDI-DrugBank.d572.s8.p6	ezetimibe	drug	_	atorvastatin	drug	_	false	drugn : no clinically significant pharmacokinetic interactions were seen when druga was co-administered with drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d572.s8.p7	ezetimibe	drug	_	simvastatin	drug	_	false	drugn : no clinically significant pharmacokinetic interactions were seen when druga was co-administered with drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d572.s8.p8	ezetimibe	drug	_	pravastatin	drug	_	false	drugn : no clinically significant pharmacokinetic interactions were seen when druga was co-administered with drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d572.s8.p9	ezetimibe	drug	_	lovastatin	drug	_	false	drugn : no clinically significant pharmacokinetic interactions were seen when druga was co-administered with drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d572.s8.p10	ezetimibe	drug	_	fluvastatin	drug	_	false	drugn : no clinically significant pharmacokinetic interactions were seen when druga was co-administered with drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d572.s9.p2	ezetimibe	drug	_	cyclosporine	drug	_	mechanism	drugn : the total druga level increased 12-fold in one renal transplant patient receiving multiple medications , including drugb .
DDI-DrugBank.d572.s10.p0	ezetimibe	drug	_	cyclosporine	drug	_	advise	patients who take both druga and drugb should be carefully monitored .
DDI-DrugBank.d572.s24.p0	ezetimibe	drug	_	HMG-CoA reductase inhibitors	group	_	false	multiple dose studies of druga given in combination with drugb -lcb- drugn -rcb- in rats and rabbits during organogenesis result in higher drugn and staticor exposures .
DDI-DrugBank.d572.s24.p1	ezetimibe	drug	_	statins	group	_	false	multiple dose studies of druga given in combination with drugn -lcb- drugb -rcb- in rats and rabbits during organogenesis result in higher drugn and staticor exposures .
DDI-DrugBank.d572.s24.p4	HMG-CoA reductase inhibitors	group	_	ezetimibe	drug	_	false	multiple dose studies of drugn given in combination with druga -lcb- drugn -rcb- in rats and rabbits during organogenesis result in higher drugb and staticor exposures .
DDI-DrugBank.d572.s24.p5	statins	group	_	ezetimibe	drug	_	false	multiple dose studies of drugn given in combination with drugn -lcb- druga -rcb- in rats and rabbits during organogenesis result in higher drugb and staticor exposures .
DDI-DrugBank.d572.s27.p0	ZETIA	brand	_	HMG-CoA reductase inhibitor	group	_	false	when druga is administered with an drugb in a woman of childbearing potential , refer to the pregnancy category and package labeling for the drugn .
DDI-DrugBank.d572.s27.p1	ZETIA	brand	_	HMG-CoA reductase inhibitor	drug	_	false	when druga is administered with an drugn in a woman of childbearing potential , refer to the pregnancy category and package labeling for the drugb .
DDI-DrugBank.d776.s2.p0	hypoglycemics	group	_	Coumarin-type anticoagulants	group	_	false	these are described in greater detail below : oral druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p1	hypoglycemics	group	_	Phenytoin	drug	_	false	these are described in greater detail below : oral druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p2	hypoglycemics	group	_	Cyclosporine	drug	_	false	these are described in greater detail below : oral druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p5	hypoglycemics	group	_	Terfenadine	drug	_	false	these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p6	hypoglycemics	group	_	Cisapride	drug	_	false	these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p7	hypoglycemics	group	_	Astemizole	drug	_	false	these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p8	hypoglycemics	group	_	Rifabutin	drug	_	false	these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p9	hypoglycemics	group	_	Tacrolimus	drug	_	false	these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p10	hypoglycemics	group	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p14	Coumarin-type anticoagulants	group	_	Phenytoin	drug	_	false	these are described in greater detail below : oral drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p15	Coumarin-type anticoagulants	group	_	Cyclosporine	drug	_	false	these are described in greater detail below : oral drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p16	Coumarin-type anticoagulants	group	_	Rifampin	drug	_	false	these are described in greater detail below : oral drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p17	Coumarin-type anticoagulants	group	_	Theophylline	drug	_	false	these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p18	Coumarin-type anticoagulants	group	_	Terfenadine	drug	_	false	these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p19	Coumarin-type anticoagulants	group	_	Cisapride	drug	_	false	these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p20	Coumarin-type anticoagulants	group	_	Astemizole	drug	_	false	these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p21	Coumarin-type anticoagulants	group	_	Rifabutin	drug	_	false	these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p22	Coumarin-type anticoagulants	group	_	Tacrolimus	drug	_	false	these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p23	Coumarin-type anticoagulants	group	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p24	Coumarin-type anticoagulants	group	_	hypoglycemics	group	_	false	these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p27	Phenytoin	drug	_	Cyclosporine	drug	_	false	these are described in greater detail below : oral drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p30	Phenytoin	drug	_	Terfenadine	drug	_	false	these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p31	Phenytoin	drug	_	Cisapride	drug	_	false	these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p32	Phenytoin	drug	_	Astemizole	drug	_	false	these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p33	Phenytoin	drug	_	Rifabutin	drug	_	false	these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p34	Phenytoin	drug	_	Tacrolimus	drug	_	false	these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p35	Phenytoin	drug	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p36	Phenytoin	drug	_	hypoglycemics	group	_	false	these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p41	Cyclosporine	drug	_	Terfenadine	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p42	Cyclosporine	drug	_	Cisapride	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p43	Cyclosporine	drug	_	Astemizole	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p44	Cyclosporine	drug	_	Rifabutin	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p45	Cyclosporine	drug	_	Tacrolimus	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p46	Cyclosporine	drug	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p47	Cyclosporine	drug	_	hypoglycemics	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p54	Rifampin	drug	_	Rifabutin	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p55	Rifampin	drug	_	Tacrolimus	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p56	Rifampin	drug	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p63	Theophylline	drug	_	Rifabutin	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p64	Theophylline	drug	_	Tacrolimus	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p65	Theophylline	drug	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p71	Terfenadine	drug	_	Rifabutin	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p72	Terfenadine	drug	_	Tacrolimus	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p73	Terfenadine	drug	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p78	Cisapride	drug	_	Rifabutin	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p79	Cisapride	drug	_	Tacrolimus	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p80	Cisapride	drug	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p84	Astemizole	drug	_	Rifabutin	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p85	Astemizole	drug	_	Tacrolimus	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p86	Astemizole	drug	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p90	Rifabutin	drug	_	Tacrolimus	drug	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p91	Rifabutin	drug	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p92	Rifabutin	drug	_	hypoglycemics	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p95	Tacrolimus	drug	_	Short-acting benzodiazepines	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p96	Tacrolimus	drug	_	hypoglycemics	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p99	Short-acting benzodiazepines	group	_	hypoglycemics	group	_	false	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
DDI-DrugBank.d776.s2.p104	DIFLUCAN	brand	_	hypoglycemic agents	group	_	effect	these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of druga with oral drugb ;
DDI-DrugBank.d776.s3.p0	DIFLUCAN	brand	_	glyburide	drug	_	effect	one fatality has been reported from hypoglycemia in association with combined druga and drugb use .
DDI-DrugBank.d776.s4.p0	DIFLUCAN	brand	_	tolbutamide	drug	_	mechanism	druga reduces the metabolism of drugb , drugn , and drugn and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4.p1	DIFLUCAN	brand	_	glyburide	drug	_	mechanism	druga reduces the metabolism of drugn , drugb , and drugn and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4.p2	DIFLUCAN	brand	_	glipizide	drug	_	mechanism	druga reduces the metabolism of drugn , drugn , and drugb and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s5.p0	DIFLUCAN	brand	_	sulfonylurea oral hypoglycemic agents	group	_	advise	when druga is used concomitantly with these or other drugb , blood glucose concentrations should be carefully monitored and the dose of the drugn should be adjusted as necessary .
DDI-DrugBank.d776.s5.p1	DIFLUCAN	brand	_	sulfonylurea	group	_	false	when druga is used concomitantly with these or other drugn , blood glucose concentrations should be carefully monitored and the dose of the drugb should be adjusted as necessary .
DDI-DrugBank.d776.s6.p2	DIFLUCAN	brand	_	coumarin-type anticoagulants	group	_	effect	drugn : prothrombin time may be increased in patients receiving concomitant druga and drugb .
DDI-DrugBank.d776.s7.p0	azole antifungals	group	_	fluconazole	drug	_	false	in post-marketing experience , as with other druga , bleeding events -lcb- bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena -rcb- have been reported in association with increases in prothrombin time in patients receiving drugb concurrently with drugn .
DDI-DrugBank.d776.s7.p1	azole antifungals	group	_	warfarin	drug	_	false	in post-marketing experience , as with other druga , bleeding events -lcb- bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena -rcb- have been reported in association with increases in prothrombin time in patients receiving drugn concurrently with drugb .
DDI-DrugBank.d776.s7.p2	fluconazole	drug	_	warfarin	drug	_	effect	in post-marketing experience , as with other drugn , bleeding events -lcb- bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena -rcb- have been reported in association with increases in prothrombin time in patients receiving druga concurrently with drugb .
DDI-DrugBank.d776.s8.p0	DIFLUCAN	brand	_	coumarin-type anticoagulants	group	_	advise	careful monitoring of prothrombin time in patients receiving druga and drugb is recommended .
DDI-DrugBank.d776.s10.p2	DIFLUCAN	brand	_	phenytoin	drug	_	mechanism	drugn : druga increases the plasma concentrations of drugb .
DDI-DrugBank.d776.s11.p0	phenytoin	drug	_	DIFLUCAN	brand	_	false	careful monitoring of druga concentrations in patients receiving drugb and drugn is recommended .
DDI-DrugBank.d776.s11.p2	DIFLUCAN	brand	_	phenytoin	drug	_	advise	careful monitoring of drugn concentrations in patients receiving druga and drugb is recommended .
DDI-DrugBank.d776.s13.p2	DIFLUCAN	brand	_	cyclosporine	drug	_	mechanism	drugn : druga may significantly increase drugb levels in renal transplant patients with or without renal impairment .
DDI-DrugBank.d776.s14.p0	cyclosporine	drug	_	DIFLUCAN	brand	_	false	careful monitoring of druga concentrations and serum creatinine is recommended in patients receiving drugb and drugn .
DDI-DrugBank.d776.s14.p2	DIFLUCAN	brand	_	cyclosporine	drug	_	advise	careful monitoring of drugn concentrations and serum creatinine is recommended in patients receiving druga and drugb .
DDI-DrugBank.d776.s16.p2	Rifampin	drug	_	DIFLUCAN	brand	_	mechanism	drugn : druga enhances the metabolism of concurrently administered drugb .
DDI-DrugBank.d776.s17.p0	DIFLUCAN	brand	_	rifampin	drug	_	advise	depending on clinical circumstances , consideration should be given to increasing the dose of druga when it is administered with drugb .
DDI-DrugBank.d776.s18.p2	DIFLUCAN	brand	_	theophylline	drug	_	mechanism	drugn : druga increases the serum concentrations of drugb .
DDI-DrugBank.d776.s19.p0	theophylline	drug	_	DIFLUCAN	brand	_	false	careful monitoring of serum druga concentrations in patients receiving drugb and drugn is recommended .
DDI-DrugBank.d776.s19.p2	DIFLUCAN	brand	_	theophylline	drug	_	advise	careful monitoring of serum drugn concentrations in patients receiving druga and drugb is recommended .
DDI-DrugBank.d776.s20.p2	azole antifungals	group	_	terfenadine	drug	_	effect	drugn : because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving druga in conjunction with drugb , interaction studies have been performed .
DDI-DrugBank.d776.s22.p0	fluconazole	drug	_	DIFLUCAN	brand	_	false	another study at a 400-mg and 800-mg daily dose of druga demonstrated that drugb taken in doses of # mg per day or greater significantly increases plasma levels of drugn when taken concomitantly .
DDI-DrugBank.d776.s22.p1	fluconazole	drug	_	terfenadine	drug	_	false	another study at a 400-mg and 800-mg daily dose of druga demonstrated that drugn taken in doses of # mg per day or greater significantly increases plasma levels of drugb when taken concomitantly .
DDI-DrugBank.d776.s22.p2	DIFLUCAN	brand	_	terfenadine	drug	_	mechanism	another study at a 400-mg and 800-mg daily dose of drugn demonstrated that druga taken in doses of # mg per day or greater significantly increases plasma levels of drugb when taken concomitantly .
DDI-DrugBank.d776.s23.p0	fluconazole	drug	_	terfenadine	drug	_	advise	the combined use of druga at doses of # mg or greater with drugb is contraindicated .
DDI-DrugBank.d776.s24.p0	fluconazole	drug	_	terfenadine	drug	_	advise	the coadministration of druga at doses lower than # mg/day with drugb should be carefully monitored .
DDI-DrugBank.d776.s25.p2	fluconazole	drug	_	cisapride	drug	_	effect	drugn : there have been reports of cardiac events , including torsade de pointes in patients to whom druga and drugb were coadministered .
DDI-DrugBank.d776.s26.p0	fluconazole	drug	_	cisapride	drug	_	mechanism	a controlled study found that concomitant druga # mg once daily and drugb # mg four times a day yielded a significant increase in drugn plasma levels and prolongation of qtc interval .
DDI-DrugBank.d776.s26.p1	fluconazole	drug	_	cisapride	drug	_	false	a controlled study found that concomitant druga # mg once daily and drugn # mg four times a day yielded a significant increase in drugb plasma levels and prolongation of qtc interval .
DDI-DrugBank.d776.s27.p0	fluconazole	drug	_	cisapride	drug	_	advise	the combined use of druga with drugb is contraindicated .
DDI-DrugBank.d776.s28.p2	fluconazole	drug	_	astemizole	drug	_	mechanism	drugn : the use of druga in patients concurrently taking drugb or other drugs metabolized by the cytochrome cyp2b6 system may be associated with elevations in serum levels of these drugs .
DDI-DrugBank.d776.s31.p2	fluconazole	drug	_	rifabutin	drug	_	effect	drugn : there have been reports of uveitis in patients to whom druga and drugb were coadministered .
DDI-DrugBank.d776.s32.p0	rifabutin	drug	_	fluconazole	drug	_	advise	patients receiving druga and drugb concomitantly should be carefully monitored .
DDI-DrugBank.d776.s33.p2	fluconazole	drug	_	tacrolimus	drug	_	effect	drugn : there have been reports of nephrotoxicity in patients to whom druga and drugb were coadministered .
DDI-DrugBank.d776.s34.p0	tacrolimus	drug	_	fluconazole	drug	_	advise	patients receiving druga and drugb concomitantly should be carefully monitored .
DDI-DrugBank.d776.s35.p3	midazolam	drug	_	fluconazole	drug	_	mechanism	drugn : following oral administration of druga , drugb resulted in substantial increases in drugn concentrations and psychomotor effects .
DDI-DrugBank.d776.s35.p5	fluconazole	drug	_	midazolam	drug	_	false	drugn : following oral administration of drugn , druga resulted in substantial increases in drugb concentrations and psychomotor effects .
DDI-DrugBank.d776.s36.p0	midazolam	drug	_	fluconazole	drug	_	effect	this effect on druga appears to be more pronounced following oral administration of drugb than with drugn administered intravenously .
DDI-DrugBank.d776.s36.p1	midazolam	drug	_	fluconazole	drug	_	false	this effect on druga appears to be more pronounced following oral administration of drugn than with drugb administered intravenously .
DDI-DrugBank.d776.s37.p0	short-acting benzodiazepines	group	_	fluconazole	drug	_	advise	if druga , which are metabolized by the cytochrome cyp2b6 system , are concomitantly administered with drugb , consideration should be given to decreasing the drugn dosage , and the patients should be appropriately monitored .
DDI-DrugBank.d776.s37.p2	fluconazole	drug	_	benzodiazepine	group	_	false	if drugn , which are metabolized by the cytochrome cyp2b6 system , are concomitantly administered with druga , consideration should be given to decreasing the drugb dosage , and the patients should be appropriately monitored .
DDI-DrugBank.d776.s38.p0	Fluconazole	drug	_	ethinyl estradiol	drug	_	mechanism	druga tablets coadministered with drugb - and drugn - containing oral drugn produced an overall mean increase in drugn and drugn levels ;
DDI-DrugBank.d776.s38.p1	Fluconazole	drug	_	levonorgestrel	drug	_	mechanism	druga tablets coadministered with drugn - and drugb - containing oral drugn produced an overall mean increase in drugn and drugn levels ;
DDI-DrugBank.d776.s38.p2	Fluconazole	drug	_	contraceptives	group	_	false	druga tablets coadministered with drugn - and drugn - containing oral drugb produced an overall mean increase in drugn and drugn levels ;
DDI-DrugBank.d776.s38.p3	Fluconazole	drug	_	ethinyl estradiol	drug	_	false	druga tablets coadministered with drugn - and drugn - containing oral drugn produced an overall mean increase in drugb and drugn levels ;
DDI-DrugBank.d776.s38.p4	Fluconazole	drug	_	levonorgestrel	drug	_	false	druga tablets coadministered with drugn - and drugn - containing oral drugn produced an overall mean increase in drugn and drugb levels ;
DDI-DrugBank.d776.s38.p5	ethinyl estradiol	drug	_	levonorgestrel	drug	_	false	drugn tablets coadministered with druga - and drugb - containing oral drugn produced an overall mean increase in drugn and drugn levels ;
DDI-DrugBank.d776.s38.p6	ethinyl estradiol	drug	_	contraceptives	group	_	false	drugn tablets coadministered with druga - and drugn - containing oral drugb produced an overall mean increase in drugn and drugn levels ;
DDI-DrugBank.d776.s38.p8	ethinyl estradiol	drug	_	levonorgestrel	drug	_	false	drugn tablets coadministered with druga - and drugn - containing oral drugn produced an overall mean increase in drugn and drugb levels ;
DDI-DrugBank.d776.s38.p9	levonorgestrel	drug	_	contraceptives	group	_	false	drugn tablets coadministered with drugn - and druga - containing oral drugb produced an overall mean increase in drugn and drugn levels ;
DDI-DrugBank.d776.s38.p10	levonorgestrel	drug	_	ethinyl estradiol	drug	_	false	drugn tablets coadministered with drugn - and druga - containing oral drugn produced an overall mean increase in drugb and drugn levels ;
DDI-DrugBank.d776.s38.p12	contraceptives	group	_	ethinyl estradiol	drug	_	false	drugn tablets coadministered with drugn - and drugn - containing oral druga produced an overall mean increase in drugb and drugn levels ;
DDI-DrugBank.d776.s38.p13	contraceptives	group	_	levonorgestrel	drug	_	false	drugn tablets coadministered with drugn - and drugn - containing oral druga produced an overall mean increase in drugn and drugb levels ;
DDI-DrugBank.d776.s38.p14	ethinyl estradiol	drug	_	levonorgestrel	drug	_	false	drugn tablets coadministered with drugn - and drugn - containing oral drugn produced an overall mean increase in druga and drugb levels ;
DDI-DrugBank.d776.s39.p0	ethinyl estradiol	drug	_	levonorgestrel	drug	_	false	however , in some patients there were decreases up to 47 % and 33 % of druga and drugb levels .
DDI-DrugBank.d776.s40.p0	ethinyl estradiol	drug	_	levonorgestrel	drug	_	false	the data presently available indicate that the decreases in some individual druga and drugb auc values with drugn treatment are likely the result of random variation .
DDI-DrugBank.d776.s40.p1	ethinyl estradiol	drug	_	fluconazole	drug	_	false	the data presently available indicate that the decreases in some individual druga and drugn auc values with drugb treatment are likely the result of random variation .
DDI-DrugBank.d776.s40.p2	levonorgestrel	drug	_	fluconazole	drug	_	false	the data presently available indicate that the decreases in some individual drugn and druga auc values with drugb treatment are likely the result of random variation .
DDI-DrugBank.d776.s41.p0	fluconazole	drug	_	ethinyl estradiol	drug	_	mechanism	while there is evidence that druga can inhibit the metabolism of drugb and drugn , there is no evidence that drugn is a net inducer of drugn or drugn metabolism .
DDI-DrugBank.d776.s41.p1	fluconazole	drug	_	levonorgestrel	drug	_	mechanism	while there is evidence that druga can inhibit the metabolism of drugn and drugb , there is no evidence that drugn is a net inducer of drugn or drugn metabolism .
DDI-DrugBank.d776.s41.p3	fluconazole	drug	_	ethinyl estradiol	drug	_	false	while there is evidence that druga can inhibit the metabolism of drugn and drugn , there is no evidence that drugn is a net inducer of drugb or drugn metabolism .
DDI-DrugBank.d776.s41.p4	fluconazole	drug	_	levonorgestrel	drug	_	false	while there is evidence that druga can inhibit the metabolism of drugn and drugn , there is no evidence that drugn is a net inducer of drugn or drugb metabolism .
DDI-DrugBank.d776.s41.p5	ethinyl estradiol	drug	_	levonorgestrel	drug	_	false	while there is evidence that drugn can inhibit the metabolism of druga and drugb , there is no evidence that drugn is a net inducer of drugn or drugn metabolism .
DDI-DrugBank.d776.s41.p6	ethinyl estradiol	drug	_	fluconazole	drug	_	false	while there is evidence that drugn can inhibit the metabolism of druga and drugn , there is no evidence that drugb is a net inducer of drugn or drugn metabolism .
DDI-DrugBank.d776.s41.p8	ethinyl estradiol	drug	_	levonorgestrel	drug	_	false	while there is evidence that drugn can inhibit the metabolism of druga and drugn , there is no evidence that drugn is a net inducer of drugn or drugb metabolism .
DDI-DrugBank.d776.s41.p9	levonorgestrel	drug	_	fluconazole	drug	_	false	while there is evidence that drugn can inhibit the metabolism of drugn and druga , there is no evidence that drugb is a net inducer of drugn or drugn metabolism .
DDI-DrugBank.d776.s41.p10	levonorgestrel	drug	_	ethinyl estradiol	drug	_	false	while there is evidence that drugn can inhibit the metabolism of drugn and druga , there is no evidence that drugn is a net inducer of drugb or drugn metabolism .
DDI-DrugBank.d776.s41.p12	fluconazole	drug	_	ethinyl estradiol	drug	_	false	while there is evidence that drugn can inhibit the metabolism of drugn and drugn , there is no evidence that druga is a net inducer of drugb or drugn metabolism .
DDI-DrugBank.d776.s41.p13	fluconazole	drug	_	levonorgestrel	drug	_	false	while there is evidence that drugn can inhibit the metabolism of drugn and drugn , there is no evidence that druga is a net inducer of drugn or drugb metabolism .
DDI-DrugBank.d776.s41.p14	ethinyl estradiol	drug	_	levonorgestrel	drug	_	false	while there is evidence that drugn can inhibit the metabolism of drugn and drugn , there is no evidence that drugn is a net inducer of druga or drugb metabolism .
DDI-DrugBank.d716.s0.p0	mazindol	drug	_	monoamine oxidase inhibitor	group	_	advise	you can not take druga if you have taken a drugb -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p1	mazindol	drug	_	MAOI	group	_	advise	you can not take druga if you have taken a drugn -lcb- drugb -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p2	mazindol	drug	_	isocarboxazid	drug	_	advise	you can not take druga if you have taken a drugn -lcb- drugn -rcb- such as drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p3	mazindol	drug	_	Marplan	brand	_	advise	you can not take druga if you have taken a drugn -lcb- drugn -rcb- such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p4	mazindol	drug	_	tranylcypromine	drug	_	advise	you can not take druga if you have taken a drugn -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p5	mazindol	drug	_	Parnate	brand	_	advise	you can not take druga if you have taken a drugn -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p6	mazindol	drug	_	phenelzine	drug	_	advise	you can not take druga if you have taken a drugn -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugb -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p7	mazindol	drug	_	Nardil	brand	_	advise	you can not take druga if you have taken a drugn -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugb -rcb- in the last # days .
DDI-DrugBank.d716.s0.p9	monoamine oxidase inhibitor	group	_	isocarboxazid	drug	_	false	you can not take drugn if you have taken a druga -lcb- drugn -rcb- such as drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p10	monoamine oxidase inhibitor	group	_	Marplan	brand	_	false	you can not take drugn if you have taken a druga -lcb- drugn -rcb- such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p11	monoamine oxidase inhibitor	group	_	tranylcypromine	drug	_	false	you can not take drugn if you have taken a druga -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p12	monoamine oxidase inhibitor	group	_	Parnate	brand	_	false	you can not take drugn if you have taken a druga -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p13	monoamine oxidase inhibitor	group	_	phenelzine	drug	_	false	you can not take drugn if you have taken a druga -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugb -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p14	monoamine oxidase inhibitor	group	_	Nardil	brand	_	false	you can not take drugn if you have taken a druga -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugb -rcb- in the last # days .
DDI-DrugBank.d716.s0.p15	MAOI	group	_	isocarboxazid	drug	_	false	you can not take drugn if you have taken a drugn -lcb- druga -rcb- such as drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p16	MAOI	group	_	Marplan	brand	_	false	you can not take drugn if you have taken a drugn -lcb- druga -rcb- such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p17	MAOI	group	_	tranylcypromine	drug	_	false	you can not take drugn if you have taken a drugn -lcb- druga -rcb- such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p18	MAOI	group	_	Parnate	brand	_	false	you can not take drugn if you have taken a drugn -lcb- druga -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , or drugn -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p19	MAOI	group	_	phenelzine	drug	_	false	you can not take drugn if you have taken a drugn -lcb- druga -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugb -lcb- drugn -rcb- in the last # days .
DDI-DrugBank.d716.s0.p20	MAOI	group	_	Nardil	brand	_	false	you can not take drugn if you have taken a drugn -lcb- druga -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugb -rcb- in the last # days .
DDI-DrugBank.d716.s1.p0	insulin	drug	_	mazindol	drug	_	advise	changes in druga and other diabetes drug therapies may be necessary during treatment with drugb .
DDI-DrugBank.d716.s2.p0	Mazindol	drug	_	guanethidine	drug	_	effect	druga may reduce the effects of drugb -lcb- drugn -rcb- .
DDI-DrugBank.d716.s2.p1	Mazindol	drug	_	Ismelin	brand	_	effect	druga may reduce the effects of drugn -lcb- drugb -rcb- .
DDI-DrugBank.d716.s5.p0	tricyclic antidepressant	group	_	amitriptyline	drug	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p1	tricyclic antidepressant	group	_	Elavil	brand	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p2	tricyclic antidepressant	group	_	amoxapine	drug	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p3	tricyclic antidepressant	group	_	Asendin	brand	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p4	tricyclic antidepressant	group	_	doxepin	drug	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p5	tricyclic antidepressant	group	_	Sinequan	brand	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p6	tricyclic antidepressant	group	_	nortriptyline	drug	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p7	tricyclic antidepressant	group	_	Pamelor	brand	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p8	tricyclic antidepressant	group	_	imipramine	drug	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p9	tricyclic antidepressant	group	_	Tofranil	brand	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p10	tricyclic antidepressant	group	_	clomipramine	drug	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p11	tricyclic antidepressant	group	_	Anafranil	brand	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p12	tricyclic antidepressant	group	_	protriptyline	drug	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p13	tricyclic antidepressant	group	_	Vivactil	brand	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , or drugn -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p14	tricyclic antidepressant	group	_	desipramine	drug	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugb -lcb- drugn -rcb- .
DDI-DrugBank.d716.s5.p15	tricyclic antidepressant	group	_	Norpramin	brand	_	false	before taking this medication , tell your doctor if you are taking a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugb -rcb- .
DDI-DrugBank.d679.s0.p0	cimetidine	drug	_	mebendazole	drug	_	mechanism	preliminary evidence suggests that druga inhibits drugb metabolism and may result in an increase in plasma concentrations of drugn .
DDI-DrugBank.d679.s0.p1	cimetidine	drug	_	mebendazole	drug	_	false	preliminary evidence suggests that druga inhibits drugn metabolism and may result in an increase in plasma concentrations of drugb .
DDI-DrugBank.d579.s0.p0	antibiotics	group	_	sulfonamides	group	_	false	patients receiving druga and drugb generally should not be treated with drugn .
DDI-DrugBank.d579.s0.p1	antibiotics	group	_	ganglion blockers	group	_	advise	patients receiving druga and drugn generally should not be treated with drugb .
DDI-DrugBank.d579.s0.p2	sulfonamides	group	_	ganglion blockers	group	_	advise	patients receiving drugn and druga generally should not be treated with drugb .
DDI-DrugBank.d579.s1.p0	Mecamylamine	drug	_	antihypertensive drugs	group	_	effect	the action of druga may be potentiated by anesthesia , other drugb and drugn .
DDI-DrugBank.d579.s1.p1	Mecamylamine	drug	_	alcohol	drug	_	effect	the action of druga may be potentiated by anesthesia , other drugn and drugb .
DDI-DrugBank.d623.s1.p0	Aminoglutethimide	drug	_	depo-subQ provera 104	brand	_	mechanism	druga administered concomitantly with drugb may significantly decrease the serum concentrations of drugn .
DDI-DrugBank.d623.s1.p1	Aminoglutethimide	drug	_	MPA	drug	_	false	druga administered concomitantly with drugn may significantly decrease the serum concentrations of drugb .
DDI-DrugBank.d623.s1.p2	depo-subQ provera 104	brand	_	MPA	drug	_	false	drugn administered concomitantly with druga may significantly decrease the serum concentrations of drugb .
DDI-DrugBank.d688.s0.p0	zidovudine	drug	_	rifabutin	drug	_	false	pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of druga or drugb to warrant dosage adjustment when drugn is administered with these drugs .
DDI-DrugBank.d688.s0.p1	zidovudine	drug	_	megestrol acetate	drug	_	false	pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of druga or drugn to warrant dosage adjustment when drugb is administered with these drugs .
DDI-DrugBank.d688.s0.p2	rifabutin	drug	_	megestrol acetate	drug	_	false	pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of drugn or druga to warrant dosage adjustment when drugb is administered with these drugs .
DDI-DrugBank.d688.s1.p0	megestrol acetate	drug	_	indinavir	drug	_	mechanism	a pharmacokinetic study demonstrated that coadministration of druga and drugb results in a significant decrease in the pharmacokinetic parameters -lcb- ~ 36 % for cmax and ~ 28 % for auc -rcb- of drugn .
DDI-DrugBank.d688.s1.p1	megestrol acetate	drug	_	indinavir	drug	_	false	a pharmacokinetic study demonstrated that coadministration of druga and drugn results in a significant decrease in the pharmacokinetic parameters -lcb- ~ 36 % for cmax and ~ 28 % for auc -rcb- of drugb .
DDI-DrugBank.d688.s2.p0	indinavir	drug	_	megestrol acetate	drug	_	advise	administration of a higher dose of druga should be considered when coadministering with drugb .
DDI-DrugBank.d688.s3.p2	indinavir	drug	_	megestrol acetate	drug	_	false	the effects of druga , drugn or drugn on the pharmacokinetics of drugb were not studied .
DDI-DrugBank.d688.s3.p4	zidovudine	drug	_	megestrol acetate	drug	_	false	the effects of drugn , druga or drugn on the pharmacokinetics of drugb were not studied .
DDI-DrugBank.d688.s3.p5	rifabutin	drug	_	megestrol acetate	drug	_	false	the effects of drugn , drugn or druga on the pharmacokinetics of drugb were not studied .
DDI-DrugBank.d643.s0.p0	Melatonin	drug	_	aspirin	brand	_	int	druga may interact with the following drugs : drugb and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p1	Melatonin	drug	_	NSAIDs	group	_	int	druga may interact with the following drugs : drugn and other drugb -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p3	Melatonin	drug	_	fluvoxamine	drug	_	int	druga may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugb -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p5	Melatonin	drug	_	beta blockers	group	_	int	druga may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugb -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p7	Melatonin	drug	_	fluoxetine	drug	_	int	druga may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugb -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p8	Melatonin	drug	_	progestin	group	_	int	druga may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugb -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p10	Melatonin	drug	_	progestin	group	_	false	druga may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugb can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p11	Melatonin	drug	_	benzodiazepenes	group	_	int	druga may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugb and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p12	Melatonin	drug	_	corticosteroids	group	_	int	druga may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p14	Melatonin	drug	_	corticosteroids	group	_	false	druga may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p15	Melatonin	drug	_	corticosteroids	group	_	false	druga may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p16	aspirin	brand	_	NSAIDs	group	_	false	drugn may interact with the following drugs : druga and other drugb -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p17	aspirin	brand	_	melatonin	drug	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugb levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p18	aspirin	brand	_	fluvoxamine	drug	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugb -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p19	aspirin	brand	_	melatonin	drug	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugb is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p21	aspirin	brand	_	melatonin	drug	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugb levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p22	aspirin	brand	_	fluoxetine	drug	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugb -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p23	aspirin	brand	_	progestin	group	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugb -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p24	aspirin	brand	_	melatonin	drug	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugb with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p25	aspirin	brand	_	progestin	group	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugb can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p26	aspirin	brand	_	benzodiazepenes	group	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugb and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p27	aspirin	brand	_	corticosteroids	group	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p28	aspirin	brand	_	melatonin	drug	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugb and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p29	aspirin	brand	_	corticosteroids	group	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p30	aspirin	brand	_	corticosteroids	group	_	false	drugn may interact with the following drugs : druga and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p31	NSAIDs	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugb levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p32	NSAIDs	group	_	fluvoxamine	drug	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugb -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p33	NSAIDs	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugb is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p35	NSAIDs	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugb levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p36	NSAIDs	group	_	fluoxetine	drug	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugb -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p37	NSAIDs	group	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugb -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p38	NSAIDs	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugb with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p39	NSAIDs	group	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugb can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p40	NSAIDs	group	_	benzodiazepenes	group	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugb and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p41	NSAIDs	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p42	NSAIDs	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugb and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p43	NSAIDs	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p44	NSAIDs	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other druga -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p45	melatonin	drug	_	fluvoxamine	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower druga levels -rcb- , drugb -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p47	melatonin	drug	_	beta blockers	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower druga levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugb -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p49	melatonin	drug	_	fluoxetine	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower druga levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugb -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p50	melatonin	drug	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower druga levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugb -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p52	melatonin	drug	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower druga levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugb can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p53	melatonin	drug	_	benzodiazepenes	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower druga levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugb and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p54	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower druga levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p56	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower druga levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p57	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower druga levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p58	fluvoxamine	drug	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , druga -lcb- bioavailability of oral drugb is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p60	fluvoxamine	drug	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , druga -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugb levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p63	fluvoxamine	drug	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , druga -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugb with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p64	fluvoxamine	drug	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , druga -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugb can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p66	fluvoxamine	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , druga -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p67	fluvoxamine	drug	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , druga -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugb and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p68	fluvoxamine	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , druga -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p69	fluvoxamine	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , druga -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p70	melatonin	drug	_	beta blockers	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral druga is increased with coadministration -rcb- , drugb -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p72	melatonin	drug	_	fluoxetine	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral druga is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugb -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p73	melatonin	drug	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral druga is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugb -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p75	melatonin	drug	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral druga is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugb can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p76	melatonin	drug	_	benzodiazepenes	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral druga is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugb and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p77	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral druga is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p79	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral druga is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p80	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral druga is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p81	beta blockers	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , druga -lcb- may decrease drugb levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p84	beta blockers	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , druga -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugb with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p85	beta blockers	group	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , druga -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugb can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p87	beta blockers	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , druga -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p88	beta blockers	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , druga -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugb and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p89	beta blockers	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , druga -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p90	beta blockers	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , druga -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p91	melatonin	drug	_	fluoxetine	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease druga levels -rcb- , drugb -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p92	melatonin	drug	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease druga levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugb -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p94	melatonin	drug	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease druga levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugb can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p95	melatonin	drug	_	benzodiazepenes	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease druga levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugb and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p96	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease druga levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p98	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease druga levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p99	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease druga levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p101	fluoxetine	drug	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , druga -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugb with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p102	fluoxetine	drug	_	progestin	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , druga -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugb can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p104	fluoxetine	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , druga -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p105	fluoxetine	drug	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , druga -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugb and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p106	fluoxetine	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , druga -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p107	fluoxetine	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , druga -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p108	progestin	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , druga -lcb- coadministration of drugb with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p111	progestin	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , druga -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p112	progestin	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , druga -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugb and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p113	progestin	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , druga -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p114	progestin	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , druga -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p115	melatonin	drug	_	progestin	group	_	effect	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of druga with drugb can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p116	melatonin	drug	_	benzodiazepenes	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of druga with drugn can inhibit ovarian function in women -rcb- , drugb and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p117	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of druga with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p119	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of druga with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p120	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of druga with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p121	progestin	group	_	benzodiazepenes	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with druga can inhibit ovarian function in women -rcb- , drugb and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p122	progestin	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with druga can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p123	progestin	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with druga can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugb and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p124	progestin	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with druga can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p125	progestin	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with druga can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p126	benzodiazepenes	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , druga and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugb -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p127	benzodiazepenes	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , druga and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugb and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p128	benzodiazepenes	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , druga and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p129	benzodiazepenes	group	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , druga and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of drugn and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d643.s0.p130	corticosteroids	group	_	melatonin	drug	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and druga -lcb- coadministration of drugb and drugn may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p133	melatonin	drug	_	corticosteroids	group	_	effect	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of druga and drugb may interfere with the efficacy of the drugn -rcb- .
DDI-DrugBank.d643.s0.p134	melatonin	drug	_	corticosteroids	group	_	false	drugn may interact with the following drugs : drugn and other drugn -lcb- may lower drugn levels -rcb- , drugn -lcb- bioavailability of oral drugn is increased with coadministration -rcb- , drugn -lcb- may decrease drugn levels -rcb- , drugn -lcb- reports of psychotic episodes when coadministered -rcb- , drugn -lcb- coadministration of drugn with drugn can inhibit ovarian function in women -rcb- , drugn and other sedating drugs -lcb- may result in additive sedation and an increased incidence of adverse effects -rcb- , and drugn -lcb- coadministration of druga and drugn may interfere with the efficacy of the drugb -rcb- .
DDI-DrugBank.d597.s0.p0	ACE inhibitors	group	_	NSAIDs	group	_	false	druga reports suggest that drugb may diminish the antihypertensive effect of drugn .
DDI-DrugBank.d597.s0.p1	ACE inhibitors	group	_	angiotensin-converting enzyme (ACE) inhibitors	group	_	false	druga reports suggest that drugn may diminish the antihypertensive effect of drugb .
DDI-DrugBank.d597.s0.p2	NSAIDs	group	_	angiotensin-converting enzyme (ACE) inhibitors	group	_	effect	drugn reports suggest that druga may diminish the antihypertensive effect of drugb .
DDI-DrugBank.d597.s1.p0	NSAIDs	group	_	ACE inhibitors	group	_	advise	this interaction should be given consideration in patients taking druga concomitantly with drugb .
DDI-DrugBank.d597.s2.p1	Aspirin	brand	_	meloxicam	drug	_	false	druga : concomitant administration of drugn -lcb- 1000 mg tid -rcb- to healthy volunteers tended to increase the auc -lcb- 10 % -rcb- and cmax -lcb- 24 % -rcb- of drugb .
DDI-DrugBank.d597.s2.p2	aspirin	brand	_	meloxicam	drug	_	mechanism	drugn : concomitant administration of druga -lcb- 1000 mg tid -rcb- to healthy volunteers tended to increase the auc -lcb- 10 % -rcb- and cmax -lcb- 24 % -rcb- of drugb .
DDI-DrugBank.d597.s4.p0	NSAIDs	group	_	meloxicam	drug	_	false	however , as with other druga , concomitant administration of drugb and drugn is not generally recommended because of the potential for increased adverse effects .
DDI-DrugBank.d597.s4.p1	NSAIDs	group	_	aspirin	brand	_	advise	however , as with other druga , concomitant administration of drugn and drugb is not generally recommended because of the potential for increased adverse effects .
DDI-DrugBank.d597.s4.p2	meloxicam	drug	_	aspirin	brand	_	advise	however , as with other drugn , concomitant administration of druga and drugb is not generally recommended because of the potential for increased adverse effects .
DDI-DrugBank.d597.s5.p0	aspirin	brand	_	MOBIC	brand	_	effect	concomitant administration of low-dose druga with drugb may result in an increased rate of gi ulceration or other complications , compared to use of drugn alone .
DDI-DrugBank.d597.s5.p1	aspirin	brand	_	MOBIC	brand	_	false	concomitant administration of low-dose druga with drugn may result in an increased rate of gi ulceration or other complications , compared to use of drugb alone .
DDI-DrugBank.d597.s6.p0	MOBIC	brand	_	aspirin	brand	_	false	druga is not a substitute for drugb for cardiovascular prophylaxis .
DDI-DrugBank.d597.s7.p2	cholestyramine	drug	_	meloxicam	drug	_	mechanism	drugn : pretreatment for four days with druga significantly increased the clearance of drugb by 50 % .
DDI-DrugBank.d597.s11.p1	Cimetidine	drug	_	meloxicam	drug	_	false	druga : concomitant administration of # mg drugn qid did not alter the single-dose pharmacokinetics of # mg drugb .
DDI-DrugBank.d597.s11.p2	cimetidine	drug	_	meloxicam	drug	_	false	drugn : concomitant administration of # mg druga qid did not alter the single-dose pharmacokinetics of # mg drugb .
DDI-DrugBank.d597.s12.p2	Meloxicam	drug	_	digoxin	drug	_	false	drugn : druga # mg once daily for # days did not alter the plasma concentration profile of drugb after b-acetyldigoxin administration for # days at clinical doses .
DDI-DrugBank.d597.s13.p0	digoxin	drug	_	meloxicam	drug	_	false	in vitro testing found no protein binding drug interaction between druga and drugb .
DDI-DrugBank.d597.s14.p0	Furosemide	drug	_	NSAIDs	group	_	false	druga : clinical studies , as well as post-marketing observations , have shown that drugb can reduce the natriuretic effect of drugn and drugn in some patients .
DDI-DrugBank.d597.s14.p2	Furosemide	drug	_	thiazide diuretics	group	_	false	druga : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d597.s14.p3	NSAIDs	group	_	furosemide	drug	_	effect	drugn : clinical studies , as well as post-marketing observations , have shown that druga can reduce the natriuretic effect of drugb and drugn in some patients .
DDI-DrugBank.d597.s14.p4	NSAIDs	group	_	thiazide diuretics	group	_	effect	drugn : clinical studies , as well as post-marketing observations , have shown that druga can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d597.s14.p5	furosemide	drug	_	thiazide diuretics	group	_	false	drugn : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of druga and drugb in some patients .
DDI-DrugBank.d597.s16.p0	furosemide	drug	_	meloxicam	drug	_	false	studies with druga agents and drugb have not demonstrated a reduction in natriuretic effect .
DDI-DrugBank.d597.s17.p0	Furosemide	drug	_	meloxicam	drug	_	false	druga : single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of drugb .
DDI-DrugBank.d597.s18.p0	furosemide	drug	_	MOBIC	brand	_	advise	nevertheless , during concomitant therapy with druga and drugb , patients should be observed closely for signs of declining renal function , as well as to assure diuretic efficacy .
DDI-DrugBank.d597.s19.p0	Lithium	drug	_	NSAIDs	group	_	false	druga : in clinical trials , drugb have produced an elevation of plasma drugn levels and a reduction in renal drugn clearance .
DDI-DrugBank.d597.s19.p3	NSAIDs	group	_	lithium	drug	_	mechanism	drugn : in clinical trials , druga have produced an elevation of plasma drugb levels and a reduction in renal drugn clearance .
DDI-DrugBank.d597.s19.p4	NSAIDs	group	_	lithium	drug	_	false	drugn : in clinical trials , druga have produced an elevation of plasma drugn levels and a reduction in renal drugb clearance .
DDI-DrugBank.d597.s20.p1	lithium	drug	_	meloxicam	drug	_	false	in a study conducted in healthy subjects , mean pre-dose druga concentration and auc were increased by 21 % in subjects receiving drugn doses ranging from # to # mg bid with drugb # mg qd as compared to subjects receiving drugn alone .
DDI-DrugBank.d597.s20.p3	lithium	drug	_	meloxicam	drug	_	mechanism	in a study conducted in healthy subjects , mean pre-dose drugn concentration and auc were increased by 21 % in subjects receiving druga doses ranging from # to # mg bid with drugb # mg qd as compared to subjects receiving drugn alone .
DDI-DrugBank.d597.s20.p5	meloxicam	drug	_	lithium	drug	_	false	in a study conducted in healthy subjects , mean pre-dose drugn concentration and auc were increased by 21 % in subjects receiving drugn doses ranging from # to # mg bid with druga # mg qd as compared to subjects receiving drugb alone .
DDI-DrugBank.d597.s22.p0	lithium	drug	_	MOBIC	brand	_	advise	patients on druga treatment should be closely monitored when drugb is introduced or withdrawn .
DDI-DrugBank.d597.s23.p2	meloxicam	drug	_	methotrexate	drug	_	false	drugn : a study in # rheumatoid_arthritis -lcb- ra -rcb- patients evaluated the effects of multiple doses of druga on the pharmacokinetics of drugb taken once weekly .
DDI-DrugBank.d597.s24.p0	Meloxicam	drug	_	methotrexate	drug	_	false	druga did not have a significant effect on the pharmacokinetics of single doses of drugb .
DDI-DrugBank.d597.s25.p0	methotrexate	drug	_	meloxicam	drug	_	false	in vitro , druga did not displace drugb from its human serum binding sites .
DDI-DrugBank.d597.s26.p2	MOBIC	brand	_	warfarin	drug	_	advise	drugn : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing druga therapy in patients receiving drugb or similar agents , since these patients are at an increased risk of bleeding .
DDI-DrugBank.d597.s27.p0	meloxicam	drug	_	warfarin	drug	_	false	the effect of druga on the anticoagulant effect of drugb was studied in a group of healthy subjects receiving daily doses of drugn that produced an inr -lcb- international normalized ratio -rcb- between # and # .
DDI-DrugBank.d597.s27.p1	meloxicam	drug	_	warfarin	drug	_	false	the effect of druga on the anticoagulant effect of drugn was studied in a group of healthy subjects receiving daily doses of drugb that produced an inr -lcb- international normalized ratio -rcb- between # and # .
DDI-DrugBank.d597.s28.p0	meloxicam	drug	_	warfarin	drug	_	false	in these subjects , druga did not alter drugb pharmacokinetics and the average anticoagulant effect of drugn as determined by prothrombin time .
DDI-DrugBank.d597.s28.p1	meloxicam	drug	_	warfarin	drug	_	false	in these subjects , druga did not alter drugn pharmacokinetics and the average anticoagulant effect of drugb as determined by prothrombin time .
DDI-DrugBank.d597.s30.p0	MOBIC	brand	_	warfarin	drug	_	advise	caution should be used when administering druga with drugb since patients on drugn may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
DDI-DrugBank.d597.s30.p1	MOBIC	brand	_	warfarin	drug	_	false	caution should be used when administering druga with drugn since patients on drugb may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
DDI-DrugBank.d625.s0.p0	ALKERAN	brand	_	live organism vaccines	group	_	false	drug interactions there are no known drug/drug interactions with oral druga vaccinations with drugb are not recommended in immunocompromised individuals drugn together with high-dose intravenous drugn has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0.p1	ALKERAN	brand	_	Nalidixic acid	drug	_	false	drug interactions there are no known drug/drug interactions with oral druga vaccinations with drugn are not recommended in immunocompromised individuals drugb together with high-dose intravenous drugn has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0.p2	ALKERAN	brand	_	melphalan	drug	_	false	drug interactions there are no known drug/drug interactions with oral druga vaccinations with drugn are not recommended in immunocompromised individuals drugn together with high-dose intravenous drugb has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0.p3	live organism vaccines	group	_	Nalidixic acid	drug	_	false	drug interactions there are no known drug/drug interactions with oral drugn vaccinations with druga are not recommended in immunocompromised individuals drugb together with high-dose intravenous drugn has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0.p4	live organism vaccines	group	_	melphalan	drug	_	false	drug interactions there are no known drug/drug interactions with oral drugn vaccinations with druga are not recommended in immunocompromised individuals drugn together with high-dose intravenous drugb has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0.p5	Nalidixic acid	drug	_	melphalan	drug	_	effect	drug interactions there are no known drug/drug interactions with oral drugn vaccinations with drugn are not recommended in immunocompromised individuals druga together with high-dose intravenous drugb has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s1.p0	melphalan	drug	_	cyclosporin	drug	_	effect	impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous druga and who subsequently received drugb to prevent graft-versus-host disease
DDI-DrugBank.d585.s0.p0	anticholinergic drugs	group	_	amantadine	drug	_	effect	the following agents may increase certain actions or side effects of druga : drugb , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p1	anticholinergic drugs	group	_	antiarrhythmic agents of class I	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugb -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p2	anticholinergic drugs	group	_	quinidine	drug	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugb -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p3	anticholinergic drugs	group	_	antihistamines	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugb , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p4	anticholinergic drugs	group	_	antipsychotic agents	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugb -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p5	anticholinergic drugs	group	_	phenothiazines	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugb -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p6	anticholinergic drugs	group	_	benzodiazepines	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugb , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p7	anticholinergic drugs	group	_	MAO inhibitors	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugb , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p8	anticholinergic drugs	group	_	narcotic analgesics	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugb -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p9	anticholinergic drugs	group	_	meperidine	drug	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugb -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p10	anticholinergic drugs	group	_	nitrates	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p11	anticholinergic drugs	group	_	nitrites	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p12	anticholinergic drugs	group	_	sympathomimetic agents	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p13	anticholinergic drugs	group	_	tricyclic antidepressants	group	_	effect	the following agents may increase certain actions or side effects of druga : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p14	amantadine	drug	_	antiarrhythmic agents of class I	group	_	false	the following agents may increase certain actions or side effects of drugn : druga , drugb -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p15	amantadine	drug	_	quinidine	drug	_	false	the following agents may increase certain actions or side effects of drugn : druga , drugn -lcb- e , g , , drugb -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p20	amantadine	drug	_	MAO inhibitors	group	_	false	the following agents may increase certain actions or side effects of drugn : druga , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugb , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p23	amantadine	drug	_	nitrates	group	_	false	the following agents may increase certain actions or side effects of drugn : druga , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p24	amantadine	drug	_	nitrites	group	_	false	the following agents may increase certain actions or side effects of drugn : druga , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p25	amantadine	drug	_	sympathomimetic agents	group	_	false	the following agents may increase certain actions or side effects of drugn : druga , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p26	amantadine	drug	_	tricyclic antidepressants	group	_	false	the following agents may increase certain actions or side effects of drugn : druga , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p32	antiarrhythmic agents of class I	group	_	MAO inhibitors	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , druga -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugb , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p35	antiarrhythmic agents of class I	group	_	nitrates	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , druga -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p36	antiarrhythmic agents of class I	group	_	nitrites	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , druga -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p37	antiarrhythmic agents of class I	group	_	sympathomimetic agents	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , druga -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p38	antiarrhythmic agents of class I	group	_	tricyclic antidepressants	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , druga -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p43	quinidine	drug	_	MAO inhibitors	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , drugn -lcb- e , g , , druga -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugb , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p46	quinidine	drug	_	nitrates	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , drugn -lcb- e , g , , druga -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p47	quinidine	drug	_	nitrites	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , drugn -lcb- e , g , , druga -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p48	quinidine	drug	_	sympathomimetic agents	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , drugn -lcb- e , g , , druga -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p49	quinidine	drug	_	tricyclic antidepressants	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , drugn -lcb- e , g , , druga -rcb- , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p62	antipsychotic agents	group	_	MAO inhibitors	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , druga -lcb- e , g , , drugn -rcb- , drugn , drugb , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.p70	phenothiazines	group	_	MAO inhibitors	group	_	false	the following agents may increase certain actions or side effects of drugn : drugn , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn -lcb- e , g , , druga -rcb- , drugn , drugb , drugn -lcb- e , g , , drugn -rcb- , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s1.p0	Anticholinergics	group	_	antiglaucoma agents	group	_	effect	druga antagonize the effects of drugb .
DDI-DrugBank.d585.s2.p0	Anticholinergic drugs	group	_	corticosteroids	group	_	effect	druga in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as drugb .
DDI-DrugBank.d585.s3.p0	Anticholinergic agents	group	_	digoxin	drug	_	mechanism	druga may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of drugb ;
DDI-DrugBank.d585.s5.p0	Anticholinergic drugs	group	_	metoclopramide	drug	_	effect	druga may antagonize the effects of drugs that alter gastrointestinal motility , such as drugb .
DDI-DrugBank.d585.s6.p0	antacids	group	_	anticholinergic agents	group	_	mechanism	because druga may interfere with the absorption of drugb , simultaneous use of these drugs should be avoided .
DDI-DrugBank.d703.s0.p10	MEPERIDINE	drug	_	NARCOTIC ANALGESICS	group	_	advise	interaction with other drugn : druga should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugb , general drugn , drugn , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p11	MEPERIDINE	drug	_	ANESTHETICS	group	_	advise	interaction with other drugn : druga should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugb , drugn , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p12	MEPERIDINE	drug	_	PHENOTHIAZINES	group	_	advise	interaction with other drugn : druga should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugb , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p13	MEPERIDINE	drug	_	TRANQUILIZERS	group	_	advise	interaction with other drugn : druga should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugb , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p14	MEPERIDINE	drug	_	SEDATIVE-HYPNOTICS	group	_	advise	interaction with other drugn : druga should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugb -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p15	MEPERIDINE	drug	_	BARBITURATES	group	_	advise	interaction with other drugn : druga should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn -lcb- including drugb -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p16	MEPERIDINE	drug	_	TRICYCLIC ANTIDEPRESSANTS	group	_	advise	interaction with other drugn : druga should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn -lcb- including drugn -rcb- , drugb and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p17	MEPERIDINE	drug	_	CNS DEPRESSANTS	group	_	advise	interaction with other drugn : druga should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugb -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p18	MEPERIDINE	drug	_	ALCOHOL	drug	_	advise	interaction with other drugn : druga should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugb -rcb- .
DDI-DrugBank.d703.s0.p20	NARCOTIC ANALGESICS	group	_	PHENOTHIAZINES	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugb , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p21	NARCOTIC ANALGESICS	group	_	TRANQUILIZERS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugb , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p22	NARCOTIC ANALGESICS	group	_	SEDATIVE-HYPNOTICS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugn , drugb -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p23	NARCOTIC ANALGESICS	group	_	BARBITURATES	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugn , drugn -lcb- including drugb -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p24	NARCOTIC ANALGESICS	group	_	TRICYCLIC ANTIDEPRESSANTS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugn , drugn -lcb- including drugn -rcb- , drugb and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p25	NARCOTIC ANALGESICS	group	_	CNS DEPRESSANTS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugb -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p26	NARCOTIC ANALGESICS	group	_	ALCOHOL	drug	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugb -rcb- .
DDI-DrugBank.d703.s0.p27	ANESTHETICS	group	_	PHENOTHIAZINES	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugb , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p28	ANESTHETICS	group	_	TRANQUILIZERS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugn , other drugb , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p32	ANESTHETICS	group	_	CNS DEPRESSANTS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugn , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugb -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p33	ANESTHETICS	group	_	ALCOHOL	drug	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugn , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugb -rcb- .
DDI-DrugBank.d703.s0.p34	PHENOTHIAZINES	group	_	TRANQUILIZERS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugb , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p35	PHENOTHIAZINES	group	_	SEDATIVE-HYPNOTICS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugn , drugb -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p36	PHENOTHIAZINES	group	_	BARBITURATES	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugn , drugn -lcb- including drugb -rcb- , drugn and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p37	PHENOTHIAZINES	group	_	TRICYCLIC ANTIDEPRESSANTS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugn , drugn -lcb- including drugn -rcb- , drugb and other drugn -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p38	PHENOTHIAZINES	group	_	CNS DEPRESSANTS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugb -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p39	PHENOTHIAZINES	group	_	ALCOHOL	drug	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugn , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugb -rcb- .
DDI-DrugBank.d703.s0.p43	TRANQUILIZERS	group	_	CNS DEPRESSANTS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other druga , drugn -lcb- including drugn -rcb- , drugn and other drugb -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p44	TRANQUILIZERS	group	_	ALCOHOL	drug	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other druga , drugn -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugb -rcb- .
DDI-DrugBank.d703.s0.p47	SEDATIVE-HYPNOTICS	group	_	CNS DEPRESSANTS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , druga -lcb- including drugn -rcb- , drugn and other drugb -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p48	SEDATIVE-HYPNOTICS	group	_	ALCOHOL	drug	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , druga -lcb- including drugn -rcb- , drugn and other drugn -lcb- including drugb -rcb- .
DDI-DrugBank.d703.s0.p50	BARBITURATES	group	_	CNS DEPRESSANTS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn -lcb- including druga -rcb- , drugn and other drugb -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p51	BARBITURATES	group	_	ALCOHOL	drug	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn -lcb- including druga -rcb- , drugn and other drugn -lcb- including drugb -rcb- .
DDI-DrugBank.d703.s0.p52	TRICYCLIC ANTIDEPRESSANTS	group	_	CNS DEPRESSANTS	group	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn -lcb- including drugn -rcb- , druga and other drugb -lcb- including drugn -rcb- .
DDI-DrugBank.d703.s0.p53	TRICYCLIC ANTIDEPRESSANTS	group	_	ALCOHOL	drug	_	false	interaction with other drugn : drugn should be used with rxfp2 caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn -lcb- including drugn -rcb- , druga and other drugn -lcb- including drugb -rcb- .
DDI-DrugBank.d636.s0.p0	anticonvulsants	group	_	Mephenytoin	drug	_	int	some druga may interact with drugb .
DDI-DrugBank.d636.s2.p0	anticonvulsants	group	_	divalproex sodium	drug	_	false	those druga include drugb , drugn , and drugn .
DDI-DrugBank.d636.s2.p1	anticonvulsants	group	_	valproic acid	drug	_	false	those druga include drugn , drugb , and drugn .
DDI-DrugBank.d636.s2.p2	anticonvulsants	group	_	phenobarbital	drug	_	false	those druga include drugn , drugn , and drugb .
DDI-DrugBank.d636.s3.p0	Mephenytoin	drug	_	steroid medications	group	_	effect	druga may also affect the effects of other drugs , which include some drugb , drugn , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p1	Mephenytoin	drug	_	warfarin	drug	_	effect	druga may also affect the effects of other drugs , which include some drugn , drugb , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p2	Mephenytoin	drug	_	anti-infective medicines	group	_	effect	druga may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugb , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p3	Mephenytoin	drug	_	furosemide	drug	_	effect	druga may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , drugb and drugn please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p4	Mephenytoin	drug	_	theophylline	drug	_	effect	druga may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , drugn and drugb please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p6	steroid medications	group	_	warfarin	drug	_	false	drugn may also affect the effects of other drugs , which include some druga , drugb , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p7	steroid medications	group	_	anti-infective medicines	group	_	false	drugn may also affect the effects of other drugs , which include some druga , drugn , certain heart medicines , birth control pills , drugb , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p8	steroid medications	group	_	furosemide	drug	_	false	drugn may also affect the effects of other drugs , which include some druga , drugn , certain heart medicines , birth control pills , drugn , drugb and drugn please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p9	steroid medications	group	_	theophylline	drug	_	false	drugn may also affect the effects of other drugs , which include some druga , drugn , certain heart medicines , birth control pills , drugn , drugn and drugb please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p10	steroid medications	group	_	Mephenytoin	drug	_	false	drugn may also affect the effects of other drugs , which include some druga , drugn , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p11	warfarin	drug	_	anti-infective medicines	group	_	false	drugn may also affect the effects of other drugs , which include some drugn , druga , certain heart medicines , birth control pills , drugb , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p12	warfarin	drug	_	furosemide	drug	_	false	drugn may also affect the effects of other drugs , which include some drugn , druga , certain heart medicines , birth control pills , drugn , drugb and drugn please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p13	warfarin	drug	_	theophylline	drug	_	false	drugn may also affect the effects of other drugs , which include some drugn , druga , certain heart medicines , birth control pills , drugn , drugn and drugb please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p14	warfarin	drug	_	Mephenytoin	drug	_	false	drugn may also affect the effects of other drugs , which include some drugn , druga , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p15	anti-infective medicines	group	_	furosemide	drug	_	false	drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , druga , drugb and drugn please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p16	anti-infective medicines	group	_	theophylline	drug	_	false	drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , druga , drugn and drugb please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p17	anti-infective medicines	group	_	Mephenytoin	drug	_	false	drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , druga , drugn and drugn please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p18	furosemide	drug	_	theophylline	drug	_	false	drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , druga and drugb please note that drugn may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p19	furosemide	drug	_	Mephenytoin	drug	_	false	drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , druga and drugn please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.p20	theophylline	drug	_	Mephenytoin	drug	_	false	drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , drugn and druga please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d699.s0.p0	Mequitazine	drug	_	CNS depressant	group	_	int	druga can interact with drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d699.s0.p1	Mequitazine	drug	_	antichlolinergic	group	_	int	druga can interact with drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d699.s0.p2	Mequitazine	drug	_	TCA	group	_	int	druga can interact with drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d699.s0.p3	Mequitazine	drug	_	MAOIs	group	_	int	druga can interact with drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d699.s0.p4	Mequitazine	drug	_	alcohol	drug	_	int	druga can interact with drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d762.s0.p0	Probenecid	drug	_	meropenem	drug	_	mechanism	druga competes with drugb for active tubular secretion and thus inhibits the renal excretion of drugn .
DDI-DrugBank.d762.s0.p1	Probenecid	drug	_	meropenem	drug	_	false	druga competes with drugn for active tubular secretion and thus inhibits the renal excretion of drugb .
DDI-DrugBank.d762.s2.p0	probenecid	drug	_	meropenem	drug	_	advise	therefore , the coadministration of druga with drugb is not recommended .
DDI-DrugBank.d762.s3.p0	meropenem	drug	_	valproic acid	drug	_	mechanism	there is evidence that druga may reduce serum levels of drugb to subtherapeutic levels -lcb- therapeutic range considered to be # to # g/ml total drugn -rcb- .
DDI-DrugBank.d762.s3.p1	meropenem	drug	_	valproate	drug	_	false	there is evidence that druga may reduce serum levels of drugn to subtherapeutic levels -lcb- therapeutic range considered to be # to # g/ml total drugb -rcb- .
DDI-DrugBank.d762.s3.p2	valproic acid	drug	_	valproate	drug	_	false	there is evidence that drugn may reduce serum levels of druga to subtherapeutic levels -lcb- therapeutic range considered to be # to # g/ml total drugb -rcb- .
DDI-DrugBank.d746.s0.p0	ARAMINE	brand	_	digitalis	group	_	false	druga should be used with caution in digitalized patients , since the combination of drugb and drugn may cause ectopic arrhythmias .
DDI-DrugBank.d746.s0.p1	ARAMINE	brand	_	sympathomimetic amines	group	_	false	druga should be used with caution in digitalized patients , since the combination of drugn and drugb may cause ectopic arrhythmias .
DDI-DrugBank.d746.s0.p2	digitalis	group	_	sympathomimetic amines	group	_	effect	drugn should be used with caution in digitalized patients , since the combination of druga and drugb may cause ectopic arrhythmias .
DDI-DrugBank.d746.s1.p0	Monoamine oxidase inhibitors	group	_	tricyclic antidepressants	group	_	false	druga or drugb may potentiate the action of drugn .
DDI-DrugBank.d746.s1.p1	Monoamine oxidase inhibitors	group	_	sympathomimetic amines	group	_	effect	druga or drugn may potentiate the action of drugb .
DDI-DrugBank.d746.s1.p2	tricyclic antidepressants	group	_	sympathomimetic amines	group	_	effect	drugn or druga may potentiate the action of drugb .
DDI-DrugBank.d605.s0.p0	SKELAXIN	brand	_	alcohol	drug	_	effect	druga may enhance the effects of drugb , drugn and other drugn .
DDI-DrugBank.d605.s0.p1	SKELAXIN	brand	_	barbiturates	group	_	effect	druga may enhance the effects of drugn , drugb and other drugn .
DDI-DrugBank.d605.s0.p2	SKELAXIN	brand	_	CNS depressants	group	_	effect	druga may enhance the effects of drugn , drugn and other drugb .
DDI-DrugBank.d630.s1.p0	aspirin	brand	_	methazolamide	drug	_	advise	caution is advised for patients receiving high-dose druga and drugb concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose drugn and drugn .
DDI-DrugBank.d630.s1.p2	aspirin	brand	_	carbonic anhydrase inhibitors	group	_	false	caution is advised for patients receiving high-dose druga and drugn concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose drugn and drugb .
DDI-DrugBank.d630.s1.p3	methazolamide	drug	_	aspirin	brand	_	false	caution is advised for patients receiving high-dose drugn and druga concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose drugb and drugn .
DDI-DrugBank.d630.s1.p4	methazolamide	drug	_	carbonic anhydrase inhibitors	group	_	false	caution is advised for patients receiving high-dose drugn and druga concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose drugn and drugb .
DDI-DrugBank.d630.s1.p5	aspirin	brand	_	carbonic anhydrase inhibitors	group	_	effect	caution is advised for patients receiving high-dose drugn and drugn concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose druga and drugb .
DDI-DrugBank.d634.s0.p2	anticoagulants	group	_	methimazole	drug	_	effect	drugn -lcb- oral -rcb- : the activity of oral druga may be potentiated by anti-vitamin-k activity attributed to drugb .
DDI-DrugBank.d756.s0.p0	opioids	group	_	levomepromazine	drug	_	effect	dosages of concomitantly administered druga should be reduced by approximately half , because drugb amplifies the therapeutic actions and side-effects of drugn .
DDI-DrugBank.d756.s0.p2	levomepromazine	drug	_	opioids	group	_	effect	dosages of concomitantly administered drugn should be reduced by approximately half , because druga amplifies the therapeutic actions and side-effects of drugb .
DDI-DrugBank.d756.s2.p0	levomepromazine	drug	_	benzodiazepines	group	_	effect	additive sedative effects and confusional states may emerge if druga is given with drugb or drugn .
DDI-DrugBank.d756.s2.p1	levomepromazine	drug	_	barbiturates	group	_	effect	additive sedative effects and confusional states may emerge if druga is given with drugn or drugb .
DDI-DrugBank.d756.s2.p2	benzodiazepines	group	_	barbiturates	group	_	false	additive sedative effects and confusional states may emerge if drugn is given with druga or drugb .
DDI-DrugBank.d756.s4.p0	levomepromazine	drug	_	anticholinergic drugs	group	_	advise	exert particular caution in combining druga with other drugb -lcb- drugn and drugn -rcb- : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4.p1	levomepromazine	drug	_	tricyclic antidepressants	group	_	advise	exert particular caution in combining druga with other drugn -lcb- drugb and drugn -rcb- : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4.p2	levomepromazine	drug	_	antiparkinsonian-agents	group	_	advise	exert particular caution in combining druga with other drugn -lcb- drugn and drugb -rcb- : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s7.p0	Caffeine	drug	_	ephedrine	drug	_	false	druga and/or stimulantes of the drugb / drugn type may counteract the specific actions of drugn .
DDI-DrugBank.d756.s7.p1	Caffeine	drug	_	amphetamine	drug	_	false	druga and/or stimulantes of the drugn / drugb type may counteract the specific actions of drugn .
DDI-DrugBank.d756.s7.p2	Caffeine	drug	_	levomepromazine	drug	_	effect	druga and/or stimulantes of the drugn / drugn type may counteract the specific actions of drugb .
DDI-DrugBank.d756.s7.p4	ephedrine	drug	_	levomepromazine	drug	_	effect	drugn and/or stimulantes of the druga / drugn type may counteract the specific actions of drugb .
DDI-DrugBank.d756.s7.p5	amphetamine	drug	_	levomepromazine	drug	_	effect	drugn and/or stimulantes of the drugn / druga type may counteract the specific actions of drugb .
DDI-DrugBank.d587.s0.p1	Celontin	brand	_	antiepileptic drugs	group	_	advise	since druga -lcb- drugn -rcb- may interact with concurrently administered drugb , periodic serum level determinations of these drugs may be necessary -lcb- eg drugn may increase the plasma concentrations of drugn and drugn -rcb- .
DDI-DrugBank.d587.s0.p2	Celontin	brand	_	methsuximide	drug	_	false	since druga -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg drugb may increase the plasma concentrations of drugn and drugn -rcb- .
DDI-DrugBank.d587.s0.p3	Celontin	brand	_	phenytoin	drug	_	false	since druga -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg drugn may increase the plasma concentrations of drugb and drugn -rcb- .
DDI-DrugBank.d587.s0.p4	Celontin	brand	_	phenobarbital	drug	_	false	since druga -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg drugn may increase the plasma concentrations of drugn and drugb -rcb- .
DDI-DrugBank.d587.s0.p5	methsuximide	drug	_	antiepileptic drugs	group	_	advise	since drugn -lcb- druga -rcb- may interact with concurrently administered drugb , periodic serum level determinations of these drugs may be necessary -lcb- eg drugn may increase the plasma concentrations of drugn and drugn -rcb- .
DDI-DrugBank.d587.s0.p7	methsuximide	drug	_	phenytoin	drug	_	false	since drugn -lcb- druga -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg drugn may increase the plasma concentrations of drugb and drugn -rcb- .
DDI-DrugBank.d587.s0.p8	methsuximide	drug	_	phenobarbital	drug	_	false	since drugn -lcb- druga -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg drugn may increase the plasma concentrations of drugn and drugb -rcb- .
DDI-DrugBank.d587.s0.p9	antiepileptic drugs	group	_	methsuximide	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary -lcb- eg drugb may increase the plasma concentrations of drugn and drugn -rcb- .
DDI-DrugBank.d587.s0.p10	antiepileptic drugs	group	_	phenytoin	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary -lcb- eg drugn may increase the plasma concentrations of drugb and drugn -rcb- .
DDI-DrugBank.d587.s0.p11	antiepileptic drugs	group	_	phenobarbital	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary -lcb- eg drugn may increase the plasma concentrations of drugn and drugb -rcb- .
DDI-DrugBank.d587.s0.p12	methsuximide	drug	_	phenytoin	drug	_	mechanism	since drugn -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg druga may increase the plasma concentrations of drugb and drugn -rcb- .
DDI-DrugBank.d587.s0.p13	methsuximide	drug	_	phenobarbital	drug	_	mechanism	since drugn -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg druga may increase the plasma concentrations of drugn and drugb -rcb- .
DDI-DrugBank.d587.s0.p14	phenytoin	drug	_	phenobarbital	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg drugn may increase the plasma concentrations of druga and drugb -rcb- .
DDI-DrugBank.d736.s1.p0	steroids	group	_	ACTH	drug	_	false	hypokalemia may develop during concomitant use of druga or drugb .
DDI-DrugBank.d736.s3.p0	Thiazides	group	_	norepinephrine	drug	_	effect	druga may decrease arterial responsiveness to drugb .
DDI-DrugBank.d736.s5.p0	Thiazide drugs	group	_	tubocurarine	drug	_	effect	druga may increase the responsiveness of drugb .
DDI-DrugBank.d736.s6.p0	Lithium	drug	_	thiazides	group	_	mechanism	druga renal clearance is reduced by drugb , increasing the risk of drugn toxicity .
DDI-DrugBank.d736.s6.p2	thiazides	group	_	lithium	drug	_	false	drugn renal clearance is reduced by druga , increasing the risk of drugb toxicity .
DDI-DrugBank.d736.s7.p0	Thiazides	group	_	antihypertensive drugs	group	_	effect	druga may add to or potentiate the action of other drugb .
DDI-DrugBank.d736.s8.p0	ganglionic adrenergic blocking drugs	group	_	peripheral adrenergic blocking drugs	group	_	false	potentiation occurs with druga or drugb .
DDI-DrugBank.d779.s0.p0	methyldopa	drug	_	antihypertensive drugs	group	_	effect	when druga is used with other drugb , potentiation of antihypertensive effect may occur .
DDI-DrugBank.d779.s2.p0	anesthetics	group	_	methyldopa	drug	_	advise	patients may require reduced doses of druga when on drugb .
DDI-DrugBank.d779.s5.p0	methyldopa	drug	_	lithium	drug	_	advise	when druga and drugb are given concomitantly the patient should be carefully monitored for symptoms of drugn toxicity .
DDI-DrugBank.d779.s5.p1	methyldopa	drug	_	lithium	drug	_	false	when druga and drugn are given concomitantly the patient should be carefully monitored for symptoms of drugb toxicity .
DDI-DrugBank.d779.s7.p0	methyldopa	drug	_	ferrous sulfate	drug	_	mechanism	several studies demonstrate a decrease in the bioavailability of druga when it is ingested with drugb or drugn .
DDI-DrugBank.d779.s7.p1	methyldopa	drug	_	ferrous gluconate	drug	_	mechanism	several studies demonstrate a decrease in the bioavailability of druga when it is ingested with drugn or drugb .
DDI-DrugBank.d779.s7.p2	ferrous sulfate	drug	_	ferrous gluconate	drug	_	false	several studies demonstrate a decrease in the bioavailability of drugn when it is ingested with druga or drugb .
DDI-DrugBank.d779.s9.p0	methyldopa	drug	_	ferrous sulfate	drug	_	advise	coadministration of druga with drugb or drugn is not recommended .
DDI-DrugBank.d779.s9.p1	methyldopa	drug	_	ferrous gluconate	drug	_	advise	coadministration of druga with drugn or drugb is not recommended .
DDI-DrugBank.d779.s9.p2	ferrous sulfate	drug	_	ferrous gluconate	drug	_	false	coadministration of drugn with druga or drugb is not recommended .
DDI-DrugBank.d779.s16.p0	Methyldopa	drug	_	VMA	drug_n	_	false	druga does not interfere with measurement of drugb -lcb- drugn -rcb- , a test for pheochromocytoma , by those methods which convert drugn to drugn .
DDI-DrugBank.d779.s16.p1	Methyldopa	drug	_	vanillylmandelic acid	drug_n	_	false	druga does not interfere with measurement of drugn -lcb- drugb -rcb- , a test for pheochromocytoma , by those methods which convert drugn to drugn .
DDI-DrugBank.d779.s16.p2	Methyldopa	drug	_	VMA	drug_n	_	false	druga does not interfere with measurement of drugn -lcb- drugn -rcb- , a test for pheochromocytoma , by those methods which convert drugb to drugn .
DDI-DrugBank.d779.s16.p3	Methyldopa	drug	_	vanillin	drug_n	_	false	druga does not interfere with measurement of drugn -lcb- drugn -rcb- , a test for pheochromocytoma , by those methods which convert drugn to drugb .
DDI-DrugBank.d779.s16.p6	VMA	drug_n	_	vanillin	drug_n	_	false	drugn does not interfere with measurement of druga -lcb- drugn -rcb- , a test for pheochromocytoma , by those methods which convert drugn to drugb .
DDI-DrugBank.d779.s16.p7	vanillylmandelic acid	drug_n	_	VMA	drug_n	_	false	drugn does not interfere with measurement of drugn -lcb- druga -rcb- , a test for pheochromocytoma , by those methods which convert drugb to drugn .
DDI-DrugBank.d779.s16.p8	vanillylmandelic acid	drug_n	_	vanillin	drug_n	_	false	drugn does not interfere with measurement of drugn -lcb- druga -rcb- , a test for pheochromocytoma , by those methods which convert drugn to drugb .
DDI-DrugBank.d779.s16.p9	VMA	drug_n	_	vanillin	drug_n	_	false	drugn does not interfere with measurement of drugn -lcb- drugn -rcb- , a test for pheochromocytoma , by those methods which convert druga to drugb .
DDI-DrugBank.d675.s0.p1	Macrolide Antibiotics	group	_	ergot alkaloid drugs	group	_	false	cyp 3a4 inhibitors -lcb- e , g , druga and drugn -rcb- there have been rare reports of serious adverse events in connection with the coadministration of certain drugb -lcb- e , g , drugn and drugn -rcb- and potent ppig 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.p2	Macrolide Antibiotics	group	_	dihydroergotamine	drug	_	false	cyp 3a4 inhibitors -lcb- e , g , druga and drugn -rcb- there have been rare reports of serious adverse events in connection with the coadministration of certain drugn -lcb- e , g , drugb and drugn -rcb- and potent ppig 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.p3	Macrolide Antibiotics	group	_	ergotamine	drug	_	false	cyp 3a4 inhibitors -lcb- e , g , druga and drugn -rcb- there have been rare reports of serious adverse events in connection with the coadministration of certain drugn -lcb- e , g , drugn and drugb -rcb- and potent ppig 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.p4	Protease Inhibitors	group	_	ergot alkaloid drugs	group	_	false	cyp 3a4 inhibitors -lcb- e , g , drugn and druga -rcb- there have been rare reports of serious adverse events in connection with the coadministration of certain drugb -lcb- e , g , drugn and drugn -rcb- and potent ppig 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.p5	Protease Inhibitors	group	_	dihydroergotamine	drug	_	false	cyp 3a4 inhibitors -lcb- e , g , drugn and druga -rcb- there have been rare reports of serious adverse events in connection with the coadministration of certain drugn -lcb- e , g , drugb and drugn -rcb- and potent ppig 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.p6	Protease Inhibitors	group	_	ergotamine	drug	_	false	cyp 3a4 inhibitors -lcb- e , g , drugn and druga -rcb- there have been rare reports of serious adverse events in connection with the coadministration of certain drugn -lcb- e , g , drugn and drugb -rcb- and potent ppig 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s2.p46	HIV protease inhibitors	group	_	reverse transcriptase inhibitors	group	_	false	examples of some of the more potent cyp 3a4 inhibitors include drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga or drugb -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- or drugn -lcb- e , g , , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d675.s2.p51	HIV protease inhibitors	group	_	azole antifungals	group	_	false	examples of some of the more potent cyp 3a4 inhibitors include drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga or drugn -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- or drugb -lcb- e , g , , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d675.s2.p52	HIV protease inhibitors	group	_	ketoconazole	drug	_	false	examples of some of the more potent cyp 3a4 inhibitors include drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga or drugn -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- or drugn -lcb- e , g , , drugb , drugn , drugn -rcb- .
DDI-DrugBank.d675.s2.p53	HIV protease inhibitors	group	_	itraconazole	drug	_	false	examples of some of the more potent cyp 3a4 inhibitors include drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga or drugn -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- or drugn -lcb- e , g , , drugn , drugb , drugn -rcb- .
DDI-DrugBank.d675.s2.p54	HIV protease inhibitors	group	_	voriconazole	drug	_	false	examples of some of the more potent cyp 3a4 inhibitors include drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga or drugn -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- or drugn -lcb- e , g , , drugn , drugn , drugb -rcb- .
DDI-DrugBank.d675.s7.p1	Methergine	brand	_	vasoconstrictors	group	_	advise	caution should be exercised when druga -lcb- drugn -rcb- is used concurrently with other drugb or drugn .
DDI-DrugBank.d675.s7.p2	Methergine	brand	_	ergot alkaloids	group	_	advise	caution should be exercised when druga -lcb- drugn -rcb- is used concurrently with other drugn or drugb .
DDI-DrugBank.d675.s7.p3	methylergonovine maleate	drug	_	vasoconstrictors	group	_	advise	caution should be exercised when drugn -lcb- druga -rcb- is used concurrently with other drugb or drugn .
DDI-DrugBank.d675.s7.p4	methylergonovine maleate	drug	_	ergot alkaloids	group	_	false	caution should be exercised when drugn -lcb- druga -rcb- is used concurrently with other drugn or drugb .
DDI-DrugBank.d675.s7.p5	vasoconstrictors	group	_	ergot alkaloids	group	_	false	caution should be exercised when drugn -lcb- drugn -rcb- is used concurrently with other druga or drugb .
DDI-DrugBank.d638.s0.p0	Ritalin	brand	_	guanethidine	drug	_	effect	druga may decrease the hypotensive effect of drugb .
DDI-DrugBank.d638.s2.p0	Ritalin	brand	_	coumarin anticoagulants	group	_	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugb , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , and drugn -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d638.s2.p1	Ritalin	brand	_	anticonvulsants	group	_	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , and drugn -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d638.s2.p2	Ritalin	brand	_	phenobarbital	drug	_	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , and drugn -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d638.s2.p3	Ritalin	brand	_	diphenylhydantoin	drug	_	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , and drugn -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d638.s2.p4	Ritalin	brand	_	primidone	drug	_	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , and drugn -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d638.s2.p5	Ritalin	brand	_	phenylbutazone	drug	_	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , and drugn -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d638.s2.p6	Ritalin	brand	_	tricyclic drugs	group	_	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , and drugb -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d638.s2.p7	Ritalin	brand	_	imipramine	drug	_	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , and drugn -lcb- drugb , drugn , drugn -rcb- .
DDI-DrugBank.d638.s2.p8	Ritalin	brand	_	clomipramine	drug	_	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , and drugn -lcb- drugn , drugb , drugn -rcb- .
DDI-DrugBank.d638.s2.p9	Ritalin	brand	_	desipramine	drug	_	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , and drugn -lcb- drugn , drugn , drugb -rcb- .
DDI-DrugBank.d638.s5.p0	methylphenidate	drug	_	clonidine	drug	_	false	the safety of using druga in combination with drugb or other centrally acting drugn has not been systemically evaluated .
DDI-DrugBank.d638.s5.p1	methylphenidate	drug	_	alpha-2 agonists	group	_	false	the safety of using druga in combination with drugn or other centrally acting drugb has not been systemically evaluated .
DDI-DrugBank.d638.s5.p2	clonidine	drug	_	alpha-2 agonists	group	_	false	the safety of using drugn in combination with druga or other centrally acting drugb has not been systemically evaluated .
DDI-DrugBank.d578.s1.p0	cyclosporin	drug	_	methylprednisolone	drug	_	mechanism	mutual inhibition of metabolism occurs with concurrent use of druga and drugb ;
DDI-DrugBank.d578.s3.p0	methylprednisolone	drug	_	cyclosporin	drug	_	effect	convulsions have been reported with concurrent use of druga and drugb .
DDI-DrugBank.d578.s4.p2	phenobarbital	drug	_	methylprednisolone	drug	_	mechanism	drugs that induce hepatic enzymes such as druga , drugn , and drugn may increase the clearance of drugb and may require increased in drugn dose to achieve the desired response .
DDI-DrugBank.d578.s4.p3	phenobarbital	drug	_	methylprednisolone	drug	_	advise	drugs that induce hepatic enzymes such as druga , drugn , and drugn may increase the clearance of drugn and may require increased in drugb dose to achieve the desired response .
DDI-DrugBank.d578.s4.p5	phenytoin	drug	_	methylprednisolone	drug	_	mechanism	drugs that induce hepatic enzymes such as drugn , druga , and drugn may increase the clearance of drugb and may require increased in drugn dose to achieve the desired response .
DDI-DrugBank.d578.s4.p6	phenytoin	drug	_	methylprednisolone	drug	_	advise	drugs that induce hepatic enzymes such as drugn , druga , and drugn may increase the clearance of drugn and may require increased in drugb dose to achieve the desired response .
DDI-DrugBank.d578.s4.p7	rifampin	drug	_	methylprednisolone	drug	_	mechanism	drugs that induce hepatic enzymes such as drugn , drugn , and druga may increase the clearance of drugb and may require increased in drugn dose to achieve the desired response .
DDI-DrugBank.d578.s4.p8	rifampin	drug	_	methylprednisolone	drug	_	advise	drugs that induce hepatic enzymes such as drugn , drugn , and druga may increase the clearance of drugn and may require increased in drugb dose to achieve the desired response .
DDI-DrugBank.d578.s5.p0	troleandomycin	drug	_	ketoconazole	drug	_	false	drugs such as druga and drugb may inhibit the metabolism of drugn and thus decrease its clearance .
DDI-DrugBank.d578.s5.p1	troleandomycin	drug	_	methylprednisolone	drug	_	mechanism	drugs such as druga and drugn may inhibit the metabolism of drugb and thus decrease its clearance .
DDI-DrugBank.d578.s5.p2	ketoconazole	drug	_	methylprednisolone	drug	_	mechanism	drugs such as drugn and druga may inhibit the metabolism of drugb and thus decrease its clearance .
DDI-DrugBank.d578.s7.p0	Methylprednisolone	drug	_	aspirin	brand	_	mechanism	druga may increase the clearance of chronic high dose drugb .
DDI-DrugBank.d578.s8.p1	salicylate	group	_	methylprednisolone	drug	_	false	this could lead to decreased druga serum levels or increase the risk of drugn toxicity when drugb is withdrawn .
DDI-DrugBank.d578.s8.p2	salicylate	group	_	methylprednisolone	drug	_	effect	this could lead to decreased drugn serum levels or increase the risk of druga toxicity when drugb is withdrawn .
DDI-DrugBank.d578.s9.p0	Aspirin	brand	_	corticosteroids	group	_	advise	druga should be used cautiously in conjunction with drugb in patients suffering from hypoprothrombinemia .
DDI-DrugBank.d578.s10.p0	methylprednisolone	drug	_	anticoagulants	group	_	false	the effect of druga on oral drugb is variable .
DDI-DrugBank.d578.s11.p0	anticoagulant	group	_	corticosteroids	group	_	effect	there are reports of enhanced as well as diminished effects of druga when given concurrently with drugb .
DDI-DrugBank.d655.s0.p0	Methscopolamine	drug	_	antidepressants	group	_	false	druga may interact with drugb -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p1	Methscopolamine	drug	_	tricyclic	group	_	int	druga may interact with drugn -lcb- drugb type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p2	Methscopolamine	drug	_	MAO inhibitors	group	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p3	Methscopolamine	drug	_	phenelzine	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p4	Methscopolamine	drug	_	linezolid	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p5	Methscopolamine	drug	_	tranylcypromine	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p6	Methscopolamine	drug	_	isocarboxazid	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p7	Methscopolamine	drug	_	selegiline	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p8	Methscopolamine	drug	_	furazolidone	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p9	Methscopolamine	drug	_	quinidine	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p10	Methscopolamine	drug	_	amantadine	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugb , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p11	Methscopolamine	drug	_	antihistamines	group	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugb -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p12	Methscopolamine	drug	_	diphenhydramine	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugb -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p13	Methscopolamine	drug	_	anticholinergics	group	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugb , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p14	Methscopolamine	drug	_	potassium chloride	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugb supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p15	Methscopolamine	drug	_	antacids	group	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugb , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p16	Methscopolamine	drug	_	absorbent-type anti-diarrhea medicines	group	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugb -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p17	Methscopolamine	drug	_	kaolin	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugb - drugn -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p18	Methscopolamine	drug	_	pectin	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugb -rcb- , drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p19	Methscopolamine	drug	_	phenothiazines	group	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p20	Methscopolamine	drug	_	chlorpromazine	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p21	Methscopolamine	drug	_	promethazine	drug	_	int	druga may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p40	antidepressants	group	_	phenothiazines	group	_	false	drugn may interact with druga -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p41	antidepressants	group	_	chlorpromazine	drug	_	false	drugn may interact with druga -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p42	antidepressants	group	_	promethazine	drug	_	false	drugn may interact with druga -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p60	tricyclic	group	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- druga type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p61	tricyclic	group	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- druga type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p62	tricyclic	group	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- druga type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p79	MAO inhibitors	group	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , druga -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p80	MAO inhibitors	group	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , druga -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p81	MAO inhibitors	group	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , druga -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p97	phenelzine	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p98	phenelzine	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p99	phenelzine	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p114	linezolid	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p115	linezolid	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p116	linezolid	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p130	tranylcypromine	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p131	tranylcypromine	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p132	tranylcypromine	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p145	isocarboxazid	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p146	isocarboxazid	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p147	isocarboxazid	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p159	selegiline	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p160	selegiline	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p161	selegiline	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p172	furazolidone	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p173	furazolidone	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p174	furazolidone	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p184	quinidine	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p185	quinidine	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p186	quinidine	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p195	amantadine	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , druga , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p196	amantadine	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , druga , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p197	amantadine	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , druga , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p205	antihistamines	group	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , druga -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p206	antihistamines	group	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , druga -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p207	antihistamines	group	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , druga -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p214	diphenhydramine	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , druga -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p215	diphenhydramine	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , druga -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p216	diphenhydramine	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , druga -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p222	anticholinergics	group	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other druga , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p223	anticholinergics	group	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other druga , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p224	anticholinergics	group	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other druga , drugn supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p229	potassium chloride	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , druga supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p230	potassium chloride	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , druga supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p231	potassium chloride	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , druga supplements , drugn , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p235	antacids	group	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , druga , drugn -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p236	antacids	group	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , druga , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p237	antacids	group	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , druga , drugn -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p240	absorbent-type anti-diarrhea medicines	group	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , druga -lcb- e , g , , drugn - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p241	absorbent-type anti-diarrhea medicines	group	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , druga -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p242	absorbent-type anti-diarrhea medicines	group	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , druga -lcb- e , g , , drugn - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p244	kaolin	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , druga - drugn -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p245	kaolin	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , druga - drugn -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p246	kaolin	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , druga - drugn -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d655.s0.p247	pectin	drug	_	phenothiazines	group	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - druga -rcb- , drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d655.s0.p248	pectin	drug	_	chlorpromazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - druga -rcb- , drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d655.s0.p249	pectin	drug	_	promethazine	drug	_	false	drugn may interact with drugn -lcb- drugn type -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , other drugn , drugn supplements , drugn , drugn -lcb- e , g , , drugn - druga -rcb- , drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d600.s1.p0	alcohol	drug	_	CNS depression-producing drugs	group	_	false	concurrent use of druga and other drugb may increase the cns depressant effects of drugn or these other medications .
DDI-DrugBank.d600.s1.p1	alcohol	drug	_	methyprylon	drug	_	effect	concurrent use of druga and other drugn may increase the cns depressant effects of drugb or these other medications .
DDI-DrugBank.d600.s1.p2	CNS depression-producing drugs	group	_	methyprylon	drug	_	effect	concurrent use of drugn and other druga may increase the cns depressant effects of drugb or these other medications .
DDI-DrugBank.d696.s0.p0	Methysergide	drug	_	narcotic analgesics	group	_	effect	druga may reverse the analgesic activity of drugb .
DDI-DrugBank.d696.s1.p0	vasoconstrictor agents	group	_	ergot alkaloids	group	_	false	concurrent use with druga including drugb , drugn , and drugn -lcb- e , g , smoking -rcb- may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1.p1	vasoconstrictor agents	group	_	sumatriptan	drug	_	false	concurrent use with druga including drugn , drugb , and drugn -lcb- e , g , smoking -rcb- may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1.p2	vasoconstrictor agents	group	_	nicotine	drug	_	false	concurrent use with druga including drugn , drugn , and drugb -lcb- e , g , smoking -rcb- may result in enhanced vasoconstriction .
DDI-DrugBank.d652.s0.p0	metoclopramide	drug	_	anticholinergic drugs	group	_	effect	the effects of druga on gastrointestinal motility are antagonized by drugb and drugn .
DDI-DrugBank.d652.s0.p1	metoclopramide	drug	_	narcotic analgesics	group	_	effect	the effects of druga on gastrointestinal motility are antagonized by drugn and drugb .
DDI-DrugBank.d652.s0.p2	anticholinergic drugs	group	_	narcotic analgesics	group	_	false	the effects of drugn on gastrointestinal motility are antagonized by druga and drugb .
DDI-DrugBank.d652.s1.p0	metoclopramide	drug	_	alcohol	drug	_	effect	additive sedative effects can occur when druga is given with drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d652.s1.p1	metoclopramide	drug	_	sedatives	group	_	effect	additive sedative effects can occur when druga is given with drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d652.s1.p2	metoclopramide	drug	_	hypnotics	group	_	effect	additive sedative effects can occur when druga is given with drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d652.s1.p3	metoclopramide	drug	_	narcotics	group	_	effect	additive sedative effects can occur when druga is given with drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d652.s1.p4	metoclopramide	drug	_	tranquilizers	group	_	effect	additive sedative effects can occur when druga is given with drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d652.s2.p0	metoclopramide	drug	_	monoamine oxi-dase inhibitors	group	_	advise	the finding that druga releases catecholamines in patients with essential hypertension suggests that it should be used cautiously , if at all , in patients receiving drugb .
DDI-DrugBank.d652.s3.p0	digoxin	drug	_	metoclopramide	drug	_	mechanism	absorption of drugs from the stomach may be diminished -lcb- e , g , , druga -rcb- by drugb , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugn , drugn , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d652.s3.p1	digoxin	drug	_	acetaminophen	drug	_	false	absorption of drugs from the stomach may be diminished -lcb- e , g , , druga -rcb- by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugb , drugn , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d652.s3.p2	digoxin	drug	_	tetracycline	drug	_	false	absorption of drugs from the stomach may be diminished -lcb- e , g , , druga -rcb- by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugn , drugb , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d652.s3.p3	digoxin	drug	_	levodopa	drug	_	false	absorption of drugs from the stomach may be diminished -lcb- e , g , , druga -rcb- by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugn , drugn , drugb , drugn , drugn -rcb- .
DDI-DrugBank.d652.s3.p4	digoxin	drug	_	ethanol	drug	_	false	absorption of drugs from the stomach may be diminished -lcb- e , g , , druga -rcb- by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugn , drugn , drugn , drugb , drugn -rcb- .
DDI-DrugBank.d652.s3.p5	digoxin	drug	_	cyclosporine	drug	_	false	absorption of drugs from the stomach may be diminished -lcb- e , g , , druga -rcb- by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugn , drugn , drugn , drugn , drugb -rcb- .
DDI-DrugBank.d652.s3.p6	metoclopramide	drug	_	acetaminophen	drug	_	mechanism	absorption of drugs from the stomach may be diminished -lcb- e , g , , drugn -rcb- by druga , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugb , drugn , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d652.s3.p7	metoclopramide	drug	_	tetracycline	drug	_	false	absorption of drugs from the stomach may be diminished -lcb- e , g , , drugn -rcb- by druga , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugn , drugb , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d652.s3.p8	metoclopramide	drug	_	levodopa	drug	_	false	absorption of drugs from the stomach may be diminished -lcb- e , g , , drugn -rcb- by druga , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugn , drugn , drugb , drugn , drugn -rcb- .
DDI-DrugBank.d652.s3.p9	metoclopramide	drug	_	ethanol	drug	_	false	absorption of drugs from the stomach may be diminished -lcb- e , g , , drugn -rcb- by druga , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugn , drugn , drugn , drugb , drugn -rcb- .
DDI-DrugBank.d652.s3.p10	metoclopramide	drug	_	cyclosporine	drug	_	false	absorption of drugs from the stomach may be diminished -lcb- e , g , , drugn -rcb- by druga , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -lcb- e , g , , drugn , drugn , drugn , drugn , drugb -rcb- .
DDI-DrugBank.d652.s6.p0	metoclopramide	drug	_	insulin	drug	_	advise	because the action of druga will influence the delivery of food to the intestines and thus the rate of absorption , drugb dosage or timing of dosage may require adjustment .
DDI-DrugBank.d588.s0.p3	Furosemide	drug	_	loop diuretics	group	_	false	drugn : druga and probably other drugb given concomitantly with drugn can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0.p4	Furosemide	drug	_	metolazone	drug	_	effect	drugn : druga and probably other drugn given concomitantly with drugb can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0.p5	loop diuretics	group	_	metolazone	drug	_	effect	drugn : drugn and probably other druga given concomitantly with drugb can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s1.p2	MYKROX	brand	_	antihypertensive drugs	group	_	advise	other drugn : when druga tablets are used with other drugb , care must be taken , especially during initial therapy .
DDI-DrugBank.d588.s4.p2	Diuretic	group	_	digitalis	group	_	effect	drugn : druga - induced hypokalemia can increase the sensitivity of the myocardium to drugb .
DDI-DrugBank.d588.s6.p0	Corticosteroids	group	_	ACTH	drug	_	false	druga or drugb : may increase the risk of hypokalemia and increase salt and water retention .
DDI-DrugBank.d588.s8.p3	Diuretic	group	_	curariform drugs	group	_	effect	drugn : druga - induced hypokalemia may enhance neuromuscular blocking effects of drugb -lcb- such as drugn -rcb- the most serious effect would be respiratory_failure which could proceed to apnea .
DDI-DrugBank.d588.s8.p4	Diuretic	group	_	tubocurarine	drug	_	effect	drugn : druga - induced hypokalemia may enhance neuromuscular blocking effects of drugn -lcb- such as drugb -rcb- the most serious effect would be respiratory_failure which could proceed to apnea .
DDI-DrugBank.d588.s10.p0	Salicylates	group	_	Non-Steroidal Anti-Inflammatory Drugs	group	_	false	druga and other drugb : may decrease the antihypertensive effects of drugn tablets .
DDI-DrugBank.d588.s10.p1	Salicylates	group	_	MYKROX	brand	_	effect	druga and other drugn : may decrease the antihypertensive effects of drugb tablets .
DDI-DrugBank.d588.s10.p2	Non-Steroidal Anti-Inflammatory Drugs	group	_	MYKROX	brand	_	effect	drugn and other druga : may decrease the antihypertensive effects of drugb tablets .
DDI-DrugBank.d588.s11.p2	Metolazone	drug	_	norepinephrine	drug	_	effect	drugn : druga may decrease arterial responsiveness to drugb , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use .
DDI-DrugBank.d588.s12.p0	Methenamine	drug	_	metolazone	drug	_	effect	druga : efficacy may be decreased due to urinary alkalizing effect of drugb .
DDI-DrugBank.d588.s13.p0	Anticoagulants	group	_	Metolazone	drug	_	false	druga : drugb , as well as other drugn , may affect the hypoprothrombinemic response to drugn ;
DDI-DrugBank.d588.s13.p1	Anticoagulants	group	_	thiazide-like diuretics	group	_	false	druga : drugn , as well as other drugb , may affect the hypoprothrombinemic response to drugn ;
DDI-DrugBank.d588.s13.p3	Metolazone	drug	_	thiazide-like diuretics	group	_	false	drugn : druga , as well as other drugb , may affect the hypoprothrombinemic response to drugn ;
DDI-DrugBank.d588.s13.p4	Metolazone	drug	_	anticoagulants	group	_	effect	drugn : druga , as well as other drugn , may affect the hypoprothrombinemic response to drugb ;
DDI-DrugBank.d588.s13.p5	thiazide-like diuretics	group	_	anticoagulants	group	_	false	drugn : drugn , as well as other druga , may affect the hypoprothrombinemic response to drugb ;
DDI-DrugBank.d706.s0.p0	reserpine	drug	_	beta-blocking agents	group	_	effect	catecholamine-depleting drugs -lcb- e , g , , druga -rcb- may have an additive effect when given with drugb .
DDI-DrugBank.d629.s0.p0	metronidazole	drug	_	coumarin	group	_	effect	oral druga has been reported to potentiate the anticoagulant effect of drugb and drugn , resulting in a prolongation of prothrombin time .
DDI-DrugBank.d629.s0.p1	metronidazole	drug	_	warfarin	drug	_	effect	oral druga has been reported to potentiate the anticoagulant effect of drugn and drugb , resulting in a prolongation of prothrombin time .
DDI-DrugBank.d629.s0.p2	coumarin	group	_	warfarin	drug	_	false	oral drugn has been reported to potentiate the anticoagulant effect of druga and drugb , resulting in a prolongation of prothrombin time .
DDI-DrugBank.d629.s1.p1	METROGEL	brand	_	metronidazole	drug	_	false	drug interactions should be kept in mind when druga -lcb- drugn gel -rcb- , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical drugb administration because of low absorption .
DDI-DrugBank.d678.s1.p0	Metopirone	brand	_	phenytoin	drug	_	mechanism	the metabolism of druga is accelerated by drugb ;
DDI-DrugBank.d678.s4.p0	Metopirone	brand	_	acetaminophen	drug	_	mechanism	druga inhibits the glucuronidation of drugb and could possibly potentiate drugn toxicity .
DDI-DrugBank.d678.s4.p1	Metopirone	brand	_	acetaminophen	drug	_	effect	druga inhibits the glucuronidation of drugn and could possibly potentiate drugb toxicity .
DDI-DrugBank.d715.s0.p0	DEMSER	brand	_	phenothiazines	group	_	advise	caution should be observed in administering druga to patients receiving drugb or drugn because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
DDI-DrugBank.d715.s0.p1	DEMSER	brand	_	haloperidol	drug	_	advise	caution should be observed in administering druga to patients receiving drugn or drugb because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
DDI-DrugBank.d715.s0.p2	phenothiazines	group	_	haloperidol	drug	_	false	caution should be observed in administering drugn to patients receiving druga or drugb because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
DDI-DrugBank.d715.s1.p0	DEMSER	brand	_	alcohol	drug	_	effect	concurrent use of druga with drugb or other drugn can increase their sedative effects .
DDI-DrugBank.d715.s1.p1	DEMSER	brand	_	CNS depressants	drug	_	effect	concurrent use of druga with drugn or other drugb can increase their sedative effects .
DDI-DrugBank.d715.s1.p2	alcohol	drug	_	CNS depressants	drug	_	false	concurrent use of drugn with druga or other drugb can increase their sedative effects .
DDI-DrugBank.d633.s0.p0	MEXITIL	brand	_	mexiletine	drug	_	false	since druga is a substrate for the metabolic pathways involving cyp2d6 and cyp1a2 enzymes , inhibition or induction of either of these enzymes would be expected to alter drugb plasma concentrations .
DDI-DrugBank.d633.s1.p0	mexiletine	drug	_	fluvoxamine	drug	_	mechanism	in a formal , single-dose interaction study -lcb- n = # males -rcb- the clearance of druga was decreased by 38 % following the coadministration of drugb , an inhibitor of cyp1a2 .
DDI-DrugBank.d633.s2.p0	propafenone	drug	_	mexiletine	drug	_	false	in another formal study -lcb- n = # extensive and n = # poor metabolizers of cyp2d6 -rcb- , coadministration of druga did not alter the kinetics of drugb in the poor cyp2d6 metabolizer group .
DDI-DrugBank.d633.s4.p0	propafenone	drug	_	mexiletine	drug	_	false	in this crossover steady state study , the pharmacokinetics of druga were unaffected in either phenotype by the coadministration of drugb .
DDI-DrugBank.d633.s5.p0	mexiletine	drug	_	propafenone	drug	_	false	addition of druga to drugb did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than drugn alone .
DDI-DrugBank.d633.s5.p1	mexiletine	drug	_	propafenone	drug	_	false	addition of druga to drugn did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than drugb alone .
DDI-DrugBank.d633.s7.p0	Mexitil	brand	_	antihypertensive	group	_	false	in a large compassionate use program druga has been used concurrently with commonly employed antianginal , drugb , and drugn without observed interactions .
DDI-DrugBank.d633.s7.p1	Mexitil	brand	_	anticoagulant drugs	group	_	false	in a large compassionate use program druga has been used concurrently with commonly employed antianginal , drugn , and drugb without observed interactions .
DDI-DrugBank.d633.s7.p2	antihypertensive	group	_	anticoagulant drugs	group	_	false	in a large compassionate use program drugn has been used concurrently with commonly employed antianginal , druga , and drugb without observed interactions .
DDI-DrugBank.d633.s8.p0	antiarrhythmics	group	_	quinidine	drug	_	false	a variety of druga such as drugb or drugn were also added , sometimes with improved control of ventricular ectopy .
DDI-DrugBank.d633.s8.p1	antiarrhythmics	group	_	propranolol	drug	_	false	a variety of druga such as drugn or drugb were also added , sometimes with improved control of ventricular ectopy .
DDI-DrugBank.d633.s8.p2	quinidine	drug	_	propranolol	drug	_	false	a variety of drugn such as druga or drugb were also added , sometimes with improved control of ventricular ectopy .
DDI-DrugBank.d633.s9.p0	phenytoin	drug	_	rifampin	drug	_	false	when druga or other hepatic enzyme inducers such as drugb and drugn have been taken concurrently with drugn , lowered drugn plasma levels have been reported .
DDI-DrugBank.d633.s9.p1	phenytoin	drug	_	phenobarbital	drug	_	false	when druga or other hepatic enzyme inducers such as drugn and drugb have been taken concurrently with drugn , lowered drugn plasma levels have been reported .
DDI-DrugBank.d633.s9.p2	phenytoin	drug	_	Mexitil	brand	_	mechanism	when druga or other hepatic enzyme inducers such as drugn and drugn have been taken concurrently with drugb , lowered drugn plasma levels have been reported .
DDI-DrugBank.d633.s9.p3	phenytoin	drug	_	Mexitil	brand	_	false	when druga or other hepatic enzyme inducers such as drugn and drugn have been taken concurrently with drugn , lowered drugb plasma levels have been reported .
DDI-DrugBank.d633.s9.p4	rifampin	drug	_	phenobarbital	drug	_	false	when drugn or other hepatic enzyme inducers such as druga and drugb have been taken concurrently with drugn , lowered drugn plasma levels have been reported .
DDI-DrugBank.d633.s9.p5	rifampin	drug	_	Mexitil	brand	_	mechanism	when drugn or other hepatic enzyme inducers such as druga and drugn have been taken concurrently with drugb , lowered drugn plasma levels have been reported .
DDI-DrugBank.d633.s9.p6	rifampin	drug	_	Mexitil	brand	_	false	when drugn or other hepatic enzyme inducers such as druga and drugn have been taken concurrently with drugn , lowered drugb plasma levels have been reported .
DDI-DrugBank.d633.s9.p7	phenobarbital	drug	_	Mexitil	brand	_	mechanism	when drugn or other hepatic enzyme inducers such as drugn and druga have been taken concurrently with drugb , lowered drugn plasma levels have been reported .
DDI-DrugBank.d633.s9.p8	phenobarbital	drug	_	Mexitil	brand	_	false	when drugn or other hepatic enzyme inducers such as drugn and druga have been taken concurrently with drugn , lowered drugb plasma levels have been reported .
DDI-DrugBank.d633.s11.p0	benzodiazepines	group	_	Mexitil	brand	_	false	in a formal study , druga were shown not to affect drugb plasma concentrations .
DDI-DrugBank.d633.s13.p0	cimetidine	drug	_	Mexitil	brand	_	mechanism	concurrent administration of druga and drugb has been reported to increase , decrease , or leave unchanged drugn plasma levels ;
DDI-DrugBank.d633.s13.p1	cimetidine	drug	_	Mexitil	brand	_	false	concurrent administration of druga and drugn has been reported to increase , decrease , or leave unchanged drugb plasma levels ;
DDI-DrugBank.d633.s15.p0	Mexitil	brand	_	digoxin	drug	_	false	druga does not alter serum drugb levels but drugn , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugn levels .
DDI-DrugBank.d633.s15.p1	Mexitil	brand	_	magnesium-aluminum hydroxide	drug	_	false	druga does not alter serum drugn levels but drugb , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugn levels .
DDI-DrugBank.d633.s15.p3	Mexitil	brand	_	digoxin	drug	_	false	druga does not alter serum drugn levels but drugn , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugb levels .
DDI-DrugBank.d633.s15.p4	digoxin	drug	_	magnesium-aluminum hydroxide	drug	_	false	drugn does not alter serum druga levels but drugb , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugn levels .
DDI-DrugBank.d633.s15.p5	digoxin	drug	_	Mexitil	brand	_	false	drugn does not alter serum druga levels but drugn , when used to treat gastrointestinal symptoms due to drugb , has been reported to lower serum drugn levels .
DDI-DrugBank.d633.s15.p7	magnesium-aluminum hydroxide	drug	_	Mexitil	brand	_	false	drugn does not alter serum drugn levels but druga , when used to treat gastrointestinal symptoms due to drugb , has been reported to lower serum drugn levels .
DDI-DrugBank.d633.s15.p8	magnesium-aluminum hydroxide	drug	_	digoxin	drug	_	mechanism	drugn does not alter serum drugn levels but druga , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugb levels .
DDI-DrugBank.d633.s15.p9	Mexitil	brand	_	digoxin	drug	_	false	drugn does not alter serum drugn levels but drugn , when used to treat gastrointestinal symptoms due to druga , has been reported to lower serum drugb levels .
DDI-DrugBank.d633.s16.p0	Mexitil	brand	_	theophylline	drug	_	mechanism	concurrent use of druga and drugb may lead to increased plasma drugn levels .
DDI-DrugBank.d633.s16.p1	Mexitil	brand	_	theophylline	drug	_	false	concurrent use of druga and drugn may lead to increased plasma drugb levels .
DDI-DrugBank.d633.s18.p7	Theophylline	drug	_	Mexitil	brand	_	false	this increase was observed at the first test point which was the second day after starting drugn , druga plasma levels returned to pre - drugb values within # hours after discontinuing drugn , if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
DDI-DrugBank.d633.s18.p8	Theophylline	drug	_	Mexitil	brand	_	mechanism	this increase was observed at the first test point which was the second day after starting drugn , druga plasma levels returned to pre - drugn values within # hours after discontinuing drugb , if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
DDI-DrugBank.d633.s18.p22	Mexitil	brand	_	theophylline	drug	_	advise	this increase was observed at the first test point which was the second day after starting drugn , drugn plasma levels returned to pre - drugn values within # hours after discontinuing drugn , if druga and drugb are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
DDI-DrugBank.d633.s18.p23	Mexitil	brand	_	theophylline	drug	_	false	this increase was observed at the first test point which was the second day after starting drugn , drugn plasma levels returned to pre - drugn values within # hours after discontinuing drugn , if druga and drugn are to be used concurrently , drugb blood levels should be monitored , particularly when the drugn dose is changed .
DDI-DrugBank.d633.s18.p26	theophylline	drug	_	Mexitil	brand	_	false	this increase was observed at the first test point which was the second day after starting drugn , drugn plasma levels returned to pre - drugn values within # hours after discontinuing drugn , if drugn and druga are to be used concurrently , drugn blood levels should be monitored , particularly when the drugb dose is changed .
DDI-DrugBank.d633.s18.p27	theophylline	drug	_	Mexitil	brand	_	false	this increase was observed at the first test point which was the second day after starting drugn , drugn plasma levels returned to pre - drugn values within # hours after discontinuing drugn , if drugn and drugn are to be used concurrently , druga blood levels should be monitored , particularly when the drugb dose is changed .
DDI-DrugBank.d633.s20.p0	caffeine	drug	_	Mexitil	brand	_	mechanism	additionally , in one controlled study in five normal subjects and seven patients , the clearance of druga was decreased 50 % following the administration of drugb .
DDI-DrugBank.d783.s0.p0	Posicor	brand	_	terfenadine	drug	_	mechanism	druga inhibits some of the liver 's ability to metabolize some other drugs - drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d783.s0.p1	Posicor	brand	_	astemizole	drug	_	mechanism	druga inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d783.s0.p2	Posicor	brand	_	cisapride	drug	_	mechanism	druga inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d783.s0.p3	Posicor	brand	_	cyclosporine	drug	_	mechanism	druga inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d783.s0.p4	Posicor	brand	_	tricyclic antidepressants	group	_	mechanism	druga inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d735.s2.p0	MYCAMINE	brand	_	mycophenolate mofetil	drug	_	false	there was no effect of a single dose or multiple doses of druga on drugb , drugn , drugn , drugn , and drugn pharmacokinetics .
DDI-DrugBank.d735.s2.p1	MYCAMINE	brand	_	cyclosporine	drug	_	false	there was no effect of a single dose or multiple doses of druga on drugn , drugb , drugn , drugn , and drugn pharmacokinetics .
DDI-DrugBank.d735.s2.p2	MYCAMINE	brand	_	tacrolimus	drug	_	false	there was no effect of a single dose or multiple doses of druga on drugn , drugn , drugb , drugn , and drugn pharmacokinetics .
DDI-DrugBank.d735.s2.p3	MYCAMINE	brand	_	prednisolone	drug	_	false	there was no effect of a single dose or multiple doses of druga on drugn , drugn , drugn , drugb , and drugn pharmacokinetics .
DDI-DrugBank.d735.s2.p4	MYCAMINE	brand	_	fluconazole	drug	_	false	there was no effect of a single dose or multiple doses of druga on drugn , drugn , drugn , drugn , and drugb pharmacokinetics .
DDI-DrugBank.d735.s2.p8	mycophenolate mofetil	drug	_	fluconazole	drug	_	false	there was no effect of a single dose or multiple doses of drugn on druga , drugn , drugn , drugn , and drugb pharmacokinetics .
DDI-DrugBank.d735.s2.p13	tacrolimus	drug	_	fluconazole	drug	_	false	there was no effect of a single dose or multiple doses of drugn on drugn , drugn , druga , drugn , and drugb pharmacokinetics .
DDI-DrugBank.d735.s3.p0	Sirolimus	drug	_	MYCAMINE	brand	_	mechanism	druga auc was increased by 21 % with no effect on cmax in the presence of steady-state drugb compared with drugn alone .
DDI-DrugBank.d735.s3.p2	MYCAMINE	brand	_	sirolimus	drug	_	false	drugn auc was increased by 21 % with no effect on cmax in the presence of steady-state druga compared with drugb alone .
DDI-DrugBank.d735.s4.p0	Nifedipine	drug	_	MYCAMINE	brand	_	mechanism	druga auc and cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state drugb compared with drugn alone .
DDI-DrugBank.d735.s4.p2	MYCAMINE	brand	_	nifedipine	drug	_	false	drugn auc and cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state druga compared with drugb alone .
DDI-DrugBank.d735.s5.p0	sirolimus	drug	_	nifedipine	drug	_	false	patients receiving druga or drugb in combination with drugn should be monitored for drugn or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p1	sirolimus	drug	_	MYCAMINE	brand	_	advise	patients receiving druga or drugn in combination with drugb should be monitored for drugn or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p3	sirolimus	drug	_	nifedipine	drug	_	false	patients receiving druga or drugn in combination with drugn should be monitored for drugn or drugb toxicity and drugn or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p5	sirolimus	drug	_	nifedipine	drug	_	false	patients receiving druga or drugn in combination with drugn should be monitored for drugn or drugn toxicity and drugn or drugb dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p6	nifedipine	drug	_	MYCAMINE	brand	_	advise	patients receiving drugn or druga in combination with drugb should be monitored for drugn or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p7	nifedipine	drug	_	sirolimus	drug	_	false	patients receiving drugn or druga in combination with drugn should be monitored for drugb or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p9	nifedipine	drug	_	sirolimus	drug	_	false	patients receiving drugn or druga in combination with drugn should be monitored for drugn or drugn toxicity and drugb or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p11	MYCAMINE	brand	_	sirolimus	drug	_	false	patients receiving drugn or drugn in combination with druga should be monitored for drugb or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p12	MYCAMINE	brand	_	nifedipine	drug	_	false	patients receiving drugn or drugn in combination with druga should be monitored for drugn or drugb toxicity and drugn or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p13	MYCAMINE	brand	_	sirolimus	drug	_	false	patients receiving drugn or drugn in combination with druga should be monitored for drugn or drugn toxicity and drugb or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p14	MYCAMINE	brand	_	nifedipine	drug	_	false	patients receiving drugn or drugn in combination with druga should be monitored for drugn or drugn toxicity and drugn or drugb dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p15	sirolimus	drug	_	nifedipine	drug	_	false	patients receiving drugn or drugn in combination with drugn should be monitored for druga or drugb toxicity and drugn or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p17	sirolimus	drug	_	nifedipine	drug	_	false	patients receiving drugn or drugn in combination with drugn should be monitored for druga or drugn toxicity and drugn or drugb dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p18	nifedipine	drug	_	sirolimus	drug	_	false	patients receiving drugn or drugn in combination with drugn should be monitored for drugn or druga toxicity and drugb or drugn dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.p20	sirolimus	drug	_	nifedipine	drug	_	false	patients receiving drugn or drugn in combination with drugn should be monitored for drugn or drugn toxicity and druga or drugb dosage should be reduced if necessary .
DDI-DrugBank.d752.s0.p0	midazolam	drug	_	azole antimycotics	group	_	advise	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cyp3a4 enzyme system -lcb- ie , some drugs in the drug classes of drugb , drugn , drugn , and drugn -rcb- .
DDI-DrugBank.d752.s0.p1	midazolam	drug	_	protease inhibitors	group	_	advise	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cyp3a4 enzyme system -lcb- ie , some drugs in the drug classes of drugn , drugb , drugn , and drugn -rcb- .
DDI-DrugBank.d752.s0.p2	midazolam	drug	_	calcium channel antagonists	group	_	advise	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cyp3a4 enzyme system -lcb- ie , some drugs in the drug classes of drugn , drugn , drugb , and drugn -rcb- .
DDI-DrugBank.d752.s0.p3	midazolam	drug	_	macrolide antibiotics	group	_	advise	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cyp3a4 enzyme system -lcb- ie , some drugs in the drug classes of drugn , drugn , drugn , and drugb -rcb- .
DDI-DrugBank.d752.s1.p5	erythromycin	drug	_	midazolam	drug	_	mechanism	drugs such as druga , drugn , drugn , drugn , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s1.p10	diltiazem	drug	_	midazolam	drug	_	mechanism	drugs such as drugn , druga , drugn , drugn , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s1.p14	verapamil	drug	_	midazolam	drug	_	mechanism	drugs such as drugn , drugn , druga , drugn , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s1.p17	ketoconazole	drug	_	midazolam	drug	_	mechanism	drugs such as drugn , drugn , drugn , druga , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s1.p19	fluconazole	drug	_	midazolam	drug	_	mechanism	drugs such as drugn , drugn , drugn , drugn , druga and drugn were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s1.p20	itraconazole	drug	_	midazolam	drug	_	mechanism	drugs such as drugn , drugn , drugn , drugn , drugn and druga were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s3.p0	ritonavir	drug	_	nelfinavir	drug	_	false	although not studied , the potent cytochrome p450 3a4 inhibitors druga and drugb may cause intense and prolonged sedation and respiratory_failure due to a decrease in plasma clearance of drugn .
DDI-DrugBank.d752.s3.p1	ritonavir	drug	_	midazolam	drug	_	mechanism	although not studied , the potent cytochrome p450 3a4 inhibitors druga and drugn may cause intense and prolonged sedation and respiratory_failure due to a decrease in plasma clearance of drugb .
DDI-DrugBank.d752.s3.p2	nelfinavir	drug	_	midazolam	drug	_	mechanism	although not studied , the potent cytochrome p450 3a4 inhibitors drugn and druga may cause intense and prolonged sedation and respiratory_failure due to a decrease in plasma clearance of drugb .
DDI-DrugBank.d752.s6.p2	rifampin	drug	_	midazolam	drug	_	mechanism	inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as druga , drugn , and drugn , induce metabolism and caused a markedly decreased c max and auc of oral drugb in adult studies .
DDI-DrugBank.d752.s6.p4	carbamazepine	drug	_	midazolam	drug	_	mechanism	inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as drugn , druga , and drugn , induce metabolism and caused a markedly decreased c max and auc of oral drugb in adult studies .
DDI-DrugBank.d752.s6.p5	phenytoin	drug	_	midazolam	drug	_	mechanism	inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as drugn , drugn , and druga , induce metabolism and caused a markedly decreased c max and auc of oral drugb in adult studies .
DDI-DrugBank.d752.s9.p0	sedatives	group	_	methylphenidate	drug	_	false	the difficulty in achieving adequate sedation may have been the result of decreased absorption of the druga due to both the gastrointestinal effects and stimulant effects of drugb .
DDI-DrugBank.d752.s10.p0	VERSED Syrup	brand	_	narcotics	group	_	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugb -lcb- eg , drugn , drugn and drugn -rcb- , drugn , drugn , drugn , drugn and drugn .
DDI-DrugBank.d752.s10.p1	VERSED Syrup	brand	_	morphine	drug	_	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugb , drugn and drugn -rcb- , drugn , drugn , drugn , drugn and drugn .
DDI-DrugBank.d752.s10.p2	VERSED Syrup	brand	_	meperidine	drug	_	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugb and drugn -rcb- , drugn , drugn , drugn , drugn and drugn .
DDI-DrugBank.d752.s10.p3	VERSED Syrup	brand	_	fentanyl	drug	_	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugn and drugb -rcb- , drugn , drugn , drugn , drugn and drugn .
DDI-DrugBank.d752.s10.p4	VERSED Syrup	brand	_	propofol	drug	_	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugn and drugn -rcb- , drugb , drugn , drugn , drugn and drugn .
DDI-DrugBank.d752.s10.p5	VERSED Syrup	brand	_	ketamine	drug	_	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugn and drugn -rcb- , drugn , drugb , drugn , drugn and drugn .
DDI-DrugBank.d752.s10.p6	VERSED Syrup	brand	_	nitrous oxide	drug	_	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugn and drugn -rcb- , drugn , drugn , drugb , drugn and drugn .
DDI-DrugBank.d752.s10.p7	VERSED Syrup	brand	_	secobarbital	drug	_	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugn and drugn -rcb- , drugn , drugn , drugn , drugb and drugn .
DDI-DrugBank.d752.s10.p8	VERSED Syrup	brand	_	droperidol	drug	_	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugn and drugn -rcb- , drugn , drugn , drugn , drugn and drugb .
DDI-DrugBank.d752.s10.p35	propofol	drug	_	ketamine	drug	_	false	the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugn and drugn -rcb- , druga , drugb , drugn , drugn and drugn .
DDI-DrugBank.d752.s10.p36	propofol	drug	_	nitrous oxide	drug	_	false	the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugn and drugn -rcb- , druga , drugn , drugb , drugn and drugn .
DDI-DrugBank.d752.s10.p37	propofol	drug	_	secobarbital	drug	_	false	the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugn and drugn -rcb- , druga , drugn , drugn , drugb and drugn .
DDI-DrugBank.d752.s10.p38	propofol	drug	_	droperidol	drug	_	false	the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn -lcb- eg , drugn , drugn and drugn -rcb- , druga , drugn , drugn , drugn and drugb .
DDI-DrugBank.d752.s12.p5	atropine	drug	_	anesthetics	group	_	false	no significant adverse interactions with common premedications -lcb- such as druga , drugn , drugn , drugn , drugn , and other drugn -rcb- or local drugb have been observed .
DDI-DrugBank.d752.s12.p10	scopolamine	drug	_	anesthetics	group	_	false	no significant adverse interactions with common premedications -lcb- such as drugn , druga , drugn , drugn , drugn , and other drugn -rcb- or local drugb have been observed .
DDI-DrugBank.d752.s12.p14	glycopyrrolate	drug	_	anesthetics	group	_	false	no significant adverse interactions with common premedications -lcb- such as drugn , drugn , druga , drugn , drugn , and other drugn -rcb- or local drugb have been observed .
DDI-DrugBank.d752.s12.p17	diazepam	drug	_	anesthetics	group	_	false	no significant adverse interactions with common premedications -lcb- such as drugn , drugn , drugn , druga , drugn , and other drugn -rcb- or local drugb have been observed .
DDI-DrugBank.d752.s12.p19	hydroxyzine	drug	_	anesthetics	group	_	false	no significant adverse interactions with common premedications -lcb- such as drugn , drugn , drugn , drugn , druga , and other drugn -rcb- or local drugb have been observed .
DDI-DrugBank.d752.s12.p20	muscle relaxants	group	_	anesthetics	group	_	false	no significant adverse interactions with common premedications -lcb- such as drugn , drugn , drugn , drugn , drugn , and other druga -rcb- or local drugb have been observed .
DDI-DrugBank.d603.s0.p0	ProAmatine	brand	_	cardiac glycosides	group	_	effect	when administered concomitantly with druga , drugb may enhance or precipitate bradycardia , a , v.
DDI-DrugBank.d603.s2.p4	phenylephrine	drug	_	ProAmatine	brand	_	effect	the use of drugs that stimulate alpha-adrenergic receptors -lcb- e , g , , druga , drugn , drugn , drugn or drugn -rcb- may enhance or potentiate the pressor effects of drugb , therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2.p5	phenylephrine	drug	_	ProAmatine	brand	_	false	the use of drugs that stimulate alpha-adrenergic receptors -lcb- e , g , , druga , drugn , drugn , drugn or drugn -rcb- may enhance or potentiate the pressor effects of drugn , therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2.p9	pseudoephedrine	drug	_	ProAmatine	brand	_	effect	the use of drugs that stimulate alpha-adrenergic receptors -lcb- e , g , , drugn , druga , drugn , drugn or drugn -rcb- may enhance or potentiate the pressor effects of drugb , therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2.p10	pseudoephedrine	drug	_	ProAmatine	brand	_	false	the use of drugs that stimulate alpha-adrenergic receptors -lcb- e , g , , drugn , druga , drugn , drugn or drugn -rcb- may enhance or potentiate the pressor effects of drugn , therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2.p13	ephedrine	drug	_	ProAmatine	brand	_	effect	the use of drugs that stimulate alpha-adrenergic receptors -lcb- e , g , , drugn , drugn , druga , drugn or drugn -rcb- may enhance or potentiate the pressor effects of drugb , therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2.p14	ephedrine	drug	_	ProAmatine	brand	_	false	the use of drugs that stimulate alpha-adrenergic receptors -lcb- e , g , , drugn , drugn , druga , drugn or drugn -rcb- may enhance or potentiate the pressor effects of drugn , therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2.p16	phenylpropanolamine	drug	_	ProAmatine	brand	_	effect	the use of drugs that stimulate alpha-adrenergic receptors -lcb- e , g , , drugn , drugn , drugn , druga or drugn -rcb- may enhance or potentiate the pressor effects of drugb , therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2.p17	phenylpropanolamine	drug	_	ProAmatine	brand	_	false	the use of drugs that stimulate alpha-adrenergic receptors -lcb- e , g , , drugn , drugn , drugn , druga or drugn -rcb- may enhance or potentiate the pressor effects of drugn , therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2.p18	dihydroergotamine	drug	_	ProAmatine	brand	_	effect	the use of drugs that stimulate alpha-adrenergic receptors -lcb- e , g , , drugn , drugn , drugn , drugn or druga -rcb- may enhance or potentiate the pressor effects of drugb , therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2.p19	dihydroergotamine	drug	_	ProAmatine	brand	_	false	the use of drugs that stimulate alpha-adrenergic receptors -lcb- e , g , , drugn , drugn , drugn , drugn or druga -rcb- may enhance or potentiate the pressor effects of drugn , therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s3.p0	ProAmatine	brand	_	fludrocortisone acetate	drug	_	false	druga has been used in patients concomitantly treated with salt-retaining steroid therapy -lcb- i , e , , drugb -rcb- , with or without salt supplementation .
DDI-DrugBank.d603.s5.p0	ProAmatine	brand	_	Alpha-adrenergic blocking agents	group	_	false	druga , drugb , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p1	ProAmatine	brand	_	prazosin	drug	_	false	druga , drugn , such as drugb , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p2	ProAmatine	brand	_	terazosin	drug	_	false	druga , drugn , such as drugn , drugb , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p3	ProAmatine	brand	_	doxazosin	drug	_	false	druga , drugn , such as drugn , drugn , and drugb , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p5	ProAmatine	brand	_	desglymidodrine	drug_n	_	false	druga , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p6	ProAmatine	brand	_	metformin	drug	_	false	druga , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p7	ProAmatine	brand	_	cimetidine	drug	_	false	druga , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p8	ProAmatine	brand	_	ranitidine	drug	_	false	druga , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p9	ProAmatine	brand	_	procainamide	drug	_	false	druga , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p10	ProAmatine	brand	_	triamterene	drug	_	false	druga , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d603.s5.p11	ProAmatine	brand	_	flecainide	drug	_	false	druga , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d603.s5.p12	ProAmatine	brand	_	quinidine	drug	_	false	druga , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d603.s5.p13	Alpha-adrenergic blocking agents	group	_	prazosin	drug	_	false	drugn , druga , such as drugb , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p14	Alpha-adrenergic blocking agents	group	_	terazosin	drug	_	false	drugn , druga , such as drugn , drugb , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p15	Alpha-adrenergic blocking agents	group	_	doxazosin	drug	_	false	drugn , druga , such as drugn , drugn , and drugb , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p16	Alpha-adrenergic blocking agents	group	_	ProAmatine	brand	_	effect	drugn , druga , such as drugn , drugn , and drugn , can antagonize the effects of drugb , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p17	Alpha-adrenergic blocking agents	group	_	desglymidodrine	drug_n	_	false	drugn , druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p18	Alpha-adrenergic blocking agents	group	_	metformin	drug	_	false	drugn , druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p19	Alpha-adrenergic blocking agents	group	_	cimetidine	drug	_	false	drugn , druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p20	Alpha-adrenergic blocking agents	group	_	ranitidine	drug	_	false	drugn , druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p21	Alpha-adrenergic blocking agents	group	_	procainamide	drug	_	false	drugn , druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p22	Alpha-adrenergic blocking agents	group	_	triamterene	drug	_	false	drugn , druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d603.s5.p23	Alpha-adrenergic blocking agents	group	_	flecainide	drug	_	false	drugn , druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d603.s5.p24	Alpha-adrenergic blocking agents	group	_	quinidine	drug	_	false	drugn , druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d603.s5.p27	prazosin	drug	_	ProAmatine	brand	_	effect	drugn , drugn , such as druga , drugn , and drugn , can antagonize the effects of drugb , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p28	prazosin	drug	_	desglymidodrine	drug_n	_	false	drugn , drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p29	prazosin	drug	_	metformin	drug	_	false	drugn , drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p30	prazosin	drug	_	cimetidine	drug	_	false	drugn , drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p31	prazosin	drug	_	ranitidine	drug	_	false	drugn , drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p32	prazosin	drug	_	procainamide	drug	_	false	drugn , drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p33	prazosin	drug	_	triamterene	drug	_	false	drugn , drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d603.s5.p34	prazosin	drug	_	flecainide	drug	_	false	drugn , drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d603.s5.p35	prazosin	drug	_	quinidine	drug	_	false	drugn , drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d603.s5.p37	terazosin	drug	_	ProAmatine	brand	_	effect	drugn , drugn , such as drugn , druga , and drugn , can antagonize the effects of drugb , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p38	terazosin	drug	_	desglymidodrine	drug_n	_	false	drugn , drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p39	terazosin	drug	_	metformin	drug	_	false	drugn , drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p40	terazosin	drug	_	cimetidine	drug	_	false	drugn , drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p41	terazosin	drug	_	ranitidine	drug	_	false	drugn , drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p42	terazosin	drug	_	procainamide	drug	_	false	drugn , drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p43	terazosin	drug	_	triamterene	drug	_	false	drugn , drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d603.s5.p44	terazosin	drug	_	flecainide	drug	_	false	drugn , drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d603.s5.p45	terazosin	drug	_	quinidine	drug	_	false	drugn , drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d603.s5.p46	doxazosin	drug	_	ProAmatine	brand	_	effect	drugn , drugn , such as drugn , drugn , and druga , can antagonize the effects of drugb , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p47	doxazosin	drug	_	desglymidodrine	drug_n	_	false	drugn , drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p48	doxazosin	drug	_	metformin	drug	_	false	drugn , drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p49	doxazosin	drug	_	cimetidine	drug	_	false	drugn , drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p50	doxazosin	drug	_	ranitidine	drug	_	false	drugn , drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p51	doxazosin	drug	_	procainamide	drug	_	false	drugn , drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p52	doxazosin	drug	_	triamterene	drug	_	false	drugn , drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d603.s5.p53	doxazosin	drug	_	flecainide	drug	_	false	drugn , drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d603.s5.p54	doxazosin	drug	_	quinidine	drug	_	false	drugn , drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d603.s5.p55	ProAmatine	brand	_	desglymidodrine	drug_n	_	false	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p56	ProAmatine	brand	_	metformin	drug	_	false	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p57	ProAmatine	brand	_	cimetidine	drug	_	false	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p58	ProAmatine	brand	_	ranitidine	drug	_	false	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p59	ProAmatine	brand	_	procainamide	drug	_	false	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p60	ProAmatine	brand	_	triamterene	drug	_	false	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d603.s5.p61	ProAmatine	brand	_	flecainide	drug	_	false	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d603.s5.p62	ProAmatine	brand	_	quinidine	drug	_	false	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d603.s5.p63	desglymidodrine	drug_n	_	metformin	drug	_	mechanism	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p64	desglymidodrine	drug_n	_	cimetidine	drug	_	mechanism	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p65	desglymidodrine	drug_n	_	ranitidine	drug	_	mechanism	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p66	desglymidodrine	drug_n	_	procainamide	drug	_	mechanism	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d603.s5.p67	desglymidodrine	drug_n	_	triamterene	drug	_	mechanism	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d603.s5.p68	desglymidodrine	drug_n	_	flecainide	drug	_	mechanism	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d603.s5.p69	desglymidodrine	drug_n	_	quinidine	drug	_	mechanism	drugn , drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn , potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga -lcb- a base -rcb- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d668.s0.p0	mifepristone	drug	_	ketoconazole	drug	_	false	although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by ppig 3a4 , it is possible that drugb , drugn , drugn , and grapefruit juice may inhibit its metabolism -lcb- increasing serum levels of drugn -rcb- .
DDI-DrugBank.d668.s0.p1	mifepristone	drug	_	itraconazole	drug	_	false	although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by ppig 3a4 , it is possible that drugn , drugb , drugn , and grapefruit juice may inhibit its metabolism -lcb- increasing serum levels of drugn -rcb- .
DDI-DrugBank.d668.s0.p2	mifepristone	drug	_	erythromycin	drug	_	false	although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by ppig 3a4 , it is possible that drugn , drugn , drugb , and grapefruit juice may inhibit its metabolism -lcb- increasing serum levels of drugn -rcb- .
DDI-DrugBank.d668.s0.p6	ketoconazole	drug	_	mifepristone	drug	_	mechanism	although specific drug or food interactions with drugn have not been studied , on the basis of this drug s metabolism by ppig 3a4 , it is possible that druga , drugn , drugn , and grapefruit juice may inhibit its metabolism -lcb- increasing serum levels of drugb -rcb- .
DDI-DrugBank.d668.s0.p8	itraconazole	drug	_	mifepristone	drug	_	mechanism	although specific drug or food interactions with drugn have not been studied , on the basis of this drug s metabolism by ppig 3a4 , it is possible that drugn , druga , drugn , and grapefruit juice may inhibit its metabolism -lcb- increasing serum levels of drugb -rcb- .
DDI-DrugBank.d668.s0.p9	erythromycin	drug	_	mifepristone	drug	_	mechanism	although specific drug or food interactions with drugn have not been studied , on the basis of this drug s metabolism by ppig 3a4 , it is possible that drugn , drugn , druga , and grapefruit juice may inhibit its metabolism -lcb- increasing serum levels of drugb -rcb- .
DDI-DrugBank.d668.s1.p0	rifampin	drug	_	dexamethasone	drug	_	false	furthermore , druga , drugb , st.
DDI-DrugBank.d668.s2.p3	anticonvulsants	group	_	mifepristone	drug	_	mechanism	john s wort , and certain druga -lcb- drugn , drugn , drugn -rcb- may induce drugb metabolism -lcb- lowering serum levels of drugn -rcb- .
DDI-DrugBank.d668.s2.p4	anticonvulsants	group	_	mifepristone	drug	_	false	john s wort , and certain druga -lcb- drugn , drugn , drugn -rcb- may induce drugn metabolism -lcb- lowering serum levels of drugb -rcb- .
DDI-DrugBank.d668.s2.p7	phenytoin	drug	_	mifepristone	drug	_	mechanism	john s wort , and certain drugn -lcb- druga , drugn , drugn -rcb- may induce drugb metabolism -lcb- lowering serum levels of drugn -rcb- .
DDI-DrugBank.d668.s2.p8	phenytoin	drug	_	mifepristone	drug	_	false	john s wort , and certain drugn -lcb- druga , drugn , drugn -rcb- may induce drugn metabolism -lcb- lowering serum levels of drugb -rcb- .
DDI-DrugBank.d668.s2.p10	phenobarbital	drug	_	mifepristone	drug	_	mechanism	john s wort , and certain drugn -lcb- drugn , druga , drugn -rcb- may induce drugb metabolism -lcb- lowering serum levels of drugn -rcb- .
DDI-DrugBank.d668.s2.p11	phenobarbital	drug	_	mifepristone	drug	_	false	john s wort , and certain drugn -lcb- drugn , druga , drugn -rcb- may induce drugn metabolism -lcb- lowering serum levels of drugb -rcb- .
DDI-DrugBank.d668.s2.p12	carbamazepine	drug	_	mifepristone	drug	_	mechanism	john s wort , and certain drugn -lcb- drugn , drugn , druga -rcb- may induce drugb metabolism -lcb- lowering serum levels of drugn -rcb- .
DDI-DrugBank.d668.s2.p13	carbamazepine	drug	_	mifepristone	drug	_	false	john s wort , and certain drugn -lcb- drugn , drugn , druga -rcb- may induce drugn metabolism -lcb- lowering serum levels of drugb -rcb- .
DDI-DrugBank.d695.s0.p0	ZAVESCA	brand	_	Cerezyme	brand	_	mechanism	while co-administration of druga appeared to increase the clearance of drugb by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of drugn .
DDI-DrugBank.d695.s0.p1	ZAVESCA	brand	_	Cerezyme	brand	_	false	while co-administration of druga appeared to increase the clearance of drugn by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of drugb .
DDI-DrugBank.d695.s1.p1	Cerezyme	brand	_	ZAVESCA	brand	_	advise	combination therapy with druga -lcb- drugn -rcb- and drugb is not indicated .
DDI-DrugBank.d695.s1.p2	imiglucerase	drug	_	ZAVESCA	brand	_	advise	combination therapy with drugn -lcb- druga -rcb- and drugb is not indicated .
DDI-DrugBank.d711.s0.p0	tetracyclines	group	_	anticoagulant	group	_	advise	because druga have been shown to depress plasma prothrombin activity , patients who are on drugb therapy may require downward adjustment of their drugn dosage .
DDI-DrugBank.d711.s0.p1	tetracyclines	group	_	anticoagulant	group	_	false	because druga have been shown to depress plasma prothrombin activity , patients who are on drugn therapy may require downward adjustment of their drugb dosage .
DDI-DrugBank.d711.s1.p0	penicillin	drug	_	tetracycline class drugs	group	_	false	since bacteriostatic drugs may interfere with the bactericidal action of druga , it is advisable to avoid giving drugb in conjunction with drugn .
DDI-DrugBank.d711.s1.p2	tetracycline class drugs	group	_	penicillin	drug	_	advise	since bacteriostatic drugs may interfere with the bactericidal action of drugn , it is advisable to avoid giving druga in conjunction with drugb .
DDI-DrugBank.d711.s2.p0	tetracyclines	group	_	antacids	group	_	false	absorption of druga is impaired by drugb containing drugn , drugn or drugn , and drugn - containing preparations .
DDI-DrugBank.d711.s2.p1	tetracyclines	group	_	aluminum	drug	_	mechanism	absorption of druga is impaired by drugn containing drugb , drugn or drugn , and drugn - containing preparations .
DDI-DrugBank.d711.s2.p2	tetracyclines	group	_	calcium	drug	_	mechanism	absorption of druga is impaired by drugn containing drugn , drugb or drugn , and drugn - containing preparations .
DDI-DrugBank.d711.s2.p3	tetracyclines	group	_	magnesium	drug	_	mechanism	absorption of druga is impaired by drugn containing drugn , drugn or drugb , and drugn - containing preparations .
DDI-DrugBank.d711.s2.p4	tetracyclines	group	_	iron	drug	_	mechanism	absorption of druga is impaired by drugn containing drugn , drugn or drugn , and drugb - containing preparations .
DDI-DrugBank.d711.s2.p5	antacids	group	_	aluminum	drug	_	false	absorption of drugn is impaired by druga containing drugb , drugn or drugn , and drugn - containing preparations .
DDI-DrugBank.d711.s2.p6	antacids	group	_	calcium	drug	_	false	absorption of drugn is impaired by druga containing drugn , drugb or drugn , and drugn - containing preparations .
DDI-DrugBank.d711.s2.p7	antacids	group	_	magnesium	drug	_	false	absorption of drugn is impaired by druga containing drugn , drugn or drugb , and drugn - containing preparations .
DDI-DrugBank.d711.s2.p8	antacids	group	_	iron	drug	_	false	absorption of drugn is impaired by druga containing drugn , drugn or drugn , and drugb - containing preparations .
DDI-DrugBank.d711.s2.p11	aluminum	drug	_	iron	drug	_	false	absorption of drugn is impaired by drugn containing druga , drugn or drugn , and drugb - containing preparations .
DDI-DrugBank.d711.s2.p13	calcium	drug	_	iron	drug	_	false	absorption of drugn is impaired by drugn containing drugn , druga or drugn , and drugb - containing preparations .
DDI-DrugBank.d711.s2.p14	magnesium	drug	_	iron	drug	_	false	absorption of drugn is impaired by drugn containing drugn , drugn or druga , and drugb - containing preparations .
DDI-DrugBank.d711.s3.p0	tetracycline	group	_	methoxyflurane	drug	_	effect	the concurrent use of druga and drugb has been reported to result in fatal renal toxicity .
DDI-DrugBank.d711.s4.p0	tetracyclines	group	_	contraceptives	group	_	effect	concurrent use of druga with oral drugb may render oral drugn less effective .
DDI-DrugBank.d711.s4.p1	tetracyclines	group	_	contraceptives	group	_	false	concurrent use of druga with oral drugn may render oral drugb less effective .
DDI-DrugBank.d573.s0.p2	minoxidil	drug	_	guanethidine	drug	_	effect	interaction with drugn : although druga does not itself cause orthostatic hypotension , its administration to patients already receiving drugb can result in profound orthostatic effects .
DDI-DrugBank.d573.s1.p0	guanethidine	drug	_	minoxidil	drug	_	advise	if at all possible druga should be discontinued well before drugb is begun .
DDI-DrugBank.d742.s5.p1	mirtazapine	drug	_	REMERON SolTab	brand	_	false	while in vitro studies have shown that druga is not a potent inhibitor of any of these enzymes , an indication that drugn is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome cyp2b6 enzymes , the concomitant use of drugb with most other drugs metabolized by these enzymes has not been formally studied .
DDI-DrugBank.d742.s5.p2	mirtazapine	drug	_	REMERON SolTab	brand	_	false	while in vitro studies have shown that drugn is not a potent inhibitor of any of these enzymes , an indication that druga is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome cyp2b6 enzymes , the concomitant use of drugb with most other drugs metabolized by these enzymes has not been formally studied .
DDI-DrugBank.d742.s7.p1	Alcohol	drug	_	mirtazapine	drug	_	false	druga : concomitant administration of drugn -lcb- equivalent to # g -rcb- had a minimal effect on plasma levels of drugb -lcb- 15 mg -rcb- in # healthy male subjects .
DDI-DrugBank.d742.s7.p2	alcohol	drug	_	mirtazapine	drug	_	mechanism	drugn : concomitant administration of druga -lcb- equivalent to # g -rcb- had a minimal effect on plasma levels of drugb -lcb- 15 mg -rcb- in # healthy male subjects .
DDI-DrugBank.d742.s8.p0	REMERON	brand	_	alcohol	drug	_	effect	however , the impairment of cognitive and motor skills produced by druga were shown to be additive with those produced by drugb .
DDI-DrugBank.d742.s9.p0	alcohol	drug	_	REMERON SolTab	brand	_	advise	accordingly , patients should be advised to avoid druga while taking drugb , drugn : concomitant administration of drugn -lcb- 15 mg -rcb- had a minimal effect on plasma levels of drugn -lcb- 15 mg -rcb- in # healthy subjects .
DDI-DrugBank.d742.s9.p1	alcohol	drug	_	Diazepam	drug	_	false	accordingly , patients should be advised to avoid druga while taking drugn , drugb : concomitant administration of drugn -lcb- 15 mg -rcb- had a minimal effect on plasma levels of drugn -lcb- 15 mg -rcb- in # healthy subjects .
DDI-DrugBank.d742.s9.p2	alcohol	drug	_	diazepam	drug	_	false	accordingly , patients should be advised to avoid druga while taking drugn , drugn : concomitant administration of drugb -lcb- 15 mg -rcb- had a minimal effect on plasma levels of drugn -lcb- 15 mg -rcb- in # healthy subjects .
DDI-DrugBank.d742.s9.p3	alcohol	drug	_	mirtazapine	drug	_	false	accordingly , patients should be advised to avoid druga while taking drugn , drugn : concomitant administration of drugn -lcb- 15 mg -rcb- had a minimal effect on plasma levels of drugb -lcb- 15 mg -rcb- in # healthy subjects .
DDI-DrugBank.d742.s9.p4	REMERON SolTab	brand	_	Diazepam	drug	_	false	accordingly , patients should be advised to avoid drugn while taking druga , drugb : concomitant administration of drugn -lcb- 15 mg -rcb- had a minimal effect on plasma levels of drugn -lcb- 15 mg -rcb- in # healthy subjects .
DDI-DrugBank.d742.s9.p5	REMERON SolTab	brand	_	diazepam	drug	_	false	accordingly , patients should be advised to avoid drugn while taking druga , drugn : concomitant administration of drugb -lcb- 15 mg -rcb- had a minimal effect on plasma levels of drugn -lcb- 15 mg -rcb- in # healthy subjects .
DDI-DrugBank.d742.s9.p6	REMERON SolTab	brand	_	mirtazapine	drug	_	false	accordingly , patients should be advised to avoid drugn while taking druga , drugn : concomitant administration of drugn -lcb- 15 mg -rcb- had a minimal effect on plasma levels of drugb -lcb- 15 mg -rcb- in # healthy subjects .
DDI-DrugBank.d742.s9.p8	Diazepam	drug	_	mirtazapine	drug	_	false	accordingly , patients should be advised to avoid drugn while taking drugn , druga : concomitant administration of drugn -lcb- 15 mg -rcb- had a minimal effect on plasma levels of drugb -lcb- 15 mg -rcb- in # healthy subjects .
DDI-DrugBank.d742.s9.p9	diazepam	drug	_	mirtazapine	drug	_	mechanism	accordingly , patients should be advised to avoid drugn while taking drugn , drugn : concomitant administration of druga -lcb- 15 mg -rcb- had a minimal effect on plasma levels of drugb -lcb- 15 mg -rcb- in # healthy subjects .
DDI-DrugBank.d742.s10.p0	REMERON	brand	_	diazepam	drug	_	effect	however , the impairment of motor skills produced by druga has been shown to be additive with those caused by drugb .
DDI-DrugBank.d742.s11.p0	diazepam	drug	_	REMERON SolTab	brand	_	advise	accordingly , patients should be advised to avoid druga and other similar drugs while taking drugb .
DDI-DrugBank.d717.s0.p0	Mitotane	drug	_	warfarin	drug	_	mechanism	druga has been reported to accelerate the metabolism of drugb by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for drugn .
DDI-DrugBank.d717.s0.p1	Mitotane	drug	_	warfarin	drug	_	false	druga has been reported to accelerate the metabolism of drugn by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for drugb .
DDI-DrugBank.d717.s1.p0	anticoagulant	group	_	Mitotane	drug	_	false	therefore , physicians should closely monitor patients for a change in druga dosage requirements when administering drugb to patients on drugn .
DDI-DrugBank.d717.s1.p2	Mitotane	drug	_	coumarin-type anticoagulants	group	_	advise	therefore , physicians should closely monitor patients for a change in drugn dosage requirements when administering druga to patients on drugb .
DDI-DrugBank.d775.s0.p1	MIVACRON	brand	_	succinylcholine	drug	_	false	although druga -lcb- a mixture of three stereoisomers -rcb- has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between drugn and drugb has not been systematically studied .
DDI-DrugBank.d775.s0.p2	MIVACRON	brand	_	succinylcholine	drug	_	false	although drugn -lcb- a mixture of three stereoisomers -rcb- has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between druga and drugb has not been systematically studied .
DDI-DrugBank.d775.s1.p0	succinylcholine	drug	_	nondepolarizing agents	group	_	effect	prior administration of druga can potentiate the neuromuscular blocking effects of drugb .
DDI-DrugBank.d775.s2.p0	succinylcholine	drug	_	MIVACRON	brand	_	advise	evidence of spontaneous recovery from druga should be observed before the administration of drugb .
DDI-DrugBank.d775.s3.p0	MIVACRON	brand	_	succinylcholine	drug	_	false	the use of druga before drugb to attenuate some of the side effects of drugn has not been studied .
DDI-DrugBank.d775.s3.p1	MIVACRON	brand	_	succinylcholine	drug	_	false	the use of druga before drugn to attenuate some of the side effects of drugb has not been studied .
DDI-DrugBank.d775.s4.p0	MIVACRON	brand	_	nondepolarizing neuromuscular blocking agents	group	_	false	there are no clinical data on the use of druga with other drugb .
DDI-DrugBank.d775.s5.p0	Isoflurane	drug	_	enflurane	drug	_	false	druga and drugb -lcb- administered with drugn / drugn to achieve # m , c.
DDI-DrugBank.d775.s5.p1	Isoflurane	drug	_	nitrous oxide	drug	_	false	druga and drugn -lcb- administered with drugb / drugn to achieve # m , c.
DDI-DrugBank.d775.s5.p2	Isoflurane	drug	_	oxygen	drug	_	false	druga and drugn -lcb- administered with drugn / drugb to achieve # m , c.
DDI-DrugBank.d775.s5.p3	enflurane	drug	_	nitrous oxide	drug	_	false	drugn and druga -lcb- administered with drugb / drugn to achieve # m , c.
DDI-DrugBank.d775.s5.p4	enflurane	drug	_	oxygen	drug	_	false	drugn and druga -lcb- administered with drugn / drugb to achieve # m , c.
DDI-DrugBank.d775.s8.p0	MIVACRON	brand	_	enflurane	drug	_	false	a greater potentiation of the neuromuscular blocking effects of druga may be expected with higher concentrations of drugb or drugn .
DDI-DrugBank.d775.s8.p1	MIVACRON	brand	_	isoflurane	drug	_	false	a greater potentiation of the neuromuscular blocking effects of druga may be expected with higher concentrations of drugn or drugb .
DDI-DrugBank.d775.s8.p2	enflurane	drug	_	isoflurane	drug	_	false	a greater potentiation of the neuromuscular blocking effects of drugn may be expected with higher concentrations of druga or drugb .
DDI-DrugBank.d775.s10.p0	nondepolarizing agents	drug	_	MIVACRON	brand	_	false	other drugs which may enhance the neuromuscular blocking action of druga such as drugb include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p1	nondepolarizing agents	drug	_	antibiotics	group	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p2	nondepolarizing agents	drug	_	aminoglycosides	group	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p3	nondepolarizing agents	drug	_	tetracyclines	group	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p4	nondepolarizing agents	drug	_	bacitracin	drug	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p5	nondepolarizing agents	drug	_	polymyxins	group	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p6	nondepolarizing agents	drug	_	lincomycin	drug	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p7	nondepolarizing agents	drug	_	clindamycin	drug	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p8	nondepolarizing agents	drug	_	colistin	drug	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p9	nondepolarizing agents	drug	_	sodium colistimethate	drug	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p10	nondepolarizing agents	drug	_	magnesium	group	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugb salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p11	nondepolarizing agents	drug	_	lithium	drug	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugb , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p12	nondepolarizing agents	drug	_	anesthetics	group	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugb , drugn , and drugn .
DDI-DrugBank.d775.s10.p13	nondepolarizing agents	drug	_	procainamide	drug	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugb , and drugn .
DDI-DrugBank.d775.s10.p14	nondepolarizing agents	drug	_	quinidine	drug	_	int	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugb .
DDI-DrugBank.d775.s10.p15	MIVACRON	brand	_	antibiotics	group	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p16	MIVACRON	brand	_	aminoglycosides	group	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p17	MIVACRON	brand	_	tetracyclines	group	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p18	MIVACRON	brand	_	bacitracin	drug	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p19	MIVACRON	brand	_	polymyxins	group	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p20	MIVACRON	brand	_	lincomycin	drug	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p21	MIVACRON	brand	_	clindamycin	drug	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p22	MIVACRON	brand	_	colistin	drug	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p23	MIVACRON	brand	_	sodium colistimethate	drug	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p24	MIVACRON	brand	_	magnesium	group	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugb salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p25	MIVACRON	brand	_	lithium	drug	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugb , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p26	MIVACRON	brand	_	anesthetics	group	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugb , drugn , and drugn .
DDI-DrugBank.d775.s10.p27	MIVACRON	brand	_	procainamide	drug	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugb , and drugn .
DDI-DrugBank.d775.s10.p28	MIVACRON	brand	_	quinidine	drug	_	int	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugb .
DDI-DrugBank.d775.s10.p110	magnesium	group	_	lithium	drug	_	false	other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugb , local drugn , drugn , and drugn .
DDI-DrugBank.d775.s10.p111	magnesium	group	_	anesthetics	group	_	false	other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugn , local drugb , drugn , and drugn .
DDI-DrugBank.d775.s10.p112	magnesium	group	_	procainamide	drug	_	false	other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugn , local drugn , drugb , and drugn .
DDI-DrugBank.d775.s10.p113	magnesium	group	_	quinidine	drug	_	false	other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugn , local drugn , drugn , and drugb .
DDI-DrugBank.d775.s11.p0	MIVACRON	brand	_	contraceptives	group	_	effect	the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma bche activity -lcb- e , g , , chronically administered oral drugb , drugn , or certain drugn -rcb- or by drugs that irreversibly inhibit plasma bche , resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugn .
DDI-DrugBank.d775.s11.p1	MIVACRON	brand	_	glucocorticoids	group	_	effect	the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma bche activity -lcb- e , g , , chronically administered oral drugn , drugb , or certain drugn -rcb- or by drugs that irreversibly inhibit plasma bche , resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugn .
DDI-DrugBank.d775.s11.p2	MIVACRON	brand	_	monoamine oxidase inhibitors	group	_	effect	the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma bche activity -lcb- e , g , , chronically administered oral drugn , drugn , or certain drugb -rcb- or by drugs that irreversibly inhibit plasma bche , resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugn .
DDI-DrugBank.d775.s11.p18	neuromuscular blocking agents	group	_	phenytoin	drug	_	effect	the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma bche activity -lcb- e , g , , chronically administered oral drugn , drugn , or certain drugn -rcb- or by drugs that irreversibly inhibit plasma bche , resistance to the neuromuscular blocking action of nondepolarizing druga has been demonstrated in patients chronically administered drugb or drugn .
DDI-DrugBank.d775.s11.p19	neuromuscular blocking agents	group	_	carbamazepine	drug	_	effect	the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma bche activity -lcb- e , g , , chronically administered oral drugn , drugn , or certain drugn -rcb- or by drugs that irreversibly inhibit plasma bche , resistance to the neuromuscular blocking action of nondepolarizing druga has been demonstrated in patients chronically administered drugn or drugb .
DDI-DrugBank.d775.s11.p20	phenytoin	drug	_	carbamazepine	drug	_	false	the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma bche activity -lcb- e , g , , chronically administered oral drugn , drugn , or certain drugn -rcb- or by drugs that irreversibly inhibit plasma bche , resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered druga or drugb .
DDI-DrugBank.d775.s12.p0	phenytoin	drug	_	carbamazepine	drug	_	false	while the effects of chronic druga or drugb therapy on the action of drugn are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d775.s12.p1	phenytoin	drug	_	MIVACRON	brand	_	effect	while the effects of chronic druga or drugn therapy on the action of drugb are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d775.s12.p2	carbamazepine	drug	_	MIVACRON	brand	_	effect	while the effects of chronic drugn or druga therapy on the action of drugb are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d775.s13.p0	corticosteroids	group	_	phenytoin	drug	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugb or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p1	corticosteroids	group	_	carbamazepine	drug	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugb - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p2	corticosteroids	group	_	antibiotics	group	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugb given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p3	corticosteroids	group	_	cisplatin	drug	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugb - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p4	corticosteroids	group	_	edrophonium	drug	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugb - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p5	corticosteroids	group	_	neostigmine	drug	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p6	corticosteroids	group	_	polymyxin B	drug	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p7	corticosteroids	group	_	bacitracin	drug	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p8	corticosteroids	group	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p9	corticosteroids	group	_	procaine	drug	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p10	corticosteroids	group	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
DDI-DrugBank.d775.s13.p11	corticosteroids	group	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p12	corticosteroids	group	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p13	phenytoin	drug	_	carbamazepine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugb - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p14	phenytoin	drug	_	antibiotics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugb given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p15	phenytoin	drug	_	cisplatin	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugb - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p16	phenytoin	drug	_	edrophonium	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugb - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p17	phenytoin	drug	_	neostigmine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p18	phenytoin	drug	_	polymyxin B	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p19	phenytoin	drug	_	bacitracin	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p20	phenytoin	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p21	phenytoin	drug	_	procaine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p22	phenytoin	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
DDI-DrugBank.d775.s13.p23	phenytoin	drug	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p24	phenytoin	drug	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p25	carbamazepine	drug	_	antibiotics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugb given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p26	carbamazepine	drug	_	cisplatin	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugb - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p27	carbamazepine	drug	_	edrophonium	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugb - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p28	carbamazepine	drug	_	neostigmine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p29	carbamazepine	drug	_	polymyxin B	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p30	carbamazepine	drug	_	bacitracin	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p31	carbamazepine	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p32	carbamazepine	drug	_	procaine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p33	carbamazepine	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
DDI-DrugBank.d775.s13.p34	carbamazepine	drug	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p35	carbamazepine	drug	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p36	antibiotics	group	_	cisplatin	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugb - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p37	antibiotics	group	_	edrophonium	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugb - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p38	antibiotics	group	_	neostigmine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p39	antibiotics	group	_	polymyxin B	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p40	antibiotics	group	_	bacitracin	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p41	antibiotics	group	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p42	antibiotics	group	_	procaine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p43	antibiotics	group	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
DDI-DrugBank.d775.s13.p44	antibiotics	group	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p45	antibiotics	group	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p46	cisplatin	drug	_	edrophonium	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugb - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p47	cisplatin	drug	_	neostigmine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p48	cisplatin	drug	_	polymyxin B	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p49	cisplatin	drug	_	bacitracin	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p50	cisplatin	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p51	cisplatin	drug	_	procaine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p52	cisplatin	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
DDI-DrugBank.d775.s13.p53	cisplatin	drug	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p54	cisplatin	drug	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p55	edrophonium	drug	_	neostigmine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p56	edrophonium	drug	_	polymyxin B	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p57	edrophonium	drug	_	bacitracin	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p58	edrophonium	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p59	edrophonium	drug	_	procaine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p60	edrophonium	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
DDI-DrugBank.d775.s13.p61	edrophonium	drug	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p62	edrophonium	drug	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p63	neostigmine	drug	_	polymyxin B	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p64	neostigmine	drug	_	bacitracin	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p65	neostigmine	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p66	neostigmine	drug	_	procaine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p67	neostigmine	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
DDI-DrugBank.d775.s13.p68	neostigmine	drug	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p69	neostigmine	drug	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p70	polymyxin B	drug	_	bacitracin	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugb - local drugn such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p71	polymyxin B	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugn - local drugb such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p72	polymyxin B	drug	_	procaine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugn - local drugn such as drugb - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p73	polymyxin B	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugn - local drugn such as drugn - general drugb - drugn or other drugn
DDI-DrugBank.d775.s13.p74	polymyxin B	drug	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugn - local drugn such as drugn - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p75	polymyxin B	drug	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugn - local drugn such as drugn - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p76	bacitracin	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or druga - local drugb such as drugn - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p77	bacitracin	drug	_	procaine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or druga - local drugn such as drugb - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p78	bacitracin	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or druga - local drugn such as drugn - general drugb - drugn or other drugn
DDI-DrugBank.d775.s13.p79	bacitracin	drug	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or druga - local drugn such as drugn - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p80	bacitracin	drug	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or druga - local drugn such as drugn - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p81	anesthetics	group	_	procaine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local druga such as drugb - general drugn - drugn or other drugn
DDI-DrugBank.d775.s13.p83	anesthetics	group	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local druga such as drugn - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p84	anesthetics	group	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local druga such as drugn - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p85	procaine	drug	_	anesthetics	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as druga - general drugb - drugn or other drugn
DDI-DrugBank.d775.s13.p86	procaine	drug	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as druga - general drugn - drugb or other drugn
DDI-DrugBank.d775.s13.p87	procaine	drug	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as druga - general drugn - drugn or other drugb
DDI-DrugBank.d775.s13.p88	anesthetics	group	_	succinylcholine	drug	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general druga - drugb or other drugn
DDI-DrugBank.d775.s13.p89	anesthetics	group	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general druga - drugn or other drugb
DDI-DrugBank.d775.s13.p90	succinylcholine	drug	_	muscle relaxants	group	_	false	some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - druga or other drugb
DDI-DrugBank.d640.s0.p0	Diuretics	group	_	ACE inhibitors	group	_	false	druga : excessive reductions in blood pressure may occur in patients on diuretic therapy when drugb are started .
DDI-DrugBank.d640.s2.p1	Potassium	drug	_	UNIVASC	brand	_	false	druga supplements and drugn : drugb can increase serum potassium because it decreases aldosterone secretion .
DDI-DrugBank.d640.s2.p2	Potassium-Sparing Diuretics	group	_	UNIVASC	brand	_	false	drugn supplements and druga : drugb can increase serum potassium because it decreases aldosterone secretion .
DDI-DrugBank.d640.s3.p4	potassium-sparing diuretics	group	_	ACE inhibitors	group	_	effect	use of druga -lcb- drugn , drugn , drugn -rcb- or drugn supplements concomitantly with drugb can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.p7	spironolactone	drug	_	potassium	drug	_	false	use of drugn -lcb- druga , drugn , drugn -rcb- or drugb supplements concomitantly with drugn can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.p8	spironolactone	drug	_	ACE inhibitors	group	_	effect	use of drugn -lcb- druga , drugn , drugn -rcb- or drugn supplements concomitantly with drugb can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.p10	triamterene	drug	_	potassium	drug	_	false	use of drugn -lcb- drugn , druga , drugn -rcb- or drugb supplements concomitantly with drugn can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.p11	triamterene	drug	_	ACE inhibitors	group	_	effect	use of drugn -lcb- drugn , druga , drugn -rcb- or drugn supplements concomitantly with drugb can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.p12	amiloride	drug	_	potassium	drug	_	false	use of drugn -lcb- drugn , drugn , druga -rcb- or drugb supplements concomitantly with drugn can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.p13	amiloride	drug	_	ACE inhibitors	group	_	effect	use of drugn -lcb- drugn , drugn , druga -rcb- or drugn supplements concomitantly with drugb can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.p14	potassium	drug	_	ACE inhibitors	group	_	effect	use of drugn -lcb- drugn , drugn , drugn -rcb- or druga supplements concomitantly with drugb can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s5.p0	Anticoagulants	group	_	warfarin	drug	_	false	oral druga : interaction studies with drugb failed to identify any clinically important effect on the serum concentrations of the drugn or on its anticoagulant effect .
DDI-DrugBank.d640.s5.p2	warfarin	drug	_	anticoagulant	group	_	false	oral drugn : interaction studies with druga failed to identify any clinically important effect on the serum concentrations of the drugb or on its anticoagulant effect .
DDI-DrugBank.d640.s6.p2	Lithium	drug	_	ACE inhibitors	group	_	false	druga : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving drugb during therapy with drugn .
DDI-DrugBank.d640.s6.p5	lithium	drug	_	ACE inhibitors	group	_	false	drugn : increased serum druga levels and symptoms of drugn toxicity have been reported in patients receiving drugb during therapy with drugn .
DDI-DrugBank.d640.s6.p7	lithium	drug	_	ACE inhibitors	group	_	false	drugn : increased serum drugn levels and symptoms of druga toxicity have been reported in patients receiving drugb during therapy with drugn .
DDI-DrugBank.d640.s6.p9	ACE inhibitors	group	_	lithium	drug	_	effect	drugn : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving druga during therapy with drugb .
DDI-DrugBank.d640.s8.p0	diuretic	group	_	lithium	drug	_	effect	if a druga is also used , the risk of drugb toxicity may be increased .
DDI-DrugBank.d640.s9.p0	UNIVASC	brand	_	hydrochlorothiazide	drug	_	false	other agents : no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugb , drugn , or drugn .
DDI-DrugBank.d640.s9.p1	UNIVASC	brand	_	digoxin	drug	_	false	other agents : no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugb , or drugn .
DDI-DrugBank.d640.s9.p2	UNIVASC	brand	_	cimetidine	drug	_	false	other agents : no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugn , or drugb .
DDI-DrugBank.d640.s10.p0	UNIVASC	brand	_	calcium-channel-blocking agents	group	_	false	druga has been used in clinical trials concomitantly with drugb , drugn , drugn , drugn , oral drugn , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.p1	UNIVASC	brand	_	diuretics	group	_	false	druga has been used in clinical trials concomitantly with drugn , drugb , drugn , drugn , oral drugn , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.p2	UNIVASC	brand	_	H2 blockers	group	_	false	druga has been used in clinical trials concomitantly with drugn , drugn , drugb , drugn , oral drugn , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.p3	UNIVASC	brand	_	digoxin	drug	_	false	druga has been used in clinical trials concomitantly with drugn , drugn , drugn , drugb , oral drugn , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.p4	UNIVASC	brand	_	hypoglycemic agents	group	_	false	druga has been used in clinical trials concomitantly with drugn , drugn , drugn , drugn , oral drugb , and cholesterol-lowering agents .
DDI-DrugBank.d580.s1.p0	ketoconazole	drug	_	mometasone furoate	drug	_	mechanism	however , druga , a potent inhibitor of cytochrome p450 3a4 , may increase plasma levels of drugb during concomitant dosing .
DDI-DrugBank.d739.s0.p0	Montelukast	drug	_	theophylline	drug	_	false	druga at a dose of # mg once daily dosed to pharmacokinetic steady state - did not cause clinically significant changes in the kinetics of a single intravenous dose of drugb -lcb- predominantly a cyp1a2 substrate -rcb- .
DDI-DrugBank.d739.s3.p0	terfenadine	drug	_	fexofenadine	drug	_	false	- did not change the plasma concentration profile of druga -lcb- a substrate of cytochrome p450 3a4 -rcb- or drugb , its carboxylated metabolite , and did not prolong the qtc interval following co-administration with drugn # mg twice daily .
DDI-DrugBank.d739.s3.p2	fexofenadine	drug	_	terfenadine	drug	_	false	- did not change the plasma concentration profile of drugn -lcb- a substrate of cytochrome p450 3a4 -rcb- or druga , its carboxylated metabolite , and did not prolong the qtc interval following co-administration with drugb # mg twice daily .
DDI-DrugBank.d739.s4.p0	Montelukast	drug	_	contraceptive	group	_	false	druga at doses of # mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral drugb containing drugn # mg/ethinyl drugn # mcg .
DDI-DrugBank.d739.s4.p1	Montelukast	drug	_	norethindrone	drug	_	false	druga at doses of # mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral drugn containing drugb # mg/ethinyl drugn # mcg .
DDI-DrugBank.d739.s4.p2	Montelukast	drug	_	estradiol	drug	_	false	druga at doses of # mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral drugn containing drugn # mg/ethinyl drugb # mcg .
DDI-DrugBank.d739.s4.p3	contraceptive	group	_	norethindrone	drug	_	false	drugn at doses of # mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral druga containing drugb # mg/ethinyl drugn # mcg .
DDI-DrugBank.d739.s4.p4	contraceptive	group	_	estradiol	drug	_	false	drugn at doses of # mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral druga containing drugn # mg/ethinyl drugb # mcg .
DDI-DrugBank.d739.s4.p5	norethindrone	drug	_	estradiol	drug	_	false	drugn at doses of # mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral drugn containing druga # mg/ethinyl drugb # mcg .
DDI-DrugBank.d739.s5.p0	prednisone	drug	_	prednisolone	drug	_	false	- did not cause any clinically significant change in plasma profiles of druga or drugb following administration of either oral drugn or intravenous drugn .
DDI-DrugBank.d739.s5.p2	prednisone	drug	_	prednisolone	drug	_	false	- did not cause any clinically significant change in plasma profiles of druga or drugn following administration of either oral drugn or intravenous drugb .
DDI-DrugBank.d739.s5.p3	prednisolone	drug	_	prednisone	drug	_	false	- did not cause any clinically significant change in plasma profiles of drugn or druga following administration of either oral drugb or intravenous drugn .
DDI-DrugBank.d739.s5.p5	prednisone	drug	_	prednisolone	drug	_	false	- did not cause any clinically significant change in plasma profiles of drugn or drugn following administration of either oral druga or intravenous drugb .
DDI-DrugBank.d739.s6.p0	Phenobarbital	drug	_	montelukast	drug	_	false	druga , which induces hepatic metabolism , decreased the auc of drugb approximately 40 % following a single 10-mg dose of drugn .
DDI-DrugBank.d739.s6.p1	Phenobarbital	drug	_	montelukast	drug	_	false	druga , which induces hepatic metabolism , decreased the auc of drugn approximately 40 % following a single 10-mg dose of drugb .
DDI-DrugBank.d739.s8.p0	phenobarbital	drug	_	rifampin	drug	_	false	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or drugb , are co-administered with drugn .
DDI-DrugBank.d739.s8.p1	phenobarbital	drug	_	montelukast	drug	_	advise	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or drugn , are co-administered with drugb .
DDI-DrugBank.d739.s8.p2	rifampin	drug	_	montelukast	drug	_	advise	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as drugn or druga , are co-administered with drugb .
DDI-DrugBank.d739.s10.p0	montelukast	drug	_	theophylline	drug	_	false	in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugb , drugn , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p1	montelukast	drug	_	prednisone	drug	_	false	in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugb , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p2	montelukast	drug	_	prednisolone	drug	_	false	in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugb , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p3	montelukast	drug	_	contraceptives	group	_	false	in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugb -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p4	montelukast	drug	_	norethindrone	drug	_	false	in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- drugb # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p5	montelukast	drug	_	ethinyl estradiol	drug	_	false	in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- drugn # mg / drugb # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p6	montelukast	drug	_	terfenadine	drug	_	false	in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugb , drugn , and drugn .
DDI-DrugBank.d739.s10.p7	montelukast	drug	_	digoxin	drug	_	false	in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugb , and drugn .
DDI-DrugBank.d739.s10.p8	montelukast	drug	_	warfarin	drug	_	false	in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugn , and drugb .
DDI-DrugBank.d739.s10.p9	theophylline	drug	_	prednisone	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugb , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p10	theophylline	drug	_	prednisolone	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugb , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p12	theophylline	drug	_	norethindrone	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugn -lcb- drugb # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p13	theophylline	drug	_	ethinyl estradiol	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugn -lcb- drugn # mg / drugb # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p14	theophylline	drug	_	terfenadine	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugb , drugn , and drugn .
DDI-DrugBank.d739.s10.p15	theophylline	drug	_	digoxin	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugb , and drugn .
DDI-DrugBank.d739.s10.p16	theophylline	drug	_	warfarin	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugn , and drugb .
DDI-DrugBank.d739.s10.p17	prednisone	drug	_	prednisolone	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugb , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p19	prednisone	drug	_	norethindrone	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugn -lcb- drugb # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p20	prednisone	drug	_	ethinyl estradiol	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugn -lcb- drugn # mg / drugb # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p21	prednisone	drug	_	terfenadine	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugb , drugn , and drugn .
DDI-DrugBank.d739.s10.p22	prednisone	drug	_	digoxin	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugb , and drugn .
DDI-DrugBank.d739.s10.p23	prednisone	drug	_	warfarin	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugn -lcb- drugn # mg / drugn # mcg -rcb- , drugn , drugn , and drugb .
DDI-DrugBank.d739.s10.p25	prednisolone	drug	_	norethindrone	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , druga , oral drugn -lcb- drugb # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p26	prednisolone	drug	_	ethinyl estradiol	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , druga , oral drugn -lcb- drugn # mg / drugb # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p30	contraceptives	group	_	norethindrone	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral druga -lcb- drugb # mg / drugn # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p31	contraceptives	group	_	ethinyl estradiol	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral druga -lcb- drugn # mg / drugb # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p35	norethindrone	drug	_	ethinyl estradiol	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- druga # mg / drugb # mcg -rcb- , drugn , drugn , and drugn .
DDI-DrugBank.d739.s10.p36	norethindrone	drug	_	terfenadine	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- druga # mg / drugn # mcg -rcb- , drugb , drugn , and drugn .
DDI-DrugBank.d739.s10.p37	norethindrone	drug	_	digoxin	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- druga # mg / drugn # mcg -rcb- , drugn , drugb , and drugn .
DDI-DrugBank.d739.s10.p38	norethindrone	drug	_	warfarin	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- druga # mg / drugn # mcg -rcb- , drugn , drugn , and drugb .
DDI-DrugBank.d739.s10.p39	ethinyl estradiol	drug	_	terfenadine	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- drugn # mg / druga # mcg -rcb- , drugb , drugn , and drugn .
DDI-DrugBank.d739.s10.p40	ethinyl estradiol	drug	_	digoxin	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- drugn # mg / druga # mcg -rcb- , drugn , drugb , and drugn .
DDI-DrugBank.d739.s10.p41	ethinyl estradiol	drug	_	warfarin	drug	_	false	in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn -lcb- drugn # mg / druga # mcg -rcb- , drugn , drugn , and drugb .
DDI-DrugBank.d739.s13.p0	Phenobarbital	drug	_	montelukast	drug	_	false	druga , which induces hepatic metabolism , decreased the auc of drugb approximately 40 % following a single 10-mg dose of drugn .
DDI-DrugBank.d739.s13.p1	Phenobarbital	drug	_	montelukast	drug	_	false	druga , which induces hepatic metabolism , decreased the auc of drugn approximately 40 % following a single 10-mg dose of drugb .
DDI-DrugBank.d739.s15.p0	phenobarbital	drug	_	rifampin	drug	_	false	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or drugb , are co-administered with drugn .
DDI-DrugBank.d739.s15.p1	phenobarbital	drug	_	montelukast	drug	_	advise	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or drugn , are co-administered with drugb .
DDI-DrugBank.d739.s15.p2	rifampin	drug	_	montelukast	drug	_	advise	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as drugn or druga , are co-administered with drugb .
DDI-DrugBank.d637.s0.p6	morphine	drug	_	CNS depressants	group	_	effect	use with other drugn : the depressant effects of druga are potentiated by the presence of other drugb such as drugn , drugn , drugn , or drugn .
DDI-DrugBank.d637.s0.p7	morphine	drug	_	alcohol	drug	_	effect	use with other drugn : the depressant effects of druga are potentiated by the presence of other drugn such as drugb , drugn , drugn , or drugn .
DDI-DrugBank.d637.s0.p8	morphine	drug	_	sedatives	group	_	effect	use with other drugn : the depressant effects of druga are potentiated by the presence of other drugn such as drugn , drugb , drugn , or drugn .
DDI-DrugBank.d637.s0.p9	morphine	drug	_	antihistaminics	group	_	effect	use with other drugn : the depressant effects of druga are potentiated by the presence of other drugn such as drugn , drugn , drugb , or drugn .
DDI-DrugBank.d637.s0.p10	morphine	drug	_	psychotropic drugs	group	_	effect	use with other drugn : the depressant effects of druga are potentiated by the presence of other drugn such as drugn , drugn , drugn , or drugb .
DDI-DrugBank.d637.s0.p11	CNS depressants	group	_	alcohol	drug	_	false	use with other drugn : the depressant effects of drugn are potentiated by the presence of other druga such as drugb , drugn , drugn , or drugn .
DDI-DrugBank.d637.s0.p12	CNS depressants	group	_	sedatives	group	_	false	use with other drugn : the depressant effects of drugn are potentiated by the presence of other druga such as drugn , drugb , drugn , or drugn .
DDI-DrugBank.d637.s0.p13	CNS depressants	group	_	antihistaminics	group	_	false	use with other drugn : the depressant effects of drugn are potentiated by the presence of other druga such as drugn , drugn , drugb , or drugn .
DDI-DrugBank.d637.s0.p14	CNS depressants	group	_	psychotropic drugs	group	_	false	use with other drugn : the depressant effects of drugn are potentiated by the presence of other druga such as drugn , drugn , drugn , or drugb .
DDI-DrugBank.d637.s1.p0	neuroleptics	group	_	morphine	drug	_	effect	use of druga in conjunction with oral drugb may increase the risk of respiratory depression , hypotension and profound sedation or coma .
DDI-DrugBank.d637.s2.p1	Mixed Agonist/Antagonist Opioid Analgesics	group	_	pentazocine	drug	_	false	interaction with druga : drugn -lcb- i , e , , drugb , drugn , drugn , or drugn -rcb- should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
DDI-DrugBank.d637.s2.p2	Mixed Agonist/Antagonist Opioid Analgesics	group	_	nalbuphine	drug	_	false	interaction with druga : drugn -lcb- i , e , , drugn , drugb , drugn , or drugn -rcb- should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
DDI-DrugBank.d637.s2.p3	Mixed Agonist/Antagonist Opioid Analgesics	group	_	butorphanol	drug	_	false	interaction with druga : drugn -lcb- i , e , , drugn , drugn , drugb , or drugn -rcb- should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
DDI-DrugBank.d637.s2.p4	Mixed Agonist/Antagonist Opioid Analgesics	group	_	buprenorphine	drug	_	false	interaction with druga : drugn -lcb- i , e , , drugn , drugn , drugn , or drugb -rcb- should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
DDI-DrugBank.d637.s2.p10	Agonist/antagonist analgesics	group	_	opioid agonist analgesic	group	_	advise	interaction with drugn : druga -lcb- i , e , , drugn , drugn , drugn , or drugn -rcb- should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d637.s2.p14	pentazocine	drug	_	opioid agonist analgesic	group	_	advise	interaction with drugn : drugn -lcb- i , e , , druga , drugn , drugn , or drugn -rcb- should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d637.s2.p17	nalbuphine	drug	_	opioid agonist analgesic	group	_	advise	interaction with drugn : drugn -lcb- i , e , , drugn , druga , drugn , or drugn -rcb- should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d637.s2.p19	butorphanol	drug	_	opioid agonist analgesic	group	_	advise	interaction with drugn : drugn -lcb- i , e , , drugn , drugn , druga , or drugn -rcb- should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d637.s2.p20	buprenorphine	drug	_	opioid agonist analgesic	group	_	advise	interaction with drugn : drugn -lcb- i , e , , drugn , drugn , drugn , or druga -rcb- should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d700.s0.p0	Antacids	group	_	Myfortic	brand	_	false	druga : absorption of a single dose of drugb was decreased when administered to # stable renal transplant patients also taking drugn - drugn containing drugn -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p1	Antacids	group	_	magnesium	drug	_	false	druga : absorption of a single dose of drugn was decreased when administered to # stable renal transplant patients also taking drugb - drugn containing drugn -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p2	Antacids	group	_	aluminum	drug	_	false	druga : absorption of a single dose of drugn was decreased when administered to # stable renal transplant patients also taking drugn - drugb containing drugn -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p4	Antacids	group	_	Myfortic	brand	_	false	druga : absorption of a single dose of drugn was decreased when administered to # stable renal transplant patients also taking drugn - drugn containing drugn -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugb was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p5	Myfortic	brand	_	magnesium	drug	_	mechanism	drugn : absorption of a single dose of druga was decreased when administered to # stable renal transplant patients also taking drugb - drugn containing drugn -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p6	Myfortic	brand	_	aluminum	drug	_	mechanism	drugn : absorption of a single dose of druga was decreased when administered to # stable renal transplant patients also taking drugn - drugb containing drugn -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p7	Myfortic	brand	_	antacids	group	_	false	drugn : absorption of a single dose of druga was decreased when administered to # stable renal transplant patients also taking drugn - drugn containing drugb -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p9	magnesium	drug	_	aluminum	drug	_	false	drugn : absorption of a single dose of drugn was decreased when administered to # stable renal transplant patients also taking druga - drugb containing drugn -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p10	magnesium	drug	_	antacids	group	_	false	drugn : absorption of a single dose of drugn was decreased when administered to # stable renal transplant patients also taking druga - drugn containing drugb -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p11	magnesium	drug	_	Myfortic	brand	_	false	drugn : absorption of a single dose of drugn was decreased when administered to # stable renal transplant patients also taking druga - drugn containing drugn -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugb was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p12	aluminum	drug	_	antacids	group	_	false	drugn : absorption of a single dose of drugn was decreased when administered to # stable renal transplant patients also taking drugn - druga containing drugb -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p13	aluminum	drug	_	Myfortic	brand	_	false	drugn : absorption of a single dose of drugn was decreased when administered to # stable renal transplant patients also taking drugn - druga containing drugn -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugb was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.p14	antacids	group	_	Myfortic	brand	_	false	drugn : absorption of a single dose of drugn was decreased when administered to # stable renal transplant patients also taking drugn - drugn containing druga -lcb- 30 ml -rcb- : the mean cmax and auc -lcb- 0-t -rcb- values for mpa were 25 % and 37 % lower , respectively , than when drugb was administered alone under fasting conditions .
DDI-DrugBank.d700.s1.p0	Myfortic	drug	_	antacids	group	_	advise	it is recommended that druga and drugb not be administered simultaneously .
DDI-DrugBank.d700.s2.p2	cyclosporine	drug	_	Myfortic	brand	_	false	drugn : when studied in stable renal transplant patients , druga , usp -lcb- modified -rcb- pharmacokinetics were unaffected by steady state dosing of drugb .
DDI-DrugBank.d700.s3.p0	Acyclovir	drug	_	Ganciclovir	drug	_	false	druga / drugb : may be taken with drugn ;
DDI-DrugBank.d700.s3.p1	Acyclovir	drug	_	Myfortic	brand	_	false	druga / drugn : may be taken with drugb ;
DDI-DrugBank.d700.s3.p2	Ganciclovir	drug	_	Myfortic	brand	_	false	drugn / druga : may be taken with drugb ;
DDI-DrugBank.d700.s5.p1	acyclovir	drug	_	MPAG	drug_n	_	false	both druga / drugn and drugb concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
DDI-DrugBank.d700.s5.p2	ganciclovir	drug	_	MPAG	drug_n	_	false	both drugn / druga and drugb concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
DDI-DrugBank.d700.s6.p0	Azathioprine	drug	_	Mycophenolate Mofetil	drug	_	false	druga / drugb : given that drugn and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugn .
DDI-DrugBank.d700.s6.p2	Azathioprine	drug	_	mycophenolate mofetil	drug	_	false	druga / drugn : given that drugn and drugb inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugn .
DDI-DrugBank.d700.s6.p3	Azathioprine	drug	_	Myfortic	brand	_	false	druga / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with drugn or drugn .
DDI-DrugBank.d700.s6.p5	Azathioprine	drug	_	mycophenolate mofetil	drug	_	false	druga / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugb .
DDI-DrugBank.d700.s6.p6	Mycophenolate Mofetil	drug	_	azathioprine	drug	_	false	drugn / druga : given that drugb and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugn .
DDI-DrugBank.d700.s6.p8	Mycophenolate Mofetil	drug	_	Myfortic	brand	_	false	drugn / druga : given that drugn and drugn inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with drugn or drugn .
DDI-DrugBank.d700.s6.p9	Mycophenolate Mofetil	drug	_	azathioprine	drug	_	false	drugn / druga : given that drugn and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugb or drugn .
DDI-DrugBank.d700.s6.p11	azathioprine	drug	_	mycophenolate mofetil	drug	_	false	drugn / drugn : given that druga and drugb inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugn .
DDI-DrugBank.d700.s6.p12	azathioprine	drug	_	Myfortic	brand	_	false	drugn / drugn : given that druga and drugn inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with drugn or drugn .
DDI-DrugBank.d700.s6.p14	azathioprine	drug	_	mycophenolate mofetil	drug	_	false	drugn / drugn : given that druga and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugb .
DDI-DrugBank.d700.s6.p15	mycophenolate mofetil	drug	_	Myfortic	brand	_	false	drugn / drugn : given that drugn and druga inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with drugn or drugn .
DDI-DrugBank.d700.s6.p16	mycophenolate mofetil	drug	_	azathioprine	drug	_	false	drugn / drugn : given that drugn and druga inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugb or drugn .
DDI-DrugBank.d700.s6.p18	Myfortic	brand	_	azathioprine	drug	_	advise	drugn / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that druga not be administered concomitantly with drugb or drugn .
DDI-DrugBank.d700.s6.p19	Myfortic	brand	_	mycophenolate mofetil	drug	_	advise	drugn / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that druga not be administered concomitantly with drugn or drugb .
DDI-DrugBank.d700.s6.p20	azathioprine	drug	_	mycophenolate mofetil	drug	_	false	drugn / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with druga or drugb .
DDI-DrugBank.d700.s7.p2	MPA	drug_n	_	mycophenolate mofetil	drug	_	false	drugn and drugs that bind bile acids : these drugs interrupt enterohepatic recirculation and reduce druga exposure when coadministered with drugb .
DDI-DrugBank.d700.s8.p0	Myfortic	drug	_	cholestyramine	drug	_	advise	therefore , do not administer druga with drugb or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile_acid sequestrates or oral drugn , because of the potential to reduce the efficacy of drugn .
DDI-DrugBank.d700.s8.p1	Myfortic	drug	_	activated charcoal	drug	_	advise	therefore , do not administer druga with drugn or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile_acid sequestrates or oral drugb , because of the potential to reduce the efficacy of drugn .
DDI-DrugBank.d700.s8.p3	cholestyramine	drug	_	activated charcoal	drug	_	false	therefore , do not administer drugn with druga or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile_acid sequestrates or oral drugb , because of the potential to reduce the efficacy of drugn .
DDI-DrugBank.d700.s8.p4	cholestyramine	drug	_	Myfortic	brand	_	false	therefore , do not administer drugn with druga or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile_acid sequestrates or oral drugn , because of the potential to reduce the efficacy of drugb .
DDI-DrugBank.d700.s8.p5	activated charcoal	drug	_	Myfortic	brand	_	false	therefore , do not administer drugn with drugn or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile_acid sequestrates or oral druga , because of the potential to reduce the efficacy of drugb .
DDI-DrugBank.d700.s9.p0	Contraceptives	group	_	Myfortic	brand	_	false	oral druga : given the different metabolism of drugb and oral drugn , no drug interaction between these two classes of drug is expected .
DDI-DrugBank.d700.s9.p2	Myfortic	brand	_	contraceptives	group	_	false	oral drugn : given the different metabolism of druga and oral drugb , no drug interaction between these two classes of drug is expected .
DDI-DrugBank.d700.s10.p0	levonorgesterol	drug	_	mycophenolate mofetil	drug	_	mechanism	however , in a drug-drug interaction study , mean druga auc was decreased by 15 % when coadministered with drugb .
DDI-DrugBank.d700.s11.p0	contraceptives	group	_	Myfortic	brand	_	advise	therefore , it is recommended that oral druga are co - administered with drugb with caution and additional birth control methods be considered .
DDI-DrugBank.d700.s12.p0	Live Vaccines	group	_	Myfortic	drug	_	false	druga : during treatment with drugb , the use of drugn should be avoided and patients should be advised that vaccinations may be less effective .
DDI-DrugBank.d700.s12.p1	Live Vaccines	group	_	live attenuated vaccines	group	_	false	druga : during treatment with drugn , the use of drugb should be avoided and patients should be advised that vaccinations may be less effective .
DDI-DrugBank.d700.s12.p2	Myfortic	drug	_	live attenuated vaccines	group	_	advise	drugn : during treatment with druga , the use of drugb should be avoided and patients should be advised that vaccinations may be less effective .
DDI-DrugBank.d763.s3.p20	phenytoin	drug	_	ondansetron	drug	_	mechanism	drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 -lcb- i , e , , druga , drugn , and drugn -rcb- , the clearance of drugb was significantly increased and drugn blood concentrations were decreased .
DDI-DrugBank.d763.s3.p21	phenytoin	drug	_	ondansetron	drug	_	mechanism	drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 -lcb- i , e , , druga , drugn , and drugn -rcb- , the clearance of drugn was significantly increased and drugb blood concentrations were decreased .
DDI-DrugBank.d763.s3.p23	carbamazepine	drug	_	ondansetron	drug	_	mechanism	drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 -lcb- i , e , , drugn , druga , and drugn -rcb- , the clearance of drugb was significantly increased and drugn blood concentrations were decreased .
DDI-DrugBank.d763.s3.p24	carbamazepine	drug	_	ondansetron	drug	_	mechanism	drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 -lcb- i , e , , drugn , druga , and drugn -rcb- , the clearance of drugn was significantly increased and drugb blood concentrations were decreased .
DDI-DrugBank.d763.s3.p25	rifampicin	drug	_	ondansetron	drug	_	mechanism	drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 -lcb- i , e , , drugn , drugn , and druga -rcb- , the clearance of drugb was significantly increased and drugn blood concentrations were decreased .
DDI-DrugBank.d763.s3.p26	rifampicin	drug	_	ondansetron	drug	_	mechanism	drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 -lcb- i , e , , drugn , drugn , and druga -rcb- , the clearance of drugn was significantly increased and drugb blood concentrations were decreased .
DDI-DrugBank.d763.s4.p0	ondansetron	drug	_	Tramadol	drug	_	false	however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs # ,3 drugb : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from # small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn # ,5 chemotherapy : tumor response to chemotherapy in the p # mouse leukemia model is not affected by drugn .
DDI-DrugBank.d763.s4.p11	ondansetron	drug	_	tramadol	drug	_	false	however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs # ,3 drugn : although no pharmacokinetic drug interaction between druga and drugb has been observed , data from # small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn # ,5 chemotherapy : tumor response to chemotherapy in the p # mouse leukemia model is not affected by drugn .
DDI-DrugBank.d763.s4.p13	ondansetron	drug	_	tramadol	drug	_	false	however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs # ,3 drugn : although no pharmacokinetic drug interaction between druga and drugn has been observed , data from # small studies indicate that drugn may be associated with an increase in patient controlled administration of drugb # ,5 chemotherapy : tumor response to chemotherapy in the p # mouse leukemia model is not affected by drugn .
DDI-DrugBank.d763.s4.p15	tramadol	drug	_	ondansetron	drug	_	false	however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs # ,3 drugn : although no pharmacokinetic drug interaction between drugn and druga has been observed , data from # small studies indicate that drugb may be associated with an increase in patient controlled administration of drugn # ,5 chemotherapy : tumor response to chemotherapy in the p # mouse leukemia model is not affected by drugn .
DDI-DrugBank.d763.s4.p18	ondansetron	drug	_	tramadol	drug	_	effect	however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs # ,3 drugn : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from # small studies indicate that druga may be associated with an increase in patient controlled administration of drugb # ,5 chemotherapy : tumor response to chemotherapy in the p # mouse leukemia model is not affected by drugn .
DDI-DrugBank.d763.s5.p2	carmustine	drug	_	ondansetron	drug	_	false	in humans , druga , drugn , and drugn do not affect the pharmacokinetics of drugb .
DDI-DrugBank.d763.s5.p4	etoposide	drug	_	ondansetron	drug	_	false	in humans , drugn , druga , and drugn do not affect the pharmacokinetics of drugb .
DDI-DrugBank.d763.s5.p5	cisplatin	drug	_	ondansetron	drug	_	false	in humans , drugn , drugn , and druga do not affect the pharmacokinetics of drugb .
DDI-DrugBank.d763.s7.p0	ondansetron	drug	_	methotrexate	drug	_	false	druga did not increase blood levels of high-dose drugb .
DDI-DrugBank.d611.s0.p0	beta adrenergic aerosol bronchodilators	group	_	Alupent	brand	_	advise	other druga should not be used concomitantly with drugb -lcb- drugn usp -rcb- because they may have additive effects .
DDI-DrugBank.d611.s0.p1	beta adrenergic aerosol bronchodilators	group	_	metaproterenol sulfate	drug	_	advise	other druga should not be used concomitantly with drugn -lcb- drugb usp -rcb- because they may have additive effects .
DDI-DrugBank.d611.s1.p0	Beta adrenergic agonists	group	_	monoamine oxidase inhibitors	group	_	advise	druga should be administered with caution to patients being treated with drugb or drugn , since the action of drugn on the vascular system may be potentiated .
DDI-DrugBank.d611.s1.p1	Beta adrenergic agonists	group	_	tricyclic antidepressants	group	_	advise	druga should be administered with caution to patients being treated with drugn or drugb , since the action of drugn on the vascular system may be potentiated .
DDI-DrugBank.d611.s1.p3	monoamine oxidase inhibitors	group	_	tricyclic antidepressants	group	_	false	drugn should be administered with caution to patients being treated with druga or drugb , since the action of drugn on the vascular system may be potentiated .
DDI-DrugBank.d611.s1.p4	monoamine oxidase inhibitors	group	_	beta adrenergic agonists	group	_	false	drugn should be administered with caution to patients being treated with druga or drugn , since the action of drugb on the vascular system may be potentiated .
DDI-DrugBank.d611.s1.p5	tricyclic antidepressants	group	_	beta adrenergic agonists	group	_	false	drugn should be administered with caution to patients being treated with drugn or druga , since the action of drugb on the vascular system may be potentiated .
DDI-DrugBank.d761.s0.p5	XENICAL	brand	_	alcohol	drug	_	false	drugn : in a multiple-dose study in # normal weight subjects , coadministration of druga and # grams of drugb -lcb- e , g , , approximately # glasses of wine -rcb- did not result in alteration of drugn pharmacokinetics , drugn pharmacodynamics -lcb- fecal fat excretion -rcb- , or systemic exposure to drugn .
DDI-DrugBank.d761.s0.p6	XENICAL	brand	_	alcohol	drug	_	false	drugn : in a multiple-dose study in # normal weight subjects , coadministration of druga and # grams of drugn -lcb- e , g , , approximately # glasses of wine -rcb- did not result in alteration of drugb pharmacokinetics , drugn pharmacodynamics -lcb- fecal fat excretion -rcb- , or systemic exposure to drugn .
DDI-DrugBank.d761.s0.p7	XENICAL	brand	_	orlistat	drug	_	false	drugn : in a multiple-dose study in # normal weight subjects , coadministration of druga and # grams of drugn -lcb- e , g , , approximately # glasses of wine -rcb- did not result in alteration of drugn pharmacokinetics , drugb pharmacodynamics -lcb- fecal fat excretion -rcb- , or systemic exposure to drugn .
DDI-DrugBank.d761.s0.p8	XENICAL	brand	_	orlistat	drug	_	false	drugn : in a multiple-dose study in # normal weight subjects , coadministration of druga and # grams of drugn -lcb- e , g , , approximately # glasses of wine -rcb- did not result in alteration of drugn pharmacokinetics , drugn pharmacodynamics -lcb- fecal fat excretion -rcb- , or systemic exposure to drugb .
DDI-DrugBank.d761.s0.p10	alcohol	drug	_	orlistat	drug	_	false	drugn : in a multiple-dose study in # normal weight subjects , coadministration of drugn and # grams of druga -lcb- e , g , , approximately # glasses of wine -rcb- did not result in alteration of drugn pharmacokinetics , drugb pharmacodynamics -lcb- fecal fat excretion -rcb- , or systemic exposure to drugn .
DDI-DrugBank.d761.s0.p11	alcohol	drug	_	orlistat	drug	_	false	drugn : in a multiple-dose study in # normal weight subjects , coadministration of drugn and # grams of druga -lcb- e , g , , approximately # glasses of wine -rcb- did not result in alteration of drugn pharmacokinetics , drugn pharmacodynamics -lcb- fecal fat excretion -rcb- , or systemic exposure to drugb .
DDI-DrugBank.d761.s0.p12	alcohol	drug	_	orlistat	drug	_	false	drugn : in a multiple-dose study in # normal weight subjects , coadministration of drugn and # grams of drugn -lcb- e , g , , approximately # glasses of wine -rcb- did not result in alteration of druga pharmacokinetics , drugb pharmacodynamics -lcb- fecal fat excretion -rcb- , or systemic exposure to drugn .
DDI-DrugBank.d761.s0.p13	alcohol	drug	_	orlistat	drug	_	false	drugn : in a multiple-dose study in # normal weight subjects , coadministration of drugn and # grams of drugn -lcb- e , g , , approximately # glasses of wine -rcb- did not result in alteration of druga pharmacokinetics , drugn pharmacodynamics -lcb- fecal fat excretion -rcb- , or systemic exposure to drugb .
DDI-DrugBank.d761.s1.p5	XENICAL	brand	_	cyclosporine	drug	_	false	drugn : preliminary data from a druga and drugb drug interaction study indicate a reduction in drugn plasma levels when drugn was coadministered with drugn .
DDI-DrugBank.d761.s1.p6	XENICAL	brand	_	cyclosporine	drug	_	false	drugn : preliminary data from a druga and drugn drug interaction study indicate a reduction in drugb plasma levels when drugn was coadministered with drugn .
DDI-DrugBank.d761.s1.p8	XENICAL	brand	_	cyclosporine	drug	_	false	drugn : preliminary data from a druga and drugn drug interaction study indicate a reduction in drugn plasma levels when drugn was coadministered with drugb .
DDI-DrugBank.d761.s1.p10	cyclosporine	drug	_	XENICAL	brand	_	false	drugn : preliminary data from a drugn and druga drug interaction study indicate a reduction in drugn plasma levels when drugb was coadministered with drugn .
DDI-DrugBank.d761.s1.p12	cyclosporine	drug	_	XENICAL	brand	_	false	drugn : preliminary data from a drugn and drugn drug interaction study indicate a reduction in druga plasma levels when drugb was coadministered with drugn .
DDI-DrugBank.d761.s1.p14	XENICAL	brand	_	cyclosporine	drug	_	mechanism	drugn : preliminary data from a drugn and drugn drug interaction study indicate a reduction in drugn plasma levels when druga was coadministered with drugb .
DDI-DrugBank.d761.s2.p4	XENICAL	brand	_	digoxin	drug	_	false	drugn : in # normal-weight subjects receiving druga # mg three times a day for # days , drugn did not alter the pharmacokinetics of a single dose of drugb .
DDI-DrugBank.d761.s2.p5	XENICAL	brand	_	digoxin	drug	_	false	drugn : in # normal-weight subjects receiving drugn # mg three times a day for # days , druga did not alter the pharmacokinetics of a single dose of drugb .
DDI-DrugBank.d761.s3.p2	beta-carotene	drug	_	XENICAL	brand	_	mechanism	drugn and analogues : a pharmacokinetic interaction study showed a 30 % reduction in druga supplement absorption when concomitantly administered with drugb .
DDI-DrugBank.d761.s4.p0	XENICAL	brand	_	vitamin E acetate	drug	_	mechanism	druga inhibited absorption of a drugb supplement by approximately 60 % .
DDI-DrugBank.d761.s5.p0	orlistat	drug	_	vitamin D	group	_	false	the effect of druga on the absorption of supplemental drugb , drugn , and nutritionally-derived drugn is not known at this time .
DDI-DrugBank.d761.s5.p1	orlistat	drug	_	vitamin A	group	_	false	the effect of druga on the absorption of supplemental drugn , drugb , and nutritionally-derived drugn is not known at this time .
DDI-DrugBank.d761.s5.p2	orlistat	drug	_	vitamin K	group	_	false	the effect of druga on the absorption of supplemental drugn , drugn , and nutritionally-derived drugb is not known at this time .
DDI-DrugBank.d761.s5.p3	vitamin D	group	_	vitamin A	group	_	false	the effect of drugn on the absorption of supplemental druga , drugb , and nutritionally-derived drugn is not known at this time .
DDI-DrugBank.d761.s5.p4	vitamin D	group	_	vitamin K	group	_	false	the effect of drugn on the absorption of supplemental druga , drugn , and nutritionally-derived drugb is not known at this time .
DDI-DrugBank.d761.s5.p5	vitamin A	group	_	vitamin K	group	_	false	the effect of drugn on the absorption of supplemental drugn , druga , and nutritionally-derived drugb is not known at this time .
DDI-DrugBank.d761.s6.p4	orlistat	drug	_	glyburide	drug	_	false	drugn : in # normal-weight subjects receiving druga # mg three times a day for # days , drugn did not alter the pharmacokinetics or pharmacodynamics -lcb- blood glucose-lowering -rcb- of drugb .
DDI-DrugBank.d761.s6.p5	orlistat	drug	_	glyburide	drug	_	false	drugn : in # normal-weight subjects receiving drugn # mg three times a day for # days , druga did not alter the pharmacokinetics or pharmacodynamics -lcb- blood glucose-lowering -rcb- of drugb .
DDI-DrugBank.d761.s7.p4	XENICAL	brand	_	nifedipine	drug	_	false	drugn -lcb- extended-release tablets -rcb- : in # normal-weight subjects receiving druga # mg three times a day for # days , drugn did not alter the bioavailability of drugb -lcb- extended-release tablets -rcb- .
DDI-DrugBank.d761.s7.p5	XENICAL	brand	_	nifedipine	drug	_	false	drugn -lcb- extended-release tablets -rcb- : in # normal-weight subjects receiving drugn # mg three times a day for # days , druga did not alter the bioavailability of drugb -lcb- extended-release tablets -rcb- .
DDI-DrugBank.d761.s8.p2	XENICAL	brand	_	contraceptives	group	_	false	oral drugn : in # normal-weight female subjects , the treatment of druga # mg three times a day for # days resulted in no changes in the ovulation-suppressing action of oral drugb .
DDI-DrugBank.d761.s9.p4	XENICAL	brand	_	phenytoin	drug	_	false	drugn : in # normal-weight subjects receiving druga # mg three times a day for # days , drugn did not alter the pharmacokinetics of a single 300-mg dose of drugb .
DDI-DrugBank.d761.s9.p5	XENICAL	brand	_	phenytoin	drug	_	false	drugn : in # normal-weight subjects receiving drugn # mg three times a day for # days , druga did not alter the pharmacokinetics of a single 300-mg dose of drugb .
DDI-DrugBank.d761.s10.p4	XENICAL	brand	_	pravastatin	drug	_	false	drugn : in a 2-way crossover study of # normal-weight , mildly hypercholesterolemic patients receiving druga # mg three times a day for # days , drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d761.s10.p5	XENICAL	brand	_	pravastatin	drug	_	false	drugn : in a 2-way crossover study of # normal-weight , mildly hypercholesterolemic patients receiving drugn # mg three times a day for # days , druga did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d761.s11.p0	Warfarin	drug	_	XENICAL	brand	_	false	druga : in # normal-weight subjects , administration of drugb # mg three times a day for # days did not result in any change in either drugn pharmacokinetics -lcb- both r - and s-enantiomers -rcb- or pharmacodynamics -lcb- prothrombin time and serum factor vii -rcb- .
DDI-DrugBank.d761.s11.p2	XENICAL	brand	_	warfarin	drug	_	false	drugn : in # normal-weight subjects , administration of druga # mg three times a day for # days did not result in any change in either drugb pharmacokinetics -lcb- both r - and s-enantiomers -rcb- or pharmacodynamics -lcb- prothrombin time and serum factor vii -rcb- .
DDI-DrugBank.d761.s13.p0	vitamin K	group	_	XENICAL	brand	_	mechanism	therefore , as druga absorption may be decreased with drugb , patients on chronic stable doses of drugn who are prescribed drugn should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13.p1	vitamin K	group	_	warfarin	drug	_	false	therefore , as druga absorption may be decreased with drugn , patients on chronic stable doses of drugb who are prescribed drugn should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13.p2	vitamin K	group	_	XENICAL	brand	_	false	therefore , as druga absorption may be decreased with drugn , patients on chronic stable doses of drugn who are prescribed drugb should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13.p3	XENICAL	brand	_	warfarin	drug	_	false	therefore , as drugn absorption may be decreased with druga , patients on chronic stable doses of drugb who are prescribed drugn should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13.p5	warfarin	drug	_	XENICAL	brand	_	advise	therefore , as drugn absorption may be decreased with drugn , patients on chronic stable doses of druga who are prescribed drugb should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d747.s0.p0	Tetracycline	group	_	antibiotic	group	_	false	druga , a bacteriostatic drugb , may antagonize the bactericidal effect of drugn and concurrent use of these drugs should be avoided .
DDI-DrugBank.d747.s0.p1	Tetracycline	group	_	penicillin	drug	_	effect	druga , a bacteriostatic drugn , may antagonize the bactericidal effect of drugb and concurrent use of these drugs should be avoided .
DDI-DrugBank.d747.s0.p2	antibiotic	group	_	penicillin	drug	_	false	drugn , a bacteriostatic druga , may antagonize the bactericidal effect of drugb and concurrent use of these drugs should be avoided .
DDI-DrugBank.d728.s1.p0	ELOXATIN	brand	_	5-FU	drug	_	false	no pharmacokinetic interaction between # mg/m2 druga and infusional drugb has been observed in patients treated every # weeks .
DDI-DrugBank.d728.s2.p0	5-FU	drug	_	ELOXATIN	brand	_	mechanism	increases of druga plasma concentrations by approximately 20 % have been observed with doses of # mg/m2 drugb dosed every # weeks .
DDI-DrugBank.d584.s0.p0	Anticoagulants	group	_	Anabolic steroids	group	_	false	druga drugb may increase sensitivity to oral drugn .
DDI-DrugBank.d584.s0.p2	Anabolic steroids	group	_	anticoagulants	group	_	effect	drugn druga may increase sensitivity to oral drugb .
DDI-DrugBank.d584.s3.p4	oxandrolone	drug	_	warfarin	drug	_	mechanism	drugn : a multidose study of druga , given as # or # mg bid in # healthy subjects concurrently treated with drugb , resulted in a mean increase in drugn half-life from # to # hours and auc from # to # ng * hr/ml : similar increases in drugn half-life and auc were also detected .
DDI-DrugBank.d584.s3.p5	oxandrolone	drug	_	S-warfarin	drug	_	false	drugn : a multidose study of druga , given as # or # mg bid in # healthy subjects concurrently treated with drugn , resulted in a mean increase in drugb half-life from # to # hours and auc from # to # ng * hr/ml : similar increases in drugn half-life and auc were also detected .
DDI-DrugBank.d584.s3.p6	oxandrolone	drug	_	R-warfarin	drug	_	false	drugn : a multidose study of druga , given as # or # mg bid in # healthy subjects concurrently treated with drugn , resulted in a mean increase in drugn half-life from # to # hours and auc from # to # ng * hr/ml : similar increases in drugb half-life and auc were also detected .
DDI-DrugBank.d584.s3.p9	S-warfarin	drug	_	R-warfarin	drug	_	false	drugn : a multidose study of drugn , given as # or # mg bid in # healthy subjects concurrently treated with drugn , resulted in a mean increase in druga half-life from # to # hours and auc from # to # ng * hr/ml : similar increases in drugb half-life and auc were also detected .
DDI-DrugBank.d584.s6.p0	oxandrolone	drug	_	warfarin	drug	_	advise	when druga therapy is initiated in a patient already receiving treatment with drugb , the inr or prothrombin time -lcb- pt -rcb- should be monitored closely and the dose of drugn adjusted as necessary until a stable target inr or pt has been achieved .
DDI-DrugBank.d584.s6.p1	oxandrolone	drug	_	warfarin	drug	_	false	when druga therapy is initiated in a patient already receiving treatment with drugn , the inr or prothrombin time -lcb- pt -rcb- should be monitored closely and the dose of drugb adjusted as necessary until a stable target inr or pt has been achieved .
DDI-DrugBank.d584.s7.p0	warfarin	drug	_	oxandrolone	drug	_	advise	furthermore , in patients receiving both drugs , careful monitoring of the inr or pt , and adjustment of the druga dosage if indicated are recommended when the drugb dose is changed or discontinued .
DDI-DrugBank.d584.s9.p0	hypoglycemic agents	group	_	Oxandrolone	drug	_	false	oral druga drugb may inhibit the metabolism of oral drugn .
DDI-DrugBank.d584.s9.p2	Oxandrolone	drug	_	hypoglycemic agents	group	_	mechanism	oral drugn druga may inhibit the metabolism of oral drugb .
DDI-DrugBank.d584.s10.p0	Adrenal steroids	group	_	ACTH	drug	_	false	druga or drugb in patients with edema , concomitant administration with drugn or drugn may increase the edema .
DDI-DrugBank.d584.s10.p1	Adrenal steroids	group	_	adrenal cortical steroids	group	_	false	druga or drugn in patients with edema , concomitant administration with drugb or drugn may increase the edema .
DDI-DrugBank.d584.s10.p2	Adrenal steroids	group	_	ACTH	drug	_	false	druga or drugn in patients with edema , concomitant administration with drugn or drugb may increase the edema .
DDI-DrugBank.d584.s10.p3	ACTH	drug	_	adrenal cortical steroids	group	_	false	drugn or druga in patients with edema , concomitant administration with drugb or drugn may increase the edema .
DDI-DrugBank.d584.s10.p5	adrenal cortical steroids	group	_	ACTH	drug	_	false	drugn or drugn in patients with edema , concomitant administration with druga or drugb may increase the edema .
DDI-DrugBank.d784.s0.p0	oxybutynin	drug	_	anticholinergic drugs	group	_	effect	the concomitant use of druga with other drugb or with other agents which produce dry mouth , constipation , somnolence -lcb- drowsiness -rcb- , and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects .
DDI-DrugBank.d784.s3.p0	oxybutynin chloride	drug	_	DITROPAN XL	brand	_	false	mean druga plasma concentrations were approximately # fold higher when drugb was administered with drugn , a potent cyp3a4 inhibitor .
DDI-DrugBank.d784.s3.p1	oxybutynin chloride	drug	_	ketoconazole	drug	_	false	mean druga plasma concentrations were approximately # fold higher when drugn was administered with drugb , a potent cyp3a4 inhibitor .
DDI-DrugBank.d784.s3.p2	DITROPAN XL	brand	_	ketoconazole	drug	_	mechanism	mean drugn plasma concentrations were approximately # fold higher when druga was administered with drugb , a potent cyp3a4 inhibitor .
DDI-DrugBank.d784.s4.p2	antimycotic agents	group	_	macrolide antibiotics	group	_	false	other inhibitors of the cytochrome p450 3a4 enzyme system , such as druga -lcb- e , g , , drugn and drugn -rcb- or drugb -lcb- e , g , , drugn and drugn -rcb- , may alter drugn mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p3	antimycotic agents	group	_	erythromycin	drug	_	false	other inhibitors of the cytochrome p450 3a4 enzyme system , such as druga -lcb- e , g , , drugn and drugn -rcb- or drugn -lcb- e , g , , drugb and drugn -rcb- , may alter drugn mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p4	antimycotic agents	group	_	clarithromycin	drug	_	false	other inhibitors of the cytochrome p450 3a4 enzyme system , such as druga -lcb- e , g , , drugn and drugn -rcb- or drugn -lcb- e , g , , drugn and drugb -rcb- , may alter drugn mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p5	antimycotic agents	group	_	oxybutynin	drug	_	mechanism	other inhibitors of the cytochrome p450 3a4 enzyme system , such as druga -lcb- e , g , , drugn and drugn -rcb- or drugn -lcb- e , g , , drugn and drugn -rcb- , may alter drugb mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p7	itraconazole	drug	_	macrolide antibiotics	group	_	false	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , druga and drugn -rcb- or drugb -lcb- e , g , , drugn and drugn -rcb- , may alter drugn mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p8	itraconazole	drug	_	erythromycin	drug	_	false	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , druga and drugn -rcb- or drugn -lcb- e , g , , drugb and drugn -rcb- , may alter drugn mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p9	itraconazole	drug	_	clarithromycin	drug	_	false	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , druga and drugn -rcb- or drugn -lcb- e , g , , drugn and drugb -rcb- , may alter drugn mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p10	itraconazole	drug	_	oxybutynin	drug	_	mechanism	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , druga and drugn -rcb- or drugn -lcb- e , g , , drugn and drugn -rcb- , may alter drugb mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p11	miconazole	drug	_	macrolide antibiotics	group	_	false	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , drugn and druga -rcb- or drugb -lcb- e , g , , drugn and drugn -rcb- , may alter drugn mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p12	miconazole	drug	_	erythromycin	drug	_	false	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , drugn and druga -rcb- or drugn -lcb- e , g , , drugb and drugn -rcb- , may alter drugn mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p13	miconazole	drug	_	clarithromycin	drug	_	false	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , drugn and druga -rcb- or drugn -lcb- e , g , , drugn and drugb -rcb- , may alter drugn mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p14	miconazole	drug	_	oxybutynin	drug	_	mechanism	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , drugn and druga -rcb- or drugn -lcb- e , g , , drugn and drugn -rcb- , may alter drugb mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p17	macrolide antibiotics	group	_	oxybutynin	drug	_	mechanism	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , drugn and drugn -rcb- or druga -lcb- e , g , , drugn and drugn -rcb- , may alter drugb mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p19	erythromycin	drug	_	oxybutynin	drug	_	mechanism	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , drugn and drugn -rcb- or drugn -lcb- e , g , , druga and drugn -rcb- , may alter drugb mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s4.p20	clarithromycin	drug	_	oxybutynin	drug	_	mechanism	other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn -lcb- e , g , , drugn and drugn -rcb- or drugn -lcb- e , g , , drugn and druga -rcb- , may alter drugb mean pharmacokinetic parameters -lcb- i , e , , cmax and auc -rcb- .
DDI-DrugBank.d784.s7.p4	antacid	group	_	oxybutynin	drug	_	false	concurrent ingestion of druga -lcb- 20 ml of drugn containing drugn , drugn , and drugn -rcb- did not significantly affect the exposure of drugb or drugn .
DDI-DrugBank.d784.s7.p5	antacid	group	_	desethyloxybutynin	drug_n	_	false	concurrent ingestion of druga -lcb- 20 ml of drugn containing drugn , drugn , and drugn -rcb- did not significantly affect the exposure of drugn or drugb .
DDI-DrugBank.d784.s7.p9	antacid	group	_	oxybutynin	drug	_	false	concurrent ingestion of drugn -lcb- 20 ml of druga containing drugn , drugn , and drugn -rcb- did not significantly affect the exposure of drugb or drugn .
DDI-DrugBank.d784.s7.p10	antacid	group	_	desethyloxybutynin	drug_n	_	false	concurrent ingestion of drugn -lcb- 20 ml of druga containing drugn , drugn , and drugn -rcb- did not significantly affect the exposure of drugn or drugb .
DDI-DrugBank.d784.s7.p13	aluminum hydroxide	drug	_	oxybutynin	drug	_	false	concurrent ingestion of drugn -lcb- 20 ml of drugn containing druga , drugn , and drugn -rcb- did not significantly affect the exposure of drugb or drugn .
DDI-DrugBank.d784.s7.p14	aluminum hydroxide	drug	_	desethyloxybutynin	drug_n	_	false	concurrent ingestion of drugn -lcb- 20 ml of drugn containing druga , drugn , and drugn -rcb- did not significantly affect the exposure of drugn or drugb .
DDI-DrugBank.d784.s7.p16	magnesium hydroxide	drug	_	oxybutynin	drug	_	false	concurrent ingestion of drugn -lcb- 20 ml of drugn containing drugn , druga , and drugn -rcb- did not significantly affect the exposure of drugb or drugn .
DDI-DrugBank.d784.s7.p17	magnesium hydroxide	drug	_	desethyloxybutynin	drug_n	_	false	concurrent ingestion of drugn -lcb- 20 ml of drugn containing drugn , druga , and drugn -rcb- did not significantly affect the exposure of drugn or drugb .
DDI-DrugBank.d784.s7.p18	simethicone	drug	_	oxybutynin	drug	_	false	concurrent ingestion of drugn -lcb- 20 ml of drugn containing drugn , drugn , and druga -rcb- did not significantly affect the exposure of drugb or drugn .
DDI-DrugBank.d784.s7.p19	simethicone	drug	_	desethyloxybutynin	drug_n	_	false	concurrent ingestion of drugn -lcb- 20 ml of drugn containing drugn , drugn , and druga -rcb- did not significantly affect the exposure of drugn or drugb .
DDI-DrugBank.d758.s0.p0	oxycodone hydrochloride	drug	_	CNS depressants	group	_	effect	the cns depressant effects of druga may be additive with that of other drugb , .
DDI-DrugBank.d753.s0.p0	CNS depressants	group	_	sedatives	group	_	false	the concomitant use of other druga including drugb , drugn , drugn , general drugn , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.p1	CNS depressants	group	_	hypnotics	group	_	false	the concomitant use of other druga including drugn , drugb , drugn , general drugn , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.p2	CNS depressants	group	_	tranquilizers	group	_	false	the concomitant use of other druga including drugn , drugn , drugb , general drugn , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.p3	CNS depressants	group	_	anesthetics	group	_	false	the concomitant use of other druga including drugn , drugn , drugn , general drugb , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.p4	CNS depressants	group	_	phenothiazines	group	_	false	the concomitant use of other druga including drugn , drugn , drugn , general drugn , drugb , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.p5	CNS depressants	group	_	opioids	group	_	false	the concomitant use of other druga including drugn , drugn , drugn , general drugn , drugn , other drugb , drugn , drugn , and drugn may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.p6	CNS depressants	group	_	tricyclic antidepressants	group	_	false	the concomitant use of other druga including drugn , drugn , drugn , general drugn , drugn , other drugn , drugb , drugn , and drugn may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.p7	CNS depressants	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	the concomitant use of other druga including drugn , drugn , drugn , general drugn , drugn , other drugn , drugn , drugb , and drugn may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.p8	CNS depressants	group	_	alcohol	drug	_	false	the concomitant use of other druga including drugn , drugn , drugn , general drugn , drugn , other drugn , drugn , drugn , and drugb may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.p17	hypnotics	group	_	tranquilizers	group	_	false	the concomitant use of other drugn including drugn , druga , drugb , general drugn , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
DDI-DrugBank.d753.s2.p0	Anticholinergics	group	_	opioid analgesics	group	_	effect	druga or other medications with anticholinergic activity when used concurrently with drugb may result in increased risk of urinary retention and/or severe constipation , which may lead to paralytic ileus .
DDI-DrugBank.d753.s3.p0	oxymorphone	drug	_	propofol	drug	_	effect	it has been reported that the incidence of bradycardia was increased when druga was combined with drugb for induction of anesthesia .
DDI-DrugBank.d753.s4.p0	cimetidine	drug	_	opioid analgesics	group	_	effect	in addition , cns toxicity has been reported -lcb- confusion , disorientation , respiratory depression , apnea , seizures -rcb- following coadministration of druga with drugb ;
DDI-DrugBank.d670.s0.p0	INVEGA	brand	_	Paliperidone	drug	_	false	potential for druga to affect other drugs drugb is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome cyp2b6 isozymes .
DDI-DrugBank.d670.s6.p0	paliperidone	drug	_	INVEGA	brand	_	false	given the primary cns effects of druga , drugb should be used with caution in combination with other drugn and drugn .
DDI-DrugBank.d670.s6.p1	paliperidone	drug	_	centrally acting drugs	group	_	advise	given the primary cns effects of druga , drugn should be used with caution in combination with other drugb and drugn .
DDI-DrugBank.d670.s6.p2	paliperidone	drug	_	alcohol	drug	_	advise	given the primary cns effects of druga , drugn should be used with caution in combination with other drugn and drugb .
DDI-DrugBank.d670.s6.p3	INVEGA	brand	_	centrally acting drugs	group	_	advise	given the primary cns effects of drugn , druga should be used with caution in combination with other drugb and drugn .
DDI-DrugBank.d670.s6.p4	INVEGA	brand	_	alcohol	drug	_	advise	given the primary cns effects of drugn , druga should be used with caution in combination with other drugn and drugb .
DDI-DrugBank.d670.s6.p5	centrally acting drugs	group	_	alcohol	drug	_	false	given the primary cns effects of drugn , drugn should be used with caution in combination with other druga and drugb .
DDI-DrugBank.d670.s7.p0	Paliperidone	drug	_	levodopa	drug	_	effect	druga may antagonize the effect of drugb and other drugn .
DDI-DrugBank.d670.s7.p1	Paliperidone	drug	_	dopamine agonists	group	_	effect	druga may antagonize the effect of drugn and other drugb .
DDI-DrugBank.d670.s7.p2	levodopa	drug	_	dopamine agonists	group	_	false	drugn may antagonize the effect of druga and other drugb .
DDI-DrugBank.d670.s9.p0	INVEGA	brand	_	Paliperidone	drug	_	false	potential for other drugs to affect druga drugb is not a substrate of cyp1a2 , cyp2a6 , cyp2c9 , and cyp2c19 , so that an interaction with inhibitors or inducers of these isozymes is unlikely .
DDI-DrugBank.d680.s1.p0	pantoprazole	drug	_	theophylline	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugb , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p1	pantoprazole	drug	_	cisapride	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugb , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p2	pantoprazole	drug	_	antipyrine	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugb , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p3	pantoprazole	drug	_	caffeine	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugb , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p4	pantoprazole	drug	_	carbamazepine	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugb , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p5	pantoprazole	drug	_	diazepam	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugb -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p6	pantoprazole	drug	_	desmethyldiazepam	drug_n	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p7	pantoprazole	drug	_	diclofenac	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p8	pantoprazole	drug	_	naproxen	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p9	pantoprazole	drug	_	piroxicam	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p10	pantoprazole	drug	_	digoxin	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p11	pantoprazole	drug	_	ethanol	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p12	pantoprazole	drug	_	glyburide	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p13	pantoprazole	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p14	pantoprazole	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p15	pantoprazole	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p16	pantoprazole	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p17	pantoprazole	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p18	pantoprazole	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p19	pantoprazole	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p20	pantoprazole	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p21	pantoprazole	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p22	pantoprazole	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p23	pantoprazole	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p36	theophylline	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p37	theophylline	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p38	theophylline	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p39	theophylline	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p40	theophylline	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p41	theophylline	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p42	theophylline	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p43	theophylline	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p44	theophylline	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p45	theophylline	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p46	theophylline	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p58	cisapride	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p59	cisapride	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p60	cisapride	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p61	cisapride	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p62	cisapride	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p63	cisapride	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p64	cisapride	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p65	cisapride	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p66	cisapride	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p67	cisapride	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p68	cisapride	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p79	antipyrine	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p80	antipyrine	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p81	antipyrine	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p82	antipyrine	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p83	antipyrine	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p84	antipyrine	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p85	antipyrine	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p86	antipyrine	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p87	antipyrine	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p88	antipyrine	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p89	antipyrine	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p99	caffeine	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p100	caffeine	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p101	caffeine	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p102	caffeine	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p103	caffeine	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p104	caffeine	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p105	caffeine	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p106	caffeine	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p107	caffeine	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p108	caffeine	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p109	caffeine	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p118	carbamazepine	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p119	carbamazepine	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p120	carbamazepine	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p121	carbamazepine	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p122	carbamazepine	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p123	carbamazepine	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p124	carbamazepine	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p125	carbamazepine	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p126	carbamazepine	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p127	carbamazepine	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p128	carbamazepine	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p136	diazepam	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p137	diazepam	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p138	diazepam	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p139	diazepam	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p140	diazepam	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p141	diazepam	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p142	diazepam	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p143	diazepam	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p144	diazepam	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p145	diazepam	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p146	diazepam	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p153	desmethyldiazepam	drug_n	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p154	desmethyldiazepam	drug_n	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p155	desmethyldiazepam	drug_n	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p156	desmethyldiazepam	drug_n	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p157	desmethyldiazepam	drug_n	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p158	desmethyldiazepam	drug_n	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p159	desmethyldiazepam	drug_n	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p160	desmethyldiazepam	drug_n	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p161	desmethyldiazepam	drug_n	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p162	desmethyldiazepam	drug_n	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p163	desmethyldiazepam	drug_n	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p169	diclofenac	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p170	diclofenac	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p171	diclofenac	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p172	diclofenac	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p173	diclofenac	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p174	diclofenac	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p175	diclofenac	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p176	diclofenac	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p177	diclofenac	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p178	diclofenac	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p179	diclofenac	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p184	naproxen	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p185	naproxen	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p186	naproxen	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p187	naproxen	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p188	naproxen	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p189	naproxen	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p190	naproxen	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p191	naproxen	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p192	naproxen	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p193	naproxen	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p194	naproxen	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p198	piroxicam	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p199	piroxicam	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p200	piroxicam	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p201	piroxicam	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p202	piroxicam	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p203	piroxicam	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p204	piroxicam	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p205	piroxicam	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p206	piroxicam	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p207	piroxicam	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p208	piroxicam	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p211	digoxin	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p212	digoxin	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p213	digoxin	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p214	digoxin	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p215	digoxin	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p216	digoxin	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p217	digoxin	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p218	digoxin	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p219	digoxin	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p220	digoxin	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p221	digoxin	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p223	ethanol	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p224	ethanol	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p225	ethanol	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p226	ethanol	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p227	ethanol	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p228	ethanol	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p229	ethanol	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p230	ethanol	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p231	ethanol	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p232	ethanol	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p233	ethanol	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s1.p234	glyburide	drug	_	contraceptive	group	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugb -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p235	glyburide	drug	_	levonorgestrel	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn -lcb- drugb / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p236	glyburide	drug	_	ethinyl estradiol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn -lcb- drugn / drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p237	glyburide	drug	_	metoprolol	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn -lcb- drugn / drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p238	glyburide	drug	_	nifedipine	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p239	glyburide	drug	_	phenytoin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p240	glyburide	drug	_	warfarin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p241	glyburide	drug	_	midazolam	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d680.s1.p242	glyburide	drug	_	clarithromycin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d680.s1.p243	glyburide	drug	_	metronidazole	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d680.s1.p244	glyburide	drug	_	amoxicillin	drug	_	false	based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- and its active metabolite , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn -lcb- drugn / drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d680.s5.p0	proton pump inhibitors	group	_	pantoprazole	drug	_	false	there have been postmarketing reports of increased inr and prothrombin time in patients receiving druga , including drugb , and drugn concomitantly .
DDI-DrugBank.d680.s5.p1	proton pump inhibitors	group	_	warfarin	drug	_	effect	there have been postmarketing reports of increased inr and prothrombin time in patients receiving druga , including drugn , and drugb concomitantly .
DDI-DrugBank.d680.s5.p2	pantoprazole	drug	_	warfarin	drug	_	effect	there have been postmarketing reports of increased inr and prothrombin time in patients receiving drugn , including druga , and drugb concomitantly .
DDI-DrugBank.d680.s7.p0	proton pump inhibitors	group	_	warfarin	drug	_	advise	patients treated with druga and drugb concomitantly should be monitored for increases in inr and prothrombin time .
DDI-DrugBank.d680.s8.p0	pantoprazole	drug	_	ketoconazole	drug	_	mechanism	because of profound and long lasting inhibition of gastric acid secretion , druga may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability -lcb- eg , drugb , drugn esters , and drugn salts -rcb- .
DDI-DrugBank.d680.s8.p1	pantoprazole	drug	_	ampicillin	drug	_	mechanism	because of profound and long lasting inhibition of gastric acid secretion , druga may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability -lcb- eg , drugn , drugb esters , and drugn salts -rcb- .
DDI-DrugBank.d680.s8.p2	pantoprazole	drug	_	iron	drug	_	mechanism	because of profound and long lasting inhibition of gastric acid secretion , druga may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability -lcb- eg , drugn , drugn esters , and drugb salts -rcb- .
DDI-DrugBank.d680.s9.p1	tetrahydrocannabinol	drug	_	proton pump inhibitors	group	_	false	laboratory tests there have been reports of false-positive urine screening tests for druga -lcb- drugn -rcb- in patients receiving most drugb , including drugn .
DDI-DrugBank.d680.s9.p2	tetrahydrocannabinol	drug	_	pantoprazole	drug	_	false	laboratory tests there have been reports of false-positive urine screening tests for druga -lcb- drugn -rcb- in patients receiving most drugn , including drugb .
DDI-DrugBank.d680.s9.p3	THC	drug	_	proton pump inhibitors	group	_	false	laboratory tests there have been reports of false-positive urine screening tests for drugn -lcb- druga -rcb- in patients receiving most drugb , including drugn .
DDI-DrugBank.d680.s9.p4	THC	drug	_	pantoprazole	drug	_	false	laboratory tests there have been reports of false-positive urine screening tests for drugn -lcb- druga -rcb- in patients receiving most drugn , including drugb .
DDI-DrugBank.d680.s9.p5	proton pump inhibitors	group	_	pantoprazole	drug	_	false	laboratory tests there have been reports of false-positive urine screening tests for drugn -lcb- drugn -rcb- in patients receiving most druga , including drugb .
DDI-DrugBank.d726.s1.p0	ketoconazole	drug	_	paricalcitol	drug	_	mechanism	a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugb auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p29	paricalcitol	drug	_	ketoconazole	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugb le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p31	paricalcitol	drug	_	ketoconazole	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugb and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p32	paricalcitol	drug	_	atazanavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p33	paricalcitol	drug	_	clarithromycin	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p34	paricalcitol	drug	_	indinavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p35	paricalcitol	drug	_	itraconazole	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p36	paricalcitol	drug	_	nefazodone	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p37	paricalcitol	drug	_	nelfinavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p38	paricalcitol	drug	_	ritonavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p39	paricalcitol	drug	_	saquinavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
DDI-DrugBank.d726.s1.p40	paricalcitol	drug	_	telithromycin	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
DDI-DrugBank.d726.s1.p41	paricalcitol	drug	_	voriconazole	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since druga is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
DDI-DrugBank.d726.s1.p42	ketoconazole	drug	_	paricalcitol	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugb with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p44	ketoconazole	drug	_	atazanavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p45	ketoconazole	drug	_	clarithromycin	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p46	ketoconazole	drug	_	indinavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p47	ketoconazole	drug	_	itraconazole	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p48	ketoconazole	drug	_	nefazodone	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p49	ketoconazole	drug	_	nelfinavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p50	ketoconazole	drug	_	ritonavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p51	ketoconazole	drug	_	saquinavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
DDI-DrugBank.d726.s1.p52	ketoconazole	drug	_	telithromycin	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
DDI-DrugBank.d726.s1.p53	ketoconazole	drug	_	voriconazole	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and druga le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
DDI-DrugBank.d726.s1.p54	paricalcitol	drug	_	ketoconazole	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugb and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p55	paricalcitol	drug	_	atazanavir	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugn and other strong cyp2b6 3a inhibitors including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p56	paricalcitol	drug	_	clarithromycin	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugn and other strong cyp2b6 3a inhibitors including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p57	paricalcitol	drug	_	indinavir	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p58	paricalcitol	drug	_	itraconazole	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p59	paricalcitol	drug	_	nefazodone	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p60	paricalcitol	drug	_	nelfinavir	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p61	paricalcitol	drug	_	ritonavir	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p62	paricalcitol	drug	_	saquinavir	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
DDI-DrugBank.d726.s1.p63	paricalcitol	drug	_	telithromycin	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
DDI-DrugBank.d726.s1.p64	paricalcitol	drug	_	voriconazole	drug	_	advise	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing druga with drugn and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
DDI-DrugBank.d726.s1.p65	ketoconazole	drug	_	atazanavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with druga and other strong cyp2b6 3a inhibitors including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p66	ketoconazole	drug	_	clarithromycin	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with druga and other strong cyp2b6 3a inhibitors including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p67	ketoconazole	drug	_	indinavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with druga and other strong cyp2b6 3a inhibitors including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p68	ketoconazole	drug	_	itraconazole	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with druga and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p69	ketoconazole	drug	_	nefazodone	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with druga and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p70	ketoconazole	drug	_	nelfinavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with druga and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p71	ketoconazole	drug	_	ritonavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with druga and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
DDI-DrugBank.d726.s1.p72	ketoconazole	drug	_	saquinavir	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with druga and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
DDI-DrugBank.d726.s1.p73	ketoconazole	drug	_	telithromycin	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with druga and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
DDI-DrugBank.d726.s1.p74	ketoconazole	drug	_	voriconazole	drug	_	false	a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0 - , since drugn is partially metabolized by cytochrome_p450_family_3_subfamily_a and drugn le is known to be a strong inhibitor of cytochrome cyp2b6 3a enzyme , care should be taken while dosing drugn with druga and other strong cyp2b6 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
DDI-DrugBank.d726.s2.p0	Zemplar	brand	_	ketoconazole	drug	_	advise	dose adjustment of druga capsules may be required , and ipth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor such as drugb .
DDI-DrugBank.d726.s3.p0	fat-soluble vitamins	group	_	cholestyramine	drug	_	mechanism	drugs that impair intestinal absorption of druga , such as drugb , may interfere with the absorption of drugn capsules .
DDI-DrugBank.d726.s3.p1	fat-soluble vitamins	group	_	Zemplar	brand	_	false	drugs that impair intestinal absorption of druga , such as drugn , may interfere with the absorption of drugb capsules .
DDI-DrugBank.d726.s3.p2	cholestyramine	drug	_	Zemplar	brand	_	mechanism	drugs that impair intestinal absorption of drugn , such as druga , may interfere with the absorption of drugb capsules .
DDI-DrugBank.d581.s2.p0	lithium	drug	_	Neulasta	brand	_	advise	patients receiving druga and drugb should have more frequent monitoring of neutrophil counts .
DDI-DrugBank.d741.s0.p0	methadone	drug	_	PEG-Intron	brand	_	mechanism	in a pharmacokinetic study of # chronic hepatitis c patients concomitantly receiving druga , treatment with drugb once weekly for # weeks was associated with a mean increase of 16 % in drugn auc ;
DDI-DrugBank.d741.s0.p2	PEG-Intron	brand	_	methadone	drug	_	false	in a pharmacokinetic study of # chronic hepatitis c patients concomitantly receiving drugn , treatment with druga once weekly for # weeks was associated with a mean increase of 16 % in drugb auc ;
DDI-DrugBank.d744.s0.p0	insulin	drug	_	hypoglycemic	group	_	false	acromegalic patients with diabetes mellitus being treated with druga and/or oral drugb agents may require dose reductions of these therapeutic agents after the initiation of therapy with drugn .
DDI-DrugBank.d744.s0.p1	insulin	drug	_	SOMAVERT	brand	_	advise	acromegalic patients with diabetes mellitus being treated with druga and/or oral drugn agents may require dose reductions of these therapeutic agents after the initiation of therapy with drugb .
DDI-DrugBank.d744.s0.p2	hypoglycemic	group	_	SOMAVERT	brand	_	advise	acromegalic patients with diabetes mellitus being treated with drugn and/or oral druga agents may require dose reductions of these therapeutic agents after the initiation of therapy with drugb .
DDI-DrugBank.d744.s1.p0	opioids	group	_	pegvisomant	drug	_	mechanism	in clinical studies , patients on druga often needed higher serum drugb concentrations to achieve appropriate igf1 suppression compared with patients not receiving drugn .
DDI-DrugBank.d744.s1.p2	pegvisomant	drug	_	opioids	group	_	false	in clinical studies , patients on drugn often needed higher serum druga concentrations to achieve appropriate igf1 suppression compared with patients not receiving drugb .
DDI-DrugBank.d641.s2.p0	probenecid	drug	_	ALIMTA	brand	_	mechanism	concomitant administration of substances that are also tubularly secreted -lcb- e , g , , druga -rcb- could potentially result in delayed clearance of drugb .
DDI-DrugBank.d641.s3.p0	ibuprofen	drug	_	ALIMTA	brand	_	false	although druga -lcb- 400 mg qid -rcb- can be administered with drugb in patients with normal renal function -lcb- creatinine clearance # ml/min -rcb- , caution should be used when administering drugn concurrently with drugn to patients with mild to moderate renal insufficiency -lcb- creatinine clearance from # to # ml/min -rcb- .
DDI-DrugBank.d641.s3.p2	ibuprofen	drug	_	ALIMTA	brand	_	false	although druga -lcb- 400 mg qid -rcb- can be administered with drugn in patients with normal renal function -lcb- creatinine clearance # ml/min -rcb- , caution should be used when administering drugn concurrently with drugb to patients with mild to moderate renal insufficiency -lcb- creatinine clearance from # to # ml/min -rcb- .
DDI-DrugBank.d641.s3.p3	ALIMTA	brand	_	ibuprofen	drug	_	false	although drugn -lcb- 400 mg qid -rcb- can be administered with druga in patients with normal renal function -lcb- creatinine clearance # ml/min -rcb- , caution should be used when administering drugb concurrently with drugn to patients with mild to moderate renal insufficiency -lcb- creatinine clearance from # to # ml/min -rcb- .
DDI-DrugBank.d641.s3.p5	ibuprofen	drug	_	ALIMTA	brand	_	advise	although drugn -lcb- 400 mg qid -rcb- can be administered with drugn in patients with normal renal function -lcb- creatinine clearance # ml/min -rcb- , caution should be used when administering druga concurrently with drugb to patients with mild to moderate renal insufficiency -lcb- creatinine clearance from # to # ml/min -rcb- .
DDI-DrugBank.d641.s4.p0	NSAIDs	group	_	ALIMTA	brand	_	advise	patients with mild to moderate renal insufficiency should avoid taking druga with short elimination half-lives for a period of # days before , the day of , and # days following administration of drugb .
DDI-DrugBank.d641.s5.p0	ALIMTA	brand	_	NSAIDs	group	_	false	in the absence of data regarding potential interaction between druga and drugb with longer half-lives , all patients taking these drugn should interrupt dosing for at least # days before , the day of , and # days following drugn administration .
DDI-DrugBank.d641.s5.p1	ALIMTA	brand	_	NSAIDs	group	_	false	in the absence of data regarding potential interaction between druga and drugn with longer half-lives , all patients taking these drugb should interrupt dosing for at least # days before , the day of , and # days following drugn administration .
DDI-DrugBank.d641.s5.p4	NSAIDs	group	_	ALIMTA	brand	_	false	in the absence of data regarding potential interaction between drugn and druga with longer half-lives , all patients taking these drugn should interrupt dosing for at least # days before , the day of , and # days following drugb administration .
DDI-DrugBank.d641.s5.p5	NSAIDs	group	_	ALIMTA	brand	_	advise	in the absence of data regarding potential interaction between drugn and drugn with longer half-lives , all patients taking these druga should interrupt dosing for at least # days before , the day of , and # days following drugb administration .
DDI-DrugBank.d671.s2.p0	CYLERT	brand	_	antiepileptic medications	group	_	effect	decreased seizure threshold has been reported in patients receiving druga concomitantly with drugb .
DDI-DrugBank.d665.s0.p2	bacteriostatic antibiotics	group	_	penicillins	group	_	effect	concurrent administration of druga -lcb- e , g , , drugn , drugn -rcb- may diminish the bactericidal effects of drugb by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0.p4	erythromycin	drug	_	penicillins	group	_	effect	concurrent administration of drugn -lcb- e , g , , druga , drugn -rcb- may diminish the bactericidal effects of drugb by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0.p5	tetracycline	drug	_	penicillins	group	_	effect	concurrent administration of drugn -lcb- e , g , , drugn , druga -rcb- may diminish the bactericidal effects of drugb by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s6.p0	Penicillin	group	_	probenecid	drug	_	mechanism	druga blood levels may be prolonged by concurrent administration of drugb which blocks the renal tubular secretion of drugn .
DDI-DrugBank.d665.s6.p2	probenecid	drug	_	penicillins	group	_	false	drugn blood levels may be prolonged by concurrent administration of druga which blocks the renal tubular secretion of drugb .
DDI-DrugBank.d757.s0.p2	alcohol	drug	_	pentazocine	drug	_	advise	usage with drugn : due to the potential for increased cns depressants effects , druga should be used with caution in patients who are currently receiving drugb .
DDI-DrugBank.d659.s0.p0	TRENTAL	brand	_	anticoagulants	group	_	effect	although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with druga with and without drugb or drugn .
DDI-DrugBank.d659.s0.p1	TRENTAL	brand	_	platelet aggregation inhibitors	group	_	effect	although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with druga with and without drugn or drugb .
DDI-DrugBank.d659.s0.p2	anticoagulants	group	_	platelet aggregation inhibitors	group	_	false	although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with drugn with and without druga or drugb .
DDI-DrugBank.d659.s2.p0	TRENTAL	brand	_	theophylline	drug	_	mechanism	concomitant administration of druga and drugb - containing drugs leads to increased drugn levels and drugn toxicity in some individuals .
DDI-DrugBank.d659.s2.p1	TRENTAL	brand	_	theophylline	drug	_	false	concomitant administration of druga and drugn - containing drugs leads to increased drugb levels and drugn toxicity in some individuals .
DDI-DrugBank.d659.s2.p2	TRENTAL	brand	_	theophylline	drug	_	false	concomitant administration of druga and drugn - containing drugs leads to increased drugn levels and drugb toxicity in some individuals .
DDI-DrugBank.d659.s4.p0	TRENTAL	brand	_	antihypertensive drugs	group	_	false	druga has been used concurrently with drugb , drugn , drugn , drugn , drugn , and drugn , without observed problems .
DDI-DrugBank.d659.s4.p1	TRENTAL	brand	_	beta blockers	group	_	false	druga has been used concurrently with drugn , drugb , drugn , drugn , drugn , and drugn , without observed problems .
DDI-DrugBank.d659.s4.p2	TRENTAL	brand	_	digitalis	group	_	false	druga has been used concurrently with drugn , drugn , drugb , drugn , drugn , and drugn , without observed problems .
DDI-DrugBank.d659.s4.p3	TRENTAL	brand	_	diuretics	group	_	false	druga has been used concurrently with drugn , drugn , drugn , drugb , drugn , and drugn , without observed problems .
DDI-DrugBank.d659.s4.p4	TRENTAL	brand	_	antidiabetic agents	group	_	false	druga has been used concurrently with drugn , drugn , drugn , drugn , drugb , and drugn , without observed problems .
DDI-DrugBank.d659.s4.p5	TRENTAL	brand	_	antiarrhythmics	group	_	false	druga has been used concurrently with drugn , drugn , drugn , drugn , drugn , and drugb , without observed problems .
DDI-DrugBank.d650.s0.p0	Dopamine antagonists	group	_	neuroleptics	group	_	false	druga , such as the drugb -lcb- drugn , drugn , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugn -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p1	Dopamine antagonists	group	_	phenothiazines	group	_	false	druga , such as the drugn -lcb- drugb , drugn , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugn -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p2	Dopamine antagonists	group	_	butyrophenones	group	_	false	druga , such as the drugn -lcb- drugn , drugb , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugn -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p3	Dopamine antagonists	group	_	thioxanthines	group	_	false	druga , such as the drugn -lcb- drugn , drugn , drugb -rcb- or drugn , ordinarily should not be administered concurrently with drugn -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p4	Dopamine antagonists	group	_	metoclopramide	drug	_	false	druga , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugb , ordinarily should not be administered concurrently with drugn -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p5	Dopamine antagonists	group	_	Permax	brand	_	advise	druga , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugb -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p6	Dopamine antagonists	group	_	dopamine agonist	group	_	false	druga , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugn -lcb- a drugb -rcb- ;
DDI-DrugBank.d650.s0.p10	neuroleptics	group	_	metoclopramide	drug	_	false	drugn , such as the druga -lcb- drugn , drugn , drugn -rcb- or drugb , ordinarily should not be administered concurrently with drugn -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p11	neuroleptics	group	_	Permax	brand	_	advise	drugn , such as the druga -lcb- drugn , drugn , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugb -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p12	neuroleptics	group	_	dopamine agonist	group	_	false	drugn , such as the druga -lcb- drugn , drugn , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugn -lcb- a drugb -rcb- ;
DDI-DrugBank.d650.s0.p15	phenothiazines	group	_	metoclopramide	drug	_	false	drugn , such as the drugn -lcb- druga , drugn , drugn -rcb- or drugb , ordinarily should not be administered concurrently with drugn -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p16	phenothiazines	group	_	Permax	brand	_	advise	drugn , such as the drugn -lcb- druga , drugn , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugb -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p17	phenothiazines	group	_	dopamine agonist	group	_	false	drugn , such as the drugn -lcb- druga , drugn , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugn -lcb- a drugb -rcb- ;
DDI-DrugBank.d650.s0.p19	butyrophenones	group	_	metoclopramide	drug	_	false	drugn , such as the drugn -lcb- drugn , druga , drugn -rcb- or drugb , ordinarily should not be administered concurrently with drugn -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p20	butyrophenones	group	_	Permax	brand	_	advise	drugn , such as the drugn -lcb- drugn , druga , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugb -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p21	butyrophenones	group	_	dopamine agonist	group	_	false	drugn , such as the drugn -lcb- drugn , druga , drugn -rcb- or drugn , ordinarily should not be administered concurrently with drugn -lcb- a drugb -rcb- ;
DDI-DrugBank.d650.s0.p22	thioxanthines	group	_	metoclopramide	drug	_	false	drugn , such as the drugn -lcb- drugn , drugn , druga -rcb- or drugb , ordinarily should not be administered concurrently with drugn -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p23	thioxanthines	group	_	Permax	brand	_	advise	drugn , such as the drugn -lcb- drugn , drugn , druga -rcb- or drugn , ordinarily should not be administered concurrently with drugb -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p24	thioxanthines	group	_	dopamine agonist	group	_	false	drugn , such as the drugn -lcb- drugn , drugn , druga -rcb- or drugn , ordinarily should not be administered concurrently with drugn -lcb- a drugb -rcb- ;
DDI-DrugBank.d650.s0.p25	metoclopramide	drug	_	Permax	brand	_	advise	drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or druga , ordinarily should not be administered concurrently with drugb -lcb- a drugn -rcb- ;
DDI-DrugBank.d650.s0.p26	metoclopramide	drug	_	dopamine agonist	group	_	false	drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or druga , ordinarily should not be administered concurrently with drugn -lcb- a drugb -rcb- ;
DDI-DrugBank.d781.s0.p1	Diuretics	group	_	ACEON	brand	_	false	druga : patients on drugn , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of drugb tablets therapy .
DDI-DrugBank.d781.s0.p2	diuretics	group	_	ACEON	brand	_	effect	drugn : patients on druga , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of drugb tablets therapy .
DDI-DrugBank.d781.s1.p0	diuretic	group	_	perindopril	drug	_	effect	the possibility of hypotensive effects can be minimized by either discontinuing the druga or increasing the salt intake prior to initiation of treatment with drugb .
DDI-DrugBank.d781.s2.p0	diuretics	group	_	ACEON	brand	_	advise	if druga can not be interrupted , close medical supervision should be provided with the first dose of drugb tablets , for at least two hours and until blood pressure has stabilized for another hour .
DDI-DrugBank.d781.s3.p0	perindopril	drug	_	diuretics	group	_	false	the rate and extent of druga absorption and elimination are not affected by concomitant drugb .
DDI-DrugBank.d781.s4.p0	perindoprilat	drug_n	_	diuretics	group	_	false	the bioavailability of druga was reduced by drugb , however , and this was associated with a decrease in plasma ace inhibition .
DDI-DrugBank.d781.s5.p1	Potassium	drug	_	ACEON	brand	_	false	druga supplements and drugn : drugb tablets may increase serum potassium because of its potential to decrease aldosterone production .
DDI-DrugBank.d781.s5.p2	Potassium-Sparing Diuretics	group	_	ACEON	brand	_	false	drugn supplements and druga : drugb tablets may increase serum potassium because of its potential to decrease aldosterone production .
DDI-DrugBank.d781.s6.p4	potassium-sparing diuretics	group	_	indomethacin	drug	_	false	use of druga -lcb- drugn , drugn , drugn and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugb , drugn , drugn and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p5	potassium-sparing diuretics	group	_	heparin	drug	_	false	use of druga -lcb- drugn , drugn , drugn and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugn , drugb , drugn and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p6	potassium-sparing diuretics	group	_	cyclosporine	drug	_	false	use of druga -lcb- drugn , drugn , drugn and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugn , drugn , drugb and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p10	spironolactone	drug	_	indomethacin	drug	_	false	use of drugn -lcb- druga , drugn , drugn and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugb , drugn , drugn and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p11	spironolactone	drug	_	heparin	drug	_	false	use of drugn -lcb- druga , drugn , drugn and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugn , drugb , drugn and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p12	spironolactone	drug	_	cyclosporine	drug	_	false	use of drugn -lcb- druga , drugn , drugn and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugn , drugn , drugb and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p15	amiloride	drug	_	indomethacin	drug	_	false	use of drugn -lcb- drugn , druga , drugn and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugb , drugn , drugn and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p16	amiloride	drug	_	heparin	drug	_	false	use of drugn -lcb- drugn , druga , drugn and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugn , drugb , drugn and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p17	amiloride	drug	_	cyclosporine	drug	_	false	use of drugn -lcb- drugn , druga , drugn and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugn , drugn , drugb and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p19	triamterene	drug	_	indomethacin	drug	_	false	use of drugn -lcb- drugn , drugn , druga and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugb , drugn , drugn and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p20	triamterene	drug	_	heparin	drug	_	false	use of drugn -lcb- drugn , drugn , druga and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugn , drugb , drugn and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p21	triamterene	drug	_	cyclosporine	drug	_	false	use of drugn -lcb- drugn , drugn , druga and others -rcb- , drugn supplements or other drugs capable of increasing serum potassium -lcb- drugn , drugn , drugb and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p22	potassium	drug	_	indomethacin	drug	_	false	use of drugn -lcb- drugn , drugn , drugn and others -rcb- , druga supplements or other drugs capable of increasing serum potassium -lcb- drugb , drugn , drugn and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p23	potassium	drug	_	heparin	drug	_	false	use of drugn -lcb- drugn , drugn , drugn and others -rcb- , druga supplements or other drugs capable of increasing serum potassium -lcb- drugn , drugb , drugn and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.p24	potassium	drug	_	cyclosporine	drug	_	false	use of drugn -lcb- drugn , drugn , drugn and others -rcb- , druga supplements or other drugs capable of increasing serum potassium -lcb- drugn , drugn , drugb and others -rcb- can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s10.p0	diuretic	group	_	lithium	drug	_	false	use of a druga may further increase the risk of drugb toxicity .
DDI-DrugBank.d781.s11.p5	digoxin	drug	_	ACEON	brand	_	false	drugn : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with drugb tablets , but an effect of drugn on the plasma concentration of drugn / drugn has not been excluded .
DDI-DrugBank.d781.s11.p7	digoxin	drug	_	perindopril	drug	_	false	drugn : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with drugn tablets , but an effect of drugn on the plasma concentration of drugb / drugn has not been excluded .
DDI-DrugBank.d781.s11.p8	digoxin	drug	_	perindoprilat	drug_n	_	false	drugn : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with drugn tablets , but an effect of drugn on the plasma concentration of drugn / drugb has not been excluded .
DDI-DrugBank.d781.s11.p9	ACEON	brand	_	digoxin	drug	_	false	drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with druga tablets , but an effect of drugb on the plasma concentration of drugn / drugn has not been excluded .
DDI-DrugBank.d781.s11.p10	ACEON	brand	_	perindopril	drug	_	false	drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with druga tablets , but an effect of drugn on the plasma concentration of drugb / drugn has not been excluded .
DDI-DrugBank.d781.s11.p11	ACEON	brand	_	perindoprilat	drug_n	_	false	drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with druga tablets , but an effect of drugn on the plasma concentration of drugn / drugb has not been excluded .
DDI-DrugBank.d781.s11.p12	digoxin	drug	_	perindopril	drug	_	mechanism	drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with drugn tablets , but an effect of druga on the plasma concentration of drugb / drugn has not been excluded .
DDI-DrugBank.d781.s11.p13	digoxin	drug	_	perindoprilat	drug_n	_	mechanism	drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with drugn tablets , but an effect of druga on the plasma concentration of drugn / drugb has not been excluded .
DDI-DrugBank.d781.s12.p2	perindopril	drug	_	gentamicin	drug	_	int	drugn : animal data have suggested the possibility of interaction between druga and drugb .
DDI-DrugBank.d781.s15.p0	ACEON	brand	_	perindopril	drug	_	false	food interaction : oral administration of druga tablets with food does not significantly lower the rate or extent of drugb absorption relative to the fasted state .
DDI-DrugBank.d750.s0.p0	alcohol	drug	_	phentermine hydrochloride	drug	_	int	concomitant use of druga with drugb may result in an adverse drug interaction .
DDI-DrugBank.d725.s0.p0	Vasopressors	group	_	metaraminol	drug	_	false	druga , particularly drugb , may cause serious cardiac arrhythmias during drugn anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d725.s0.p1	Vasopressors	group	_	halothane	drug	_	effect	druga , particularly drugn , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d725.s0.p2	metaraminol	drug	_	halothane	drug	_	effect	drugn , particularly druga , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d725.s1.p3	sympathomimetic pressor amines	group	_	monoamine oxidase inhibitors	group	_	effect	drugn : the pressor effect of druga is markedly potentiated in patients receiving drugb -lcb- drugn -rcb- .
DDI-DrugBank.d725.s1.p4	sympathomimetic pressor amines	group	_	MAOI	group	_	effect	drugn : the pressor effect of druga is markedly potentiated in patients receiving drugn -lcb- drugb -rcb- .
DDI-DrugBank.d725.s3.p0	adrenergic agents	group	_	tricyclic antidepressants	group	_	effect	the pressor response of druga may also be potentiated by drugb .
DDI-DrugBank.d689.s0.p0	Vasopressors	group	_	metaraminol	drug	_	false	druga , particularly drugb , may cause serious cardiac arrhythmias during drugn anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d689.s0.p1	Vasopressors	group	_	halothane	drug	_	effect	druga , particularly drugn , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d689.s0.p2	metaraminol	drug	_	halothane	drug	_	effect	drugn , particularly druga , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d689.s1.p0	MAO Inhibitors	group	_	sympathomimetic pressor amines	group	_	false	druga - the pressor effect of drugb is markedly potentiated in patients receiving drugn -lcb- drugn -rcb- .
DDI-DrugBank.d689.s1.p1	MAO Inhibitors	group	_	monoamine oxidase inhibitors	group	_	false	druga - the pressor effect of drugn is markedly potentiated in patients receiving drugb -lcb- drugn -rcb- .
DDI-DrugBank.d689.s1.p2	MAO Inhibitors	group	_	MAOI	group	_	false	druga - the pressor effect of drugn is markedly potentiated in patients receiving drugn -lcb- drugb -rcb- .
DDI-DrugBank.d689.s1.p3	sympathomimetic pressor amines	group	_	monoamine oxidase inhibitors	group	_	effect	drugn - the pressor effect of druga is markedly potentiated in patients receiving drugb -lcb- drugn -rcb- .
DDI-DrugBank.d689.s1.p4	sympathomimetic pressor amines	group	_	MAOI	group	_	effect	drugn - the pressor effect of druga is markedly potentiated in patients receiving drugn -lcb- drugb -rcb- .
DDI-DrugBank.d689.s3.p0	adrenergic agents	group	_	tricyclic antidepressants	group	_	effect	the pressor response of druga may also be potentiated by drugb .
DDI-DrugBank.d627.s0.p0	Pilocarpine	drug	_	beta adrenergic antagonists	group	_	advise	druga should be administered with caution to patients taking drugb because of the possibility of conduction disturbances .
DDI-DrugBank.d627.s4.p0	acetylsalicylic acid	drug	_	calcium	drug	_	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d627.s4.p2	acetylsalicylic acid	drug	_	hydroxychloroquine sulfate	drug	_	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d627.s4.p3	acetylsalicylic acid	drug	_	ibuprofen	drug	_	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d627.s4.p4	acetylsalicylic acid	drug	_	levothyroxine sodium	drug	_	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d627.s4.p5	acetylsalicylic acid	drug	_	medroxyprogesterone acetate	drug	_	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d627.s4.p6	acetylsalicylic acid	drug	_	methotrexate	drug	_	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d627.s4.p8	acetylsalicylic acid	drug	_	naproxen	drug	_	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d627.s4.p9	acetylsalicylic acid	drug	_	omeprazole	drug	_	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d627.s4.p10	acetylsalicylic acid	drug	_	paracetamol	drug	_	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d627.s4.p11	acetylsalicylic acid	drug	_	prednisone	drug	_	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d666.s0.p0	reserpine	drug	_	beta-blocking agents	group	_	effect	catecholamine-depleting drugs -lcb- e , g , , druga -rcb- may have an additive effect when given with drugb .
DDI-DrugBank.d666.s2.p0	Pindolol	drug	_	antihypertensive agents	group	_	false	druga has been used with a variety of drugb , including drugn , drugn , and drugn without unexpected adverse interactions .
DDI-DrugBank.d666.s2.p1	Pindolol	drug	_	hydrochlorothiazide	drug	_	false	druga has been used with a variety of drugn , including drugb , drugn , and drugn without unexpected adverse interactions .
DDI-DrugBank.d666.s2.p2	Pindolol	drug	_	hydralazine	drug	_	false	druga has been used with a variety of drugn , including drugn , drugb , and drugn without unexpected adverse interactions .
DDI-DrugBank.d666.s2.p3	Pindolol	drug	_	guanethidine	drug	_	false	druga has been used with a variety of drugn , including drugn , drugn , and drugb without unexpected adverse interactions .
DDI-DrugBank.d666.s2.p4	antihypertensive agents	group	_	hydrochlorothiazide	drug	_	false	drugn has been used with a variety of druga , including drugb , drugn , and drugn without unexpected adverse interactions .
DDI-DrugBank.d666.s2.p5	antihypertensive agents	group	_	hydralazine	drug	_	false	drugn has been used with a variety of druga , including drugn , drugb , and drugn without unexpected adverse interactions .
DDI-DrugBank.d666.s2.p6	antihypertensive agents	group	_	guanethidine	drug	_	false	drugn has been used with a variety of druga , including drugn , drugn , and drugb without unexpected adverse interactions .
DDI-DrugBank.d666.s3.p0	Pindolol	drug	_	thioridazine	drug	_	mechanism	druga has been shown to increase serum drugb levels when both drugs are co-administered .
DDI-DrugBank.d635.s0.p0	short-acting beta adrenergic aerosol bronchodilators	group	_	MAXAIR AUTOHALER	brand	_	advise	other druga should not be used concomitantly with drugb because they may have additive effects .
DDI-DrugBank.d656.s1.p1	coumarin-type anticoagulants	group	_	FELDENE	brand	_	false	although this has not occurred in in vitro studies with druga , interactions with drugn have been reported with drugb since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugn to patients on drugn and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.p2	coumarin-type anticoagulants	group	_	FELDENE	brand	_	false	although this has not occurred in in vitro studies with druga , interactions with drugn have been reported with drugn since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugb to patients on drugn and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.p4	coumarin-type anticoagulants	group	_	FELDENE	brand	_	int	although this has not occurred in in vitro studies with drugn , interactions with druga have been reported with drugb since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugn to patients on drugn and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.p5	coumarin-type anticoagulants	group	_	FELDENE	brand	_	false	although this has not occurred in in vitro studies with drugn , interactions with druga have been reported with drugn since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugb to patients on drugn and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.p8	FELDENE	brand	_	coumarin-type anticoagulants	group	_	false	although this has not occurred in in vitro studies with drugn , interactions with drugn have been reported with druga since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugn to patients on drugb and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.p9	FELDENE	brand	_	coumarin-type anticoagulants	group	_	advise	although this has not occurred in in vitro studies with drugn , interactions with drugn have been reported with drugn since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering druga to patients on drugb and other highly protein-bound drugs .
DDI-DrugBank.d656.s2.p0	piroxicam	drug	_	FELDENE	brand	_	false	plasma levels of druga are depressed to approximately 80 % of their normal values when drugb is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p1	piroxicam	drug	_	aspirin	brand	_	false	plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugb -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p2	piroxicam	drug	_	antacids	group	_	false	plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugb has no effect on drugn plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p4	piroxicam	drug	_	Nonsteroidal anti-inflammatory agents	group	_	false	plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugb , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p5	piroxicam	drug	_	FELDENE	brand	_	false	plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugn , including drugb , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p6	piroxicam	drug	_	lithium	drug	_	false	plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2.p7	FELDENE	brand	_	aspirin	brand	_	mechanism	plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugb -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p8	FELDENE	brand	_	antacids	group	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugb has no effect on drugn plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p9	FELDENE	brand	_	piroxicam	drug	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugb plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p10	FELDENE	brand	_	Nonsteroidal anti-inflammatory agents	group	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugb , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p12	FELDENE	brand	_	lithium	drug	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2.p13	aspirin	brand	_	antacids	group	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with druga -lcb- 3900 mg/day -rcb- , but concomitant administration of drugb has no effect on drugn plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p14	aspirin	brand	_	piroxicam	drug	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with druga -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugb plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p15	aspirin	brand	_	Nonsteroidal anti-inflammatory agents	group	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with druga -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugb , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p16	aspirin	brand	_	FELDENE	brand	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with druga -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugn , including drugb , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p17	aspirin	brand	_	lithium	drug	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with druga -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2.p18	antacids	group	_	piroxicam	drug	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of druga has no effect on drugb plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p19	antacids	group	_	Nonsteroidal anti-inflammatory agents	group	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of druga has no effect on drugn plasma levels , drugb , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p20	antacids	group	_	FELDENE	brand	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of druga has no effect on drugn plasma levels , drugn , including drugb , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p21	antacids	group	_	lithium	drug	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of druga has no effect on drugn plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2.p22	piroxicam	drug	_	Nonsteroidal anti-inflammatory agents	group	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on druga plasma levels , drugb , including drugn , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p23	piroxicam	drug	_	FELDENE	brand	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on druga plasma levels , drugn , including drugb , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p24	piroxicam	drug	_	lithium	drug	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on druga plasma levels , drugn , including drugn , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2.p25	Nonsteroidal anti-inflammatory agents	group	_	FELDENE	brand	_	false	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , druga , including drugb , have been reported to increase steady state plasma drugn levels .
DDI-DrugBank.d656.s2.p26	Nonsteroidal anti-inflammatory agents	group	_	lithium	drug	_	mechanism	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , druga , including drugn , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2.p27	FELDENE	brand	_	lithium	drug	_	mechanism	plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn -lcb- 3900 mg/day -rcb- , but concomitant administration of drugn has no effect on drugn plasma levels , drugn , including druga , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s3.p0	lithium	drug	_	FELDENE	brand	_	advise	it is recommended that plasma druga levels be monitored when initiating , adjusting and discontinuing drugb .
DDI-DrugBank.d622.s0.p0	atropine	drug	_	pralidoxime	drug	_	effect	when druga and drugb are used together , the signs of atropinization -lcb- flushing , mydriasis , tachycardia , dryness of the mouth and nose -rcb- may occur earlier than might be expected when drugn is used alone .
DDI-DrugBank.d622.s0.p2	pralidoxime	drug	_	atropine	drug	_	false	when drugn and druga are used together , the signs of atropinization -lcb- flushing , mydriasis , tachycardia , dryness of the mouth and nose -rcb- may occur earlier than might be expected when drugb is used alone .
DDI-DrugBank.d622.s1.p0	atropine	drug	_	pralidoxime	drug	_	false	this is especially true if the total dose of druga has been large and the administration of drugb has been delayed .
DDI-DrugBank.d622.s2.p0	pralidoxime	drug	_	barbiturates	group	_	false	2 - # the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of druga : since drugb are potentiated by the drugn , they should be used cautiously in the treatment of convulsions ;
DDI-DrugBank.d622.s2.p1	pralidoxime	drug	_	anticholinesterases	group	_	false	2 - # the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of druga : since drugn are potentiated by the drugb , they should be used cautiously in the treatment of convulsions ;
DDI-DrugBank.d622.s2.p2	barbiturates	group	_	anticholinesterases	group	_	effect	2 - # the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of drugn : since druga are potentiated by the drugb , they should be used cautiously in the treatment of convulsions ;
DDI-DrugBank.d737.s0.p0	Carbidopa	drug	_	Levodopa	drug	_	false	druga / drugb : drugn / drugn does not influence the pharmacokinetics of drugn in healthy volunteers -lcb- n = 10 -rcb- .
DDI-DrugBank.d737.s0.p8	Carbidopa	drug	_	pramipexole	drug	_	false	drugn / drugn : druga / drugn does not influence the pharmacokinetics of drugb in healthy volunteers -lcb- n = 10 -rcb- .
DDI-DrugBank.d737.s0.p9	Levodopa	drug	_	pramipexole	drug	_	false	drugn / drugn : drugn / druga does not influence the pharmacokinetics of drugb in healthy volunteers -lcb- n = 10 -rcb- .
DDI-DrugBank.d737.s2.p1	Selegiline	drug	_	pramipexole	drug	_	false	druga : in healthy volunteers -lcb- n = 11 -rcb- , drugn did not influence the pharmacokinetics of drugb .
DDI-DrugBank.d737.s2.p2	selegiline	drug	_	pramipexole	drug	_	false	drugn : in healthy volunteers -lcb- n = 11 -rcb- , druga did not influence the pharmacokinetics of drugb .
DDI-DrugBank.d737.s3.p2	amantadine	drug	_	pramipexole	drug	_	false	drugn : population pharmacokinetic analysis suggests that druga is unlikely to alter the oral clearance of drugb -lcb- n = 54 -rcb- .
DDI-DrugBank.d737.s4.p1	Cimetidine	drug	_	pramipexole	drug	_	false	druga : drugn , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in drugb auc and a 40 % increase in half-life -lcb- n = 12 -rcb- .
DDI-DrugBank.d737.s4.p2	Cimetidine	drug	_	pramipexole	drug	_	mechanism	drugn : druga , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in drugb auc and a 40 % increase in half-life -lcb- n = 12 -rcb- .
DDI-DrugBank.d737.s5.p1	Probenecid	drug	_	pramipexole	drug	_	false	druga : drugn , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence drugb pharmacokinetics -lcb- n = 12 -rcb- .
DDI-DrugBank.d737.s5.p2	Probenecid	drug	_	pramipexole	drug	_	false	drugn : druga , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence drugb pharmacokinetics -lcb- n = 12 -rcb- .
DDI-DrugBank.d737.s6.p6	cimetidine	drug	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p7	cimetidine	drug	_	cephalosporins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugb , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p8	cimetidine	drug	_	penicillins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugb , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p9	cimetidine	drug	_	indomethacin	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugb , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p10	cimetidine	drug	_	hydrochlorothiazide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugb , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p11	cimetidine	drug	_	chlorpropamide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugb -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p12	cimetidine	drug	_	pramipexole	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p18	ranitidine	drug	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p19	ranitidine	drug	_	cephalosporins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugb , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p20	ranitidine	drug	_	penicillins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugb , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p21	ranitidine	drug	_	indomethacin	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugb , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p22	ranitidine	drug	_	hydrochlorothiazide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugb , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p23	ranitidine	drug	_	chlorpropamide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugb -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p24	ranitidine	drug	_	pramipexole	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p29	diltiazem	drug	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p30	diltiazem	drug	_	cephalosporins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugb , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p31	diltiazem	drug	_	penicillins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugb , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p32	diltiazem	drug	_	indomethacin	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugb , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p33	diltiazem	drug	_	hydrochlorothiazide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugb , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p34	diltiazem	drug	_	chlorpropamide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugb -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p35	diltiazem	drug	_	pramipexole	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p39	triamterene	drug	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p40	triamterene	drug	_	cephalosporins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugb , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p41	triamterene	drug	_	penicillins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugb , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p42	triamterene	drug	_	indomethacin	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugb , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p43	triamterene	drug	_	hydrochlorothiazide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugb , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p44	triamterene	drug	_	chlorpropamide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugb -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p45	triamterene	drug	_	pramipexole	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p48	verapamil	drug	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , and drugn -rcb- decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p49	verapamil	drug	_	cephalosporins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugb , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p50	verapamil	drug	_	penicillins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugb , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p51	verapamil	drug	_	indomethacin	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugb , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p52	verapamil	drug	_	hydrochlorothiazide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugb , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p53	verapamil	drug	_	chlorpropamide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugb -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p54	verapamil	drug	_	pramipexole	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p56	quinidine	drug	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , and drugn -rcb- decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p57	quinidine	drug	_	cephalosporins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugb , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p58	quinidine	drug	_	penicillins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugb , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p59	quinidine	drug	_	indomethacin	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugb , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p60	quinidine	drug	_	hydrochlorothiazide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugb , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p61	quinidine	drug	_	chlorpropamide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugb -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p62	quinidine	drug	_	pramipexole	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p63	quinine	drug	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and druga -rcb- decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p64	quinine	drug	_	cephalosporins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and druga -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugb , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p65	quinine	drug	_	penicillins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and druga -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugb , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p66	quinine	drug	_	indomethacin	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and druga -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugb , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p67	quinine	drug	_	hydrochlorothiazide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and druga -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugb , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p68	quinine	drug	_	chlorpropamide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and druga -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugb -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p69	quinine	drug	_	pramipexole	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and druga -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p70	pramipexole	drug	_	cephalosporins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugb , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p71	pramipexole	drug	_	penicillins	group	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugb , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p72	pramipexole	drug	_	indomethacin	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugb , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p73	pramipexole	drug	_	hydrochlorothiazide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugb , and drugn -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p74	pramipexole	drug	_	chlorpropamide	drug	_	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and drugb -rcb- are likely to have little effect on the oral clearance of drugn .
DDI-DrugBank.d737.s6.p80	cephalosporins	group	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , druga , drugn , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p84	penicillins	group	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , druga , drugn , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p87	indomethacin	drug	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , druga , drugn , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p89	hydrochlorothiazide	drug	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , druga , and drugn -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6.p90	chlorpropamide	drug	_	pramipexole	drug	_	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system -lcb- e , g , , drugn , drugn , drugn , drugn , and druga -rcb- are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s10.p9	pramipexole	drug	_	dopamine agonist	group	_	false	drugn : since druga is a drugb , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p10	pramipexole	drug	_	dopamine antagonists	group	_	false	drugn : since druga is a drugn , it is possible that drugb , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p11	pramipexole	drug	_	neuroleptics	group	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugb -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p12	pramipexole	drug	_	phenothiazines	group	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugn -lcb- drugb , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p13	pramipexole	drug	_	butyrophenones	group	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugb , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p14	pramipexole	drug	_	thioxanthenes	group	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugb -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p15	pramipexole	drug	_	metoclopramide	group	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p16	pramipexole	drug	_	MIRAPEX	brand	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10.p17	dopamine agonist	group	_	dopamine antagonists	group	_	false	drugn : since drugn is a druga , it is possible that drugb , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p18	dopamine agonist	group	_	neuroleptics	group	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugb -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p19	dopamine agonist	group	_	phenothiazines	group	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugn -lcb- drugb , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p20	dopamine agonist	group	_	butyrophenones	group	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugn -lcb- drugn , drugb , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p21	dopamine agonist	group	_	thioxanthenes	group	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugb -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p22	dopamine agonist	group	_	metoclopramide	group	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p23	dopamine agonist	group	_	MIRAPEX	brand	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10.p24	dopamine antagonists	group	_	neuroleptics	group	_	false	drugn : since drugn is a drugn , it is possible that druga , such as the drugb -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p25	dopamine antagonists	group	_	phenothiazines	group	_	false	drugn : since drugn is a drugn , it is possible that druga , such as the drugn -lcb- drugb , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p26	dopamine antagonists	group	_	butyrophenones	group	_	false	drugn : since drugn is a drugn , it is possible that druga , such as the drugn -lcb- drugn , drugb , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p27	dopamine antagonists	group	_	thioxanthenes	group	_	false	drugn : since drugn is a drugn , it is possible that druga , such as the drugn -lcb- drugn , drugn , drugb -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p28	dopamine antagonists	group	_	metoclopramide	group	_	false	drugn : since drugn is a drugn , it is possible that druga , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p29	dopamine antagonists	group	_	MIRAPEX	brand	_	effect	drugn : since drugn is a drugn , it is possible that druga , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10.p33	neuroleptics	group	_	metoclopramide	group	_	false	drugn : since drugn is a drugn , it is possible that drugn , such as the druga -lcb- drugn , drugn , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p34	neuroleptics	group	_	MIRAPEX	brand	_	effect	drugn : since drugn is a drugn , it is possible that drugn , such as the druga -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10.p37	phenothiazines	group	_	metoclopramide	group	_	false	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- druga , drugn , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p38	phenothiazines	group	_	MIRAPEX	brand	_	effect	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- druga , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10.p40	butyrophenones	group	_	metoclopramide	group	_	false	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , druga , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p41	butyrophenones	group	_	MIRAPEX	brand	_	effect	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , druga , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10.p42	thioxanthenes	group	_	metoclopramide	group	_	false	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , druga -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d737.s10.p43	thioxanthenes	group	_	MIRAPEX	brand	_	effect	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , druga -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10.p44	metoclopramide	group	_	MIRAPEX	brand	_	effect	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or druga , may diminish the effectiveness of drugb .
DDI-DrugBank.d632.s0.p0	SYMLIN	brand	_	anticholinergic agents	group	_	advise	due to its effects on gastric emptying , druga therapy should not be considered for patients taking drugs that alter gastrointestinal motility -lcb- e , g , , drugb such as drugn -rcb- and agents that slow the intestinal absorption of nutrients -lcb- e , g , , drugn -rcb- .
DDI-DrugBank.d632.s0.p1	SYMLIN	brand	_	atropine	drug	_	advise	due to its effects on gastric emptying , druga therapy should not be considered for patients taking drugs that alter gastrointestinal motility -lcb- e , g , , drugn such as drugb -rcb- and agents that slow the intestinal absorption of nutrients -lcb- e , g , , drugn -rcb- .
DDI-DrugBank.d632.s0.p2	SYMLIN	brand	_	alpha glucosidase inhibitors	group	_	advise	due to its effects on gastric emptying , druga therapy should not be considered for patients taking drugs that alter gastrointestinal motility -lcb- e , g , , drugn such as drugn -rcb- and agents that slow the intestinal absorption of nutrients -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d632.s0.p4	anticholinergic agents	group	_	alpha glucosidase inhibitors	group	_	false	due to its effects on gastric emptying , drugn therapy should not be considered for patients taking drugs that alter gastrointestinal motility -lcb- e , g , , druga such as drugn -rcb- and agents that slow the intestinal absorption of nutrients -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d632.s0.p5	atropine	drug	_	alpha glucosidase inhibitors	group	_	false	due to its effects on gastric emptying , drugn therapy should not be considered for patients taking drugs that alter gastrointestinal motility -lcb- e , g , , drugn such as druga -rcb- and agents that slow the intestinal absorption of nutrients -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d632.s3.p0	analgesics	group	_	SYMLIN	brand	_	advise	when the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness -lcb- such as druga -rcb- , the agent should be administered at least # hour prior to or # hours after drugb injection .
DDI-DrugBank.d632.s4.p0	sulfonylureas	group	_	biguanides	group	_	false	in clinical trials , the concomitant use of druga or drugb did not alter the adverse event profile of drugn .
DDI-DrugBank.d632.s4.p1	sulfonylureas	group	_	SYMLIN	brand	_	false	in clinical trials , the concomitant use of druga or drugn did not alter the adverse event profile of drugb .
DDI-DrugBank.d632.s4.p2	biguanides	group	_	SYMLIN	brand	_	false	in clinical trials , the concomitant use of drugn or druga did not alter the adverse event profile of drugb .
DDI-DrugBank.d632.s5.p0	SYMLIN	brand	_	antidiabetic agents	group	_	false	no formal interaction studies have been performed to assess the effect of druga on the kinetics of oral drugb .
DDI-DrugBank.d632.s6.p0	SYMLIN	brand	_	Insulin	drug	_	false	mixing druga and drugb the pharmacokinetic parameters of drugn were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant drugn immediately prior to injection .
DDI-DrugBank.d632.s6.p2	SYMLIN	brand	_	human insulin	drug	_	false	mixing druga and drugn the pharmacokinetic parameters of drugn were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant drugb immediately prior to injection .
DDI-DrugBank.d632.s6.p3	Insulin	drug	_	SYMLIN	brand	_	false	mixing drugn and druga the pharmacokinetic parameters of drugb were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant drugn immediately prior to injection .
DDI-DrugBank.d632.s6.p5	SYMLIN	brand	_	human insulin	drug	_	mechanism	mixing drugn and drugn the pharmacokinetic parameters of druga were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant drugb immediately prior to injection .
DDI-DrugBank.d632.s7.p0	SYMLIN	brand	_	insulin	drug	_	false	thus , druga and drugb should not be mixed and must be administered separately .
DDI-DrugBank.d653.s1.p2	phenobarbital	drug	_	corticosteroids	group	_	mechanism	drugs that induce hepatic enzymes such as druga , drugn and drugn may increase the clearance of drugb and may require increases in drugn dose to achieve the desired response .
DDI-DrugBank.d653.s1.p3	phenobarbital	drug	_	corticosteroid	group	_	mechanism	drugs that induce hepatic enzymes such as druga , drugn and drugn may increase the clearance of drugn and may require increases in drugb dose to achieve the desired response .
DDI-DrugBank.d653.s1.p5	phenytoin	drug	_	corticosteroids	group	_	mechanism	drugs that induce hepatic enzymes such as drugn , druga and drugn may increase the clearance of drugb and may require increases in drugn dose to achieve the desired response .
DDI-DrugBank.d653.s1.p6	phenytoin	drug	_	corticosteroid	group	_	mechanism	drugs that induce hepatic enzymes such as drugn , druga and drugn may increase the clearance of drugn and may require increases in drugb dose to achieve the desired response .
DDI-DrugBank.d653.s1.p7	rifampin	drug	_	corticosteroids	group	_	mechanism	drugs that induce hepatic enzymes such as drugn , drugn and druga may increase the clearance of drugb and may require increases in drugn dose to achieve the desired response .
DDI-DrugBank.d653.s1.p8	rifampin	drug	_	corticosteroid	group	_	mechanism	drugs that induce hepatic enzymes such as drugn , drugn and druga may increase the clearance of drugn and may require increases in drugb dose to achieve the desired response .
DDI-DrugBank.d653.s2.p0	troleandomycin	drug	_	ketoconazole	drug	_	false	drugs such as druga and drugb may inhibit the metabolism of drugn and thus decrease their clearance .
DDI-DrugBank.d653.s2.p1	troleandomycin	drug	_	corticosteroids	group	_	mechanism	drugs such as druga and drugn may inhibit the metabolism of drugb and thus decrease their clearance .
DDI-DrugBank.d653.s2.p2	ketoconazole	drug	_	corticosteroids	group	_	mechanism	drugs such as drugn and druga may inhibit the metabolism of drugb and thus decrease their clearance .
DDI-DrugBank.d653.s4.p0	Corticosteroids	group	_	aspirin	brand	_	mechanism	druga may increase the clearance of chronic high dose drugb .
DDI-DrugBank.d653.s5.p1	salicylate	group	_	corticosteroid	group	_	false	this could lead to decreased druga serum levels or increase the risk of drugn toxicity when drugb is withdrawn .
DDI-DrugBank.d653.s5.p2	salicylate	group	_	corticosteroid	group	_	effect	this could lead to decreased drugn serum levels or increase the risk of druga toxicity when drugb is withdrawn .
DDI-DrugBank.d653.s6.p0	Aspirin	brand	_	corticosteroids	group	_	advise	druga should be used cautiously in conjunction with drugb in patients suffering from hypoprothrombinemia .
DDI-DrugBank.d653.s7.p0	corticosteroids	group	_	anticoagulants	group	_	effect	the effect of druga on oral drugb is variable .
DDI-DrugBank.d653.s8.p0	anticoagulants	group	_	corticosteroids	group	_	effect	there are reports of enhanced as well as diminished effects of druga when given concurrently with drugb .
DDI-DrugBank.d780.s0.p0	Anticholinesterases	group	_	procaine hydrochloride	drug	_	false	druga : concurrent use of drugb and drugn may result in increased systemic toxicity since drugn inhibit the breakdown of drugn .
DDI-DrugBank.d780.s0.p1	Anticholinesterases	group	_	anticholinesterase agents	group	_	false	druga : concurrent use of drugn and drugb may result in increased systemic toxicity since drugn inhibit the breakdown of drugn .
DDI-DrugBank.d780.s0.p3	Anticholinesterases	group	_	procaine hydrochloride	drug	_	false	druga : concurrent use of drugn and drugn may result in increased systemic toxicity since drugn inhibit the breakdown of drugb .
DDI-DrugBank.d780.s0.p4	procaine hydrochloride	drug	_	anticholinesterase agents	group	_	effect	drugn : concurrent use of druga and drugb may result in increased systemic toxicity since drugn inhibit the breakdown of drugn .
DDI-DrugBank.d780.s0.p5	procaine hydrochloride	drug	_	anticholinesterases	group	_	false	drugn : concurrent use of druga and drugn may result in increased systemic toxicity since drugb inhibit the breakdown of drugn .
DDI-DrugBank.d780.s0.p7	anticholinesterase agents	group	_	anticholinesterases	group	_	false	drugn : concurrent use of drugn and druga may result in increased systemic toxicity since drugb inhibit the breakdown of drugn .
DDI-DrugBank.d780.s0.p8	anticholinesterase agents	group	_	procaine hydrochloride	drug	_	false	drugn : concurrent use of drugn and druga may result in increased systemic toxicity since drugn inhibit the breakdown of drugb .
DDI-DrugBank.d780.s0.p9	anticholinesterases	group	_	procaine hydrochloride	drug	_	mechanism	drugn : concurrent use of drugn and drugn may result in increased systemic toxicity since druga inhibit the breakdown of drugb .
DDI-DrugBank.d780.s4.p0	CNS depressant	group	_	procaine hydrochloride	drug	_	false	druga medications : concurrent use of drugb and drugn may result in additive depressant effects .
DDI-DrugBank.d780.s4.p2	procaine hydrochloride	drug	_	CNS depressant medications	group	_	effect	drugn medications : concurrent use of druga and drugb may result in additive depressant effects .
DDI-DrugBank.d780.s5.p2	Hyaluronidase	drug	_	procaine hydrochloride	drug	_	mechanism	drugn : druga may increase the diffusion rate of drugb , resulting in a decreased time of onset , but an increase in systemic toxicity .
DDI-DrugBank.d780.s6.p1	Neuromuscular blocking agents	group	_	procaine hydrochloride	drug	_	false	druga -lcb- such as drugn -rcb- : concurrent use of drugb and drugn may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6.p3	suxamethonium chloride	drug	_	procaine hydrochloride	drug	_	false	drugn -lcb- such as druga -rcb- : concurrent use of drugb and drugn may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6.p4	suxamethonium chloride	drug	_	neuromuscular blocking agents	group	_	false	drugn -lcb- such as druga -rcb- : concurrent use of drugn and drugb may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6.p5	procaine hydrochloride	drug	_	neuromuscular blocking agents	group	_	effect	drugn -lcb- such as drugn -rcb- : concurrent use of druga and drugb may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s7.p0	Sulfonamides	group	_	procaine hydrochloride	drug	_	false	druga : concurrent use of drugb and drugn may result in a reduction of the antibacterial action of the drugn .
DDI-DrugBank.d780.s7.p3	procaine hydrochloride	drug	_	sulfonamides	group	_	effect	drugn : concurrent use of druga and drugb may result in a reduction of the antibacterial action of the drugn .
DDI-DrugBank.d780.s7.p4	procaine hydrochloride	drug	_	sulfonamide	group	_	false	drugn : concurrent use of druga and drugn may result in a reduction of the antibacterial action of the drugb .
DDI-DrugBank.d780.s8.p1	Acetazolamide	drug	_	procaine hydrochloride	drug	_	false	druga : concurrent use of drugn and drugb may extend the plasma half-life of drugn .
DDI-DrugBank.d780.s8.p2	Acetazolamide	drug	_	procaine	drug	_	false	druga : concurrent use of drugn and drugn may extend the plasma half-life of drugb .
DDI-DrugBank.d780.s8.p3	acetazolamide	drug	_	procaine hydrochloride	drug	_	mechanism	drugn : concurrent use of druga and drugb may extend the plasma half-life of drugn .
DDI-DrugBank.d780.s8.p4	acetazolamide	drug	_	procaine	drug	_	false	drugn : concurrent use of druga and drugn may extend the plasma half-life of drugb .
DDI-DrugBank.d676.s0.p9	hypotensive agents	group	_	phenothiazines	group	_	false	to minimize cns depression and possible potentiation , drugn , drugn , drugn , druga or drugb should be used with caution .
DDI-DrugBank.d676.s2.p0	Matulane	brand	_	sympathomimetic drugs	group	_	advise	because druga exhibits some maoa inhibitory activity , drugb , drugn drugs -lcb- e , g , , drugn , drugn -rcb- and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p1	Matulane	brand	_	tricyclic antidepressant	group	_	advise	because druga exhibits some maoa inhibitory activity , drugn , drugb drugs -lcb- e , g , , drugn , drugn -rcb- and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p2	Matulane	brand	_	amitriptyline HCl	drug	_	advise	because druga exhibits some maoa inhibitory activity , drugn , drugn drugs -lcb- e , g , , drugb , drugn -rcb- and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p3	Matulane	brand	_	imipramine HCl	drug	_	advise	because druga exhibits some maoa inhibitory activity , drugn , drugn drugs -lcb- e , g , , drugn , drugb -rcb- and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p4	Matulane	brand	_	tyramine	drug_n	_	advise	because druga exhibits some maoa inhibitory activity , drugn , drugn drugs -lcb- e , g , , drugn , drugn -rcb- and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p5	sympathomimetic drugs	group	_	tricyclic antidepressant	group	_	false	because drugn exhibits some maoa inhibitory activity , druga , drugb drugs -lcb- e , g , , drugn , drugn -rcb- and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p6	sympathomimetic drugs	group	_	amitriptyline HCl	drug	_	false	because drugn exhibits some maoa inhibitory activity , druga , drugn drugs -lcb- e , g , , drugb , drugn -rcb- and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p7	sympathomimetic drugs	group	_	imipramine HCl	drug	_	false	because drugn exhibits some maoa inhibitory activity , druga , drugn drugs -lcb- e , g , , drugn , drugb -rcb- and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p8	sympathomimetic drugs	group	_	tyramine	drug_n	_	false	because drugn exhibits some maoa inhibitory activity , druga , drugn drugs -lcb- e , g , , drugn , drugn -rcb- and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p9	tricyclic antidepressant	group	_	amitriptyline HCl	drug	_	false	because drugn exhibits some maoa inhibitory activity , drugn , druga drugs -lcb- e , g , , drugb , drugn -rcb- and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p10	tricyclic antidepressant	group	_	imipramine HCl	drug	_	false	because drugn exhibits some maoa inhibitory activity , drugn , druga drugs -lcb- e , g , , drugn , drugb -rcb- and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p11	tricyclic antidepressant	group	_	tyramine	drug_n	_	false	because drugn exhibits some maoa inhibitory activity , drugn , druga drugs -lcb- e , g , , drugn , drugn -rcb- and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p13	amitriptyline HCl	drug	_	tyramine	drug_n	_	false	because drugn exhibits some maoa inhibitory activity , drugn , drugn drugs -lcb- e , g , , druga , drugn -rcb- and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.p14	imipramine HCl	drug	_	tyramine	drug_n	_	false	because drugn exhibits some maoa inhibitory activity , drugn , drugn drugs -lcb- e , g , , drugn , druga -rcb- and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d734.s0.p0	Thiazide diuretics	group	_	phenothiazines	group	_	effect	druga may accentuate the orthostatic hypotension that may occur with drugb .
DDI-DrugBank.d734.s1.p0	guanethidine	drug	_	phenothiazines	group	_	effect	antihypertensive effects of druga and related compounds may be counteracted when drugb are used concomitantly .
DDI-DrugBank.d734.s2.p0	propranolol	drug	_	phenothiazines	group	_	mechanism	concomitant administration of druga with drugb results in increased plasma levels of both drugs .
DDI-DrugBank.d628.s0.p0	DIPRIVAN	brand	_	narcotics	group	_	effect	the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugb -lcb- eg , drugn , drugn , and drugn , etc. .
DDI-DrugBank.d628.s0.p1	DIPRIVAN	brand	_	morphine	drug	_	effect	the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugn -lcb- eg , drugb , drugn , and drugn , etc. .
DDI-DrugBank.d628.s0.p2	DIPRIVAN	brand	_	meperidine	drug	_	effect	the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugn -lcb- eg , drugn , drugb , and drugn , etc. .
DDI-DrugBank.d628.s0.p3	DIPRIVAN	brand	_	fentanyl	drug	_	effect	the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugn -lcb- eg , drugn , drugn , and drugb , etc. .
DDI-DrugBank.d628.s1.p0	opioids	group	_	sedatives	group	_	false	and combinations of druga and drugb -lcb- eg , drugn , drugn , drugn , drugn , etc , -rcb- .
DDI-DrugBank.d628.s1.p1	opioids	group	_	benzodiazepines	group	_	false	and combinations of druga and drugn -lcb- eg , drugb , drugn , drugn , drugn , etc , -rcb- .
DDI-DrugBank.d628.s1.p2	opioids	group	_	barbiturates	group	_	false	and combinations of druga and drugn -lcb- eg , drugn , drugb , drugn , drugn , etc , -rcb- .
DDI-DrugBank.d628.s1.p3	opioids	group	_	chloral hydrate	drug	_	false	and combinations of druga and drugn -lcb- eg , drugn , drugn , drugb , drugn , etc , -rcb- .
DDI-DrugBank.d628.s1.p4	opioids	group	_	droperidol	drug	_	false	and combinations of druga and drugn -lcb- eg , drugn , drugn , drugn , drugb , etc , -rcb- .
DDI-DrugBank.d628.s3.p0	DIPRIVAN	brand	_	analgesic agents	group	_	advise	during maintenance of anesthesia or sedation , the rate of druga injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drugb -lcb- eg , drugn or drugn -rcb- .
DDI-DrugBank.d628.s3.p1	DIPRIVAN	brand	_	nitrous oxide	drug	_	advise	during maintenance of anesthesia or sedation , the rate of druga injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drugn -lcb- eg , drugb or drugn -rcb- .
DDI-DrugBank.d628.s3.p2	DIPRIVAN	brand	_	opioids	group	_	advise	during maintenance of anesthesia or sedation , the rate of druga injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drugn -lcb- eg , drugn or drugb -rcb- .
DDI-DrugBank.d628.s4.p2	isoflurane	drug	_	DIPRIVAN	brand	_	false	the concurrent administration of potent inhalational agents -lcb- eg , druga , drugn , and drugn -rcb- during maintenance with drugb injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4.p4	enflurane	drug	_	DIPRIVAN	brand	_	false	the concurrent administration of potent inhalational agents -lcb- eg , drugn , druga , and drugn -rcb- during maintenance with drugb injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4.p5	halothane	drug	_	DIPRIVAN	brand	_	false	the concurrent administration of potent inhalational agents -lcb- eg , drugn , drugn , and druga -rcb- during maintenance with drugb injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s6.p0	DIPRIVAN	brand	_	neuromuscular blocking agents	group	_	false	druga injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used drugb -lcb- eg , drugn and drugn -rcb- .
DDI-DrugBank.d628.s6.p1	DIPRIVAN	brand	_	succinylcholine	drug	_	false	druga injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used drugn -lcb- eg , drugb and drugn -rcb- .
DDI-DrugBank.d628.s6.p2	DIPRIVAN	brand	_	nondepolarizing muscle relaxants	group	_	false	druga injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used drugn -lcb- eg , drugn and drugb -rcb- .
DDI-DrugBank.d690.s0.p0	propoxyphene	drug	_	CNS depressants	group	_	effect	the cns-depressant effect of druga is additive with that of other drugb , including drugn .
DDI-DrugBank.d690.s0.p1	propoxyphene	drug	_	alcohol	drug	_	effect	the cns-depressant effect of druga is additive with that of other drugn , including drugb .
DDI-DrugBank.d690.s0.p2	CNS depressants	group	_	alcohol	drug	_	false	the cns-depressant effect of drugn is additive with that of other druga , including drugb .
DDI-DrugBank.d690.s3.p0	propoxyphene	drug	_	antidepressants	group	_	false	such occurrences have been reported when druga was administered to patients on drugb , drugn , or drugn - like drugs .
DDI-DrugBank.d690.s3.p1	propoxyphene	drug	_	anticonvulsants	group	_	false	such occurrences have been reported when druga was administered to patients on drugn , drugb , or drugn - like drugs .
DDI-DrugBank.d690.s3.p2	propoxyphene	drug	_	warfarin	drug	_	false	such occurrences have been reported when druga was administered to patients on drugn , drugn , or drugb - like drugs .
DDI-DrugBank.d690.s3.p3	antidepressants	group	_	anticonvulsants	group	_	false	such occurrences have been reported when drugn was administered to patients on druga , drugb , or drugn - like drugs .
DDI-DrugBank.d690.s3.p4	antidepressants	group	_	warfarin	drug	_	false	such occurrences have been reported when drugn was administered to patients on druga , drugn , or drugb - like drugs .
DDI-DrugBank.d690.s3.p5	anticonvulsants	group	_	warfarin	drug	_	false	such occurrences have been reported when drugn was administered to patients on drugn , druga , or drugb - like drugs .
DDI-DrugBank.d606.s0.p0	MAO inhibitors	group	_	beta adrenergic blockers	group	_	false	druga and drugb increase the effects of drugn .
DDI-DrugBank.d606.s0.p1	MAO inhibitors	group	_	pseudoephedrine	drug	_	effect	druga and drugn increase the effects of drugb .
DDI-DrugBank.d606.s0.p2	beta adrenergic blockers	group	_	pseudoephedrine	drug	_	effect	drugn and druga increase the effects of drugb .
DDI-DrugBank.d606.s1.p0	Sympathomimetics	group	_	methyldopa	drug	_	effect	druga may reduce the antihypertensive effects of drugb , drugn , drugn and drugn .
DDI-DrugBank.d606.s1.p1	Sympathomimetics	group	_	mecamylamine	drug	_	effect	druga may reduce the antihypertensive effects of drugn , drugb , drugn and drugn .
DDI-DrugBank.d606.s1.p2	Sympathomimetics	group	_	reserpine	drug	_	effect	druga may reduce the antihypertensive effects of drugn , drugn , drugb and drugn .
DDI-DrugBank.d606.s1.p3	Sympathomimetics	group	_	veratrum alkaloids	group	_	effect	druga may reduce the antihypertensive effects of drugn , drugn , drugn and drugb .
DDI-DrugBank.d631.s0.p0	Pyrimethamine	drug	_	sulfonamides	group	_	false	druga may be used with drugb , drugn and other drugn , and with other drugn .
DDI-DrugBank.d631.s0.p1	Pyrimethamine	drug	_	quinine	drug	_	false	druga may be used with drugn , drugb and other drugn , and with other drugn .
DDI-DrugBank.d631.s0.p2	Pyrimethamine	drug	_	antimalarials	group	_	false	druga may be used with drugn , drugn and other drugb , and with other drugn .
DDI-DrugBank.d631.s0.p3	Pyrimethamine	drug	_	antibiotics	group	_	false	druga may be used with drugn , drugn and other drugn , and with other drugb .
DDI-DrugBank.d631.s0.p6	sulfonamides	group	_	antibiotics	group	_	false	drugn may be used with druga , drugn and other drugn , and with other drugb .
DDI-DrugBank.d631.s0.p8	quinine	drug	_	antibiotics	group	_	false	drugn may be used with drugn , druga and other drugn , and with other drugb .
DDI-DrugBank.d631.s0.p9	antimalarials	group	_	antibiotics	group	_	false	drugn may be used with drugn , drugn and other druga , and with other drugb .
DDI-DrugBank.d631.s3.p0	lorazepam	drug	_	pyrimethamine	drug	_	effect	mild hepatotoxicity has been reported in some patients when druga and drugb were administered concomitantly .
DDI-DrugBank.d648.s0.p1	Cholestyramine	drug	_	raloxifene	drug	_	false	druga : drugn causes a 60 % reduction in the absorption and enterohepatic cycling of drugb and should not be coadministered with drugn .
DDI-DrugBank.d648.s0.p2	Cholestyramine	drug	_	EVISTA	brand	_	false	druga : drugn causes a 60 % reduction in the absorption and enterohepatic cycling of drugn and should not be coadministered with drugb .
DDI-DrugBank.d648.s0.p3	Cholestyramine	drug	_	raloxifene	drug	_	mechanism	drugn : druga causes a 60 % reduction in the absorption and enterohepatic cycling of drugb and should not be coadministered with drugn .
DDI-DrugBank.d648.s0.p4	Cholestyramine	drug	_	EVISTA	brand	_	advise	drugn : druga causes a 60 % reduction in the absorption and enterohepatic cycling of drugn and should not be coadministered with drugb .
DDI-DrugBank.d648.s0.p5	raloxifene	drug	_	EVISTA	brand	_	false	drugn : drugn causes a 60 % reduction in the absorption and enterohepatic cycling of druga and should not be coadministered with drugb .
DDI-DrugBank.d648.s1.p2	EVISTA	brand	_	warfarin	drug	_	false	drugn : the coadministration of druga and drugb has not been assessed under chronic conditions .
DDI-DrugBank.d648.s3.p0	EVISTA	brand	_	warfarin	drug	_	advise	if druga is given concurrently with drugb , prothrombin time should be monitored .
DDI-DrugBank.d648.s5.p0	raloxifene	drug	_	warfarin	drug	_	false	in vitro , druga did not affect the binding of drugb , drugn , or drugn .
DDI-DrugBank.d648.s5.p1	raloxifene	drug	_	phenytoin	drug	_	false	in vitro , druga did not affect the binding of drugn , drugb , or drugn .
DDI-DrugBank.d648.s5.p2	raloxifene	drug	_	tamoxifen	drug	_	false	in vitro , druga did not affect the binding of drugn , drugn , or drugb .
DDI-DrugBank.d648.s6.p0	EVISTA	brand	_	clofibrate	drug	_	advise	caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d648.s6.p1	EVISTA	brand	_	indomethacin	drug	_	advise	caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d648.s6.p2	EVISTA	brand	_	naproxen	drug	_	advise	caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d648.s6.p3	EVISTA	brand	_	ibuprofen	drug	_	advise	caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d648.s6.p4	EVISTA	brand	_	diazepam	drug	_	advise	caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d648.s6.p5	EVISTA	brand	_	diazoxide	drug	_	advise	caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d590.s0.p0	TRITEC	brand	_	clarithromycin	drug	_	mechanism	coadministration of druga with drugb resulted in increased plasma drugn concentrations -lcb- 57 % -rcb- , increased plasma bismuth trough concentrations -lcb- 48 % -rcb- , and increased drugn plasma concentrations -lcb- 31 % -rcb- .
DDI-DrugBank.d590.s0.p1	TRITEC	brand	_	ranitidine	drug	_	false	coadministration of druga with drugn resulted in increased plasma drugb concentrations -lcb- 57 % -rcb- , increased plasma bismuth trough concentrations -lcb- 48 % -rcb- , and increased drugn plasma concentrations -lcb- 31 % -rcb- .
DDI-DrugBank.d590.s0.p2	TRITEC	brand	_	14- hydroxy- clarithromycin	drug_n	_	false	coadministration of druga with drugn resulted in increased plasma drugn concentrations -lcb- 57 % -rcb- , increased plasma bismuth trough concentrations -lcb- 48 % -rcb- , and increased drugb plasma concentrations -lcb- 31 % -rcb- .
DDI-DrugBank.d590.s0.p3	clarithromycin	drug	_	ranitidine	drug	_	false	coadministration of drugn with druga resulted in increased plasma drugb concentrations -lcb- 57 % -rcb- , increased plasma bismuth trough concentrations -lcb- 48 % -rcb- , and increased drugn plasma concentrations -lcb- 31 % -rcb- .
DDI-DrugBank.d590.s0.p5	ranitidine	drug	_	14- hydroxy- clarithromycin	drug_n	_	false	coadministration of drugn with drugn resulted in increased plasma druga concentrations -lcb- 57 % -rcb- , increased plasma bismuth trough concentrations -lcb- 48 % -rcb- , and increased drugb plasma concentrations -lcb- 31 % -rcb- .
DDI-DrugBank.d590.s1.p0	aspirin	brand	_	salicylate	group	_	false	coadministration with druga results in a slight decrease in the rate of drugb absorption that is clinically unimportant .
DDI-DrugBank.d590.s2.p0	antacid	group	_	ranitidine	drug	_	mechanism	coadministration with a high dose of druga -lcb- 170 meq -rcb- results in a 28 % decrease in plasma concentrations of drugb and may decrease plasma concentrations of bismuth from drugn .
DDI-DrugBank.d590.s2.p1	antacid	group	_	TRITEC	brand	_	mechanism	coadministration with a high dose of druga -lcb- 170 meq -rcb- results in a 28 % decrease in plasma concentrations of drugn and may decrease plasma concentrations of bismuth from drugb .
DDI-DrugBank.d590.s2.p2	ranitidine	drug	_	TRITEC	brand	_	false	coadministration with a high dose of drugn -lcb- 170 meq -rcb- results in a 28 % decrease in plasma concentrations of druga and may decrease plasma concentrations of bismuth from drugb .
DDI-DrugBank.d590.s4.p0	ranitidine	drug	_	ZANTAC	brand	_	false	for information on drug interactions associated with druga , refer to the drugb package insert .
DDI-DrugBank.d654.s0.p0	ketoconazole	drug	_	retapamulin	drug	_	false	co-administration of oral druga # mg twice daily increased drugb geometric mean auc -lcb- 0-24 -rcb- and cmax by 81 % after topical application of drugn ointment , 1 % on the abraded skin of healthy adult males .
DDI-DrugBank.d654.s0.p1	ketoconazole	drug	_	retapamulin	drug	_	mechanism	co-administration of oral druga # mg twice daily increased drugn geometric mean auc -lcb- 0-24 -rcb- and cmax by 81 % after topical application of drugb ointment , 1 % on the abraded skin of healthy adult males .
DDI-DrugBank.d654.s1.p1	retapamulin	drug	_	ketoconazole	drug	_	false	due to low systemic exposure to druga following topical application in patients , dosage adjustments for drugn are unnecessary when co-administered with cyp3a4 inhibitors , such as drugb .
DDI-DrugBank.d654.s1.p2	retapamulin	drug	_	ketoconazole	drug	_	false	due to low systemic exposure to drugn following topical application in patients , dosage adjustments for druga are unnecessary when co-administered with cyp3a4 inhibitors , such as drugb .
DDI-DrugBank.d654.s2.p0	ALTABAX	brand	_	retapamulin	drug	_	false	based on in vitro p450 inhibition studies and the low systemic exposure observed following topical application of druga , drugb is unlikely to affect the metabolism of other cyp2b6 substrates .
DDI-DrugBank.d618.s1.p0	heparin	drug	_	vitamin K antagonists	group	_	false	in addition to bleeding associated with druga and drugb , drugs that alter platelet function -lcb- such as drugn , drugn , and drugn -rcb- may increase the risk of bleeding if administered prior to or after drugn therapy .
DDI-DrugBank.d618.s1.p1	heparin	drug	_	aspirin	brand	_	false	in addition to bleeding associated with druga and drugn , drugs that alter platelet function -lcb- such as drugb , drugn , and drugn -rcb- may increase the risk of bleeding if administered prior to or after drugn therapy .
DDI-DrugBank.d618.s1.p2	heparin	drug	_	dipyridamole	drug	_	false	in addition to bleeding associated with druga and drugn , drugs that alter platelet function -lcb- such as drugn , drugb , and drugn -rcb- may increase the risk of bleeding if administered prior to or after drugn therapy .
DDI-DrugBank.d618.s1.p3	heparin	drug	_	abciximab	drug	_	false	in addition to bleeding associated with druga and drugn , drugs that alter platelet function -lcb- such as drugn , drugn , and drugb -rcb- may increase the risk of bleeding if administered prior to or after drugn therapy .
DDI-DrugBank.d618.s1.p4	heparin	drug	_	Retavase	brand	_	effect	in addition to bleeding associated with druga and drugn , drugs that alter platelet function -lcb- such as drugn , drugn , and drugn -rcb- may increase the risk of bleeding if administered prior to or after drugb therapy .
DDI-DrugBank.d618.s1.p5	vitamin K antagonists	group	_	aspirin	brand	_	false	in addition to bleeding associated with drugn and druga , drugs that alter platelet function -lcb- such as drugb , drugn , and drugn -rcb- may increase the risk of bleeding if administered prior to or after drugn therapy .
DDI-DrugBank.d618.s1.p6	vitamin K antagonists	group	_	dipyridamole	drug	_	false	in addition to bleeding associated with drugn and druga , drugs that alter platelet function -lcb- such as drugn , drugb , and drugn -rcb- may increase the risk of bleeding if administered prior to or after drugn therapy .
DDI-DrugBank.d618.s1.p7	vitamin K antagonists	group	_	abciximab	drug	_	false	in addition to bleeding associated with drugn and druga , drugs that alter platelet function -lcb- such as drugn , drugn , and drugb -rcb- may increase the risk of bleeding if administered prior to or after drugn therapy .
DDI-DrugBank.d618.s1.p8	vitamin K antagonists	group	_	Retavase	brand	_	effect	in addition to bleeding associated with drugn and druga , drugs that alter platelet function -lcb- such as drugn , drugn , and drugn -rcb- may increase the risk of bleeding if administered prior to or after drugb therapy .
DDI-DrugBank.d618.s1.p11	aspirin	brand	_	Retavase	brand	_	effect	in addition to bleeding associated with drugn and drugn , drugs that alter platelet function -lcb- such as druga , drugn , and drugn -rcb- may increase the risk of bleeding if administered prior to or after drugb therapy .
DDI-DrugBank.d618.s1.p13	dipyridamole	drug	_	Retavase	brand	_	effect	in addition to bleeding associated with drugn and drugn , drugs that alter platelet function -lcb- such as drugn , druga , and drugn -rcb- may increase the risk of bleeding if administered prior to or after drugb therapy .
DDI-DrugBank.d618.s1.p14	abciximab	drug	_	Retavase	brand	_	effect	in addition to bleeding associated with drugn and drugn , drugs that alter platelet function -lcb- such as drugn , drugn , and druga -rcb- may increase the risk of bleeding if administered prior to or after drugb therapy .
DDI-DrugBank.d698.s0.p1	Vitamin B2	drug	_	Alcohol	drug	_	false	interactions for druga -lcb- drugn -rcb- : drugb - impairs the intestinal absorption of drugn
DDI-DrugBank.d698.s0.p3	Riboflavin	drug	_	Alcohol	drug	_	false	interactions for drugn -lcb- druga -rcb- : drugb - impairs the intestinal absorption of drugn
DDI-DrugBank.d698.s0.p5	Alcohol	drug	_	riboflavin	drug	_	mechanism	interactions for drugn -lcb- drugn -rcb- : druga - impairs the intestinal absorption of drugb
DDI-DrugBank.d698.s1.p0	Probenecid	drug	_	riboflavin	drug	_	mechanism	druga - concurrent use decreases gastrointestinal absorption of drugb ;
DDI-DrugBank.d698.s2.p0	riboflavin	drug	_	probenecid	drug	_	effect	requirements for druga may be increased in patients receiving drugb .
DDI-DrugBank.d710.s0.p2	cimetidine	drug	_	rimantadine	drug	_	false	drugn : the effects of chronic druga use on the metabolism of drugb are not known .
DDI-DrugBank.d710.s1.p0	rimantadine HCl	drug	_	Cimetidine	drug	_	mechanism	when a single # mg dose of druga was administered one hour after the initiation of drugb -lcb- 300 mg four times a day -rcb- , the apparent total drugn clearance of this single dose in normal healthy adults was reduced by 18 % -lcb- compared to the apparent total drugn clearance in the same subjects in the absence of drugn -rcb- .
DDI-DrugBank.d710.s1.p3	rimantadine HCl	drug	_	cimetidine	drug	_	false	when a single # mg dose of druga was administered one hour after the initiation of drugn -lcb- 300 mg four times a day -rcb- , the apparent total drugn clearance of this single dose in normal healthy adults was reduced by 18 % -lcb- compared to the apparent total drugn clearance in the same subjects in the absence of drugb -rcb- .
DDI-DrugBank.d710.s1.p4	Cimetidine	drug	_	rimantadine	drug	_	false	when a single # mg dose of drugn was administered one hour after the initiation of druga -lcb- 300 mg four times a day -rcb- , the apparent total drugb clearance of this single dose in normal healthy adults was reduced by 18 % -lcb- compared to the apparent total drugn clearance in the same subjects in the absence of drugn -rcb- .
DDI-DrugBank.d710.s1.p5	Cimetidine	drug	_	rimantadine	drug	_	false	when a single # mg dose of drugn was administered one hour after the initiation of druga -lcb- 300 mg four times a day -rcb- , the apparent total drugn clearance of this single dose in normal healthy adults was reduced by 18 % -lcb- compared to the apparent total drugb clearance in the same subjects in the absence of drugn -rcb- .
DDI-DrugBank.d710.s1.p8	rimantadine	drug	_	cimetidine	drug	_	false	when a single # mg dose of drugn was administered one hour after the initiation of drugn -lcb- 300 mg four times a day -rcb- , the apparent total druga clearance of this single dose in normal healthy adults was reduced by 18 % -lcb- compared to the apparent total drugn clearance in the same subjects in the absence of drugb -rcb- .
DDI-DrugBank.d710.s1.p9	rimantadine	drug	_	cimetidine	drug	_	false	when a single # mg dose of drugn was administered one hour after the initiation of drugn -lcb- 300 mg four times a day -rcb- , the apparent total drugn clearance of this single dose in normal healthy adults was reduced by 18 % -lcb- compared to the apparent total druga clearance in the same subjects in the absence of drugb -rcb- .
DDI-DrugBank.d710.s2.p0	Acetaminophen	drug	_	Rimantadine HCl	drug	_	false	druga : drugb , # mg , was given twice daily for # days to # healthy volunteers .
DDI-DrugBank.d710.s5.p0	acetaminophen	drug	_	rimantadine	drug	_	mechanism	coadministration with druga reduced the peak concentration and auc values for drugb by approximately 11 % .
DDI-DrugBank.d710.s6.p0	Aspirin	brand	_	Rimantadine HCl	drug	_	false	druga : drugb , # mg , was given twice daily fro # days to # healthy volunteers .
DDI-DrugBank.d710.s9.p0	rimantadine	drug	_	aspirin	brand	_	mechanism	peak plasma concentrations and auc of druga were reduced approximately 10 % in the presence of drugb .
DDI-DrugBank.d596.s4.p0	warfarin	drug	_	Exelon	brand	_	false	the elevation of prothrombin time induced by druga is not affected by administration of drugb .
DDI-DrugBank.d596.s6.p0	rivastigmine	drug	_	digoxin	drug	_	false	single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of drugb , drugn , drugn , or drugn .
DDI-DrugBank.d596.s6.p1	rivastigmine	drug	_	warfarin	drug	_	false	single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of drugn , drugb , drugn , or drugn .
DDI-DrugBank.d596.s6.p2	rivastigmine	drug	_	diazepam	drug	_	false	single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of drugn , drugn , drugb , or drugn .
DDI-DrugBank.d596.s6.p3	rivastigmine	drug	_	fluoxetine	drug	_	false	single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of drugn , drugn , drugn , or drugb .
DDI-DrugBank.d596.s7.p0	rivastigmine	drug	_	antacids	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugb -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p1	rivastigmine	drug	_	antihypertensives	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn -lcb- n = 77 -rcb- , drugb -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p2	rivastigmine	drug	_	calcium channel blockers	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugb -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p3	rivastigmine	drug	_	antidiabetics	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugb -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p4	rivastigmine	drug	_	nonsteroidal anti-inflammatory drugs	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugb -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p5	rivastigmine	drug	_	estrogens	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugb -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p6	rivastigmine	drug	_	salicylate analgesics	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugb -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p7	rivastigmine	drug	_	antianginals	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugb -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p8	rivastigmine	drug	_	antihistamines	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugb -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p13	antacids	group	_	estrogens	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugb -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p14	antacids	group	_	salicylate analgesics	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugb -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p15	antacids	group	_	antianginals	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugb -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p16	antacids	group	_	antihistamines	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , drugn -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugn -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugb -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s7.p25	calcium channel blockers	group	_	nonsteroidal anti-inflammatory drugs	group	_	false	population pk analysis with a database of # patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn -lcb- n = 77 -rcb- , drugn -lcb- n = 72 -rcb- , druga -lcb- n = 75 -rcb- , drugn -lcb- n = 21 -rcb- , drugb -lcb- n = 79 -rcb- , drugn -lcb- n = 70 -rcb- , drugn -lcb- n = 177 -rcb- , drugn -lcb- n = 35 -rcb- , and drugn -lcb- n = 15 -rcb- .
DDI-DrugBank.d596.s8.p2	cholinesterase inhibitors	group	_	anticholinergic medications	group	_	int	use with drugn : because of their mechanism of action , druga have the potential to interfere with the activity of drugb .
DDI-DrugBank.d596.s9.p0	Cholinomimetics	group	_	Cholinesterase Inhibitors	group	_	false	use with druga and other drugb : a synergistic effect may be expected when drugn are given concurrently with drugn , similar drugn or drugn such as drugn .
DDI-DrugBank.d596.s9.p11	cholinesterase inhibitors	group	_	succinylcholine	drug	_	effect	use with drugn and other drugn : a synergistic effect may be expected when druga are given concurrently with drugb , similar drugn or drugn such as drugn .
DDI-DrugBank.d596.s9.p12	cholinesterase inhibitors	group	_	neuromuscular blocking agents	group	_	effect	use with drugn and other drugn : a synergistic effect may be expected when druga are given concurrently with drugn , similar drugb or drugn such as drugn .
DDI-DrugBank.d596.s9.p13	cholinesterase inhibitors	group	_	cholinergic agonists	group	_	effect	use with drugn and other drugn : a synergistic effect may be expected when druga are given concurrently with drugn , similar drugn or drugb such as drugn .
DDI-DrugBank.d596.s9.p14	cholinesterase inhibitors	group	_	bethanechol	drug	_	effect	use with drugn and other drugn : a synergistic effect may be expected when druga are given concurrently with drugn , similar drugn or drugn such as drugb .
DDI-DrugBank.d596.s9.p17	succinylcholine	drug	_	bethanechol	drug	_	false	use with drugn and other drugn : a synergistic effect may be expected when drugn are given concurrently with druga , similar drugn or drugn such as drugb .
DDI-DrugBank.d596.s9.p19	neuromuscular blocking agents	group	_	bethanechol	drug	_	false	use with drugn and other drugn : a synergistic effect may be expected when drugn are given concurrently with drugn , similar druga or drugn such as drugb .
DDI-DrugBank.d596.s9.p20	cholinergic agonists	group	_	bethanechol	drug	_	false	use with drugn and other drugn : a synergistic effect may be expected when drugn are given concurrently with drugn , similar drugn or druga such as drugb .
DDI-DrugBank.d661.s0.p1	ZEMURON	brand	_	succinylcholine	drug	_	false	drug interactions : the use of druga -lcb- drugn -rcb- injection before drugb , for the purpose of attenuating some of the side effects of drugn , has not been studied .
DDI-DrugBank.d661.s0.p2	ZEMURON	brand	_	succinylcholine	drug	_	false	drug interactions : the use of druga -lcb- drugn -rcb- injection before drugn , for the purpose of attenuating some of the side effects of drugb , has not been studied .
DDI-DrugBank.d661.s0.p3	rocuronium bromide	drug	_	succinylcholine	drug	_	false	drug interactions : the use of drugn -lcb- druga -rcb- injection before drugb , for the purpose of attenuating some of the side effects of drugn , has not been studied .
DDI-DrugBank.d661.s0.p4	rocuronium bromide	drug	_	succinylcholine	drug	_	false	drug interactions : the use of drugn -lcb- druga -rcb- injection before drugn , for the purpose of attenuating some of the side effects of drugb , has not been studied .
DDI-DrugBank.d661.s1.p0	ZEMURON	brand	_	succinylcholine	drug	_	advise	if druga is administered following administration of drugb , it should not be given until recovery from drugn has been observed .
DDI-DrugBank.d661.s1.p1	ZEMURON	brand	_	succinylcholine	drug	_	false	if druga is administered following administration of drugn , it should not be given until recovery from drugb has been observed .
DDI-DrugBank.d661.s2.p0	ZEMURON	brand	_	succinylcholine	drug	_	false	the median duration of action of druga # mg/kg administered after a # mg/kg dose of drugb when t # returned to 75 % of control was # minutes -lcb- range 14-57 , n = 12 -rcb- vs.
DDI-DrugBank.d661.s4.p0	ZEMURON	brand	_	nondepolarizing muscle relaxants	group	_	false	there are no controlled studies documenting the use of druga before or after other drugb .
DDI-DrugBank.d591.s0.p0	Ropivacaine	drug	_	anesthetics	group	_	advise	druga should be used with caution in patients receiving other local drugb or agents structurally related to drugn , since the toxic effects of these drugs are additive .
DDI-DrugBank.d591.s0.p1	Ropivacaine	drug	_	amide-type local anesthetics	group	_	false	druga should be used with caution in patients receiving other local drugn or agents structurally related to drugb , since the toxic effects of these drugs are additive .
DDI-DrugBank.d591.s2.p0	ropivacaine	drug	_	fluvoxamine	drug	_	mechanism	in vivo , the plasma clearance of druga was reduced by 70 % during coadministration of drugb -lcb- 25 mg bid for # days -rcb- , a selective and potent cyp1a2 inhibitor .
DDI-DrugBank.d591.s3.p0	fluvoxamine	drug	_	Ropivacaine	drug	_	int	thus strong inhibitors of cytochrome p4501a2 , such as druga , given concomitantly during administration of drugb , can interact with drugn leading to increased drugn plasma levels .
DDI-DrugBank.d591.s3.p1	fluvoxamine	drug	_	Ropivacaine	drug	_	false	thus strong inhibitors of cytochrome p4501a2 , such as druga , given concomitantly during administration of drugn , can interact with drugb leading to increased drugn plasma levels .
DDI-DrugBank.d591.s3.p2	fluvoxamine	drug	_	ropivacaine	drug	_	false	thus strong inhibitors of cytochrome p4501a2 , such as druga , given concomitantly during administration of drugn , can interact with drugn leading to increased drugb plasma levels .
DDI-DrugBank.d591.s5.p0	theophylline	drug	_	imipramine	drug	_	false	possible interactions with drugs known to be metabolized by cyp1a2 via competitive inhibition such as druga and drugb may also occur .
DDI-DrugBank.d591.s6.p0	ketoconazole	drug	_	ropivacaine	drug	_	false	coadministration of a selective and potent inhibitor of cyp3a4 , druga -lcb- 100 mg bid for # days with drugb infusion administered # hour after drugn -rcb- caused a 15 % reduction in in-vivo plasma clearance of drugn .
DDI-DrugBank.d591.s6.p2	ketoconazole	drug	_	ropivacaine	drug	_	mechanism	coadministration of a selective and potent inhibitor of cyp3a4 , druga -lcb- 100 mg bid for # days with drugn infusion administered # hour after drugn -rcb- caused a 15 % reduction in in-vivo plasma clearance of drugb .
DDI-DrugBank.d591.s6.p3	ropivacaine	drug	_	ketoconazole	drug	_	false	coadministration of a selective and potent inhibitor of cyp3a4 , drugn -lcb- 100 mg bid for # days with druga infusion administered # hour after drugb -rcb- caused a 15 % reduction in in-vivo plasma clearance of drugn .
DDI-DrugBank.d591.s6.p5	ketoconazole	drug	_	ropivacaine	drug	_	false	coadministration of a selective and potent inhibitor of cyp3a4 , drugn -lcb- 100 mg bid for # days with drugn infusion administered # hour after druga -rcb- caused a 15 % reduction in in-vivo plasma clearance of drugb .
DDI-DrugBank.d609.s0.p0	gemfibrozil	drug	_	rosiglitazone	drug	_	mechanism	an inhibitor of cyp2c8 -lcb- such as druga -rcb- may increase the auc of drugb and an inducer of cyp2c8 -lcb- such as drugn -rcb- may decrease the auc of drugn .
DDI-DrugBank.d609.s0.p1	gemfibrozil	drug	_	rifampin	drug	_	false	an inhibitor of cyp2c8 -lcb- such as druga -rcb- may increase the auc of drugn and an inducer of cyp2c8 -lcb- such as drugb -rcb- may decrease the auc of drugn .
DDI-DrugBank.d609.s0.p2	gemfibrozil	drug	_	rosiglitazone	drug	_	false	an inhibitor of cyp2c8 -lcb- such as druga -rcb- may increase the auc of drugn and an inducer of cyp2c8 -lcb- such as drugn -rcb- may decrease the auc of drugb .
DDI-DrugBank.d609.s0.p3	rosiglitazone	drug	_	rifampin	drug	_	false	an inhibitor of cyp2c8 -lcb- such as drugn -rcb- may increase the auc of druga and an inducer of cyp2c8 -lcb- such as drugb -rcb- may decrease the auc of drugn .
DDI-DrugBank.d609.s0.p5	rifampin	drug	_	rosiglitazone	drug	_	mechanism	an inhibitor of cyp2c8 -lcb- such as drugn -rcb- may increase the auc of drugn and an inducer of cyp2c8 -lcb- such as druga -rcb- may decrease the auc of drugb .
DDI-DrugBank.d709.s1.p0	Terfenadine	drug	_	astemizole	drug	_	false	concomitant administrations not recommended : - druga and drugb : certain drugn interact with drugn and drugn leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.p7	macrolides	group	_	terfenadine	drug	_	int	concomitant administrations not recommended : - drugn and drugn : certain druga interact with drugb and drugn leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.p8	macrolides	group	_	astemizole	drug	_	int	concomitant administrations not recommended : - drugn and drugn : certain druga interact with drugn and drugb leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.p9	terfenadine	drug	_	astemizole	drug	_	false	concomitant administrations not recommended : - drugn and drugn : certain drugn interact with druga and drugb leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s3.p1	roxithromycin	drug	_	terfenadine	drug	_	false	although such a reaction has not been demonstrated with druga , concomitant administration of drugn with drugb or drugn is not recommended .
DDI-DrugBank.d709.s3.p2	roxithromycin	drug	_	astemizole	drug	_	false	although such a reaction has not been demonstrated with druga , concomitant administration of drugn with drugn or drugb is not recommended .
DDI-DrugBank.d709.s3.p3	roxithromycin	drug	_	terfenadine	drug	_	advise	although such a reaction has not been demonstrated with drugn , concomitant administration of druga with drugb or drugn is not recommended .
DDI-DrugBank.d709.s3.p4	roxithromycin	drug	_	astemizole	drug	_	advise	although such a reaction has not been demonstrated with drugn , concomitant administration of druga with drugn or drugb is not recommended .
DDI-DrugBank.d709.s3.p5	terfenadine	drug	_	astemizole	drug	_	false	although such a reaction has not been demonstrated with drugn , concomitant administration of drugn with druga or drugb is not recommended .
DDI-DrugBank.d709.s4.p0	Cisapride	drug	_	pimozide	drug	_	false	- druga , drugb : other drugs such as drugn or drugn , which are metabolised by hepatic cytochrome_p450_family_3_subfamily_a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias -lcb- typically torsades de pointe -rcb- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugn .
DDI-DrugBank.d709.s4.p7	cisapride	drug	_	pimozide	drug	_	false	- drugn , drugn : other drugs such as druga or drugb , which are metabolised by hepatic cytochrome_p450_family_3_subfamily_a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias -lcb- typically torsades de pointe -rcb- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugn .
DDI-DrugBank.d709.s4.p8	cisapride	drug	_	macrolide antibacterials	group	_	mechanism	- drugn , drugn : other drugs such as druga or drugn , which are metabolised by hepatic cytochrome_p450_family_3_subfamily_a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias -lcb- typically torsades de pointe -rcb- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugb .
DDI-DrugBank.d709.s4.p9	pimozide	drug	_	macrolide antibacterials	group	_	false	- drugn , drugn : other drugs such as drugn or druga , which are metabolised by hepatic cytochrome_p450_family_3_subfamily_a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias -lcb- typically torsades de pointe -rcb- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugb .
DDI-DrugBank.d770.s4.p0	diphosphonate	group	_	Calcitonin (salmon)	drug	_	effect	however , in patients with paget 's disease prior druga use appears to reduce the anti-resorptive response to drugb nasal spray .
DDI-DrugBank.d576.s1.p0	ASPIRIN	brand	_	SALICYLATE DRUGS	group	_	false	druga and other drugb will be additive to drugn and may increase plasma concentrations of drugn to toxic levels .
DDI-DrugBank.d576.s1.p1	ASPIRIN	brand	_	DISALCID	brand	_	effect	druga and other drugn will be additive to drugb and may increase plasma concentrations of drugn to toxic levels .
DDI-DrugBank.d576.s1.p2	ASPIRIN	brand	_	SALICYLIC ACID	drug	_	false	druga and other drugn will be additive to drugn and may increase plasma concentrations of drugb to toxic levels .
DDI-DrugBank.d576.s1.p3	SALICYLATE DRUGS	group	_	DISALCID	brand	_	effect	drugn and other druga will be additive to drugb and may increase plasma concentrations of drugn to toxic levels .
DDI-DrugBank.d576.s1.p4	SALICYLATE DRUGS	group	_	SALICYLIC ACID	drug	_	false	drugn and other druga will be additive to drugn and may increase plasma concentrations of drugb to toxic levels .
DDI-DrugBank.d576.s1.p5	DISALCID	brand	_	SALICYLIC ACID	drug	_	false	drugn and other drugn will be additive to druga and may increase plasma concentrations of drugb to toxic levels .
DDI-DrugBank.d576.s4.p0	Salicylates	group	_	anticoagulant drugs	group	_	effect	druga given concomitantly with drugb may predispose to systemic bleeding .
DDI-DrugBank.d576.s5.p0	Salicylates	group	_	antidiabetic drugs	group	_	effect	druga may enhance the hypoglycemic effect of oral drugb of the sulfonylurea class .
DDI-DrugBank.d576.s6.p0	Salicylate	group	_	penicillin	drug	_	mechanism	druga competes with a number of drugs for protein binding sites , notably drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
DDI-DrugBank.d576.s6.p1	Salicylate	group	_	thiopental	drug	_	mechanism	druga competes with a number of drugs for protein binding sites , notably drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
DDI-DrugBank.d576.s6.p2	Salicylate	group	_	thyroxine	drug	_	mechanism	druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
DDI-DrugBank.d576.s6.p3	Salicylate	group	_	triiodothyronine	drug	_	mechanism	druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
DDI-DrugBank.d576.s6.p4	Salicylate	group	_	phenytoin	drug	_	mechanism	druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and possibly drugn .
DDI-DrugBank.d576.s6.p5	Salicylate	group	_	sulfinpyrazone	drug	_	mechanism	druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and possibly drugn .
DDI-DrugBank.d576.s6.p6	Salicylate	group	_	naproxen	drug	_	mechanism	druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and possibly drugn .
DDI-DrugBank.d576.s6.p7	Salicylate	group	_	warfarin	drug	_	mechanism	druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and possibly drugn .
DDI-DrugBank.d576.s6.p8	Salicylate	group	_	methotrexate	drug	_	mechanism	druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and possibly drugn .
DDI-DrugBank.d576.s6.p9	Salicylate	group	_	corticosteroids	group	_	mechanism	druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugb .
DDI-DrugBank.d576.s6.p18	penicillin	drug	_	corticosteroids	group	_	false	drugn competes with a number of drugs for protein binding sites , notably druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugb .
DDI-DrugBank.d576.s6.p26	thiopental	drug	_	corticosteroids	group	_	false	drugn competes with a number of drugs for protein binding sites , notably drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugb .
DDI-DrugBank.d576.s6.p33	thyroxine	drug	_	corticosteroids	group	_	false	drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugb .
DDI-DrugBank.d576.s6.p39	triiodothyronine	drug	_	corticosteroids	group	_	false	drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , and possibly drugb .
DDI-DrugBank.d576.s6.p44	phenytoin	drug	_	corticosteroids	group	_	false	drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , and possibly drugb .
DDI-DrugBank.d576.s6.p48	sulfinpyrazone	drug	_	corticosteroids	group	_	false	drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , and possibly drugb .
DDI-DrugBank.d576.s6.p51	naproxen	drug	_	corticosteroids	group	_	false	drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , and possibly drugb .
DDI-DrugBank.d576.s6.p53	warfarin	drug	_	corticosteroids	group	_	false	drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , and possibly drugb .
DDI-DrugBank.d576.s6.p54	methotrexate	drug	_	corticosteroids	group	_	false	drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , and possibly drugb .
DDI-DrugBank.d607.s1.p0	Leukine	brand	_	lithium	drug	_	effect	drugs which may potentiate the myeloproliferative effects of druga , such as drugb and drugn , should be used with caution .
DDI-DrugBank.d607.s1.p1	Leukine	brand	_	corticosteroids	group	_	effect	drugs which may potentiate the myeloproliferative effects of druga , such as drugn and drugb , should be used with caution .
DDI-DrugBank.d607.s1.p2	lithium	drug	_	corticosteroids	group	_	false	drugs which may potentiate the myeloproliferative effects of drugn , such as druga and drugb , should be used with caution .
DDI-DrugBank.d771.s1.p0	Scopolamine	drug	_	sedatives	group	_	advise	druga should be used with care in patients taking other drugs that are capable of causing cns effects such as drugb , drugn , or drugn .
DDI-DrugBank.d771.s1.p1	Scopolamine	drug	_	tranquilizers	group	_	advise	druga should be used with care in patients taking other drugs that are capable of causing cns effects such as drugn , drugb , or drugn .
DDI-DrugBank.d771.s1.p2	Scopolamine	drug	_	alcohol	drug	_	advise	druga should be used with care in patients taking other drugs that are capable of causing cns effects such as drugn , drugn , or drugb .
DDI-DrugBank.d601.s0.p0	Barbiturates	group	_	contraceptives	group	_	int	druga may decrease the effectiveness of oral drugb , certain drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d601.s0.p1	Barbiturates	group	_	antibiotics	group	_	int	druga may decrease the effectiveness of oral drugn , certain drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d601.s0.p2	Barbiturates	group	_	quinidine	group	_	int	druga may decrease the effectiveness of oral drugn , certain drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d601.s0.p3	Barbiturates	group	_	theophylline	drug	_	int	druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d601.s0.p4	Barbiturates	group	_	corticosteroids	group	_	int	druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d601.s0.p5	Barbiturates	group	_	anticoagulants	group	_	int	druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d601.s0.p6	Barbiturates	group	_	beta blockers	group	_	int	druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d619.s0.p0	selegiline	drug	_	meperidine	drug	_	effect	the occurrence of stupor , muscular rigidity , severe agitation , and elevated temperature has been reported in some patients receiving the combination of druga and drugb .
DDI-DrugBank.d619.s2.p0	meperidine	drug	_	MAOIs	group	_	int	this is typical of the interaction of druga and drugb .
DDI-DrugBank.d619.s4.p0	tricyclic antidepressants	group	_	ELDEPRYL	brand	_	effect	severe toxicity has also been reported in patients receiving the combination of druga and drugb and drugn and drugn .
DDI-DrugBank.d619.s4.p1	tricyclic antidepressants	group	_	selective serotonin reuptake inhibitors	group	_	false	severe toxicity has also been reported in patients receiving the combination of druga and drugn and drugb and drugn .
DDI-DrugBank.d619.s4.p2	tricyclic antidepressants	group	_	ELDEPRYL	brand	_	false	severe toxicity has also been reported in patients receiving the combination of druga and drugn and drugn and drugb .
DDI-DrugBank.d619.s5.p0	selegiline	drug	_	sympathomimetic medication	group	_	effect	one case of hypertensive crisis has been reported in a patient taking the recommended doses of druga and a drugb -lcb- drugn -rcb- .
DDI-DrugBank.d619.s5.p1	selegiline	drug	_	ephedrine	drug	_	effect	one case of hypertensive crisis has been reported in a patient taking the recommended doses of druga and a drugn -lcb- drugb -rcb- .
DDI-DrugBank.d694.s0.p2	digoxin	drug	_	sitagliptin	drug	_	mechanism	drugn : there was a slight increase in the area under the curve -lcb- auc , 11 % -rcb- and mean peak drug concentration -lcb- cmax , 18 % -rcb- of druga with the co-administration of # mg drugb for # days .
DDI-DrugBank.d694.s2.p0	digoxin	drug	_	JANUVIA	brand	_	false	no dosage adjustment of druga or drugb is recommended .
DDI-DrugBank.d595.s1.p0	norepinephrine	drug	_	dobutamine	drug	_	false	druga and drugb are incompatible with drugn solution .
DDI-DrugBank.d595.s1.p1	norepinephrine	drug	_	sodium bicarbonate	drug	_	int	druga and drugn are incompatible with drugb solution .
DDI-DrugBank.d595.s1.p2	dobutamine	drug	_	sodium bicarbonate	drug	_	int	drugn and druga are incompatible with drugb solution .
DDI-DrugBank.d595.s2.p0	sodium bicarbonate	drug	_	calcium	drug	_	false	the addition of druga to parenteral solutions containing drugb should be avoided , except where compatibility has been previously established .
DDI-DrugBank.d738.s0.p0	VESIcare	brand	_	ketoconazole	drug	_	advise	do not exceed a # mg daily dose of druga when administered with therapeutic doses of drugb or other potent cyp3a4 inhibitors .
DDI-DrugBank.d738.s1.p2	solifenacin	drug	_	moxifloxacin	drug	_	false	patients with congenital or acquired qt prolongation in a study of the effect of druga on the qt interval in # healthy women , the qt prolonging effect appeared less with drugn # mg than with # mg -lcb- three times the maximum recommended dose -rcb- , and the effect of drugn # mg did not appear as large as that of the positive control drugb at its therapeutic dose .
DDI-DrugBank.d738.s1.p4	solifenacin	drug	_	moxifloxacin	drug	_	false	patients with congenital or acquired qt prolongation in a study of the effect of drugn on the qt interval in # healthy women , the qt prolonging effect appeared less with druga # mg than with # mg -lcb- three times the maximum recommended dose -rcb- , and the effect of drugn # mg did not appear as large as that of the positive control drugb at its therapeutic dose .
DDI-DrugBank.d738.s1.p5	solifenacin	drug	_	moxifloxacin	drug	_	false	patients with congenital or acquired qt prolongation in a study of the effect of drugn on the qt interval in # healthy women , the qt prolonging effect appeared less with drugn # mg than with # mg -lcb- three times the maximum recommended dose -rcb- , and the effect of druga # mg did not appear as large as that of the positive control drugb at its therapeutic dose .
DDI-DrugBank.d599.s6.p0	GH	drug	_	antipyrine	drug	_	mechanism	limited published data indicate that druga treatment increases cytochrome cyp2b6 -lcb- cp450 -rcb- mediated drugb clearance in man .
DDI-DrugBank.d599.s7.p0	GH	drug	_	corticosteroids	group	_	mechanism	these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes -lcb- e , g , , drugb , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d599.s7.p1	GH	drug	_	sex steroids	group	_	mechanism	these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes -lcb- e , g , , drugn , drugb , drugn , drugn -rcb- .
DDI-DrugBank.d599.s7.p2	GH	drug	_	anticonvulsants	group	_	mechanism	these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes -lcb- e , g , , drugn , drugn , drugb , drugn -rcb- .
DDI-DrugBank.d599.s7.p3	GH	drug	_	cyclosporin	drug	_	mechanism	these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes -lcb- e , g , , drugn , drugn , drugn , drugb -rcb- .
DDI-DrugBank.d602.s0.p0	NEXAVAR	brand	_	irinotecan	drug	_	advise	caution is recommended when administering druga with compounds that are metabolized/eliminated predominantly by the ugt1a1 pathway -lcb- e , g , drugb -rcb- .
DDI-DrugBank.d602.s1.p0	NEXAVAR	brand	_	doxorubicin	drug	_	mechanism	concomitant treatment with druga resulted in a 21 % increase in the auc of drugb .
DDI-DrugBank.d602.s2.p0	doxorubicin	drug	_	NEXAVAR	brand	_	advise	caution is recommended when administering druga with drugb .
DDI-DrugBank.d727.s0.p0	Zidovudine	drug	_	stavudine	drug	_	effect	druga competitively inhibits the intracellular phosphorylation of drugb .
DDI-DrugBank.d727.s1.p0	zidovudine	drug	_	ZERIT	brand	_	advise	therefore , use of druga in combination with drugb should be avoided .
DDI-DrugBank.d727.s2.p0	stavudine	drug	_	doxorubicin	drug	_	effect	in vitro data indicate that the phosphorylation of druga is also inhibited at relevant concentrations by drugb and drugn .
DDI-DrugBank.d727.s2.p1	stavudine	drug	_	ribavirin	drug	_	effect	in vitro data indicate that the phosphorylation of druga is also inhibited at relevant concentrations by drugn and drugb .
DDI-DrugBank.d727.s2.p2	doxorubicin	drug	_	ribavirin	drug	_	false	in vitro data indicate that the phosphorylation of drugn is also inhibited at relevant concentrations by druga and drugb .
DDI-DrugBank.d777.s0.p0	Streptase	brand	_	Streptokinase	drug	_	false	the interaction of druga , drugb , with other drugs has not been well studied .
DDI-DrugBank.d777.s1.p0	Anticoagulants	group	_	Antiplatelet Agents	group	_	false	use of druga and drugb -- drugn , drugn , alone or in combination with drugn and drugn , may cause bleeding complications .
DDI-DrugBank.d777.s1.p1	Anticoagulants	group	_	Streptase	brand	_	false	use of druga and drugn -- drugb , drugn , alone or in combination with drugn and drugn , may cause bleeding complications .
DDI-DrugBank.d777.s1.p2	Anticoagulants	group	_	Streptokinase	drug	_	false	use of druga and drugn -- drugn , drugb , alone or in combination with drugn and drugn , may cause bleeding complications .
DDI-DrugBank.d777.s1.p3	Anticoagulants	group	_	antiplatelet agents	group	_	false	use of druga and drugn -- drugn , drugn , alone or in combination with drugb and drugn , may cause bleeding complications .
DDI-DrugBank.d777.s1.p5	Antiplatelet Agents	group	_	Streptase	brand	_	false	use of drugn and druga -- drugb , drugn , alone or in combination with drugn and drugn , may cause bleeding complications .
DDI-DrugBank.d777.s1.p6	Antiplatelet Agents	group	_	Streptokinase	drug	_	false	use of drugn and druga -- drugn , drugb , alone or in combination with drugn and drugn , may cause bleeding complications .
DDI-DrugBank.d777.s1.p8	Antiplatelet Agents	group	_	anticoagulants	group	_	false	use of drugn and druga -- drugn , drugn , alone or in combination with drugn and drugb , may cause bleeding complications .
DDI-DrugBank.d777.s1.p9	Streptase	brand	_	Streptokinase	drug	_	false	use of drugn and drugn -- druga , drugb , alone or in combination with drugn and drugn , may cause bleeding complications .
DDI-DrugBank.d777.s1.p10	Streptase	brand	_	antiplatelet agents	group	_	effect	use of drugn and drugn -- druga , drugn , alone or in combination with drugb and drugn , may cause bleeding complications .
DDI-DrugBank.d777.s1.p11	Streptase	brand	_	anticoagulants	group	_	effect	use of drugn and drugn -- druga , drugn , alone or in combination with drugn and drugb , may cause bleeding complications .
DDI-DrugBank.d777.s1.p12	Streptokinase	drug	_	antiplatelet agents	group	_	effect	use of drugn and drugn -- drugn , druga , alone or in combination with drugb and drugn , may cause bleeding complications .
DDI-DrugBank.d777.s1.p13	Streptokinase	drug	_	anticoagulants	group	_	effect	use of drugn and drugn -- drugn , druga , alone or in combination with drugn and drugb , may cause bleeding complications .
DDI-DrugBank.d777.s1.p14	antiplatelet agents	group	_	anticoagulants	group	_	false	use of drugn and drugn -- drugn , drugn , alone or in combination with druga and drugb , may cause bleeding complications .
DDI-DrugBank.d777.s3.p0	aspirin	brand	_	Streptokinase	drug	_	false	in the treatment of acute mi , druga , when not otherwise contraindicated , should be administered with drugb -lcb- see below -rcb- .
DDI-DrugBank.d777.s4.p0	Antiplatelets	group	_	aspirin	brand	_	false	anticoagulation and druga after treatment for myocardial infarction -- in the treatment of acute myocardial infarction , the use of drugb has been shown to reduce the incidence of reinfarction and stroke .
DDI-DrugBank.d777.s5.p0	aspirin	brand	_	Streptokinase	drug	_	effect	the addition of druga to drugb causes a minimal increase in the risk of minor bleeding -lcb- # % vs , # % -rcb- , but does not appear to increase the incidence of major bleeding -lcb- see
DDI-DrugBank.d647.s1.p0	Streptozocin	drug	_	doxorubicin	drug	_	mechanism	druga has been reported to prolong the elimination half-life of drugb and may lead to severe bone marrow suppression ;
DDI-DrugBank.d647.s2.p0	doxorubicin	drug	_	ZANOSAR	brand	_	advise	a reduction of the druga dosage should be considered in patients receiving drugb concurrently .
DDI-DrugBank.d647.s3.p0	streptozocin	drug	_	phenytoin	drug	_	effect	the concurrent use of druga and drugb has been reported in one case to result in reduced drugn cytotoxicity .
DDI-DrugBank.d647.s3.p2	phenytoin	drug	_	streptozocin	drug	_	false	the concurrent use of drugn and druga has been reported in one case to result in reduced drugb cytotoxicity .
DDI-DrugBank.d732.s0.p0	CHEMET	brand	_	iron	drug	_	false	druga is not known to interact with other drugs including drugb supplements ;
DDI-DrugBank.d732.s2.p0	CHEMET	brand	_	CaNa 2 EDTA	drug	_	advise	concomitant administration of druga with other chelation therapy , such as drugb is not recommended .
DDI-DrugBank.d649.s0.p0	Sulfamethizole	drug	_	barbiturates	group	_	effect	druga may increase the effects of drugb , drugn , and drugn .
DDI-DrugBank.d649.s0.p1	Sulfamethizole	drug	_	tolbutamide	drug	_	effect	druga may increase the effects of drugn , drugb , and drugn .
DDI-DrugBank.d649.s0.p2	Sulfamethizole	drug	_	uricosurics	group	_	effect	druga may increase the effects of drugn , drugn , and drugb .
DDI-DrugBank.d649.s1.p4	thiazides	group	_	methotrexate	drug	_	false	it may also interact with druga -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugb -rcb- , drugn -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d649.s1.p6	thiazides	group	_	phenytoin	drug	_	false	it may also interact with druga -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d649.s1.p10	cyclosporine	drug	_	methotrexate	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , druga -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugb -rcb- , drugn -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d649.s1.p11	cyclosporine	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , druga -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugb -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d649.s1.p12	cyclosporine	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , druga -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d649.s1.p15	sulfonylurea agents	group	_	methotrexate	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , druga -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugb -rcb- , drugn -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d649.s1.p16	sulfonylurea agents	group	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , druga -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugb -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d649.s1.p17	sulfonylurea agents	group	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , druga -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d649.s1.p19	warfarin	drug	_	methotrexate	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , druga -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugb -rcb- , drugn -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d649.s1.p20	warfarin	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , druga -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugb -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d649.s1.p21	warfarin	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , druga -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d649.s1.p23	methotrexate	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , druga -lcb- decreased renal excretion of drugn -rcb- , drugb -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d649.s1.p24	methotrexate	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , druga -lcb- decreased renal excretion of drugn -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d649.s1.p25	methotrexate	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of druga -rcb- , drugb -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d649.s1.p26	methotrexate	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of druga -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d577.s0.p0	diuretics	group	_	thiazides	group	_	false	in elderly patients concurrently receiving certain druga , primarily drugb , an increased incidence of thrombopenia with purpura has been reported .
DDI-DrugBank.d577.s1.p0	sulfamethoxazole	drug	_	anticoagulant	group	_	false	it has been reported that druga may prolong the prothrombin time in patients who are receiving the drugb drugn .
DDI-DrugBank.d577.s1.p1	sulfamethoxazole	drug	_	warfarin	drug	_	effect	it has been reported that druga may prolong the prothrombin time in patients who are receiving the drugn drugb .
DDI-DrugBank.d577.s1.p2	anticoagulant	group	_	warfarin	drug	_	false	it has been reported that drugn may prolong the prothrombin time in patients who are receiving the druga drugb .
DDI-DrugBank.d577.s3.p0	Sulfamethoxazole	drug	_	phenytoin	drug	_	mechanism	druga may inhibit the hepatic metabolism of drugb .
DDI-DrugBank.d577.s4.p0	sulfamethoxazole	drug	_	phenytoin	drug	_	mechanism	at a # - g dose , druga produced a slight but significant increase in the half-life of drugb but did not produce a corresponding decrease in the metabolic clearance rate .
DDI-DrugBank.d577.s6.p0	Sulfonamides	group	_	methotrexate	drug	_	mechanism	druga can also displace drugb from plasma protein-binding sites , thus increasing free drugn concentrations .
DDI-DrugBank.d577.s6.p1	Sulfonamides	group	_	methotrexate	drug	_	false	druga can also displace drugn from plasma protein-binding sites , thus increasing free drugb concentrations .
DDI-DrugBank.d693.s0.p0	folic acid	drug	_	digoxin	drug	_	false	reduced absorption of druga and drugb have been reported when those agents were administered concomitantly with drugn .
DDI-DrugBank.d693.s0.p1	folic acid	drug	_	sulfasalazine	drug	_	mechanism	reduced absorption of druga and drugn have been reported when those agents were administered concomitantly with drugb .
DDI-DrugBank.d693.s0.p2	digoxin	drug	_	sulfasalazine	drug	_	mechanism	reduced absorption of drugn and druga have been reported when those agents were administered concomitantly with drugb .
DDI-DrugBank.d693.s1.p0	sulfasalazine	drug	_	methotrexate	drug	_	false	when daily doses of druga # g and weekly doses of drugb # mg were coadministered to # rheumatoid_arthritis patients in a drug-drug interaction study , the pharmacokinetic disposition of the drugs was not altered .
DDI-DrugBank.d693.s2.p0	sulfasalazine	drug	_	methotrexate	drug	_	false	daily doses of druga # g -lcb- maximum # g -rcb- and weekly doses of drugb # mg -lcb- maximum # mg -rcb- were administered alone or in combination to # rheumatoid_arthritis patients in two controlled 52-week clinical studies .
DDI-DrugBank.d682.s0.p0	Sulfoxone	drug	_	barbiturates	group	_	effect	druga may increase the effects of drugb , drugn , and drugn .
DDI-DrugBank.d682.s0.p1	Sulfoxone	drug	_	tolbutamide	drug	_	effect	druga may increase the effects of drugn , drugb , and drugn .
DDI-DrugBank.d682.s0.p2	Sulfoxone	drug	_	uricosurics	group	_	effect	druga may increase the effects of drugn , drugn , and drugb .
DDI-DrugBank.d682.s1.p4	thiazides	group	_	methotrexate	drug	_	false	it may also interact with druga -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugb -rcb- , drugn -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d682.s1.p6	thiazides	group	_	phenytoin	drug	_	false	it may also interact with druga -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d682.s1.p10	cyclosporine	drug	_	methotrexate	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , druga -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugb -rcb- , drugn -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d682.s1.p11	cyclosporine	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , druga -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugb -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d682.s1.p12	cyclosporine	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , druga -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d682.s1.p15	sulfonylurea agents	group	_	methotrexate	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , druga -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugb -rcb- , drugn -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d682.s1.p16	sulfonylurea agents	group	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , druga -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugb -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d682.s1.p17	sulfonylurea agents	group	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , druga -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d682.s1.p19	warfarin	drug	_	methotrexate	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , druga -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugb -rcb- , drugn -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d682.s1.p20	warfarin	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , druga -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugb -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d682.s1.p21	warfarin	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , druga -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of drugn -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d682.s1.p23	methotrexate	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , druga -lcb- decreased renal excretion of drugn -rcb- , drugb -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d682.s1.p24	methotrexate	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , druga -lcb- decreased renal excretion of drugn -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d682.s1.p25	methotrexate	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of druga -rcb- , drugb -lcb- decreased hepatic clearance of drugn -rcb- .
DDI-DrugBank.d682.s1.p26	methotrexate	drug	_	phenytoin	drug	_	false	it may also interact with drugn -lcb- increased thrombocytopenia -rcb- , drugn -lcb- increased nephrotoxicity -rcb- , drugn -lcb- increased hypoglycemic response -rcb- , drugn -lcb- increased anticoagulant effect -rcb- , drugn -lcb- decreased renal excretion of druga -rcb- , drugn -lcb- decreased hepatic clearance of drugb -rcb- .
DDI-DrugBank.d720.s1.p0	ergotamine	drug	_	ergot-type medications	group	_	false	because there is a theoretical basis that these effects may be additive , use of druga - containing or drugb -lcb- like drugn or drugn -rcb- and drugn within # hours of each other should be avoided .
DDI-DrugBank.d720.s1.p2	ergotamine	drug	_	methysergide	drug	_	false	because there is a theoretical basis that these effects may be additive , use of druga - containing or drugn -lcb- like drugn or drugb -rcb- and drugn within # hours of each other should be avoided .
DDI-DrugBank.d720.s1.p3	ergotamine	drug	_	sumatriptan	drug	_	advise	because there is a theoretical basis that these effects may be additive , use of druga - containing or drugn -lcb- like drugn or drugn -rcb- and drugb within # hours of each other should be avoided .
DDI-DrugBank.d720.s1.p6	ergot-type medications	group	_	sumatriptan	drug	_	advise	because there is a theoretical basis that these effects may be additive , use of drugn - containing or druga -lcb- like drugn or drugn -rcb- and drugb within # hours of each other should be avoided .
DDI-DrugBank.d720.s1.p8	dihydroergotamine	drug	_	sumatriptan	drug	_	advise	because there is a theoretical basis that these effects may be additive , use of drugn - containing or drugn -lcb- like druga or drugn -rcb- and drugb within # hours of each other should be avoided .
DDI-DrugBank.d720.s1.p9	methysergide	drug	_	sumatriptan	drug	_	advise	because there is a theoretical basis that these effects may be additive , use of drugn - containing or drugn -lcb- like drugn or druga -rcb- and drugb within # hours of each other should be avoided .
DDI-DrugBank.d720.s2.p0	MAO-A inhibitors	group	_	sumatriptan	drug	_	mechanism	druga reduce drugb clearance , significantly increasing systemic exposure .
DDI-DrugBank.d720.s3.p0	sumatriptan succinate	drug	_	MAO-A inhibitors	group	_	advise	therefore , the use of druga tablets in patients receiving drugb is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p1	sumatriptan succinate	drug	_	Selective serotonin reuptake inhibitors	group	_	false	therefore , the use of druga tablets in patients receiving drugn is contraindicated , drugb -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p2	sumatriptan succinate	drug	_	SSRIs	group	_	false	therefore , the use of druga tablets in patients receiving drugn is contraindicated , drugn -lcb- drugb -rcb- -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p3	sumatriptan succinate	drug	_	fluoxetine	drug	_	false	therefore , the use of druga tablets in patients receiving drugn is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugb , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p4	sumatriptan succinate	drug	_	fluvoxamine	drug	_	false	therefore , the use of druga tablets in patients receiving drugn is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugb , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p5	sumatriptan succinate	drug	_	paroxetine	drug	_	false	therefore , the use of druga tablets in patients receiving drugn is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugb , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p6	sumatriptan succinate	drug	_	sertraline	drug	_	false	therefore , the use of druga tablets in patients receiving drugn is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugn , drugb -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p8	MAO-A inhibitors	group	_	Selective serotonin reuptake inhibitors	group	_	false	therefore , the use of drugn tablets in patients receiving druga is contraindicated , drugb -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p9	MAO-A inhibitors	group	_	SSRIs	group	_	false	therefore , the use of drugn tablets in patients receiving druga is contraindicated , drugn -lcb- drugb -rcb- -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p10	MAO-A inhibitors	group	_	fluoxetine	drug	_	false	therefore , the use of drugn tablets in patients receiving druga is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugb , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p11	MAO-A inhibitors	group	_	fluvoxamine	drug	_	false	therefore , the use of drugn tablets in patients receiving druga is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugb , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p12	MAO-A inhibitors	group	_	paroxetine	drug	_	false	therefore , the use of drugn tablets in patients receiving druga is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugb , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p13	MAO-A inhibitors	group	_	sertraline	drug	_	false	therefore , the use of drugn tablets in patients receiving druga is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugn , drugb -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d720.s3.p14	MAO-A inhibitors	group	_	sumatriptan	drug	_	false	therefore , the use of drugn tablets in patients receiving druga is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3.p20	Selective serotonin reuptake inhibitors	group	_	sumatriptan	drug	_	effect	therefore , the use of drugn tablets in patients receiving drugn is contraindicated , druga -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3.p25	SSRIs	group	_	sumatriptan	drug	_	effect	therefore , the use of drugn tablets in patients receiving drugn is contraindicated , drugn -lcb- druga -rcb- -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3.p29	fluoxetine	drug	_	sumatriptan	drug	_	effect	therefore , the use of drugn tablets in patients receiving drugn is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , druga , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3.p32	fluvoxamine	drug	_	sumatriptan	drug	_	effect	therefore , the use of drugn tablets in patients receiving drugn is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , druga , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3.p34	paroxetine	drug	_	sumatriptan	drug	_	effect	therefore , the use of drugn tablets in patients receiving drugn is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , druga , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3.p35	sertraline	drug	_	sumatriptan	drug	_	effect	therefore , the use of drugn tablets in patients receiving drugn is contraindicated , drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugn , druga -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s4.p0	sumatriptan	drug	_	SSRI	group	_	advise	if concomitant treatment with druga and an drugb is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d639.s0.p0	SUTENT	brand	_	ketoconazole	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p1	SUTENT	brand	_	itraconazole	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p2	SUTENT	brand	_	clarithromycin	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p3	SUTENT	brand	_	atazanavir	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p4	SUTENT	brand	_	indinavir	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p5	SUTENT	brand	_	nefazodone	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p6	SUTENT	brand	_	nelfinavir	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p7	SUTENT	brand	_	ritonavir	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p8	SUTENT	brand	_	saquinavir	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p9	SUTENT	brand	_	telithromycin	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p10	SUTENT	brand	_	voriconizole	drug	_	mechanism	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- may increases drugn concentrations .
DDI-DrugBank.d639.s0.p11	SUTENT	brand	_	sunitinib	drug	_	false	co-administration of druga with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p22	ketoconazole	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p32	itraconazole	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p41	clarithromycin	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p49	atazanavir	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p56	indinavir	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p62	nefazodone	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p67	nelfinavir	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p71	ritonavir	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p74	saquinavir	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p76	telithromycin	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s0.p77	voriconizole	drug	_	sunitinib	drug	_	false	co-administration of drugn with strong inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga -rcb- may increases drugb concentrations .
DDI-DrugBank.d639.s2.p0	SUTENT	brand	_	dexamethasone	drug	_	mechanism	co-administration of druga with inducers of the cyp3a4 family -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn , drugn , st , johns wort -rcb- may decrease drugn concentrations .
DDI-DrugBank.d639.s2.p1	SUTENT	brand	_	phenytoin	drug	_	mechanism	co-administration of druga with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn , drugn , st , johns wort -rcb- may decrease drugn concentrations .
DDI-DrugBank.d639.s2.p2	SUTENT	brand	_	carbamazepine	drug	_	mechanism	co-administration of druga with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn , drugn , st , johns wort -rcb- may decrease drugn concentrations .
DDI-DrugBank.d639.s2.p3	SUTENT	brand	_	rifampin	drug	_	mechanism	co-administration of druga with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn , drugn , st , johns wort -rcb- may decrease drugn concentrations .
DDI-DrugBank.d639.s2.p4	SUTENT	brand	_	rifabutin	drug	_	mechanism	co-administration of druga with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn , drugn , st , johns wort -rcb- may decrease drugn concentrations .
DDI-DrugBank.d639.s2.p5	SUTENT	brand	_	rifapentin	drug	_	mechanism	co-administration of druga with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb , drugn , st , johns wort -rcb- may decrease drugn concentrations .
DDI-DrugBank.d639.s2.p6	SUTENT	brand	_	phenobarbital	drug	_	mechanism	co-administration of druga with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugb , st , johns wort -rcb- may decrease drugn concentrations .
DDI-DrugBank.d639.s2.p7	SUTENT	brand	_	sunitinib	drug	_	false	co-administration of druga with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , st , johns wort -rcb- may decrease drugb concentrations .
DDI-DrugBank.d639.s2.p14	dexamethasone	drug	_	sunitinib	drug	_	false	co-administration of drugn with inducers of the cyp3a4 family -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , drugn , st , johns wort -rcb- may decrease drugb concentrations .
DDI-DrugBank.d639.s2.p20	phenytoin	drug	_	sunitinib	drug	_	false	co-administration of drugn with inducers of the cyp3a4 family -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , drugn , st , johns wort -rcb- may decrease drugb concentrations .
DDI-DrugBank.d639.s2.p25	carbamazepine	drug	_	sunitinib	drug	_	false	co-administration of drugn with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , drugn , st , johns wort -rcb- may decrease drugb concentrations .
DDI-DrugBank.d639.s2.p29	rifampin	drug	_	sunitinib	drug	_	false	co-administration of drugn with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , drugn , st , johns wort -rcb- may decrease drugb concentrations .
DDI-DrugBank.d639.s2.p32	rifabutin	drug	_	sunitinib	drug	_	false	co-administration of drugn with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , drugn , st , johns wort -rcb- may decrease drugb concentrations .
DDI-DrugBank.d639.s2.p34	rifapentin	drug	_	sunitinib	drug	_	false	co-administration of drugn with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , drugn , st , johns wort -rcb- may decrease drugb concentrations .
DDI-DrugBank.d639.s2.p35	phenobarbital	drug	_	sunitinib	drug	_	false	co-administration of drugn with inducers of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , druga , st , johns wort -rcb- may decrease drugb concentrations .
DDI-DrugBank.d723.s0.p1	acetylcholine chloride	drug	_	carbachol	drug	_	false	other eye drops or medications such as druga -lcb- drugn -rcb- and drugb -lcb- drugn , drugn -rcb- may decrease the effects of drugn ophthalmic .
DDI-DrugBank.d723.s0.p2	acetylcholine chloride	drug	_	Carboptic	brand	_	false	other eye drops or medications such as druga -lcb- drugn -rcb- and drugn -lcb- drugb , drugn -rcb- may decrease the effects of drugn ophthalmic .
DDI-DrugBank.d723.s0.p3	acetylcholine chloride	drug	_	Isopto Carbachol	brand	_	false	other eye drops or medications such as druga -lcb- drugn -rcb- and drugn -lcb- drugn , drugb -rcb- may decrease the effects of drugn ophthalmic .
DDI-DrugBank.d723.s0.p4	acetylcholine chloride	drug	_	suprofen	drug	_	effect	other eye drops or medications such as druga -lcb- drugn -rcb- and drugn -lcb- drugn , drugn -rcb- may decrease the effects of drugb ophthalmic .
DDI-DrugBank.d723.s0.p5	Miochol	brand	_	carbachol	drug	_	false	other eye drops or medications such as drugn -lcb- druga -rcb- and drugb -lcb- drugn , drugn -rcb- may decrease the effects of drugn ophthalmic .
DDI-DrugBank.d723.s0.p6	Miochol	brand	_	Carboptic	brand	_	false	other eye drops or medications such as drugn -lcb- druga -rcb- and drugn -lcb- drugb , drugn -rcb- may decrease the effects of drugn ophthalmic .
DDI-DrugBank.d723.s0.p7	Miochol	brand	_	Isopto Carbachol	brand	_	false	other eye drops or medications such as drugn -lcb- druga -rcb- and drugn -lcb- drugn , drugb -rcb- may decrease the effects of drugn ophthalmic .
DDI-DrugBank.d723.s0.p8	Miochol	brand	_	suprofen	drug	_	effect	other eye drops or medications such as drugn -lcb- druga -rcb- and drugn -lcb- drugn , drugn -rcb- may decrease the effects of drugb ophthalmic .
DDI-DrugBank.d723.s0.p11	carbachol	drug	_	suprofen	drug	_	effect	other eye drops or medications such as drugn -lcb- drugn -rcb- and druga -lcb- drugn , drugn -rcb- may decrease the effects of drugb ophthalmic .
DDI-DrugBank.d723.s0.p13	Carboptic	brand	_	suprofen	drug	_	effect	other eye drops or medications such as drugn -lcb- drugn -rcb- and drugn -lcb- druga , drugn -rcb- may decrease the effects of drugb ophthalmic .
DDI-DrugBank.d723.s0.p14	Isopto Carbachol	brand	_	suprofen	drug	_	effect	other eye drops or medications such as drugn -lcb- drugn -rcb- and drugn -lcb- drugn , druga -rcb- may decrease the effects of drugb ophthalmic .
DDI-DrugBank.d704.s0.p0	FLOMAX	brand	_	alpha-adrenergic blocking agents	group	_	false	drug-drug interactions : the pharmacokinetic and pharmacodynamic interactions between druga capsules and other drugb have not been determined .
DDI-DrugBank.d704.s1.p0	FLOMAX	brand	_	alpha-adrenergic blocking agents	group	_	advise	however , interactions may be expected and druga capsules should not be used in combination with other drugb .
DDI-DrugBank.d704.s2.p0	cimetidine	drug	_	FLOMAX	brand	_	false	the pharmacokinetic interaction between druga and drugb capsules was investigated .
DDI-DrugBank.d704.s4.p0	FLOMAX	brand	_	cimetidine	drug	_	advise	therefore , druga capsules should be used with caution in combination with drugb , particularly at doses higher than # mg .
DDI-DrugBank.d704.s5.p0	tamsulosin HCI	drug	_	warfarin	drug	_	false	results from limited in vitro and in vivo drug-drug interaction studies between druga and drugb are inconclusive .
DDI-DrugBank.d704.s6.p0	warfarin	drug	_	FLOMAX	brand	_	advise	therefore , caution should be exercised with concomitant administration of druga and drugb capsules .
DDI-DrugBank.d687.s0.p0	valproic acid	drug	_	temozolomide	drug	_	mechanism	administration of druga decreases oral clearance of drugb by about 5 % .
DDI-DrugBank.d773.s1.p0	TNKase	brand	_	heparin	drug	_	false	patients studied in clinical trials of druga were routinely treated with drugb and drugn .
DDI-DrugBank.d773.s1.p1	TNKase	brand	_	aspirin	brand	_	false	patients studied in clinical trials of druga were routinely treated with drugn and drugb .
DDI-DrugBank.d773.s1.p2	heparin	drug	_	aspirin	brand	_	false	patients studied in clinical trials of drugn were routinely treated with druga and drugb .
DDI-DrugBank.d773.s2.p2	Anticoagulants	group	_	acetylsalicylic acid	drug	_	false	druga -lcb- such as drugn and drugn -rcb- and drugs that alter platelet function -lcb- such as drugb , drugn , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d773.s2.p3	Anticoagulants	group	_	dipyridamole	drug	_	false	druga -lcb- such as drugn and drugn -rcb- and drugs that alter platelet function -lcb- such as drugn , drugb , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d773.s2.p4	Anticoagulants	group	_	TNKase	brand	_	effect	druga -lcb- such as drugn and drugn -rcb- and drugs that alter platelet function -lcb- such as drugn , drugn , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d773.s2.p6	heparin	drug	_	acetylsalicylic acid	drug	_	false	drugn -lcb- such as druga and drugn -rcb- and drugs that alter platelet function -lcb- such as drugb , drugn , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d773.s2.p7	heparin	drug	_	dipyridamole	drug	_	false	drugn -lcb- such as druga and drugn -rcb- and drugs that alter platelet function -lcb- such as drugn , drugb , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d773.s2.p8	heparin	drug	_	TNKase	brand	_	effect	drugn -lcb- such as druga and drugn -rcb- and drugs that alter platelet function -lcb- such as drugn , drugn , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d773.s2.p9	vitamin K antagonists	group	_	acetylsalicylic acid	drug	_	false	drugn -lcb- such as drugn and druga -rcb- and drugs that alter platelet function -lcb- such as drugb , drugn , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d773.s2.p10	vitamin K antagonists	group	_	dipyridamole	drug	_	false	drugn -lcb- such as drugn and druga -rcb- and drugs that alter platelet function -lcb- such as drugn , drugb , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d773.s2.p11	vitamin K antagonists	group	_	TNKase	brand	_	effect	drugn -lcb- such as drugn and druga -rcb- and drugs that alter platelet function -lcb- such as drugn , drugn , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d773.s2.p13	acetylsalicylic acid	drug	_	TNKase	brand	_	effect	drugn -lcb- such as drugn and drugn -rcb- and drugs that alter platelet function -lcb- such as druga , drugn , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d773.s2.p14	dipyridamole	drug	_	TNKase	brand	_	effect	drugn -lcb- such as drugn and drugn -rcb- and drugs that alter platelet function -lcb- such as drugn , druga , and gp iib/iiia inhibitors -rcb- may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d575.s0.p2	tolbutamide	drug	_	teniposide	drug	_	mechanism	in a study in which # different drugs were tested , therapeutically relevant concentrations of druga , drugn and drugn displaced protein-bound drugb in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0.p4	sodium salicylate	drug	_	teniposide	drug	_	mechanism	in a study in which # different drugs were tested , therapeutically relevant concentrations of drugn , druga and drugn displaced protein-bound drugb in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0.p5	sulfamethizole	drug	_	teniposide	drug	_	mechanism	in a study in which # different drugs were tested , therapeutically relevant concentrations of drugn , drugn and druga displaced protein-bound drugb in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s3.p0	teniposide	drug	_	methotrexate	drug	_	false	there was no change in the plasma kinetics of druga when coadministered with drugb .
DDI-DrugBank.d575.s5.p0	methotrexate	drug	_	teniposide	drug	_	mechanism	an increase in intracellular levels of druga was observed in vitro in the presence of drugb .
DDI-DrugBank.d645.s0.p0	terbinafine	drug	_	tolbutamide	drug	_	false	in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of drugb , drugn , drugn , and drugn .
DDI-DrugBank.d645.s0.p1	terbinafine	drug	_	ethinylestradiol	drug	_	false	in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of drugn , drugb , drugn , and drugn .
DDI-DrugBank.d645.s0.p2	terbinafine	drug	_	ethoxycoumarin	drug_n	_	false	in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of drugn , drugn , drugb , and drugn .
DDI-DrugBank.d645.s0.p3	terbinafine	drug	_	cyclosporine	drug	_	false	in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of drugn , drugn , drugn , and drugb .
DDI-DrugBank.d645.s3.p0	terbinafine	drug	_	antipyrine	drug	_	false	in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that druga does not affect the clearance of drugb or drugn .
DDI-DrugBank.d645.s3.p1	terbinafine	drug	_	digoxin	drug	_	false	in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that druga does not affect the clearance of drugn or drugb .
DDI-DrugBank.d645.s3.p2	antipyrine	drug	_	digoxin	drug	_	false	in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that drugn does not affect the clearance of druga or drugb .
DDI-DrugBank.d645.s4.p0	Terbinafine	drug	_	caffeine	drug	_	mechanism	druga decreases the clearance of drugb by 19 % .
DDI-DrugBank.d645.s5.p0	Terbinafine	drug	_	cyclosporine	drug	_	mechanism	druga increases the clearance of drugb by 15 % .
DDI-DrugBank.d645.s6.p0	terbinafine	drug	_	warfarin	drug	_	effect	there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral druga and drugb , however , a causal relationship between drugn tablets and these changes has not been established .
DDI-DrugBank.d645.s6.p1	terbinafine	drug	_	LAMISIL	brand	_	false	there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral druga and drugn , however , a causal relationship between drugb tablets and these changes has not been established .
DDI-DrugBank.d645.s6.p2	warfarin	drug	_	LAMISIL	brand	_	false	there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral drugn and druga , however , a causal relationship between drugb tablets and these changes has not been established .
DDI-DrugBank.d645.s7.p0	Terbinafine	drug	_	rifampin	drug	_	mechanism	druga clearance is increased 100 % by drugb , a cyp450 enzyme inducer , and decreased 33 % by drugn , a cyp450 enzyme inhibitor .
DDI-DrugBank.d645.s7.p1	Terbinafine	drug	_	cimetidine	drug	_	mechanism	druga clearance is increased 100 % by drugn , a cyp450 enzyme inducer , and decreased 33 % by drugb , a cyp450 enzyme inhibitor .
DDI-DrugBank.d645.s7.p2	rifampin	drug	_	cimetidine	drug	_	false	drugn clearance is increased 100 % by druga , a cyp450 enzyme inducer , and decreased 33 % by drugb , a cyp450 enzyme inhibitor .
DDI-DrugBank.d645.s8.p0	Terbinafine	drug	_	cyclosporine	drug	_	false	druga clearance is unaffected by drugb .
DDI-DrugBank.d645.s9.p0	contraceptives	group	_	hypoglycemics	group	_	false	there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d645.s9.p1	contraceptives	group	_	theophyllines	drug	_	false	there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d645.s9.p2	contraceptives	group	_	phenytoins	drug	_	false	there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d645.s9.p3	contraceptives	group	_	thiazide diuretics	group	_	false	there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d645.s9.p4	contraceptives	group	_	beta blockers	group	_	false	there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d645.s9.p5	contraceptives	group	_	calcium channel blockers	group	_	false	there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d743.s0.p2	ketoconazole	drug	_	terfenadine	drug	_	effect	drugn : spontaneous adverse reaction reports of patients taking concomitant druga with recommended doses of drugb demonstrate qt interval prolongation and rare serious cardiac events , e , g.
DDI-DrugBank.d743.s2.p0	ketoconazole	drug	_	terfenadine	drug	_	mechanism	pharmacokinetic data indicate that druga markedly inhibits the metabolism of drugb , resulting in elevated plasma drugn levels .
DDI-DrugBank.d743.s2.p1	ketoconazole	drug	_	terfenadine	drug	_	false	pharmacokinetic data indicate that druga markedly inhibits the metabolism of drugn , resulting in elevated plasma drugb levels .
DDI-DrugBank.d743.s4.p0	ketoconazole	drug	_	terfenadine	drug	_	advise	concomitant administration of druga and drugb is contraindicated .
DDI-DrugBank.d743.s5.p5	terfenadine	drug	_	itraconazole	drug	_	false	drugn : torsades de pointes and elevated parent druga levels have been reported during concomitant use of drugn and drugb in clinical trials of drugn and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.p6	terfenadine	drug	_	itraconazole	drug	_	false	drugn : torsades de pointes and elevated parent druga levels have been reported during concomitant use of drugn and drugn in clinical trials of drugb and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.p7	terfenadine	drug	_	itraconazole	drug	_	mechanism	drugn : torsades de pointes and elevated parent drugn levels have been reported during concomitant use of druga and drugb in clinical trials of drugn and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.p8	terfenadine	drug	_	itraconazole	drug	_	false	drugn : torsades de pointes and elevated parent drugn levels have been reported during concomitant use of druga and drugn in clinical trials of drugb and from foreign post-marketing sources .
DDI-DrugBank.d743.s7.p0	itraconazole	drug	_	terfenadine	drug	_	advise	concomitant administration of druga and drugb is contraindicated .
DDI-DrugBank.d743.s8.p3	azole-type antifungal agents	group	_	ketoconazole	drug	_	false	due to the chemical similarity of other druga -lcb- including drugn , drugn , and drugn -rcb- to drugb , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p4	azole-type antifungal agents	group	_	itraconazole	drug	_	false	due to the chemical similarity of other druga -lcb- including drugn , drugn , and drugn -rcb- to drugn , and drugb , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p5	azole-type antifungal agents	group	_	terfenadine	drug	_	advise	due to the chemical similarity of other druga -lcb- including drugn , drugn , and drugn -rcb- to drugn , and drugn , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p8	fluconazole	drug	_	ketoconazole	drug	_	false	due to the chemical similarity of other drugn -lcb- including druga , drugn , and drugn -rcb- to drugb , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p9	fluconazole	drug	_	itraconazole	drug	_	false	due to the chemical similarity of other drugn -lcb- including druga , drugn , and drugn -rcb- to drugn , and drugb , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p10	fluconazole	drug	_	terfenadine	drug	_	advise	due to the chemical similarity of other drugn -lcb- including druga , drugn , and drugn -rcb- to drugn , and drugn , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p12	metronidazole	drug	_	ketoconazole	drug	_	false	due to the chemical similarity of other drugn -lcb- including drugn , druga , and drugn -rcb- to drugb , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p13	metronidazole	drug	_	itraconazole	drug	_	false	due to the chemical similarity of other drugn -lcb- including drugn , druga , and drugn -rcb- to drugn , and drugb , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p14	metronidazole	drug	_	terfenadine	drug	_	advise	due to the chemical similarity of other drugn -lcb- including drugn , druga , and drugn -rcb- to drugn , and drugn , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p15	miconazole	drug	_	ketoconazole	drug	_	false	due to the chemical similarity of other drugn -lcb- including drugn , drugn , and druga -rcb- to drugb , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p16	miconazole	drug	_	itraconazole	drug	_	false	due to the chemical similarity of other drugn -lcb- including drugn , drugn , and druga -rcb- to drugn , and drugb , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p17	miconazole	drug	_	terfenadine	drug	_	advise	due to the chemical similarity of other drugn -lcb- including drugn , drugn , and druga -rcb- to drugn , and drugn , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p18	ketoconazole	drug	_	itraconazole	drug	_	false	due to the chemical similarity of other drugn -lcb- including drugn , drugn , and drugn -rcb- to druga , and drugb , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p19	ketoconazole	drug	_	terfenadine	drug	_	false	due to the chemical similarity of other drugn -lcb- including drugn , drugn , and drugn -rcb- to druga , and drugn , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.p20	itraconazole	drug	_	terfenadine	drug	_	false	due to the chemical similarity of other drugn -lcb- including drugn , drugn , and drugn -rcb- to drugn , and druga , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s9.p4	erythromycin	drug	_	clarithromycin	drug	_	false	drugn : clinical drug interaction studies indicate that druga and drugb can exert an effect on drugn metabolism by a mechanism which may be similar to that of drugn , but to a lesser extent .
DDI-DrugBank.d743.s9.p5	erythromycin	drug	_	terfenadine	drug	_	mechanism	drugn : clinical drug interaction studies indicate that druga and drugn can exert an effect on drugb metabolism by a mechanism which may be similar to that of drugn , but to a lesser extent .
DDI-DrugBank.d743.s9.p6	erythromycin	drug	_	ketoconazole	drug	_	false	drugn : clinical drug interaction studies indicate that druga and drugn can exert an effect on drugn metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
DDI-DrugBank.d743.s9.p7	clarithromycin	drug	_	terfenadine	drug	_	mechanism	drugn : clinical drug interaction studies indicate that drugn and druga can exert an effect on drugb metabolism by a mechanism which may be similar to that of drugn , but to a lesser extent .
DDI-DrugBank.d743.s9.p8	clarithromycin	drug	_	ketoconazole	drug	_	false	drugn : clinical drug interaction studies indicate that drugn and druga can exert an effect on drugn metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
DDI-DrugBank.d743.s9.p9	terfenadine	drug	_	ketoconazole	drug	_	false	drugn : clinical drug interaction studies indicate that drugn and drugn can exert an effect on druga metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
DDI-DrugBank.d743.s11.p0	erythromycin	drug	_	troleandomycin	drug	_	false	a few spontaneous accounts of qt interval prolongation with ventricular arrhythmia including torsades de pointes , have been reported in patients receiving druga or drugb .
DDI-DrugBank.d743.s12.p0	terfenadine	drug	_	clarithromycin	drug	_	advise	concomitant administration of druga with drugb , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugn , is not recommended .
DDI-DrugBank.d743.s12.p1	terfenadine	drug	_	erythromycin	drug	_	advise	concomitant administration of druga with drugn , drugb , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugn , is not recommended .
DDI-DrugBank.d743.s12.p2	terfenadine	drug	_	troleandomycin	drug	_	advise	concomitant administration of druga with drugn , drugn , or drugb is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugn , is not recommended .
DDI-DrugBank.d743.s12.p18	terfenadine	drug	_	macrolide antibiotics	group	_	advise	concomitant administration of drugn with drugn , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of druga with other drugb , including drugn , is not recommended .
DDI-DrugBank.d743.s12.p19	terfenadine	drug	_	azithromycin	drug	_	advise	concomitant administration of drugn with drugn , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of druga with other drugn , including drugb , is not recommended .
DDI-DrugBank.d743.s12.p20	macrolide antibiotics	group	_	azithromycin	drug	_	false	concomitant administration of drugn with drugn , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other druga , including drugb , is not recommended .
DDI-DrugBank.d743.s13.p0	terfenadine	drug	_	azithromycin	drug	_	false	studies to evaluate potential interactions of druga with drugb are in progress .
DDI-DrugBank.d658.s0.p0	testolactone	drug	_	anticoagulants	group	_	effect	when administered concurrently , druga may increase the effects of oral drugb ;
DDI-DrugBank.d604.s0.p0	Thalidomide	drug	_	barbiturates	group	_	effect	druga has been reported to enhance the sedative activity of drugb , drugn , drugn , and drugn .
DDI-DrugBank.d604.s0.p1	Thalidomide	drug	_	alcohol	drug	_	false	druga has been reported to enhance the sedative activity of drugn , drugb , drugn , and drugn .
DDI-DrugBank.d604.s0.p2	Thalidomide	drug	_	chlorpromazine	drug	_	false	druga has been reported to enhance the sedative activity of drugn , drugn , drugb , and drugn .
DDI-DrugBank.d604.s0.p3	Thalidomide	drug	_	reserpine	drug	_	false	druga has been reported to enhance the sedative activity of drugn , drugn , drugn , and drugb .
DDI-DrugBank.d604.s2.p0	Contraceptives	group	_	norethindrone	drug	_	false	oral druga : in # healthy women , the pharmacokinetic profiles of drugb and drugn following administration of a single dose containing # mg of drugn and # g of drugn were studied .
DDI-DrugBank.d604.s2.p1	Contraceptives	group	_	ethinyl estradiol	drug	_	false	oral druga : in # healthy women , the pharmacokinetic profiles of drugn and drugb following administration of a single dose containing # mg of drugn and # g of drugn were studied .
DDI-DrugBank.d604.s2.p2	Contraceptives	group	_	norethindrone acetate	drug	_	false	oral druga : in # healthy women , the pharmacokinetic profiles of drugn and drugn following administration of a single dose containing # mg of drugb and # g of drugn were studied .
DDI-DrugBank.d604.s2.p3	Contraceptives	group	_	ethinyl estradiol	drug	_	false	oral druga : in # healthy women , the pharmacokinetic profiles of drugn and drugn following administration of a single dose containing # mg of drugn and # g of drugb were studied .
DDI-DrugBank.d604.s2.p4	norethindrone	drug	_	ethinyl estradiol	drug	_	false	oral drugn : in # healthy women , the pharmacokinetic profiles of druga and drugb following administration of a single dose containing # mg of drugn and # g of drugn were studied .
DDI-DrugBank.d604.s2.p6	norethindrone	drug	_	ethinyl estradiol	drug	_	false	oral drugn : in # healthy women , the pharmacokinetic profiles of druga and drugn following administration of a single dose containing # mg of drugn and # g of drugb were studied .
DDI-DrugBank.d604.s2.p7	ethinyl estradiol	drug	_	norethindrone acetate	drug	_	false	oral drugn : in # healthy women , the pharmacokinetic profiles of drugn and druga following administration of a single dose containing # mg of drugb and # g of drugn were studied .
DDI-DrugBank.d604.s2.p9	norethindrone acetate	drug	_	ethinyl estradiol	drug	_	false	oral drugn : in # healthy women , the pharmacokinetic profiles of drugn and drugn following administration of a single dose containing # mg of druga and # g of drugb were studied .
DDI-DrugBank.d604.s4.p0	Thalidomide	drug	_	Hormonal Contraceptives	group	_	false	important non - druga drug interactions drugs that interfere with drugb : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p1	Thalidomide	drug	_	HIV-protease inhibitors	group	_	false	important non - druga drug interactions drugs that interfere with drugn : concomitant use of drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p2	Thalidomide	drug	_	griseofulvin	drug	_	false	important non - druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p3	Thalidomide	drug	_	modafinil	drug	_	false	important non - druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p4	Thalidomide	drug	_	penicillins	group	_	false	important non - druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p5	Thalidomide	drug	_	rifampin	drug	_	false	important non - druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p6	Thalidomide	drug	_	rifabutin	drug	_	false	important non - druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p7	Thalidomide	drug	_	phenytoin	drug	_	false	important non - druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p8	Thalidomide	drug	_	carbamazepine	drug	_	false	important non - druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p9	Hormonal Contraceptives	group	_	HIV-protease inhibitors	group	_	false	important non - drugn drug interactions drugs that interfere with druga : concomitant use of drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p10	Hormonal Contraceptives	group	_	griseofulvin	drug	_	false	important non - drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p11	Hormonal Contraceptives	group	_	modafinil	drug	_	false	important non - drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p12	Hormonal Contraceptives	group	_	penicillins	group	_	false	important non - drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p13	Hormonal Contraceptives	group	_	rifampin	drug	_	false	important non - drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p14	Hormonal Contraceptives	group	_	rifabutin	drug	_	false	important non - drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p15	Hormonal Contraceptives	group	_	phenytoin	drug	_	false	important non - drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.p16	Hormonal Contraceptives	group	_	carbamazepine	drug	_	false	important non - drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or certain herbal supplements such as st.
DDI-DrugBank.d604.s5.p0	John's Wort	drug_n	_	hormonal contraceptive agents	group	_	effect	druga with drugb may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies .
DDI-DrugBank.d686.s0.p0	Thiabendazole	drug	_	theophylline	drug	_	mechanism	druga may compete with other drugs , such as drugb , for sites of metabolism in the liver , thus elevating the serum levels of such compounds to potentially toxic levels .
DDI-DrugBank.d686.s1.p0	thiabendazole	drug	_	xanthine derivatives	group	_	advise	therefore , when concomitant use of druga and drugb is anticipated , it may be necessary to monitor blood levels and/or reduce the dosage of such compounds .
DDI-DrugBank.d697.s0.p1	Vitamin B1	drug	_	Loop Diuretics	group	_	int	interactions for druga -lcb- drugn -rcb- : drugb , oral drugn , drugn , drugn
DDI-DrugBank.d697.s0.p2	Vitamin B1	drug	_	Contraceptives	group	_	int	interactions for druga -lcb- drugn -rcb- : drugn , oral drugb , drugn , drugn
DDI-DrugBank.d697.s0.p3	Vitamin B1	drug	_	Stavudine	drug	_	int	interactions for druga -lcb- drugn -rcb- : drugn , oral drugn , drugb , drugn
DDI-DrugBank.d697.s0.p4	Vitamin B1	drug	_	Tricyclic Antidepressants	group	_	int	interactions for druga -lcb- drugn -rcb- : drugn , oral drugn , drugn , drugb
DDI-DrugBank.d697.s0.p5	Thiamine	drug	_	Loop Diuretics	group	_	int	interactions for drugn -lcb- druga -rcb- : drugb , oral drugn , drugn , drugn
DDI-DrugBank.d697.s0.p6	Thiamine	drug	_	Contraceptives	group	_	int	interactions for drugn -lcb- druga -rcb- : drugn , oral drugb , drugn , drugn
DDI-DrugBank.d697.s0.p7	Thiamine	drug	_	Stavudine	drug	_	int	interactions for drugn -lcb- druga -rcb- : drugn , oral drugn , drugb , drugn
DDI-DrugBank.d697.s0.p8	Thiamine	drug	_	Tricyclic Antidepressants	group	_	int	interactions for drugn -lcb- druga -rcb- : drugn , oral drugn , drugn , drugb
DDI-DrugBank.d697.s0.p9	Loop Diuretics	group	_	Contraceptives	group	_	false	interactions for drugn -lcb- drugn -rcb- : druga , oral drugb , drugn , drugn
DDI-DrugBank.d697.s0.p10	Loop Diuretics	group	_	Stavudine	drug	_	false	interactions for drugn -lcb- drugn -rcb- : druga , oral drugn , drugb , drugn
DDI-DrugBank.d697.s0.p11	Loop Diuretics	group	_	Tricyclic Antidepressants	group	_	false	interactions for drugn -lcb- drugn -rcb- : druga , oral drugn , drugn , drugb
DDI-DrugBank.d697.s0.p12	Contraceptives	group	_	Stavudine	drug	_	false	interactions for drugn -lcb- drugn -rcb- : drugn , oral druga , drugb , drugn
DDI-DrugBank.d697.s0.p13	Contraceptives	group	_	Tricyclic Antidepressants	group	_	false	interactions for drugn -lcb- drugn -rcb- : drugn , oral druga , drugn , drugb
DDI-DrugBank.d697.s0.p14	Stavudine	drug	_	Tricyclic Antidepressants	group	_	false	interactions for drugn -lcb- drugn -rcb- : drugn , oral drugn , druga , drugb
DDI-DrugBank.d677.s0.p0	Phenothiazines	group	_	CNS depressants	group	_	effect	druga are capable of potentiating drugb -lcb- e , g , , drugn , drugn , drugn , drugn , etc. .
DDI-DrugBank.d677.s0.p1	Phenothiazines	group	_	barbiturates	group	_	effect	druga are capable of potentiating drugn -lcb- e , g , , drugb , drugn , drugn , drugn , etc. .
DDI-DrugBank.d677.s0.p2	Phenothiazines	group	_	anesthetics	group	_	effect	druga are capable of potentiating drugn -lcb- e , g , , drugn , drugb , drugn , drugn , etc. .
DDI-DrugBank.d677.s0.p3	Phenothiazines	group	_	opiates	group	_	effect	druga are capable of potentiating drugn -lcb- e , g , , drugn , drugn , drugb , drugn , etc. .
DDI-DrugBank.d677.s0.p4	Phenothiazines	group	_	alcohol	drug	_	effect	druga are capable of potentiating drugn -lcb- e , g , , drugn , drugn , drugn , drugb , etc. .
DDI-DrugBank.d677.s1.p0	atropine	drug	_	phosphorous insecticides	drug_n	_	false	as well as druga and drugb .
DDI-DrugBank.d722.s0.p1	PURINETHOL	brand	_	TABLOID	brand	_	effect	there is usually complete cross-resistance between druga -lcb- drugn -rcb- and drugb brand drugn .
DDI-DrugBank.d722.s0.p2	PURINETHOL	brand	_	Thioguanine	drug	_	effect	there is usually complete cross-resistance between druga -lcb- drugn -rcb- and drugn brand drugb .
DDI-DrugBank.d722.s0.p3	mercaptopurine	drug	_	TABLOID	brand	_	effect	there is usually complete cross-resistance between drugn -lcb- druga -rcb- and drugb brand drugn .
DDI-DrugBank.d722.s0.p4	mercaptopurine	drug	_	Thioguanine	drug	_	effect	there is usually complete cross-resistance between drugn -lcb- druga -rcb- and drugn brand drugb .
DDI-DrugBank.d722.s0.p5	TABLOID	brand	_	Thioguanine	drug	_	false	there is usually complete cross-resistance between drugn -lcb- drugn -rcb- and druga brand drugb .
DDI-DrugBank.d722.s1.p3	aminosalicylate derivatives	group	_	thioguanine	drug	_	mechanism	as there is in vitro evidence that druga -lcb- e , g , , drugn , drugn , or drugn -rcb- inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
DDI-DrugBank.d722.s1.p6	olsalazine	drug	_	thioguanine	drug	_	mechanism	as there is in vitro evidence that drugn -lcb- e , g , , druga , drugn , or drugn -rcb- inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
DDI-DrugBank.d722.s1.p8	mesalazine	drug	_	thioguanine	drug	_	mechanism	as there is in vitro evidence that drugn -lcb- e , g , , drugn , druga , or drugn -rcb- inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
DDI-DrugBank.d722.s1.p9	sulphasalazine	drug	_	thioguanine	drug	_	mechanism	as there is in vitro evidence that drugn -lcb- e , g , , drugn , drugn , or druga -rcb- inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
DDI-DrugBank.d616.s1.p0	ZADAXIN	brand	_	immunomodulating drugs	group	_	advise	caution should be exercised when administering druga therapy in combination with other drugb .
DDI-DrugBank.d642.s0.p0	tigecycline	drug	_	warfarin	drug	_	advise	prothrombin time or other suitable anticoagulation test should be monitored if druga is administered with drugb .
DDI-DrugBank.d642.s1.p0	antibacterial drugs	group	_	contraceptives	group	_	effect	concurrent use of druga with oral drugb may render oral drugn less effective .
DDI-DrugBank.d642.s1.p1	antibacterial drugs	group	_	contraceptives	group	_	false	concurrent use of druga with oral drugn may render oral drugb less effective .
DDI-DrugBank.d721.s0.p0	SKELID	brand	_	calcium	drug	_	mechanism	the bioavailability of druga is decreased 80 % by drugb , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p1	SKELID	brand	_	calcium	drug	_	false	the bioavailability of druga is decreased 80 % by drugn , when drugb and drugn are administered at the same time , and 60 % by some drugn - or drugn - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p3	SKELID	brand	_	aluminum	drug	_	false	the bioavailability of druga is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugb - or drugn - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p4	SKELID	brand	_	magnesium	drug	_	false	the bioavailability of druga is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugb - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p5	SKELID	brand	_	antacids	drug	_	false	the bioavailability of druga is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn - containing drugb , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p8	calcium	drug	_	SKELID	brand	_	false	the bioavailability of drugn is decreased 80 % by druga , when drugn and drugb are administered at the same time , and 60 % by some drugn - or drugn - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p9	calcium	drug	_	aluminum	drug	_	false	the bioavailability of drugn is decreased 80 % by druga , when drugn and drugn are administered at the same time , and 60 % by some drugb - or drugn - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p10	calcium	drug	_	magnesium	drug	_	false	the bioavailability of drugn is decreased 80 % by druga , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugb - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p11	calcium	drug	_	antacids	drug	_	false	the bioavailability of drugn is decreased 80 % by druga , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn - containing drugb , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p12	calcium	drug	_	SKELID	brand	_	false	the bioavailability of drugn is decreased 80 % by druga , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn - containing drugn , when administered # hour before drugb .
DDI-DrugBank.d721.s0.p13	calcium	drug	_	SKELID	brand	_	false	the bioavailability of drugn is decreased 80 % by drugn , when druga and drugb are administered at the same time , and 60 % by some drugn - or drugn - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p14	calcium	drug	_	aluminum	drug	_	false	the bioavailability of drugn is decreased 80 % by drugn , when druga and drugn are administered at the same time , and 60 % by some drugb - or drugn - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p15	calcium	drug	_	magnesium	drug	_	false	the bioavailability of drugn is decreased 80 % by drugn , when druga and drugn are administered at the same time , and 60 % by some drugn - or drugb - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p16	calcium	drug	_	antacids	drug	_	false	the bioavailability of drugn is decreased 80 % by drugn , when druga and drugn are administered at the same time , and 60 % by some drugn - or drugn - containing drugb , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p17	calcium	drug	_	SKELID	brand	_	false	the bioavailability of drugn is decreased 80 % by drugn , when druga and drugn are administered at the same time , and 60 % by some drugn - or drugn - containing drugn , when administered # hour before drugb .
DDI-DrugBank.d721.s0.p18	SKELID	brand	_	aluminum	drug	_	false	the bioavailability of drugn is decreased 80 % by drugn , when drugn and druga are administered at the same time , and 60 % by some drugb - or drugn - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p19	SKELID	brand	_	magnesium	drug	_	false	the bioavailability of drugn is decreased 80 % by drugn , when drugn and druga are administered at the same time , and 60 % by some drugn - or drugb - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p20	SKELID	brand	_	antacids	drug	_	false	the bioavailability of drugn is decreased 80 % by drugn , when drugn and druga are administered at the same time , and 60 % by some drugn - or drugn - containing drugb , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p22	aluminum	drug	_	magnesium	drug	_	false	the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some druga - or drugb - containing drugn , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p23	aluminum	drug	_	antacids	drug	_	false	the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some druga - or drugn - containing drugb , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p24	aluminum	drug	_	SKELID	brand	_	mechanism	the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some druga - or drugn - containing drugn , when administered # hour before drugb .
DDI-DrugBank.d721.s0.p25	magnesium	drug	_	antacids	drug	_	false	the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or druga - containing drugb , when administered # hour before drugn .
DDI-DrugBank.d721.s0.p26	magnesium	drug	_	SKELID	brand	_	mechanism	the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or druga - containing drugn , when administered # hour before drugb .
DDI-DrugBank.d721.s0.p27	antacids	drug	_	SKELID	brand	_	false	the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn - containing druga , when administered # hour before drugb .
DDI-DrugBank.d721.s1.p0	Aspirin	brand	_	SKELID	brand	_	mechanism	druga may decrease bioavailability of drugb by up to 50 % when taken # hours after drugn .
DDI-DrugBank.d721.s1.p1	Aspirin	brand	_	SKELID	brand	_	false	druga may decrease bioavailability of drugn by up to 50 % when taken # hours after drugb .
DDI-DrugBank.d721.s2.p0	SKELID	brand	_	indomethacin	drug	_	mechanism	the bioavailability of druga is increased 2-4 fold by drugb but is not significantly altered by coadministration of drugn .
DDI-DrugBank.d721.s2.p1	SKELID	brand	_	diclofenac	drug	_	false	the bioavailability of druga is increased 2-4 fold by drugn but is not significantly altered by coadministration of drugb .
DDI-DrugBank.d721.s2.p2	indomethacin	drug	_	diclofenac	drug	_	false	the bioavailability of drugn is increased 2-4 fold by druga but is not significantly altered by coadministration of drugb .
DDI-DrugBank.d721.s3.p0	digoxin	drug	_	SKELID	brand	_	false	the pharmacokinetic parameters of druga are not significantly modified by drugb coadministration .
DDI-DrugBank.d721.s4.p0	tiludronate	drug	_	warfarin	drug	_	false	in vitro studies show that druga does not displace drugb from its binding site on protein .
DDI-DrugBank.d702.s1.p1	sympathomimetic bronchodilators	group	_	steroids	group	_	false	these include druga , drugn , and oral and inhaled drugb .
DDI-DrugBank.d702.s1.p2	methylxanthines	group	_	steroids	group	_	false	these include drugn , druga , and oral and inhaled drugb .
DDI-DrugBank.d702.s2.p0	SPIRIVA	brand	_	anticholinergic	group	_	advise	however , the co administration of druga with other drugb containing drugs -lcb- e , g , , drugn -rcb- has not been studied and is therefore not recommended .
DDI-DrugBank.d702.s2.p1	SPIRIVA	brand	_	ipratropium	drug	_	advise	however , the co administration of druga with other drugn containing drugs -lcb- e , g , , drugb -rcb- has not been studied and is therefore not recommended .
DDI-DrugBank.d702.s2.p2	anticholinergic	group	_	ipratropium	drug	_	false	however , the co administration of drugn with other druga containing drugs -lcb- e , g , , drugb -rcb- has not been studied and is therefore not recommended .
DDI-DrugBank.d751.s0.p0	AGGRASTAT	brand	_	aspirin	brand	_	false	druga has been studied on a background of drugb and drugn .
DDI-DrugBank.d751.s0.p1	AGGRASTAT	brand	_	heparin	drug	_	false	druga has been studied on a background of drugn and drugb .
DDI-DrugBank.d751.s0.p2	aspirin	brand	_	heparin	drug	_	false	drugn has been studied on a background of druga and drugb .
DDI-DrugBank.d751.s1.p0	AGGRASTAT	brand	_	heparin	drug	_	effect	the use of druga , in combination with drugb and drugn , has been associated with an increase in bleeding compared to drugn and drugn alone -lcb- see
DDI-DrugBank.d751.s1.p1	AGGRASTAT	brand	_	aspirin	brand	_	effect	the use of druga , in combination with drugn and drugb , has been associated with an increase in bleeding compared to drugn and drugn alone -lcb- see
DDI-DrugBank.d751.s1.p2	AGGRASTAT	brand	_	heparin	drug	_	false	the use of druga , in combination with drugn and drugn , has been associated with an increase in bleeding compared to drugb and drugn alone -lcb- see
DDI-DrugBank.d751.s1.p3	AGGRASTAT	brand	_	aspirin	drug	_	false	the use of druga , in combination with drugn and drugn , has been associated with an increase in bleeding compared to drugn and drugb alone -lcb- see
DDI-DrugBank.d751.s1.p4	heparin	drug	_	aspirin	brand	_	false	the use of drugn , in combination with druga and drugb , has been associated with an increase in bleeding compared to drugn and drugn alone -lcb- see
DDI-DrugBank.d751.s1.p6	heparin	drug	_	aspirin	drug	_	false	the use of drugn , in combination with druga and drugn , has been associated with an increase in bleeding compared to drugn and drugb alone -lcb- see
DDI-DrugBank.d751.s1.p7	aspirin	brand	_	heparin	drug	_	false	the use of drugn , in combination with drugn and druga , has been associated with an increase in bleeding compared to drugb and drugn alone -lcb- see
DDI-DrugBank.d751.s1.p9	heparin	drug	_	aspirin	drug	_	false	the use of drugn , in combination with drugn and drugn , has been associated with an increase in bleeding compared to druga and drugb alone -lcb- see
DDI-DrugBank.d624.s0.p1	TOBI	brand	_	dornase alfa	drug	_	false	in clinical studies of druga , patients taking drugn concomitantly with drugb -lcb- drugn , genentech -rcb- , drugn , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p2	TOBI	brand	_	PULMOZYME	brand	_	false	in clinical studies of druga , patients taking drugn concomitantly with drugn -lcb- drugb , genentech -rcb- , drugn , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p3	TOBI	brand	_	(beta)-agonists	group	_	false	in clinical studies of druga , patients taking drugn concomitantly with drugn -lcb- drugn , genentech -rcb- , drugb , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p4	TOBI	brand	_	corticosteroids	group	_	false	in clinical studies of druga , patients taking drugn concomitantly with drugn -lcb- drugn , genentech -rcb- , drugn , inhaled drugb , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p5	TOBI	brand	_	anti-pseudomonal antibiotics	group	_	false	in clinical studies of druga , patients taking drugn concomitantly with drugn -lcb- drugn , genentech -rcb- , drugn , inhaled drugn , other drugb , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p6	TOBI	brand	_	aminoglycosides	group	_	false	in clinical studies of druga , patients taking drugn concomitantly with drugn -lcb- drugn , genentech -rcb- , drugn , inhaled drugn , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p7	TOBI	brand	_	dornase alfa	drug	_	effect	in clinical studies of drugn , patients taking druga concomitantly with drugb -lcb- drugn , genentech -rcb- , drugn , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p8	TOBI	brand	_	PULMOZYME	brand	_	effect	in clinical studies of drugn , patients taking druga concomitantly with drugn -lcb- drugb , genentech -rcb- , drugn , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p9	TOBI	brand	_	(beta)-agonists	group	_	effect	in clinical studies of drugn , patients taking druga concomitantly with drugn -lcb- drugn , genentech -rcb- , drugb , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p10	TOBI	brand	_	corticosteroids	group	_	effect	in clinical studies of drugn , patients taking druga concomitantly with drugn -lcb- drugn , genentech -rcb- , drugn , inhaled drugb , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p11	TOBI	brand	_	anti-pseudomonal antibiotics	group	_	effect	in clinical studies of drugn , patients taking druga concomitantly with drugn -lcb- drugn , genentech -rcb- , drugn , inhaled drugn , other drugb , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p12	TOBI	brand	_	aminoglycosides	group	_	effect	in clinical studies of drugn , patients taking druga concomitantly with drugn -lcb- drugn , genentech -rcb- , drugn , inhaled drugn , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p14	dornase alfa	drug	_	(beta)-agonists	group	_	false	in clinical studies of drugn , patients taking drugn concomitantly with druga -lcb- drugn , genentech -rcb- , drugb , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p17	dornase alfa	drug	_	aminoglycosides	group	_	false	in clinical studies of drugn , patients taking drugn concomitantly with druga -lcb- drugn , genentech -rcb- , drugn , inhaled drugn , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p18	PULMOZYME	brand	_	(beta)-agonists	group	_	false	in clinical studies of drugn , patients taking drugn concomitantly with drugn -lcb- druga , genentech -rcb- , drugb , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p21	PULMOZYME	brand	_	aminoglycosides	group	_	false	in clinical studies of drugn , patients taking drugn concomitantly with drugn -lcb- druga , genentech -rcb- , drugn , inhaled drugn , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p22	(beta)-agonists	group	_	corticosteroids	group	_	false	in clinical studies of drugn , patients taking drugn concomitantly with drugn -lcb- drugn , genentech -rcb- , druga , inhaled drugb , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p23	(beta)-agonists	group	_	anti-pseudomonal antibiotics	group	_	false	in clinical studies of drugn , patients taking drugn concomitantly with drugn -lcb- drugn , genentech -rcb- , druga , inhaled drugn , other drugb , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p24	(beta)-agonists	group	_	aminoglycosides	group	_	false	in clinical studies of drugn , patients taking drugn concomitantly with drugn -lcb- drugn , genentech -rcb- , druga , inhaled drugn , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p26	corticosteroids	group	_	aminoglycosides	group	_	false	in clinical studies of drugn , patients taking drugn concomitantly with drugn -lcb- drugn , genentech -rcb- , drugn , inhaled druga , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.p27	anti-pseudomonal antibiotics	group	_	aminoglycosides	group	_	false	in clinical studies of drugn , patients taking drugn concomitantly with drugn -lcb- drugn , genentech -rcb- , drugn , inhaled drugn , other druga , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s2.p0	diuretics	group	_	aminoglycoside	group	_	effect	some druga can enhance drugb toxicity by altering drugn concentrations in serum and tissue .
DDI-DrugBank.d624.s2.p1	diuretics	group	_	antibiotic	group	_	false	some druga can enhance drugn toxicity by altering drugb concentrations in serum and tissue .
DDI-DrugBank.d624.s2.p2	aminoglycoside	group	_	antibiotic	group	_	false	some drugn can enhance druga toxicity by altering drugb concentrations in serum and tissue .
DDI-DrugBank.d624.s3.p0	TOBI	brand	_	ethacrynic acid	drug	_	advise	druga should not be administered concomitantly with drugb , drugn , drugn , or drugn .
DDI-DrugBank.d624.s3.p1	TOBI	brand	_	furosemide	drug	_	advise	druga should not be administered concomitantly with drugn , drugb , drugn , or drugn .
DDI-DrugBank.d624.s3.p2	TOBI	brand	_	urea	drug	_	advise	druga should not be administered concomitantly with drugn , drugn , drugb , or drugn .
DDI-DrugBank.d624.s3.p3	TOBI	brand	_	mannitol	drug	_	advise	druga should not be administered concomitantly with drugn , drugn , drugn , or drugb .
DDI-DrugBank.d608.s0.p0	warfarin	drug	_	tolmetin	drug	_	false	the in vitro binding of druga to human plasma proteins is unaffected by drugb , and drugn does not alter the prothrombin time of normal volunteers .
DDI-DrugBank.d608.s0.p1	warfarin	drug	_	tolmetin	drug	_	false	the in vitro binding of druga to human plasma proteins is unaffected by drugn , and drugb does not alter the prothrombin time of normal volunteers .
DDI-DrugBank.d608.s1.p0	TOLECTIN	brand	_	warfarin	drug	_	effect	however , increased prothrombin time and bleeding have been reported in patients on concomitant druga and drugb therapy .
DDI-DrugBank.d608.s2.p0	TOLECTIN	brand	_	anticoagulants	group	_	advise	therefore , caution should be exercised when administering druga to patients on drugb .
DDI-DrugBank.d608.s3.p0	sulfonylureas	group	_	insulin	drug	_	false	in adult diabetic patients under treatment with either druga or drugb there is no change in the clinical effects of either drugn or the drugn .
DDI-DrugBank.d608.s3.p1	sulfonylureas	group	_	TOLECTIN	brand	_	false	in adult diabetic patients under treatment with either druga or drugn there is no change in the clinical effects of either drugb or the drugn .
DDI-DrugBank.d608.s3.p2	sulfonylureas	group	_	hypoglycemic agents	group	_	false	in adult diabetic patients under treatment with either druga or drugn there is no change in the clinical effects of either drugn or the drugb .
DDI-DrugBank.d608.s3.p3	insulin	drug	_	TOLECTIN	brand	_	false	in adult diabetic patients under treatment with either drugn or druga there is no change in the clinical effects of either drugb or the drugn .
DDI-DrugBank.d608.s3.p4	insulin	drug	_	hypoglycemic agents	group	_	false	in adult diabetic patients under treatment with either drugn or druga there is no change in the clinical effects of either drugn or the drugb .
DDI-DrugBank.d608.s3.p5	TOLECTIN	brand	_	hypoglycemic agents	group	_	false	in adult diabetic patients under treatment with either drugn or drugn there is no change in the clinical effects of either druga or the drugb .
DDI-DrugBank.d608.s4.p0	TOLECTIN	brand	_	methotrexate	drug	_	advise	caution should be used if druga is administered concomitantly with drugb .
DDI-DrugBank.d608.s5.p0	TOLECTIN	brand	_	nonsteroidal anti-inflammatory drugs	group	_	false	druga and other drugb have been reported to reduce the tubular secretion of drugn in an animal model , possibly enhancing the toxicity of drugn .
DDI-DrugBank.d608.s5.p1	TOLECTIN	brand	_	methotrexate	drug	_	mechanism	druga and other drugn have been reported to reduce the tubular secretion of drugb in an animal model , possibly enhancing the toxicity of drugn .
DDI-DrugBank.d608.s5.p2	TOLECTIN	brand	_	methotrexate	drug	_	false	druga and other drugn have been reported to reduce the tubular secretion of drugn in an animal model , possibly enhancing the toxicity of drugb .
DDI-DrugBank.d608.s5.p3	nonsteroidal anti-inflammatory drugs	group	_	methotrexate	drug	_	mechanism	drugn and other druga have been reported to reduce the tubular secretion of drugb in an animal model , possibly enhancing the toxicity of drugn .
DDI-DrugBank.d608.s5.p4	nonsteroidal anti-inflammatory drugs	group	_	methotrexate	drug	_	false	drugn and other druga have been reported to reduce the tubular secretion of drugn in an animal model , possibly enhancing the toxicity of drugb .
DDI-DrugBank.d765.s0.p0	Ketoconazole	drug	_	tolterodine	drug	_	mechanism	cyp3a4 inhibitors : druga , an inhibitor of the drug metabolizing enzyme cyp3a4 , significantly increased plasma concentrations of drugb when coadministered to subjects who were poor metabolizers -lcb- see clinical pharmacology , variability in metabolism and drug-drug interactions -rcb- .
DDI-DrugBank.d765.s1.p0	ketoconazole	drug	_	azole antifungals	group	_	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other drugb -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or drugn or drugn , the recommended dose of drugn is # mg daily .
DDI-DrugBank.d765.s1.p1	ketoconazole	drug	_	itraconazole	drug	_	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugb , drugn -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or drugn or drugn , the recommended dose of drugn is # mg daily .
DDI-DrugBank.d765.s1.p2	ketoconazole	drug	_	miconazole	drug	_	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugb -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or drugn or drugn , the recommended dose of drugn is # mg daily .
DDI-DrugBank.d765.s1.p3	ketoconazole	drug	_	macrolide antibiotics	group	_	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugb -lcb- eg , drugn , drugn -rcb- or drugn or drugn , the recommended dose of drugn is # mg daily .
DDI-DrugBank.d765.s1.p4	ketoconazole	drug	_	erythromycin	drug	_	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugb , drugn -rcb- or drugn or drugn , the recommended dose of drugn is # mg daily .
DDI-DrugBank.d765.s1.p5	ketoconazole	drug	_	clarithromycin	drug	_	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugn , drugb -rcb- or drugn or drugn , the recommended dose of drugn is # mg daily .
DDI-DrugBank.d765.s1.p6	ketoconazole	drug	_	cyclosporine	drug	_	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or drugb or drugn , the recommended dose of drugn is # mg daily .
DDI-DrugBank.d765.s1.p7	ketoconazole	drug	_	vinblastine	drug	_	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or drugn or drugb , the recommended dose of drugn is # mg daily .
DDI-DrugBank.d765.s1.p8	ketoconazole	drug	_	DETROL LA	brand	_	advise	for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or drugn or drugn , the recommended dose of drugb is # mg daily .
DDI-DrugBank.d765.s1.p16	azole antifungals	group	_	DETROL LA	brand	_	advise	for patients receiving drugn or other potent cyp3a4 inhibitors such as other druga -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or drugn or drugn , the recommended dose of drugb is # mg daily .
DDI-DrugBank.d765.s1.p23	itraconazole	drug	_	DETROL LA	brand	_	advise	for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , druga , drugn -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or drugn or drugn , the recommended dose of drugb is # mg daily .
DDI-DrugBank.d765.s1.p29	miconazole	drug	_	DETROL LA	brand	_	advise	for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , druga -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or drugn or drugn , the recommended dose of drugb is # mg daily .
DDI-DrugBank.d765.s1.p34	macrolide antibiotics	group	_	DETROL LA	brand	_	advise	for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or druga -lcb- eg , drugn , drugn -rcb- or drugn or drugn , the recommended dose of drugb is # mg daily .
DDI-DrugBank.d765.s1.p38	erythromycin	drug	_	DETROL LA	brand	_	advise	for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , druga , drugn -rcb- or drugn or drugn , the recommended dose of drugb is # mg daily .
DDI-DrugBank.d765.s1.p41	clarithromycin	drug	_	DETROL LA	brand	_	advise	for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugn , druga -rcb- or drugn or drugn , the recommended dose of drugb is # mg daily .
DDI-DrugBank.d765.s1.p42	cyclosporine	drug	_	vinblastine	drug	_	false	for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or druga or drugb , the recommended dose of drugn is # mg daily .
DDI-DrugBank.d765.s1.p43	cyclosporine	drug	_	DETROL LA	brand	_	advise	for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or druga or drugn , the recommended dose of drugb is # mg daily .
DDI-DrugBank.d765.s1.p44	vinblastine	drug	_	DETROL LA	brand	_	advise	for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn -lcb- eg , drugn , drugn -rcb- or drugn -lcb- eg , drugn , drugn -rcb- or drugn or druga , the recommended dose of drugb is # mg daily .
DDI-DrugBank.d712.s1.p0	paclitaxel	drug	_	HERCEPTIN	brand	_	mechanism	administration of druga in combination with drugb resulted in a two-fold decrease in drugn clearance in a non-human primate study and in a # - fold increase in drugn serum levels in clinical studies .
DDI-DrugBank.d712.s1.p1	paclitaxel	drug	_	HERCEPTIN	brand	_	false	administration of druga in combination with drugn resulted in a two-fold decrease in drugb clearance in a non-human primate study and in a # - fold increase in drugn serum levels in clinical studies .
DDI-DrugBank.d712.s1.p2	paclitaxel	drug	_	HERCEPTIN	brand	_	false	administration of druga in combination with drugn resulted in a two-fold decrease in drugn clearance in a non-human primate study and in a # - fold increase in drugb serum levels in clinical studies .
DDI-DrugBank.d774.s0.p0	Trilostane	drug	_	aminoglutethimide	drug	_	int	druga may interact with drugb or drugn -lcb- causing too great a decrease in adrenal function -rcb- .
DDI-DrugBank.d774.s0.p1	Trilostane	drug	_	mitotane	drug	_	int	druga may interact with drugn or drugb -lcb- causing too great a decrease in adrenal function -rcb- .
DDI-DrugBank.d774.s0.p2	aminoglutethimide	drug	_	mitotane	drug	_	false	drugn may interact with druga or drugb -lcb- causing too great a decrease in adrenal function -rcb- .
DDI-DrugBank.d598.s0.p0	Trimethoprim	drug	_	phenytoin	drug	_	mechanism	druga may inhibit the hepatic metabolism of drugb .
DDI-DrugBank.d598.s1.p0	Trimethoprim	drug	_	phenytoin	drug	_	mechanism	druga , given at a common clinical dosage , increased the drugb half-life by 51 % and decreased the drugn metabolic clearance rate by 30 % .
DDI-DrugBank.d598.s1.p1	Trimethoprim	drug	_	phenytoin	drug	_	mechanism	druga , given at a common clinical dosage , increased the drugn half-life by 51 % and decreased the drugb metabolic clearance rate by 30 % .
DDI-DrugBank.d766.s1.p0	trimetrexate	drug	_	erythromycin	drug	_	effect	agents that might be coadministered with druga in acquired_immune_deficiency_syndrome patients for other indications that could elicit this activity include drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d766.s1.p1	trimetrexate	drug	_	rifampin	drug	_	effect	agents that might be coadministered with druga in acquired_immune_deficiency_syndrome patients for other indications that could elicit this activity include drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d766.s1.p2	trimetrexate	drug	_	rifabutin	drug	_	effect	agents that might be coadministered with druga in acquired_immune_deficiency_syndrome patients for other indications that could elicit this activity include drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d766.s1.p3	trimetrexate	drug	_	ketoconazole	drug	_	effect	agents that might be coadministered with druga in acquired_immune_deficiency_syndrome patients for other indications that could elicit this activity include drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d766.s1.p4	trimetrexate	drug	_	fluconazole	drug	_	effect	agents that might be coadministered with druga in acquired_immune_deficiency_syndrome patients for other indications that could elicit this activity include drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d766.s2.p0	cimetidine	drug	_	trimetrexate	drug	_	mechanism	in vitro perfusion of isolated rat liver has shown that druga caused a significant reduction in drugb metabolism and that drugn altered the relative concentration of tmq metabolites possibly by competing for sulfate metabolites .
DDI-DrugBank.d766.s2.p1	cimetidine	drug	_	acetaminophen	drug	_	false	in vitro perfusion of isolated rat liver has shown that druga caused a significant reduction in drugn metabolism and that drugb altered the relative concentration of tmq metabolites possibly by competing for sulfate metabolites .
DDI-DrugBank.d766.s2.p2	trimetrexate	drug	_	acetaminophen	drug	_	false	in vitro perfusion of isolated rat liver has shown that drugn caused a significant reduction in druga metabolism and that drugb altered the relative concentration of tmq metabolites possibly by competing for sulfate metabolites .
DDI-DrugBank.d766.s3.p3	imidazole drugs	group	_	trimetrexate	drug	_	mechanism	based on an in vitro rat liver model , nitrogen substituted druga -lcb- drugn , drugn , drugn -rcb- were potent , non-competitive inhibitors of drugb metabolism .
DDI-DrugBank.d766.s3.p6	clotrimazole	drug	_	trimetrexate	drug	_	mechanism	based on an in vitro rat liver model , nitrogen substituted drugn -lcb- druga , drugn , drugn -rcb- were potent , non-competitive inhibitors of drugb metabolism .
DDI-DrugBank.d766.s3.p8	ketoconazole	drug	_	trimetrexate	drug	_	mechanism	based on an in vitro rat liver model , nitrogen substituted drugn -lcb- drugn , druga , drugn -rcb- were potent , non-competitive inhibitors of drugb metabolism .
DDI-DrugBank.d766.s3.p9	miconazole	drug	_	trimetrexate	drug	_	mechanism	based on an in vitro rat liver model , nitrogen substituted drugn -lcb- drugn , drugn , druga -rcb- were potent , non-competitive inhibitors of drugb metabolism .
DDI-DrugBank.d615.s0.p0	Triprolidine	drug	_	central nervous system depressants	group	_	effect	druga may enhance the sedative effects of drugb including drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d615.s0.p1	Triprolidine	drug	_	alcohol	drug	_	effect	druga may enhance the sedative effects of drugn including drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d615.s0.p2	Triprolidine	drug	_	barbiturates	group	_	effect	druga may enhance the sedative effects of drugn including drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d615.s0.p3	Triprolidine	drug	_	hypnotics	group	_	effect	druga may enhance the sedative effects of drugn including drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d615.s0.p4	Triprolidine	drug	_	narcotic analgesics	group	_	effect	druga may enhance the sedative effects of drugn including drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d615.s0.p5	Triprolidine	drug	_	sedatives	group	_	effect	druga may enhance the sedative effects of drugn including drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d615.s0.p6	Triprolidine	drug	_	tranquillisers	group	_	effect	druga may enhance the sedative effects of drugn including drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d615.s0.p7	central nervous system depressants	group	_	alcohol	drug	_	false	drugn may enhance the sedative effects of druga including drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d615.s0.p8	central nervous system depressants	group	_	barbiturates	group	_	false	drugn may enhance the sedative effects of druga including drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d615.s0.p9	central nervous system depressants	group	_	hypnotics	group	_	false	drugn may enhance the sedative effects of druga including drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d615.s0.p10	central nervous system depressants	group	_	narcotic analgesics	group	_	false	drugn may enhance the sedative effects of druga including drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d615.s0.p11	central nervous system depressants	group	_	sedatives	group	_	false	drugn may enhance the sedative effects of druga including drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d615.s0.p12	central nervous system depressants	group	_	tranquillisers	group	_	false	drugn may enhance the sedative effects of druga including drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d615.s1.p0	anticholinergic drugs	group	_	atropine	drug	_	false	the effects of druga , such as drugb and drugn may be enhanced by the concomitant administration of drugn .
DDI-DrugBank.d615.s1.p1	anticholinergic drugs	group	_	tricyclic antidepressants	group	_	false	the effects of druga , such as drugn and drugb may be enhanced by the concomitant administration of drugn .
DDI-DrugBank.d615.s1.p2	anticholinergic drugs	group	_	triprolidine	drug	_	effect	the effects of druga , such as drugn and drugn may be enhanced by the concomitant administration of drugb .
DDI-DrugBank.d615.s1.p3	atropine	drug	_	tricyclic antidepressants	group	_	false	the effects of drugn , such as druga and drugb may be enhanced by the concomitant administration of drugn .
DDI-DrugBank.d615.s1.p4	atropine	drug	_	triprolidine	drug	_	effect	the effects of drugn , such as druga and drugn may be enhanced by the concomitant administration of drugb .
DDI-DrugBank.d615.s1.p5	tricyclic antidepressants	group	_	triprolidine	drug	_	effect	the effects of drugn , such as drugn and druga may be enhanced by the concomitant administration of drugb .
DDI-DrugBank.d713.s0.p0	Sanctura	brand	_	anticholinergic agents	group	_	effect	the concomitant use of druga with other drugb that produce dry mouth , constipation , and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects .
DDI-DrugBank.d713.s2.p1	Sanctura	brand	_	digoxin	drug	_	false	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugb , drugn , drugn , drugn , drugn , drugn and drugn -rcb- .
DDI-DrugBank.d713.s2.p2	Sanctura	brand	_	procainamide	drug	_	false	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugb , drugn , drugn , drugn , drugn and drugn -rcb- .
DDI-DrugBank.d713.s2.p3	Sanctura	brand	_	pancuronium	drug	_	false	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugn , drugb , drugn , drugn , drugn and drugn -rcb- .
DDI-DrugBank.d713.s2.p4	Sanctura	brand	_	morphine	drug	_	false	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugn , drugn , drugb , drugn , drugn and drugn -rcb- .
DDI-DrugBank.d713.s2.p5	Sanctura	brand	_	vancomycin	drug	_	false	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugn , drugn , drugn , drugb , drugn and drugn -rcb- .
DDI-DrugBank.d713.s2.p6	Sanctura	brand	_	metformin	drug	_	false	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugn , drugn , drugn , drugn , drugb and drugn -rcb- .
DDI-DrugBank.d713.s2.p7	Sanctura	brand	_	tenofovir	drug	_	false	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugn , drugn , drugn , drugn , drugn and drugb -rcb- .
DDI-DrugBank.d713.s2.p8	Sanctura	brand	_	digoxin	drug	_	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugb , drugn , drugn , drugn , drugn , drugn and drugn -rcb- .
DDI-DrugBank.d713.s2.p9	Sanctura	brand	_	procainamide	drug	_	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugb , drugn , drugn , drugn , drugn and drugn -rcb- .
DDI-DrugBank.d713.s2.p10	Sanctura	brand	_	pancuronium	drug	_	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugn , drugb , drugn , drugn , drugn and drugn -rcb- .
DDI-DrugBank.d713.s2.p11	Sanctura	brand	_	morphine	drug	_	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugn , drugn , drugb , drugn , drugn and drugn -rcb- .
DDI-DrugBank.d713.s2.p12	Sanctura	brand	_	vancomycin	drug	_	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugn , drugn , drugn , drugb , drugn and drugn -rcb- .
DDI-DrugBank.d713.s2.p13	Sanctura	brand	_	metformin	drug	_	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugn , drugn , drugn , drugn , drugb and drugn -rcb- .
DDI-DrugBank.d713.s2.p14	Sanctura	brand	_	tenofovir	drug	_	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -lcb- e , g , drugn , drugn , drugn , drugn , drugn , drugn and drugb -rcb- .
DDI-DrugBank.d669.s0.p0	vancomycin	drug	_	anesthetic agents	group	_	effect	concomitant administration of druga and drugb has been associated with erythema and histamine-like flushing and anaphylactoid reactions .
DDI-DrugBank.d613.s0.p0	vigabatrin	drug	_	carbamazepine	drug	_	mechanism	a study published in # found that druga causes a statistically significant increase in plasma clearance of drugb .
DDI-DrugBank.d613.s1.p0	vigabatrin	drug	_	phenytoin	drug	_	mechanism	in 1984 , drs rimmer and richens at the university of wales reported that administering druga with drugb lowered the serum drugn concentration in patients with treatment-resistant epilepsy .
DDI-DrugBank.d613.s1.p1	vigabatrin	drug	_	phenytoin	drug	_	false	in 1984 , drs rimmer and richens at the university of wales reported that administering druga with drugn lowered the serum drugb concentration in patients with treatment-resistant epilepsy .
DDI-DrugBank.d651.s0.p0	contraceptives	group	_	vitamin A	group	_	mechanism	drug interactions : women on oral druga have shown a significant increase in plasma drugb levels .
DDI-DrugBank.d759.s0.p0	ascorbic acid	drug	_	bishydroxycoumarin	drug	_	mechanism	limited evidence suggests that druga may influence the intensity and duration of action of drugb .
DDI-DrugBank.d769.s0.p0	Coumarin-Derivative Anticoagulants	group	_	ZOLINZA	brand	_	false	druga : prolongation of prothrombin time -lcb- pt -rcb- and international normalized ratio -lcb- inr -rcb- were observed in patients receiving drugb concomitantly with drugn .
DDI-DrugBank.d769.s0.p2	ZOLINZA	brand	_	coumarin-derivative anticoagulants	group	_	effect	drugn : prolongation of prothrombin time -lcb- pt -rcb- and international normalized ratio -lcb- inr -rcb- were observed in patients receiving druga concomitantly with drugb .
DDI-DrugBank.d769.s1.p0	ZOLINZA	brand	_	coumarin derivatives	group	_	advise	physicians should carefully monitor pt and inr in patients concurrently administered druga and drugb .
DDI-DrugBank.d769.s2.p0	HDAC Inhibitors	group	_	ZOLINZA	brand	_	false	other druga severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of drugb and other drugn -lcb- e , g , , drugn -rcb- .
DDI-DrugBank.d769.s2.p2	HDAC Inhibitors	group	_	valproic acid	drug	_	false	other druga severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of drugn and other drugn -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d769.s2.p3	ZOLINZA	brand	_	HDAC inhibitors	group	_	effect	other drugn severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of druga and other drugb -lcb- e , g , , drugn -rcb- .
DDI-DrugBank.d769.s2.p4	ZOLINZA	brand	_	valproic acid	drug	_	effect	other drugn severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of druga and other drugn -lcb- e , g , , drugb -rcb- .
